0001493152-22-008391.txt : 20220331 0001493152-22-008391.hdr.sgml : 20220331 20220331151624 ACCESSION NUMBER: 0001493152-22-008391 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 62 CONFORMED PERIOD OF REPORT: 20211231 FILED AS OF DATE: 20220331 DATE AS OF CHANGE: 20220331 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CalEthos, Inc. CENTRAL INDEX KEY: 0001174891 STANDARD INDUSTRIAL CLASSIFICATION: REAL ESTATE INVESTMENT TRUSTS [6798] IRS NUMBER: 000000000 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-50331 FILM NUMBER: 22791875 BUSINESS ADDRESS: STREET 1: THREE SUGAR CREEK CENTER STREET 2: SUITE 100 CITY: SUGAR LAND STATE: TX ZIP: 77478 BUSINESS PHONE: 713-929-3863 MAIL ADDRESS: STREET 1: THREE SUGAR CREEK CENTER STREET 2: SUITE 100 CITY: SUGAR LAND STATE: TX ZIP: 77478 FORMER COMPANY: FORMER CONFORMED NAME: RealSource Residential, Inc DATE OF NAME CHANGE: 20130814 FORMER COMPANY: FORMER CONFORMED NAME: UPSTREAM BIOSCIENCES INC. DATE OF NAME CHANGE: 20090422 FORMER COMPANY: FORMER CONFORMED NAME: FORCE ENERGY CORP. DATE OF NAME CHANGE: 20090415 10-K 1 form10-k.htm
0001174891 false FY 1,000 P0Y P0Y 0001174891 2021-01-01 2021-12-31 0001174891 2021-06-30 0001174891 2022-03-15 0001174891 2021-12-31 0001174891 2020-12-31 0001174891 BUUZ:SeriesAConvertiblePreferredStockMember 2021-12-31 0001174891 BUUZ:SeriesAConvertiblePreferredStockMember 2020-12-31 0001174891 2020-01-01 2020-12-31 0001174891 us-gaap:PreferredStockMember BUUZ:SeriesAConvertiblePreferredStockMember 2019-12-31 0001174891 us-gaap:CommonStockMember 2019-12-31 0001174891 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001174891 BUUZ:StockSubscriptionReceivableMember 2019-12-31 0001174891 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001174891 us-gaap:RetainedEarningsMember 2019-12-31 0001174891 2019-12-31 0001174891 us-gaap:PreferredStockMember BUUZ:SeriesAConvertiblePreferredStockMember 2020-12-31 0001174891 us-gaap:CommonStockMember 2020-12-31 0001174891 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001174891 BUUZ:StockSubscriptionReceivableMember 2020-12-31 0001174891 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001174891 us-gaap:RetainedEarningsMember 2020-12-31 0001174891 us-gaap:PreferredStockMember BUUZ:SeriesAConvertiblePreferredStockMember 2020-01-01 2020-12-31 0001174891 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001174891 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001174891 BUUZ:StockSubscriptionReceivableMember 2020-01-01 2020-12-31 0001174891 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0001174891 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001174891 us-gaap:PreferredStockMember BUUZ:SeriesAConvertiblePreferredStockMember 2021-01-01 2021-12-31 0001174891 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001174891 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001174891 BUUZ:StockSubscriptionReceivableMember 2021-01-01 2021-12-31 0001174891 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0001174891 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001174891 us-gaap:PreferredStockMember BUUZ:SeriesAConvertiblePreferredStockMember 2021-12-31 0001174891 us-gaap:CommonStockMember 2021-12-31 0001174891 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001174891 BUUZ:StockSubscriptionReceivableMember 2021-12-31 0001174891 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001174891 us-gaap:RetainedEarningsMember 2021-12-31 0001174891 BUUZ:AIQMember 2021-11-05 0001174891 2021-11-04 2021-11-05 0001174891 country:KR 2021-11-04 2021-11-05 0001174891 country:KR BUUZ:AIQMember 2021-11-04 2021-11-05 0001174891 country:KR BUUZ:AIQMember 2021-11-05 0001174891 BUUZ:RestrictedStockAwardMember 2021-01-01 2021-12-31 0001174891 BUUZ:RestrictedStockAwardMember 2020-01-01 2020-12-31 0001174891 BUUZ:ConvertiblePromissoryNotesAndAccruedInterestMember 2021-01-01 2021-12-31 0001174891 BUUZ:ConvertiblePromissoryNotesAndAccruedInterestMember 2020-01-01 2020-12-31 0001174891 BUUZ:SeriesAWarrantsIssuedWithConvertiblePromissoryNotesMember 2021-01-01 2021-12-31 0001174891 BUUZ:SeriesAWarrantsIssuedWithConvertiblePromissoryNotesMember 2020-01-01 2020-12-31 0001174891 BUUZ:SeriesBWarrantsToBeIssuedUponExerciseOfSeriesAWarrantMember 2021-01-01 2021-12-31 0001174891 BUUZ:SeriesBWarrantsToBeIssuedUponExerciseOfSeriesAWarrantMember 2020-01-01 2020-12-31 0001174891 BUUZ:WarrantsIssuedForServicesMember 2021-01-01 2021-12-31 0001174891 BUUZ:WarrantsIssuedForServicesMember 2020-01-01 2020-12-31 0001174891 BUUZ:StockOptionsMember 2021-01-01 2021-12-31 0001174891 BUUZ:StockOptionsMember 2020-01-01 2020-12-31 0001174891 BUUZ:MOneAdvisorsMember 2021-01-01 2021-12-31 0001174891 BUUZ:MOneAdvisorsMember 2020-01-01 2020-12-31 0001174891 BUUZ:PromissoryNoteMember 2021-01-11 0001174891 BUUZ:PromissoryNoteMember 2021-01-10 2021-01-11 0001174891 BUUZ:PromissoryNoteMember BUUZ:BorrowerMember 2021-01-10 2021-01-11 0001174891 BUUZ:PromissoryNoteMember 2021-10-27 0001174891 BUUZ:PromissoryNoteMember 2021-02-19 0001174891 BUUZ:PromissoryNoteMember 2021-02-18 2021-02-19 0001174891 BUUZ:PromissoryNoteMember 2021-12-31 0001174891 BUUZ:PromissoryNoteMember 2021-04-05 0001174891 BUUZ:PromissoryNoteMember 2021-04-04 2021-04-05 0001174891 BUUZ:PromissoryNoteOneMember 2021-04-22 0001174891 BUUZ:PromissoryNoteOneMember 2021-04-20 2021-04-22 0001174891 BUUZ:PromissoryNoteOneMember 2021-12-31 0001174891 BUUZ:PromissoryNoteTwoMember 2021-07-01 0001174891 BUUZ:PromissoryNoteTwoMember 2021-06-29 2021-07-01 0001174891 BUUZ:PromissoryNoteTwoMember 2021-12-31 0001174891 BUUZ:PromissoryNoteMember 2021-07-12 0001174891 BUUZ:PromissoryNoteMember 2021-07-11 2021-07-12 0001174891 BUUZ:PromissoryNoteMember 2021-08-10 0001174891 BUUZ:PromissoryNoteMember 2021-08-09 2021-08-10 0001174891 BUUZ:PromissoryNoteMember 2021-08-31 0001174891 BUUZ:PromissoryNoteMember 2021-08-29 2021-08-31 0001174891 BUUZ:PromissoryNoteMember 2021-09-30 0001174891 BUUZ:PromissoryNoteMember 2021-10-31 0001174891 BUUZ:PromissoryNoteThreeMember 2020-12-31 0001174891 BUUZ:PromissoryNoteThreeMember 2020-01-01 2020-12-31 0001174891 BUUZ:PromissoryNoteMember 2020-01-01 2020-12-31 0001174891 BUUZ:PromissoryNoteThreeMember 2021-12-31 0001174891 BUUZ:PromissoryNoteMember 2021-01-01 2021-12-31 0001174891 BUUZ:ConvertiblePromissoryNoteOneMember 2021-12-31 0001174891 BUUZ:ConvertiblePromissoryNoteTwoMember 2021-12-31 0001174891 BUUZ:ConvertiblePromissoryNoteOneMember 2021-01-01 2021-12-31 0001174891 BUUZ:ConvertiblePromissoryNoteTwoMember 2021-01-01 2021-12-31 0001174891 us-gaap:WarrantMember 2021-12-31 0001174891 us-gaap:WarrantMember srt:MinimumMember 2021-12-31 0001174891 us-gaap:WarrantMember srt:MaximumMember 2021-12-31 0001174891 us-gaap:WarrantMember 2021-01-01 2021-12-31 0001174891 us-gaap:WarrantMember srt:MinimumMember 2021-01-01 2021-12-31 0001174891 us-gaap:WarrantMember srt:MaximumMember 2021-01-01 2021-12-31 0001174891 BUUZ:ConvertiblePromissoryNoteMember 2020-12-31 0001174891 BUUZ:ConvertiblePromissoryNoteMember 2020-01-01 2020-12-31 0001174891 us-gaap:SeriesAPreferredStockMember BUUZ:ConvertiblePromissoryNoteMember 2020-01-01 2020-12-31 0001174891 us-gaap:WarrantMember 2020-12-31 0001174891 us-gaap:ConvertibleNotesPayableMember srt:MinimumMember 2020-12-31 0001174891 us-gaap:ConvertibleNotesPayableMember srt:MaximumMember 2020-12-31 0001174891 us-gaap:ConvertibleNotesPayableMember 2020-12-31 0001174891 us-gaap:ConvertibleNotesPayableMember 2019-12-31 0001174891 us-gaap:ConvertibleNotesPayableMember 2021-01-01 2021-12-31 0001174891 us-gaap:ConvertibleNotesPayableMember 2020-01-01 2020-12-31 0001174891 us-gaap:ConvertibleNotesPayableMember 2021-12-31 0001174891 us-gaap:ConvertibleNotesPayableMember srt:MinimumMember 2021-12-31 0001174891 us-gaap:ConvertibleNotesPayableMember srt:MaximumMember 2021-12-31 0001174891 BUUZ:TechnologyDevelopmentAgreementMember BUUZ:PICOCELCoLtdMember 2021-12-23 0001174891 BUUZ:TechnologyDevelopmentAgreementMember BUUZ:PICOCELCoLtdMember 2021-12-01 2021-12-31 0001174891 2022-01-01 2022-12-31 0001174891 BUUZ:TechnologyDevelopmentAgreementMember BUUZ:PICOCELCoLtdMember 2021-01-01 2021-12-31 0001174891 BUUZ:SeriesAConvertiblePreferredStockMember 2021-01-01 2021-12-31 0001174891 BUUZ:SeriesAConvertiblePreferredStockMember 2020-02-10 2020-02-11 0001174891 BUUZ:TerminationAgreementMember 2021-01-01 2021-01-31 0001174891 srt:ChiefExecutiveOfficerMember 2021-01-01 2021-03-31 0001174891 srt:ChiefFinancialOfficerMember 2021-03-30 0001174891 srt:ChiefFinancialOfficerMember 2021-03-31 0001174891 srt:ChiefFinancialOfficerMember 2021-01-01 2021-03-31 0001174891 BUUZ:ConsultantsMember 2021-10-01 2021-10-31 0001174891 BUUZ:ConsultantsMember 2021-08-16 2021-08-17 0001174891 srt:ChiefExecutiveOfficerMember 2021-08-16 2021-08-17 0001174891 BUUZ:ConsultantsMember 2021-01-01 2021-12-31 0001174891 BUUZ:ConsultantsMember 2021-12-31 0001174891 BUUZ:NewConsultingAgreementMember BUUZ:ShareholderMember 2021-02-01 2021-02-28 0001174891 BUUZ:NewConsultingAgreementMember BUUZ:ShareholderMember 2021-02-28 0001174891 BUUZ:NewConsultingAgreementMember BUUZ:ShareholderMember 2020-01-01 2020-12-31 0001174891 BUUZ:NewConsultingAgreementMember BUUZ:ShareholderMember 2021-01-01 2021-12-31 0001174891 BUUZ:LetterofUnderstandingMember 2021-05-31 0001174891 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2021-05-01 2021-05-31 0001174891 us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2021-05-01 2021-05-31 0001174891 us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2021-05-01 2021-05-31 0001174891 2021-05-31 0001174891 2021-05-01 2021-05-31 0001174891 2021-09-15 0001174891 2021-09-14 2021-09-15 0001174891 us-gaap:RestrictedStockMember 2021-12-31 0001174891 2019-01-01 2019-12-31 0001174891 us-gaap:MeasurementInputExpectedTermMember 2021-12-31 0001174891 us-gaap:MeasurementInputExpectedTermMember srt:MinimumMember 2020-12-31 0001174891 us-gaap:MeasurementInputExpectedTermMember srt:MaximumMember 2020-12-31 0001174891 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MinimumMember 2021-12-31 0001174891 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MaximumMember 2021-12-31 0001174891 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MinimumMember 2020-12-31 0001174891 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MaximumMember 2020-12-31 0001174891 us-gaap:MeasurementInputPriceVolatilityMember srt:MinimumMember 2021-12-31 0001174891 us-gaap:MeasurementInputPriceVolatilityMember srt:MaximumMember 2021-12-31 0001174891 us-gaap:MeasurementInputPriceVolatilityMember srt:MinimumMember 2020-12-31 0001174891 us-gaap:MeasurementInputPriceVolatilityMember srt:MaximumMember 2020-12-31 0001174891 us-gaap:MeasurementInputExpectedDividendRateMember 2021-12-31 0001174891 us-gaap:MeasurementInputExpectedDividendRateMember 2020-12-31 0001174891 us-gaap:MeasurementInputSharePriceMember srt:MinimumMember 2021-12-31 0001174891 us-gaap:MeasurementInputSharePriceMember srt:MaximumMember 2021-12-31 0001174891 us-gaap:MeasurementInputSharePriceMember srt:MinimumMember 2020-12-31 0001174891 us-gaap:MeasurementInputSharePriceMember srt:MaximumMember 2020-12-31 0001174891 BUUZ:AIQMember 2021-12-23 0001174891 us-gaap:SubsequentEventMember 2022-03-31 0001174891 us-gaap:SubsequentEventMember 2022-03-01 0001174891 us-gaap:SubsequentEventMember 2022-03-02 2022-03-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure iso4217:KRW

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K

 

(Mark One)

 

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2021

 

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission file number 000-50331

 

CalEthos, Inc.

(Exact name of registrant as specified in its charter)

 

Nevada   98-0371433
(State or other jurisdiction of
incorporation or organization)
  (I.R.S. Employer
Identification No.)

 

11753 Willard Avenue Tustin, California   92782
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (714) 352-5315

 

Securities registered under Section 12(b) of the Act:

 

None   N/A
Title of each class   Name of each exchange on which registered

 

Securities registered under Section 12(g) of the Act:

 

Common Stock, $0.001 par value

(Title of class)

 

Indicate by checkmark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No

 

Indicate by checkmark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes ☐ No

 

Indicate by checkmark whether the registrant has (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

 

Indicate by checkmark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
    Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No

 

The aggregate market value of the voting and non-voting common stock, other than shares held by persons who may be deemed affiliates of the registrant, as of June 30, 2021, the last day of the registrant’s most recently completed second fiscal quarter, was $7,249,894, computed by reference to the closing sales price for the registrant’s common stock on June 30, 2021, as reported on The OTC Pink Market.

 

As of March 15, 2022, there were 25,995,621 outstanding shares of the registrant’s common stock, par value $0.001 per share.

 

 

 

 

 

 

CalEthos, Inc.

 

Annual Report on Form 10-K

For the Fiscal-Year Ended December 31, 2021

 

TABLE OF CONTENTS

 

    Page
     
Cautionary Note Regarding Forward Looking Statements ii
     
PART I  
     
Item 1. Business. 4
Item 1A. Risk Factors. 6
Item 1B. Unresolved Staff Comments 7
Item 2. Properties. 7
Item 3. Legal Proceedings. 7
Item 4. Mine Safety Disclosures 7
     
PART II  
     
Item 5. Market for Common Equity, Related Shareholder Matters and Issuer Purchases of Equity Securities Market Information. 8
Item 6. Selected Financial Data. 8
Item 7. Management’s Discussion and Analysis of Financial Condition and Result of Operations. 8
Item 7A. Quantitative and Qualitative Disclosures about Market Risk. 12
Item 8. Financial Statements and Supplementary Data. 12
Item 9. Changes In and Disagreements with Accountants On Accounting and Financial Disclosure. 13
Item 9A. Controls and Procedures. 13
Item 9B. Other Information. 14
     
PART III  
     
Item 10. Directors, Executive Officers, Promoters and Control Persons; Compliance With Section 16(A) of the Exchange Act. 15
Item 11. Executive Compensation 17
Item 12. Security Ownership of Certain Beneficial Owners and Management 22
Item 13. Certain Relationships and Related Transactions and Director Independence. 23
Item 14. Principal Accountant Fees and Services. 23
     
Part IV  
     
Item 15. Exhibits 24

 

i

 

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

The statements contained in this report with respect to our financial condition, results of operations and business that are not historical facts are “forward-looking statements”. Forward-looking statements can be identified by the use of forward-looking terminology, such as “anticipate”, “believe”, “expect”, “plan”, “intend”, “seek”, “estimate”, “project”, “could”, “may” or the negative thereof or other variations thereon, or by discussions of strategy that involve risks and uncertainties. Management wishes to caution the reader of the forward-looking statements that any such statements that are contained in this report reflect our current beliefs with respect to future events and involve known and unknown risks, uncertainties and other factors, including, but not limited to, economic, competitive, regulatory, technological, key employees, and general business factors affecting our operations, markets, growth, services, products and other factors, some of which are described in this report and some of which are discussed in our other filings with the Securities and Exchange Commission. These forward-looking statements are only estimates or predictions. No assurances can be given regarding the achievement of future results, as actual results may differ materially as a result of risks facing our company, and actual events may differ from the assumptions underlying the statements that have been made regarding anticipated events.

 

Important factors to consider in evaluating any forward-looking statements include:

 

  our ability to complete the design and construction of our proposed product offerings;
     
  our ability to implement our business plan;
     
  our ability to attract key personnel;
     
  our ability to operate profitably;
     
  our ability to efficiently and effectively finance our operations, and/or purchase orders;
     
  inability to achieve future sales levels or other operating results;
     
  inability to raise additional financing for working capital;
     
  inability to efficiently manage our operations;
     
  the inability of management to effectively implement our strategies and business plans;
     
  the unavailability of funds for capital expenditures and/or general working capital;
     
  the fact that our accounting policies and methods are fundamental to how we report our financial condition and results of operations, and they may require management to make estimates about matters that are inherently uncertain;
     
  deterioration in general or regional economic conditions;
     
  changes in U.S. GAAP or in the legal, regulatory and legislative environments in the markets in which we operate;
     
  adverse state or federal legislation or regulation that increases the costs of compliance, or adverse findings by a regulator with respect to existing operations;

 

These risk factors should be considered in connection with any subsequent written or oral forward-looking statements that we or persons acting on our behalf may issue. All written and oral forward looking statements made in connection with this report that are attributable to our company or persons acting on our behalf are expressly qualified in their entirety by these cautionary statements. Given these uncertainties, we caution investors not to unduly rely on our forward-looking statements. We do not undertake any obligation to review or confirm analysts’ expectations or estimates or to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date of this report or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

 

Notwithstanding the above, Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), expressly state that the safe harbor for forward-looking statements does not apply to companies that issue penny stock. If, as now, we are considered to be an issuer of penny stock, the safe harbor for forward-looking statements may not apply to us at certain times.

 

Throughout this report, unless otherwise designated, the terms “we,” “us,” “our,” “the Company” and “our company” refer to CalEthos, Inc., a Nevada corporation. All amounts are in U.S. Dollars, unless otherwise indicated.

 

ii

 

 

Item 1.Business.

 

Corporate History and Recent Developments

 

We were incorporated pursuant to the laws of the State of Nevada on March 20, 2002 under the name Integrated Brand Solutions Inc., and on February 6, 2006, we changed our name to Upstream Biosciences Inc. From 2006 to December 2009, our company operated as a biotechnology company, and from 2010 until May 2013, our company had no operating business.

 

On May 24, 2013, our then majority stockholders sold their interests in our company to RealSource Acquisition Group, LLC, a Utah limited liability company, and Chesterfield Faring Ltd., a New York corporation, and on July 11, 2013, we changed our corporate name to RealSource Residential, Inc. Our initial business strategy in 2013 was to engage in various real estate related businesses. However, in 2016 we disposed of all of our real estate and other assets and continued operations as a public “shell” company.

 

On September 12, 2018, M1 Advisors, LLC, a Delaware limited liability company controlled by Michael Campbell, our current Chief Executive Officer and a director of our company (“M1 Advisors”), acquired a controlling interest in our company, and on December 20, 2018, we filed a Certificate of Amendment to our Articles of Incorporation with the Secretary of State of the State of Nevada to (i) change our corporate name from “RealSource Residential, Inc.” to “CalEthos, Inc.” and(ii) to increase our authorized shares of common stock from 4,000,000 shares to 100,000,000 shares. This amendment became effective immediately upon filing on December 20, 2018.

 

Prior to the outbreak of the 2020 COVID-19 pandemic we had intended to focus our business development efforts on building a chain of large-format cannabis superstores to serve the needs of the rapidly-growing Southern California cannabis market. We spent over two years putting together business opportunities for retail licenses, store leases and display agreements with brands while trying to find adequate financing to fund our business plan. However, at the end of 2020, we concluded that there were too many issues in the cannabis industry due to federal legalization and that adequate funding was not available for us to execute our plans. This caused us to review other business opportunities and prospects and, after many months of research, we determined there was a sizable opportunity to create high-performance computer systems for bitcoin miners as an alternative to the Chinese mining machine manufacturers that controlled that market in the bitcoin industry for the last 10 or more years.

 

In September 2021, we closed a convertible debt financing of $3.5 million to fund the initial phase of product development. In connection with such capital raise, our board of directors determined that we are no longer a shell company, as defined in Rule 12b-2 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). In connection with our change of business direction, we have started the process of changing our corporate name to AIQ Blockchain, Inc., which we intend to complete upon receipt of all requisite regulatory approvals.

 

On November 5, 2021, AIQ System Inc. (“AIQ”) was incorporated in Seoul, Republic of Korea. AIQ is authorized to issue 3 million shares of common stock. At the date of incorporation, 10,000 shares were issued to the Company for 100,000,000 Korean Won or approximately $89,000 for 100% ownership of AIQ.

 

AIQ is in the business of (1) developing and manufacturing computer chips and system, (2) importing and exporting semiconductors and electronic products, (3) wholesale and retail business of semiconductors and electronic products, and (4) any and all business activities incidental to the foregoing activities.

 

Plan of Operations

 

As of the filing of this Report, it is the intention of the board of directors for our company to develop and manufacture high-performance computer systems that are scalable, upgradeable, and cost effective for processing cryptocurrencies, tokens and blockchain-based transactions. In October 2021, Hyuncheol Kim joined our company as our Chief Technology Officer and we established AIQ Systems, a South Korea subsidiary company, and contracted an engineering design team to start the development of an ASIC chip, which we plan to incorporate into our planned industrial-grade immersion-cooled bitcoin mining system. Currently, the first phase of ASIC chip development is complete and we are now waiting for the release by one of the qualified semiconductor foundries of a low-voltage design kit that will allow us to move to the next phase of chip development. In parallel to setting up our South Korean subsidiary and organizing our engineering teams, we have been working with various semiconductor foundries to get a low-voltage 5 nanometer (nm) design kit that will allow us to produce a competitive system with good performance and low energy consumption. In addition, we have been working with various immersion-cooling system manufacturers to custom design a system around our ASIC chips that meets the performance and energy consumption requirements of large U.S. bitcoin mining companies.

 

4

 

 

Currently, there is a global chip shortage, which may continue causing a delay or efforts to secure a supply agreement with one of semiconductor foundry companies that have the technology to meet our design specifications. The continuation of this shortage will delay the completion of the development of our chip and bitcoin mining system, and ultimately the time when we are able to produce chips for our planned bitcoin mining systems.

 

We do not intend to directly manufacture any chips we design and use in our products. Instead, we intend to utilize what is known as a “fabless model”, whereby we will cooperate with world-class production partners for all phases of the manufacturing process of our ICs (chips), including wafer fabrication and packaging and testing. Under the fabless model, we will be able to leverage the expertise of industry leaders that are certified by the ISO in such areas as fabrication, assembly, quality control and assurance, reliability and testing. In addition, the fabless model will allow us to avoid many of the significant costs and risks associated with owning and operating various fabrication and packaging and testing facilities. Our fabrication partners will be responsible for procurement of the majority of the raw materials used in the production of our planned ICs. As a result, we can focus our resources on research and development, product design and additional quality assurances. We intend to work closely with leading global production partners, including the leading semiconductor foundries and IC fabrication companies.

 

Once we are able to get an adequate design kit from a foundry, the ASIC chip and immersion-cooled system development is expected to take from six to eight months to complete. At the final stages of development, we plan to complete a 1MW immersion-cooled bitcoin mining system for testing and customer demonstration. We are planning to design the systems to require over 50% less energy than conventional air-cooled bitcoin mining operations that currently make up over 90% of the global bitcoin mining fleet.

 

As we move through the chip and immersion-cooled bitcoin mining system development process, we intend to continue to refine and finalize the course of action needed to implement our business plan and operations. As a result, management has not fully determined our actual short-term or long-term capital requirements, which management expects to be substantial.

 

It is anticipated that we will incur expenses in the implementation of the business plan described herein, and such expenses will require substantial financing to complete the development of our ASIC chip and immersion-cooled bitcoin mining system and to achieve our goals. Our failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development plans, any commercialization efforts or other operations. We may not be able to secure financing on favorable terms, or at all, to meet our future capital needs. In addition, even if we are able to obtain sufficient funding to commence our business operations, we may need to pursue additional financing in the future to make expenditures and/or investments to support the growth of our business and may require additional capital to pursue our business objectives and respond to new competitive pressures, pay extraordinary expenses or fund our growth, including through acquisitions. Additional funds, however, may not be available when we need them on terms that are acceptable to us, or at all. If we are unable to obtain adequate financing or financing on terms satisfactory to us when we require it, our ability to commence our proposed business operations, to continue to grow and support our business and to respond to business challenges could be significantly limited.

 

We currently have only limited capital with which to pay these anticipated expenses. To fund our business plan going forward, we intend to raise funds from investors by issuing common stock, preferred stock and/or debt securities.

 

5

 

 

Competition

 

Cryptocurrency mining machines comprise the overwhelming majority of blockchain hardware. The global Bitcoin mining machine market is relatively concentrated with a few large players, most of which are China-based companies that have been in business for five or more years and control the majority of market share.

 

Our competitors include many well-known domestic and international players. We expect that competition in the Bitcoin mining industry will continue to be intense as we compete not only with existing players that have been focused on Bitcoin mining, but also new entrants that include well-established players in the semiconductor industry, and players who were not predisposed to this industry in the past. Some of these competitors may also have stronger brand names, greater access to capital, longer histories, longer relationships with their suppliers or customers and more resources than we do.

 

Intellectual Property

 

Our intellectual property consists of computer code for and FPGA simulation of an ASIC chip for bitcoin mining that is designed to be integrated in immersion-cooled bitcoin mining systems. We intend to rely on a combination of patent, copyright, trademark and trade secret laws in the United States and other jurisdictions, as well as contractual protections, to protect our proprietary technology. However, as of the date of this Report, we do not have any patents or registered trademarks.

 

We cannot provide any assurance that our proprietary rights with respect to our products will be viable or have value in the future since the validity, enforceability and type of protection of proprietary rights in software-related industries are uncertain and still evolving.

 

Despite our efforts to protect our proprietary rights, unauthorized parties may attempt to copy aspects of our products or to obtain and use information that we regard as proprietary. Policing unauthorized use of our products is difficult, and while we are unable to determine the extent to which piracy of our software products exists, software piracy can be expected to be a persistent problem. In addition, the laws of some foreign countries do not protect proprietary rights to as great an extent as do the laws of the United States, and effective copyright, trademark, trade secret and patent protection may not be available in those jurisdictions. Our means of protecting our proprietary rights may not be adequate to protect us from the infringement or misappropriation of such rights by others.

 

Further, in recent years, there has been significant litigation in the United States involving patents and other intellectual property rights, particularly in the software and Internet-related industries. We can become subject to intellectual property infringement claims as the number of our competitors grows and our products and services overlap with competitive offerings. These claims, even if not meritorious, could be expensive to defend and could divert management’s attention from operating our business. If we become liable to third parties for infringing their intellectual property rights, we could be required to pay a substantial award of damages and to develop non-infringing technology, obtain a license or cease selling the products that contain the infringing intellectual property. We may be unable to develop non-infringing technology or obtain a license on commercially reasonable terms, if at all.

 

Employees

 

We currently do not have any employees and our officers and directors are serving our company as consultants and independent contractors.

 

Item 1A.Risk Factors.

 

We are a smaller reporting company, as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information under this item.

 

6

 

 

Item 1B.Unresolved Staff Comments.

 

None.

 

Item 2.Properties.

 

We do not own any real property. Our executive office is located at 11753 Willard Avenue, Tustin, California 92782, in the office of Michael Campbell, our Chief Executive Officer. We are not charged rent for the use of this space. We believe our existing facilities are sufficient for our current operations.

 

Item 3.Legal Proceedings.

 

We know of no material active or pending legal proceeding against our company, nor are we involved as a plaintiff in any material proceeding or pending litigation, except as follows.

 

On January 3, 2022, a complaint was filed against our company in the Superior Court of California, County of Los Angeles titled Michael Sekula v. CalEthos Inc, Michael Campbell and Does 1-25 (Case No. 22STCV00121) for, among other matters, failure to pay wages, fraud and other wage-related claims. In the complaint, the plaintiff claims he worked under a consulting agreement as Vice President of Brand Management of our company and was to be paid $4,000 per month and to receive an option to purchase 50,000 shares of our common stock that was to vest quarterly over the term of the agreement. In the complaint, the plaintiff alleges that, on or around March 27, 2020, we ceased paying the plaintiff despite the plaintiff’s continuing efforts on behalf of our company and that we agreed to continue to accrue his monthly retainer amount until such time that we received at least $100,000 in funding. Plaintiff further alleges that he continued to work for our company for 38 additional weeks in reliance on our promise of payment. The plaintiff claims that our refusal to make the promised payments amounts to violations of the California labor laws and seeks damages in excess of $450,000.

 

We intend to dispute these claims and to defend this litigation vigorously. However, due to the inherent uncertainties of litigation, the ultimate outcome of this litigations is uncertain. An unfavorable outcome in this litigation could materially and adversely affect our business, financial condition and results of operations.

 

Item 4.Mine Safety Disclosures.

 

Not Applicable.

 

7

 

 

PART II

 

Item 5.Market For Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases Of Equity Securities.

 

Our common stock is listed for quotation on the OTC Pink Market under the trading symbol “BUUZ.” We have applied to FINRA to change our trading symbol to “AIQB”. Trading in our common stock in the over-the-counter market has been limited and the quotations set forth below are not necessarily indicative of actual market values. The following table sets forth, for the periods indicated, the high and low closing prices for each quarter within the last two fiscal years ended December 31, 2021 as reported by the quotation service operated by the OTC Markets Group. All quotations for the OTC Pink Market reflect inter-dealer prices, without retail mark-up, mark-down or commission and may not necessarily represent actual transactions.

 

Quarter Ended  High   Low 
December 31, 2021  $4.25   $1.97 
September 30, 2021   2.70    1.92 
June 30, 2021   3.30    0.40 
March 31, 2021   1.00    0.03 
December 31, 2020   0.02    0.02 
September 30, 2020   0.11    0.11 
June 30, 2020   0.11    0.11 
March 31 2020   1.25    1.25 

 

On March 15, 2022, the closing price for our common stock on the OTC Pink Market as reported by the quotation service operated by the OTC Markets Group was $1.96.

 

Transfer Agent

 

Nevada Agency and Transfer Company is the registrar and transfer agent for our common shares. Their address is 50 West Liberty, Suite 880 Reno, Nevada, 89501 Telephone: 775-322-0626, Facsimile: 775-322-5623.

 

Holders of Our Common Stock

 

As of March 15, 2022, there were 55 registered holders of record of our common stock. As of such date, 25,995,621 shares of common stock were issued and outstanding. The number of our shareholders of record excludes any estimate by us of the number of beneficial owners of shares held in street name, the accuracy of which cannot be guaranteed.

 

Dividend Policy

 

We have not declared or paid any cash dividends since inception. Although there are no restrictions that limit our ability to pay dividends on our common shares, we do not intend to pay dividends for the foreseeable future.

 

Item 6.Selected Financial Data.

 

We are a “smaller reporting company” as defined by Regulation S-K and as such, are not required to provide the information contained in this item pursuant to Regulation S-K.

 

Item 7.Management’s Discussion and Analysis of Financial Condition and Results of Operation.

 

The following discussion should be read in conjunction with our audited financial statements and the related notes that appear elsewhere in this Annual report. The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward looking statements. Factors that could cause or contribute to such differences include those discussed below and elsewhere in this Annual Report.

 

Our audited financial statements are stated in United States dollars and are prepared in accordance with United States generally accepted accounting principles.

 

8

 

 

Plan of Operations

 

As of the filing of this Report, it is the intention of the board of directors for our company to develop and manufacture high-performance computer systems that are scalable, upgradeable, and cost effective for processing cryptocurrencies, tokens and blockchain-based transactions. In November 2021, we established AIQ Systems, a subsidiary company in South Korea, and contracted an engineering design team to start the development of an ASIC chip, which we plan to incorporate into an industrial-grade immersion-cooled bitcoin mining system. Currently, the first phase of ASIC chip development is complete, we are now waiting for the release by one of the qualified semiconductor foundries of a low-voltage design kit that will allow us to move to the next phase of chip development. In parallel to chip development, we have been working with a number of vendors that can supply immersion-cooled systems that will be altered to accommodate the electrical distribution and cooling specifications we require to meet our system performance and energy consumption goals.

 

As we move through the chip and immersion-cooled bitcoin mining system development process, we will continue to refine and finalize the course of action needed to implement our business plan and operations. As a result, management has not fully determined our actual short-term or long-term capital requirements, which management expects to be substantial.

 

It is anticipated that we will incur expenses in the implementation of the business plan described herein, and such expenses will require substantial financing to complete the development of our ASIC chip and immersion-cooled bitcoin mining system and to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development plans, any commercialization efforts or other operations. We may not be able to secure financing on favorable terms, or at all, to meet our future capital needs. In addition, even if we are able to obtain sufficient funding to commence our business operations, we may need to pursue additional financing in the future to make expenditures and/or investments to support the growth of our business and may require additional capital to pursue our business objectives and respond to new competitive pressures, pay extraordinary expenses or fund our growth, including through acquisitions. Additional funds, however, may not be available when we need them on terms that are acceptable to us, or at all. If we are unable to obtain adequate financing or financing on terms satisfactory to us when we require it, our ability to commence our proposed business operations, to continue to grow and support our business and to respond to business challenges could be significantly limited.

 

We currently have only limited capital with which to pay these anticipated expenses. To fund our business plan going forward, we intend to raise funds from investors by issuing common stock, preferred stock and/or debt securities.

 

Results of Operations for the years ended December 31, 2021 and 2020

 

The following summary should be read in conjunction with our audited financial statements for the years ended December 31, 2021 and 2020.

 

  

For the years ended

December 31,

 
   2021   2020 
Revenues  $-   $- 
Operating Expenses          
Professional fees   6,095,000    340,000 
General and administrative   57,000    51,000 
Total Expenses   6,152,000    391,000 
Loss from operations   (6,152,000)   (391,000)
Financing costs   (597,000)   (227,000)
Loss on extinguishment of series A convertible preferred stock   -    (138,000)
Net loss  $(6,749,000)  $(756,000)

 

9

 

 

Revenue

 

For the years ended December 31, 2021 and 2020, we had no revenues.

 

Expenses

 

Our operating expenses increased from $391,000 in the year ended December 31, 2020 to $6,152,000 in the year ended December 31, 2021, which represented an increase of $5,761,000. The increase was attributable to (1) accretion of stock-based compensation related to the restricted stock awards issued to two consultants amounting to $4,791,000, (2) vested warrants amounting to $847,000, and (3) other expenses such as filing, legal and transfer agent fees and consulting fees paid to outside third parties in 2021.

 

Financing Costs

 

Our financing cost increased from $227,000 in the year ended December 31, 2020 to $597,000 in the year ended December 31, 2021, which represented an increase of $370,000. Financing costs increased due to the issuance of convertible promissory notes with associated interest and discount.

 

Loss on extinguishment of series A convertible preferred stock

 

For the year ended December 31, 2020, our loss on extinguishment of series A convertible preferred stock of approximately $138,000 was attributable to the difference between the fair value of the issued Notes as an extinguishment and book basis of the series A preferred stock, and the fair value of the warrants issued.

 

Liquidity and Capital Resources

 

Our financial position as of December 31 in each of the years indicated was as follows:

 

Working Capital

 

   As of December 31, 
   2021   2020 
Current assets  $3,054,000   $2,000 
Current liabilities   (3,632,000)   (1,325,000)
Working deficit  $(578,000)  $(1,323,000)

 

Our working capital improved from a $1,323,000 deficit as of December 31, 2020 to a deficit of $578,000 as of December 31, 2021 for a total change of $745,000. The improved working capital was due to the combined effect of the issuance of convertible debentures and the forgiveness of debt during the year.

 

Cash Flows

 

  

For the years ended

December 31,

 
   2021   2020 
Net cash used in operating activities  $(565,000)  $(182,000)
Net cash used in investing activities   (38,000)   - 
Net cash provided by financing activities   3,652,000    59,000 
Effect of exchange rate changes   (2,000)   - 
Change in cash during the period   3,047,000    (123,000)
Cash, beginning of period   -    123,000 
Cash, end of period  $3,047,000   $- 

 

10

 

 

Cash used in operating activities increased by approximately $382,000, which is predominantly related to the increase in our expenditures for filing fees, legal fees, transfer agent fees and consulting fees paid during the year.

 

In line with our current plan of operations, we made a $38,000 deposit to an engineering and design firm for the design and development work for our ASIC chip.

 

Cash provided by financing activities increased by $3,592,000 primarily due to the proceeds from the issuance of convertible debentures.

 

Going Concern

 

The audited financial statements included in this Report have been prepared on a going concern basis, which implies that our company will continue to realize its assets and discharge its liabilities and commitments in the normal course of business. We are presently in the development stage and, apart from our cash balances, have only limited assets. Our company has not generated revenues in the last two fiscal years, has never paid any dividends and is unlikely to pay dividends or generate earnings in the immediate or foreseeable future. The continuation of our company as a going concern is dependent upon: (i) continued financial support from our shareholders; (ii) the ability of our company to continue raising necessary debt or equity financing to achieve its operating objectives; and (iii) our ability to acquire assets and establish a business or merge or otherwise acquire business opportunities.

 

Our independent auditors included an explanatory paragraph in their report on our financial statements for the year ended December 31, 2021 regarding concerns about our ability to continue as a going concern. In addition, our financial statements contain further note disclosures in this regard. The implementation of our business plan is dependent upon our ability to continue raising sufficient new capital from equity or debt markets in order to fund our on-going operating losses and real estate acquisition activities. The issuance of additional equity securities could result in a significant dilution in the equity interests of our current stockholders.

 

Application of Critical Accounting Policies

 

The preparation of financial statements in conformity with United States generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying disclosures of our company. Although these estimates are based on management’s knowledge of current events and actions that our company may undertake in the future, actual results may differ from such estimates.

 

Principles of Consolidation

  

The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary from the formation date. All material intercompany transactions and balances have been eliminated in consolidation.

 

11

 

 

Foreign Currency Translation

 

The financial statements of our foreign subsidiary, for which the functional currency is the local currency, are translated into U.S. dollars using the exchange rate at the consolidated balance sheet date for assets and liabilities and a weighted-average exchange rate during the year for revenue, expenses, gains and losses. Translation adjustments are recorded as other comprehensive income (loss) within shareholders’ equity (deficit). Gains or losses from foreign currency transactions are recognized in the consolidated statements of operations.

 

Debt and Debt Discounts

 

In accordance with ASC 470-20, Debt with Conversion and Other Options, the Company first allocates the cash proceeds of the notes between the notes and the warrants on a relative fair value basis, secondly, proceeds are then allocated to the conversion feature.

 

The Company accounts for debt discounts originating in connection with conversion features that remain embedded in the related notes in accordance with ASC 470-20. These costs are classified on the balance sheet as a direct deduction from the debt liability. The Company amortizes these costs over the term of its debt agreements as financing cost in the consolidated statement of operations and comprehensive loss.

 

Stock-Based Compensation

 

We account for our stock-based compensation under ASC 718, “Compensation – Stock Compensation” using the fair value based method. Under this method, compensation cost is measured at the grant date based on the value of the award and is recognized over the service period, which is usually the vesting period. This guidance establishes standards for the accounting for transactions in which an entity exchanges it equity instruments for goods or services. It also addresses transactions in which an entity incurs liabilities in exchange for goods or services that are based on the fair value of the entity’s equity instruments or that may be settled by the issuance of those equity instruments.

 

We use the fair value method for equity instruments granted to non-employees and use the BSM model for measuring the fair value of options. The stock based fair value compensation is determined as of the date of the grant (measurement date) and is recognized over the vesting periods.

 

Recent Accounting Pronouncements

 

The Company’s management reviewed all recently issued accounting standard updates (“ASU’s”) not yet adopted by the Company and does not believe the future adoptions of any such ASU’s may be expected to cause a material impact on the Company’s consolidated financial condition or the results of its operations.

 

Off-Balance Sheet Arrangements

 

We have no significant off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial position, revenues and expenses, results of operations, liquidity, capital expenditures or capital resources that are material to stockholders.

 

Item 7A.Quantitative and Qualitative Disclosures About Market Risk.

 

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, we are not required to provide this information.

 

Item 8.Financial Statements and Supplementary Data.

 

Our financial statements and notes thereto and the reports of RBSM LLP, our independent registered public accounting firm, are set forth on pages F-1 through F-20 of this Report.

 

12

 

 

Item 9.Changes In and Disagreements With Accountants On Accounting and Financial Disclosure.

 

Not Applicable

 

Item 9A.Controls and Procedures.

 

Disclosure Controls and Procedures

 

As required by paragraph (b) of Rules 13a-15 or 15d-15 under the Exchange Act, our principal executive officer and principal financial officer evaluated our company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) as of the end of the period covered by this Annual Report on Form 10-K. Based on this evaluation, these officers concluded that as of the end of the period covered by this Annual Report on Form 10-K, these disclosure controls and procedures were not effective.

 

The conclusion that our disclosure controls and procedures were not effective was due to the presence of material weaknesses in internal control over financial reporting as identified below under the heading “Management’s Report on Internal Control Over Financial Reporting.” Management anticipates that such disclosure controls and procedures will not be effective until the material weaknesses are remediated.

 

Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within our company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdown can occur because of simple error or mistake.

 

Management’s Report on Internal Control Over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) for our company. Our internal control over financial reporting is designed to provide reasonable assurance, not absolute assurance, regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles in the United States of America. Internal control over financial reporting includes those policies and procedures that: (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles in the United States of America, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. In addition, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions and that the degree of compliance with the policies or procedures may deteriorate.

 

Our management, including our principal executive officer and principal financial officer, conducted an evaluation of the design and operation of our internal control over financial reporting as of December 31, 2021 based on the criteria set forth in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. This evaluation included review of the documentation of controls, evaluation of the design effectiveness of controls, testing of the operating effectiveness of controls and a conclusion on this evaluation. Based on this evaluation, our management concluded our internal control over financial reporting was not effective as at December 31, 2021 due to the following material weaknesses which are indicative of many small companies with small staff: (i) inadequate segregation of duties and effective risk assessment; (ii) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of both US GAAP and SEC guidelines; (iii) inadequate security and restricted access to computer systems including insufficient disaster recovery plans; and (iv) no written whistle-blower policy.

 

13

 

 

We plan to take steps to enhance and improve the design of our internal controls over financial reporting when our company has sufficient staff to allocate responsibilities. During the period covered by this Report, we have not been able to remediate the material weaknesses identified above. To remediate such weaknesses, we plan to implement the following changes once our financial resources will support the required staffing level: (i) appoint additional qualified personnel to address inadequate segregation of duties and ineffective risk management; (ii) adopt sufficient written policies and procedures for accounting and financial reporting and a whistle-blower policy; and (iii) implement sufficient security and restricted access measures regarding our computer systems and implement a disaster recovery plan. The remediation efforts set out in (i) and (iii) are largely dependent upon our company securing additional financing to cover the costs of implementing the changes required. If we are unsuccessful in securing such funds, remediation efforts may be adversely effected in a material manner.

 

This Report does not include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting. Our internal control over financial reporting was not subject to attestation by our independent registered public accounting firm pursuant to temporary rules of the Securities and Exchange Commission that permit us to provide only management’s report in this Report.

 

Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within our company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake.

 

Changes In Internal Control Over Financial Reporting.

 

There were no changes in our internal control over financial reporting during the year ended December 31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

Item 9B.Other Information.

 

None.

 

14

 

 

PART III

 

Item 10.Directors, Executive Officers and Corporate Governance.

 

Directors and Executive Officers

 

Our directors and executive officers, their ages and their positions held with our company are as follows:

 

Name   Age   Position(s) Held with the Company
Michael Campbell   66   Chairman of the Board and Chief Executive Officer
Dean S. Skupen   61   Chief Financial Officer
Hyuncheol Peter Kim   47   Chief Technical Officer
Steven Shum   51   Director
Sean Fontenot   38   Director

 

There are no arrangements between our directors and any other person pursuant to which our directors were nominated or elected for their positions. There are no family relationships among our directors or officers.

 

The following biographical information regarding our directors and executive officers.

 

Michael Campbell. Mr. Campbell became our Chief Executive Officer on September 12, 2018. For the past 20 years, Mr. Campbell has been the managing director of M1 Advisors LLC, a business advisory and consulting firm that has engineered, orchestrated and provided support and services to numerous private-to-public transitions, debt and equity financings and hyper-organic-growth and consolidation strategies in a wide range of industries. In addition, from December 2011 to February 2017, Mr. Campbell was the Chief Executive Officer and a director of NXChain, Inc., a publicly-traded start-up shell company in the cryptocurrency business that was a successor to AgriVest Americas Inc., a publicly-traded start-up shell company that sought to acquire cattle ranches in Brazil for conversion to soybean farms. Mr. Campbell spent the first 20 years of his career in the high-tech industry creating and operating various companies that included a computer retailing operation, data-storage peripheral company with three computer disk-drive manufacturing companies through joint ventures with the Russian, Chinese and Spanish governments, a specialized call-center company for telco broadband provisioning and an online broadband services ordering and order aggregation company with the Regional Bell Operating Companies.

 

Dean S. Skupen. Mr. Skupen became our Chief Financial Officer on September 12, 2018. Mr. Skupen is a business advisor who has provided various financial accounting services to, or acted as the Interim Chief Financial Officer for, a number of public companies since 2010. Prior to that, he was a Partner at Stonefield Josephson, Inc. (now Marcum, LLP), an accounting firm with five offices throughout California where he provided auditing and consulting services to public companies and to privately-held entrepreneurial companies transitioning to public ownership in diverse industries. Mr. Skupen graduated from the University of Southern California with a Bachelor of Science degree in Accounting. In addition, he is licensed as a Certified Public Accountant in the State of California.

 

Hyuncheol (Peter) Kim. Mr. Kim became our Chief Technical Officer on August 17, 2021, and President of our South Korean subsidiary, AIQ System Co. LTD, in October 2021. Mr. Kim has 20 years of experience in the high-tech industry working as an engineer and executive in chip development, software, communications, and IT services. Mr. Kim has a long-term relationship with the Korean IT industry through his involvement in projects with Samsung, LG, KT (Korea Telecom), Hyundai Electronics, and SK Hynix. Previously, he was the President of Aracore, a South Korean based Canadian ASIC chip development company that developed a 10nm SHA-256 ASIC chip for bitcoin mining machines. Mr. Kim has also been involved in chip developments that included a Protocol Packet Classification chip for network security equipment and a Network Processor Unit for a high-performance fiber backbone router and switch. Mr. Kim has been a Samsung Foundry VIP customer since 2018.

 

15

 

 

Steven M. Shum. Mr. Shum has been Chief Executive Officer of INVO Bioscience (NASDAQ: INVO) since October 2019 and a member of the board of directors of INVO Bioscience since October 2017. Prior to INVO Bioscience, Mr. Shun served as Chief Financial Officer of Eastside Distilling (NASDAQ: EAST) from October 2015 to November 2019. Prior to joining Eastside, Mr. Shum was an employee and a member of the board of directors of XZERES Corp. (OTCQB:XPWR), a global renewable energy company, from October 2008 until April 2015, where he served in various officer roles, including Chief Operating Officer from September 2014 until April 2015, Chief Financial Officer, Principal Accounting Officer and Secretary from April 2010 until September 2014 (under former name, Cascade Wind Corp) and Chief Executive Officer and President from October 2008 to August 2010. Mr. Shum also serves as the managing principal of Core Fund Management, LP and the Fund Manager of Core Fund, LP. He was a founder of Revere Data LLC (now part of Factset Research Systems, Inc.) and served as its Executive Vice President for four years, heading up the product development efforts and contributing to operations, business development, and sales. He spent six years as an investment research analyst and portfolio manager of D.N.B. Capital Management, Inc. His previous employers include Red Chip Review and Laughlin Group of Companies. He earned a B.S. in Finance and a B.S. in General Management from Portland State University in 1992.

 

Sean Fontenot. Mr. Fontenot has spent 20 years as a self-employed IT and network specialist and in 2017 became an executive producer of independent films. Mr. Fontenot is a technology enthusiast and film producer that manages a 5013c foundation dedicated to (i) educating the public on the history of video, arcade, and computer gaming - including the technical aspects and the impact of games on society; (ii) fostering public interest in software development and gaming hardware to enable technological growth and inspire the next generation of developers, and (iii) developing public space for action sports’ recreation - including mentoring youths and building programs designed to help bridge the gender gap in various action sports categories as well as underserved community members.

 

All of our officers are currently serving in such capacities as consultants to our company, and we presently have no employees. Mr. Campbell and Mr. Kim devote a majority of their time to advancing the company’s mission and executing our business plan. Management intends to spend as much time as is necessary to exercise its fiduciary duties as officers and directors of our company.

 

Involvement in Certain Legal Proceedings

 

None of our directors and executive officers have been involved in any of the following events during the past ten years:

 

  1. any bankruptcy petition filed by or against any business of which such person was a general partner or executive officer either at the time of the bankruptcy or within two years prior to that time;
     
  2. any conviction in a criminal proceeding or being subject to a pending criminal proceeding (excluding traffic violations and other minor offences);
     
  3. being subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining, barring, suspending or otherwise limiting his involvement in any type of business, securities or banking activities;
     
  4. being found by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission or the Commodity Futures Trading Commission to have violated a federal or state securities or commodities law, where the judgment has not been reversed, suspended, or vacated;
     
  5. being the subject of, or a party to, any federal or state judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended or vacated, relating to an alleged violation of (i) any federal or state securities or commodities law or regulation; (ii) any law or regulation respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease- and-desist order, or removal or prohibition order; or (iii) any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or being the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization (as defined in Section 3(a)(26) of the Securities Exchange Act of 1934), any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange Act), or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.

 

16

 

 

Director Independence

 

Our board of directors has reviewed the composition of our board of directors and the independence of each director. Based upon information requested from and provided by each director concerning his background, employment and affiliations, including family relationships, our board of directors has determined that each of Steven Shum and Sean Fontenot is an “independent director” as defined under Rule 5605(a)(2) of the Nasdaq Marketplace Rules. In making such determinations, our board of directors considered the relationships that each such non-employee director has with our company and all other facts and circumstances our board of directors deemed relevant in determining independence, including the beneficial ownership of our capital stock by each non-employee director.

 

Board Committees

 

We do not have a standing Audit Committee. We do not believe that the lack of an Audit Committee has had or will have any adverse effect on our financial statements, based upon current operations; however, our board of directors will consider establishing an Audit Committee of independent directors as the number of directors increases. Until such time, our board of directors will perform the duties of an Audit Committee including delegating an auditor firm and interacting with them.

 

We do not have a standing Compensation Committee. Presently, our executive officers, who constitute our only employees, do not take salary or other benefits from our company. As we continue to develop our initial products and commence selling such products on a wholesale or retail basis, we expect to increase the size of our board to include independent directors who will approve the compensation arrangements with our executive officers.

 

We also do not have a Nominating Committee as we have not adopted any procedures by which security holders may recommend nominees to our board of directors.

 

Code of Ethics

 

Effective March 28, 2022, our Board of Directors adopted an amended Code of Business Conduct and Ethics that applies to, among other persons, members of our board of directors, our company’s officers, contractors, consultants and advisors. We will provide a copy of the Code of Business Conduct and Ethics to any person without charge, upon request. Requests can be sent to our company at the address on the cover of this Annual Report.

 

Section 16(a) Beneficial Ownership Compliance

 

Section 16(a) of the Securities Exchange Act requires our executive officers and directors, and persons who own more than 10% of our common stock, to file reports regarding ownership of, and transactions in, our securities with the Securities and Exchange Commission and to provide us with copies of those filings. Based solely on our review of the copies of such forms received by us, or written representations from certain reporting persons, and without conducting any independent investigation of our own we believe that during the fiscal year ended December 31, 2021, all filing requirements applicable to our officers, directors and greater than 10% percent beneficial owners were complied with.

 

Item 11.Executive Compensation.

 

The following table sets forth all compensation awarded to, earned by or paid to the executive officers of our company during the years ended December 31, 2021 and 2020. No compensation was paid to any other executive officer of our company during such periods.

 

17

 

 

SUMMARY COMPENSATION TABLE

 

Name and Principal Position  Fiscal
Year
   Salary
($)
   Bonus
($)
   Stock Awards ($)   Option Awards
($)
   Non-Equity Incentive Plan Compensation
($)
   Nonqualified Deferred Compensation Earnings
($)
   All Other Compensation ($)   Total
($)
 
                                     
Michael Campbell(1)   2021    -    -    $2,895,000(1)    -    -    -    $200,064(2)  $3,095,064(2)
Chief Executive Officer   2020    -    -    -    -                -    -    180,000(2)   180,000(2)
Dean S. Skupen   2021    -     -     75,000     -     -              -     30,000(3)   105,000(3)
Chief Financial Officer   2020    -     -          -    -    -         
Hyuncheol Peter Kim   2021    -     -     19,300,000(1)    -    -    -    

66,664

(4)   

19,366,664

(4)
    2020                                       

 

 

(1) Represents a restricted stock share award that vests as to 50% of the shares upon the completion of the first two phases of chip development, which include the “FPGA Simulation” and “Tape Out” of our planned 5 nanometer ASIC chip, and will vest as to the remaining 50% of the shares upon the completion of the next two phases of the chip development that include the completion of the Foundry Mask for production in the semiconductor foundry and initial production run of chips and the completion of a bitcoin mining system ready for sale to customers; provided, however, that if we do not raise sufficient capital to complete the Foundry Mask, initial production run of chips and completion of a bitcoin mining system ready for sale to customers within six months of completing the first two phases of development, then all unvested shares will vest upon the completion of the first two milestones. Notwithstanding the foregoing, no shares will vest on any vesting date if the consultant is no longer providing services to us as an employee or consultant.
(2) Represents amounts earned by Mr. Campbell under his consulting agreement.
(3) Represents amounts earned by Mr. Skupen under his consulting agreement. All 2020 compensation was accrued but deferred to 2021.
(4) Represents amounts earned by Mr. Kim under his consulting agreement. Mr. Kim commenced his consulting relationship with our company in September 2021.

 

Consulting Agreements

 

On August 17, 2021, we entered into consulting agreements with M1 Advisors LLC, a limited liability company controlled by Michael Campbell, our sole director and Chief Executive Officer (“M1 Advisors”), and Hyuncheol Kim, pursuant to which M1 Advisors agreed to continue to provide consulting services to our company and to cause Mr. Campbell to serve as our Chief Executive Officer, and Mr. Kim agreed to provide consulting services and to serve as our Chief Technology Officer. The term of M1 Advisor’s agreement is for a period of one year, which will automatically renew unless either party gives written notice to the other of termination not less than 30 days prior to the then-current term. The consulting agreement of Mr. Kim will continue so long as we are continuing with our research and development efforts to develop a five nanometer ASIC chip for bitcoin mining machines and a completed bitcoin mining system (the “Project”), and thereafter will continue for a one-year term, which will automatically renew unless either party gives written notice to the other of termination not less than 30 days prior to the then-current term. Pursuant to such agreements, each of M1 Advisors and Mr. Kim will be paid consulting fees at the rate of $200,000 per annum for providing as many hours of work as is necessary and reasonably required to meet our development schedule and achieve the mutually agreed to goals of our company. .

 

In addition, pursuant to such consulting agreements, M1 Advisors was granted a restricted stock award of 1,500,000 shares of common stock and Mr. Kim was granted a restricted stock award of 10,000,000 shares of common stock. Such restricted stock awards vest as to 50% of the shares upon the completion of the first two phases of chip development, which include the “FPGA Simulation” and “Tape Out” of our planned 5 nanometer ASIC chip, and will vest as to the remaining 50% of the shares upon the completion of the next two phases of the chip development that include the completion of the Foundry Mask for production in the semiconductor foundry and initial production run of chips and the completion of a bitcoin mining system ready for sale to customers; provided, however, that if we do not raise sufficient capital to complete the Foundry Mask, initial production run of chips and completion of a bitcoin mining system ready for sale to customers within six months of completing the first two phases of development, then all unvested shares will vest upon the completion of the first two milestones. Notwithstanding the foregoing, no shares will vest on any vesting date if the consultant is no longer providing services to us as an employee or consultant.

 

On October 20, 2018, we entered into a consulting agreement with DSS Consulting Corporation, a corporation controlled by Dean Skupen, our Chief Financial Officer (“DSS Consulting”), pursuant to which DSS Consulting agreed to continue to provide consulting services to our company and to cause Mr. Skupen to serve as our Chief Financial Officer. The agreement with DSS Consulting will continue until terminated by either party. Pursuant to such agreement, DSS Consulting was issued 250,000 shares of common stock in March 2019 and DSS Consulting will be paid a monthly consulting fee in the amount of $5,000.

 

Each of our consulting agreements contains customary confidentiality restrictions and work-product provisions, as well as customary non-competition covenants and non-solicitation covenants with respect to our employees, consultants and customers.

 

Equity Compensation Plan Information

 

The following table provides information as of December 31, 2021, regarding our compensation plans under which equity securities are authorized for issuance:

 

Plan category   Number of
Securities to
be Issued
Upon
Exercise of
Outstanding
Options,
Warrants
and Rights
    Weighted-
Average
Exercise
Price of
Outstanding
Options,
Warrants and
Rights
    Number of
Securities
Remaining
Available
for Future
Issuance
Under Equity
Compensation
Plans (Excluding
Securities
Reflected
in Column (a))
 
    (a)    (b)    (c) 
2021 Equity compensation plan approved by security holders       —     2,500,000  
Equity compensation plans not approved by security holders       —      
Total      $    2,500,000  

 

2021 Equity Incentive Plan

 

On October 4, 2021, we adopted our 2021 Equity Incentive Plan (the “Equity Plan”) to provide an additional means to attract, motivate, retain and reward selected employees and other eligible persons. Our stockholders also approved the Equity Plan on October 4, 2021. Employees, officers, directors and consultants that provide services to us or one of our subsidiaries were eligible to receive awards under the Equity Plan. Awards under the Equity Plan are issuable in the form of incentive or nonqualified stock options, stock appreciation rights, stock bonuses, restricted stock, stock units and other forms of awards including cash awards.

 

As of December 31, 2021, no equity grants had been made under the Equity Plan, and 2,500,000 shares authorized under the Equity Plan remained available for award purposes.

 

Purpose. The purpose of the Equity Plan is to further and promote the interests of our company and its stockholders by enabling us to attract, retain and motivate employees, directors and consultants, or those who will become employees, directors or consultants, and to align the interests of those individuals with the interests of our stockholders.

 

Administration. The Equity Plan will be administered by an independent compensation committee appointed by the Board (the “Compensation Committee”), which will have general administrative authority for the Equity Plan. In the event that the Board has not appointed the Compensation Committee, then the Board shall have all the powers of the Compensation Committee under the Equity Plan. The Compensation Committee may delegate certain limited authority to one or more of our senior executive officers to grant awards to employees who are not subject to Section 16 of the Exchange Act. Additionally, the Compensation Committee may designate persons other than members of the Compensation Committee to carry out the day-to-day ministerial administration of the Equity Plan (other than with regard to the selection for participation in the Equity Plan and/or the granting of any awards to participants) under such conditions and limitations as prescribed by the Compensation Committee (the appropriate acting body, be it the Compensation Committee, the Board, or an executive officer within his or her delegated authority, is referred to herein as the “Administrator”). The Administrator’s determinations under the Equity Plan need not be uniform and may be made selectively among the Equity Plan’s participants, whether or not such participants are similarly situated.

 

18

 

 

The Administrator has broad authority under the Equity Plan with respect to award grants including, without limitation, the authority to:

 

select the Equity Plan’s participants;

 

make awards in such amounts and form as the Administrator shall determine;

 

impose such restrictions, terms and conditions upon such awards as the Administrator shall deem appropriate; and

 

correct any technical defect(s) or technical omission(s), or reconciling any technical inconsistency(ies), in the Equity Plan and/or any award agreement.

 

Eligibility. Persons eligible to receive awards under the Equity Plan include employees, directors and consultants, or those who will become employees, directors or consultants, of our company and/or its subsidiaries. Notwithstanding the above, incentive stock options may only be granted under the Equity Plan to our employees.

 

Authorized Shares. The maximum number of shares of common stock that may be initially issued or transferred pursuant to awards under the Equity Plan shall not exceed 2,500,000 shares, all of which may be issued as any type of award permitted under the Equity Plan, including, but not limited to, incentive stock options.

 

Types of Awards. The Equity Plan authorizes awards of stock options and restricted shares of common stock.

 

A stock option is the right to purchase shares of common stock at a future date at a specified price per share (the “Exercise Price”). The per share Exercise Price of an option generally may not be less than the fair market value of a share of common stock on the date of grant. The maximum term of an option is ten years from the date of grant. An option may either be an incentive stock option or a nonqualified stock option. Incentive stock option benefits are taxed differently from nonqualified stock options, as described under “Federal Income Tax Consequences of Awards Under the Plan” below. Incentive stock options are also subject to more restrictive terms and are limited in amount by the U.S. Internal Revenue Code (the “Code”) and the Equity Plan. Incentive stock options may only be granted to employees of our company or a subsidiary.

 

Restricted shares are shares of common stock granted to Equity Plan participants, subject to such restrictions, terms and conditions, if any, as the Administrator deems appropriate, including, without limitation, (a) restrictions on the sale, assignment, transfer, hypothecation or other disposition of such shares, (b) the requirement that the participant deposit such shares with our company while such shares are subject to such restrictions, and (c) the requirement that such shares be forfeited upon termination of employment or service with our company for any reason or for specified reasons within a specified period of time or for other reasons (including, without limitation, the failure to achieve designated performance goals). Upon satisfaction or lapse of the applicable restrictions, terms, and conditions, subject to applicable securities laws, the participant will receive shares of common stock in exchange for such restricted shares.

 

Dividend Equivalents; Deferrals. The Administrator may provide for the deferred payment of awards and may determine the other terms applicable to deferrals. The Administrator may provide that awards under the Equity Plan earn dividends or dividend equivalents based on the amount of dividends paid on outstanding shares of common stock.

 

Assumption and Termination of Awards. Generally, and subject to limited exceptions set forth in the Equity Plan, if we dissolve or undergo certain corporate transactions such as a merger, business combination, or other reorganization, or a sale of substantially all of its assets, all awards then-outstanding under the Equity Plan will become fully vested or paid, as applicable, and will terminate or be terminated in such circumstances, unless the Administrator provides for the assumption, substitution or other continuation of the award. The Administrator also has the discretion to establish other change in control provisions with respect to awards granted under the Equity Plan. For example, the Administrator could provide for the acceleration of vesting or payment of an award in connection with a corporate event that is not described above and provide that any such acceleration shall be automatic upon the occurrence of any such event.

 

19

 

 

Clawback. We may cancel any award under the Equity Plan, require reimbursement from a participant, and effect any other right of recoupment of equity or other compensation provided under the Equity Plan in accordance with any clawback policies adopted by us.

 

Transfer Restrictions. Subject to certain exceptions contained in the Equity Plan, awards under the Equity Plan generally are not transferable by the recipient other than by will or the laws of descent and distribution and are generally exercisable, during the recipient’s lifetime, only by the recipient. Any amounts payable or shares issuable pursuant to an award generally will be paid only to the recipient or the recipient’s beneficiary or representative. The Administrator has discretion, however, to establish written conditions and procedures for the transfer of awards to other persons or entities, provided that such transfers comply with applicable federal and state securities laws.

 

Adjustments. As is customary in incentive plans of this nature, each share limit and the number and kind of shares available under the Equity Plan and any outstanding awards, as well as the exercise or purchase prices of awards, and performance targets under certain types of performance-based awards, are subject to adjustment in the event of certain reorganizations, mergers, combinations, recapitalizations, stock splits, stock dividends, or other similar events that change the number or kind of shares outstanding, and extraordinary dividends or distributions of property to the stockholders.

 

No Limit on Other Authority. The Equity Plan does not limit the authority of the Board or any committee to grant awards or authorize any other compensation, with or without reference to the our common stock, under any other plan or authority.

 

Termination of or Changes to the Equity Plan. The Board may amend or terminate the Equity Plan at any time and in any manner. Stockholder approval for an amendment will be required only to the extent then required by applicable law or any applicable listing agency or required under Sections 422 or 424 of the Code to preserve the intended tax consequences of the plan. For example, stockholder approval will be required for any amendment that proposes to increase the maximum number of shares that may be delivered with respect to awards granted under the Equity Plan (adjustments as a result of stock splits or similar events will not, however, be considered an amendment requiring stockholder approval). Unless terminated earlier by the Board, the authority to grant new awards under the Equity Plan will terminate on October 4, 2031. Outstanding awards, as well as the Administrator’s authority with respect thereto, generally will continue following the expiration or termination of the Equity Plan. Generally speaking, outstanding awards may be amended by the Administrator (except for a repricing), but the consent of the award holder is required if the amendment (or any Equity Plan amendment) materially and adversely affects the holder.

 

Federal Income Tax Consequences of Awards under the Plan.

 

The U.S. federal income tax consequences of the Equity Plan under current federal law, which is subject to change, are summarized in the following discussion of the general tax principles applicable to the Equity Plan. This summary is not intended to be exhaustive and, among other considerations, does not describe the deferred compensation provisions of Section 409A of the Code to the extent an award is subject to and does not satisfy those rules, nor does it describe certain elections under the Code (such as an election under Code Section 83(b)), alternative minimum tax, or state, local, or international tax consequences.

 

With respect to nonqualified stock options, we are generally entitled to deduct, and the participant recognizes taxable income in an amount equal to the difference between the option exercise price and the fair market value of the shares at the time of exercise. With respect to incentive stock options, we are generally not entitled to a deduction nor does the participant recognize income at the time of exercise, although the participant may be subject to the U.S. federal alternative minimum tax. Upon a disposition of shares acquired by exercise of an incentive stock option before the end of the applicable incentive stock option holding periods, the participant generally must recognize ordinary income equal to the lesser of (i) the fair market value of the shares at the date of exercise minus the exercise price or (ii) the amount realized upon the disposition of the incentive stock option shares minus the exercise price. Otherwise, a participant’s disposition of shares acquired upon the exercise of an option (including an incentive stock option for which the incentive stock option holding periods are met) generally will result in only capital gain or loss.

 

20

 

 

With respect to restricted shares, we are generally entitled to deduct and the participant recognizes taxable income in an amount equal to the excess of the fair market value over the price paid (if any) only at the time the restrictions lapse (unless the recipient elects to accelerate recognition as of the date of grant).

 

If an award is accelerated under the Equity Plan in connection with a “change in control” (as this term is used under the Code), we may not be permitted to deduct the portion of the compensation attributable to the acceleration (“parachute payments”) if it exceeds certain threshold limits under the Code (and certain related excise taxes may be triggered).

 

We have the authority and the right to deduct or withhold, or require a participant to remit to us, an amount sufficient to satisfy any income, payroll, and other taxes (including, without limitation, pursuant to the Federal Insurance Contributions Act and the Federal Unemployment Tax Act) to the extent required by law to be withheld with respect to any taxable event concerning a participant arising as a result of an award under the Equity Plan.

 

Outstanding Equity Awards At Annual Period End

 

The following table sets forth outstanding equity awards to our named executive officers as of December 31, 2021.

 

   Option Awards   Stock Awards 
Name (a)  Number of
Securities
Underlying
Unexercised
Options (#)
Exercisable
(b)
   Option
Exercise
Price
(e)
   Option
Expiration
Date
(f)
  Number of
Shares or
Units of
Stock that
have not
Vested
(g)
   Market
Value of
Shares or
Units of
Stock that
have not
Vested
(h)
 
Michael Campbell                       
Restricted Stock Grant(1)      $   N/A   1,500,000   $2,895,000 
                        
Hyuncheol Peter Kim                       
Restricted Stock Grant(1)      $   N/A   10,000,000   $19,300,000 

 

 

  (1) Such restricted stock awards vest as to 50% of the shares upon the completion of the first two phases of chip development, which include the “FPGA Simulation” and “Tape Out” of our planned 5 nanometer ASIC chip, and will vest as to the remaining 50% of the shares upon the completion of the next two phases of the chip development that include the completion of the Foundry Mask for production in the semiconductor foundry and initial production run of chips and the completion of a bitcoin mining system ready for sale to customers; provided, however, that if we do not raise sufficient capital to complete the Foundry Mask, initial production run of chips and completion of a bitcoin mining system ready for sale to customers within six months of completing the first two phases of development, then all unvested shares will vest upon the completion of the first two milestones. Notwithstanding the foregoing, no shares will vest on any vesting date if the consultant is no longer providing services to us as an employee or consultant.

 

Aggregated Option Exercises

 

There were no options exercised by any officer or director of our company during the year ended December 31, 2021.

 

Directors Compensation

 

No director compensation was paid during the years ended December 31, 2021 and 2020 in the form of cash expenses, stock awards, option awards, non-equity incentive plan compensation, pension value and nonqualified deferred compensation earnings or any other type of compensation. We do not currently pay any cash fees to our directors, nor do we pay directors’ expenses in attending board meetings.

 

Employment Agreements

 

We are not presently a party to any employment agreements.

 

21

 

 

Pension and Retirement Plans

 

Currently, we do not offer any annuity, pension or retirement benefits to be paid to any of our officers, directors or employees, in the event of retirement.

 

Item 12.Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

 

The following table sets forth, as of March 15, 2022, the names, addresses and number of shares of common stock beneficially owned by (i) all persons known to our management to be beneficial owners of more than 5% of the outstanding shares of our common stock, (ii) each director of our company, (iii) each named Executive Officer and (iv) all executive officers and directors of our company as a group (except as indicated, each beneficial owner listed exercises sole voting power and sole dispositive power over the shares beneficially owned):

 

   Amount and     
   Nature of     
Name and Address of  Beneficial   Percent 
Beneficial Owner  Ownership   of Class(1) 
M1 Advisors LLC(2)   8,954,199    46.84%
(Michael Campbell)(2)   8,954,199    46.84%
Dean Skupen(3)   325,000    1.70%
Hyuncheol Peter Kim   -    

-

%
Steven Shum   4,655    0.02%
Sean Fontenot(4)   4,620,000    24.17%
All executive officers and directors as a group
(5 persons)
   

13,903,854

    72.73%
5% Stockholders:          
David Unsworth (5)   1,435,000    7.51%
The Cooper Family Living Trust Dtd 7/20/98 (6)   1,079,000    5.65%

 

(1) As of March 15, 2022, there were 25,995,621 shares of common stock outstanding. Except as indicated in the footnotes to this table, we believe that all persons named in the table have sole voting and investment power with respect to all common stock shown as beneficially owned by them. In accordance with the rules of the Securities and Exchange Commission (the “Commission”), a person or entity is deemed to be the beneficial owner of common stock that can be acquired by such person or entity within sixty (60) days upon the exercise of options or warrants or other rights to acquire common stock. Each beneficial owner’s percentage ownership is determined by assuming that options and warrants that are held by such person (but not those held by any other person) and which are exercisable within sixty (60) days have been exercised. The inclusion herein of such shares listed as beneficially owned does not constitute an admission of beneficial ownership.
(2) Represents shares of common stock owned of record by M1 Advisors LLC, a company controlled by Michael Campbell. The address of Michael Campbell and M1 Advisors LLC is 11753 Willard Avenue, Tustin, CA 92782. Mr. Campbell has sole voting and investment power over the shares held by M1 Advisors LLC.
(3) Represents shares of common stock owned of record by DSS Consulting Corporation, a company controlled by Dean Skupen. DSS Consulting Corporation’s address is 2945 Townsgate Road, Suite 200, West Lake Village CA 91361. Mr. Skupen has sole voting and investment power over the shares held by DSS Consulting Corporation.
(4) Represents 3,080,000 shares of common stock issuable upon the conversion of a convertible note, and 1,540,000 shares of common stock issuable upon the exercise of warrants, owned of record by Nanosha Investments, LLC, a company controlled by Sean Fontenot. The address of Nanosha Investments, LLC is 1202 Walnut Avenue, Long Beach, CA 90813. Mr. Fontenot has sole voting and investment power over the securities held by Nanosha Investments, LLC.
(5) David Unsworth’s address is 246 Bayview Avenue, Belvedere CA 94920.
(6) Piers and Sally Cooper are the trustees of The Cooper Family Living Trust Dated 7/20/98. The address of the trust is 452 Lakeview Way, Emerald Hills, CA 94062.

 

22

 

 

Item 13.Certain Relationships and Related Transactions, and Director Independence.

 

To the best of our knowledge, except as set forth below, during the last fiscal year, there were no material transactions, or series of similar transactions, or any currently proposed transactions, or series of similar transactions, to which we were or are to be a party, in which the amount involved exceeds $120,000 or one percent of the average total assets at year end for each of the last two fiscal years, and in which any director or executive officer, or any security holder who is known by us to own of record or beneficially more than 5% of any class of our common stock, or any member of the immediate family of any of the foregoing persons, has an interest.

 

Item 14.Principal Accountant Fees And Services.

 

Audit Fees

 

The aggregate fees billed for professional services rendered by RBSM LLP, our principal accountants for the years ended December 31, 2021 and 2020, for the audit of financial statements, quarterly reviews of our interim financial statements and services normally provided by the independent accountant in connection with statutory and regulatory filings or engagements for these periods were as follows:

 

   For the Years ended December 31, 
   2021   2020 
Audit Fees and Audit Related Fees  $50,000   $15,000 
Tax Fees        
All Other Fees        
Total  $50,000   $15,000 

  

In the above table, “audit fees” are fees billed by our company’s external auditor for services provided in auditing our company’s financial statements for the periods indicated above. “Audit-related fees” are fees not included in audit fees that are billed by the auditor for assurance and related services, including quarterly reviews, that are reasonably related to the performance of the audit of our company’s financial statements. “Tax fees” are fees billed by the auditor for professional services rendered for tax compliance, tax advice and tax planning. “All other fees” are fees billed by the auditor for products and services not included in the foregoing categories.

 

Our board of directors pre-approves all services provided by our independent auditors. All of the above services and fees were reviewed and approved by our board of directors either before or after the respective services were rendered.

 

23

 

 

PART IV

 

Item.15. Exhibits, Financial Statement Schedules.

 

Exhibit    
Number   Description
     
3.1   Articles of Incorporation (incorporated by reference to Exhibit 3.1 to our Registration Statement on Form SB-2 filed on July 5, 2002).
     
3.2   Certificate of Change filed with the Nevada Secretary of State on December 20, 2005 (incorporated by reference to Exhibit 99.1 to our Current Report on Form 8-K filed on December 29, 2005).
     
3.3   Articles of Merger filed with the Nevada Secretary of State on February 6, 2006 (incorporated by reference to Exhibit 2.1 to our Current Report on Form 8-K filed on February 9, 2006).
     
3.4   Certificate of Amendment filed with the Nevada Secretary of State on November 27, 2006 (incorporated by reference from Exhibit 99.1 to Current Report on Form 8-K filed on November 30, 2006).
     
3.5   Articles of Merger filed with the Nevada Secretary of State on February 6, 2006 (incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K filed on February 9, 2006).
     
3.6   Articles of Merger filed with the Nevada Secretary of State on July 15, 2013 (incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K filed on July 19, 2013).
     
3.7   Certificate of Change filed with the Nevada Secretary of State on August 28, 2018 (incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K filed on August 29, 2018).
     
3.8   Certificate of Designation of Series A Preferred Stock filed with the Nevada Secretary of State on September 12, 2018 (incorporated by reference to Exhibit 3.2 to our Current Report on Form 8-K filed on September 14, 2018).
     
3.9   Amendment to Certificate of Designation After Issuance of Class or Series filed with the Nevada Secretary of State on October 29, 2018 (incorporated by reference to Exhibit 2.1 to our Current Report on Form 8-K filed on October 29, 2018).
     
3.10   Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to our Current Report on Form 8-K filed on July 19, 2013).
     
10.1   2021 Equity Incentive Plan (incorporated by reference to Exhibit Annex A to our Schedule 14C Information Statement filed on October 21, 2021).
     
10.2   Form of OID Convertible Promissory Note due February 28, 2021 (incorporated by reference to Exhibit 10.4 to our Annual Report on Form 10-K filed on March 30, 2021).
     
10.3   Form of Series A Warrant (incorporated by reference to Exhibit 10.5 to our Annual Report on Form 10-K filed on March 30, 2021).
   
10.4   Form of OID Promissory Note dated September 15, 2021 (incorporated by reference to Exhibit 4.1 to our Current Report on Form 8-K filed on September 21, 2021).
     
10.5   Form of Series A Warrant dated September 15, 2021 (incorporated by reference to Exhibit 4.2 to our Current Report on Form 8-K filed on September 21, 2021).

 

24

 

 

Exhibit    
Number   Description
10.6   Restricted Share Aware Agreement dated August 17, 2021 between CalEthos Inc. and M1 Advisors LLC (incorporated by reference to Exhibit 4.3 to our Current Report on Form 8-K filed on September 21, 2021).
     
10.7   Restricted Share Aware Agreement dated August 17, 2021 between CalEthos Inc. and Hyuncheol Kim (incorporated by reference to Exhibit 4.4 to our Current Report on Form 8-K filed on September 21, 2021).
     
10.8   Warrant dated September 15, 2021 of CalEthos to Mireya Lange (incorporated by reference to Exhibit 4.5 to our Current Report on Form 8-K filed on September 21, 2021).
     
10.9   Consulting Agreement dated as of August 17, 2021 between CalEthos Inc. and M1 Advisors LLC (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on September 21, 2021).
     
10.10   Consulting Agreement dated as of August 17, 2021 between CalEthos Inc. an Hyuncheol Kim (incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K filed on September 21, 2021).
     
10.11   Registration Rights Agreement dated as of September 15, 2021 between CalEthos Inc. and Nonosha Investments LLC (incorporated by reference to Exhibit 10.3 to our Current Report on Form 8-K filed on September 21, 2021).
     
10.12   Consulting Agreement dated as of October 10, 2018 between CalEthos Inc. and DSS Consulting Corporation.
     
14   Code of Conduct and Ethics of CalEthos Inc.
     
31.1   Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.***
     
31.2   Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.***
     
32.1   Certification of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.***
     
101.ins**   Inline XBRL Instance Document
     
101.xsd**  

Inline XBRL Taxonomy Extension Schema Document

     
101.cal**   Inline XBRL Taxonomy Extension Calculation Linkbase Document
     
101.def**   Inline XBRL Taxonomy Extension Definition Linkbase Document
     
101.lab**   Inline XBRL Taxonomy Extension Label Linkbase Document
     
101.pre**   Inline XBRL Taxonomy Extension Presentation Linkbase Document
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

** Furnished. Not filed. Not incorporated by reference. Not subject to liability.
*** A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

25

 

 

SIGNATURES

 

Pursuant to the requirements of the Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on the 31st day of March 2022.

 

  CalEthos, Inc.
     
  By: /s/ Michael Campbell
  Name: Michael Campbell
  Title: Chief Executive Officer
    (Principal Executive Officer)

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

Signature   Title   Date
         
/s/ Michael Campbell   Chief Executive Officer and Director   Date: March 31, 2022
Michael Campbell   (Principal Executive Officer)    
         
/s/ Dean S. Skupen   Chief Financial Officer   Date: March 31, 2022
Dean S. Skupen   (Principal Accounting Officer)    
         
/s/ Sean Fontenot   Director   Date: March 31, 2022
Sean Fontenot   (Director)    
         
/s/ Steven Shum   Director   Date: March 31, 2022
Steven Shum   (Director)    

 

26

 

 

CalEthos, Inc.

For the Years Ended December 31, 2021 and 2020

 

Index to the Consolidated Financial Statements

 

Contents Page(s)
   
Report of Independent Registered Public Accounting Firm PCAOB ID 587 F-2
   
Consolidated Balance Sheets as of December 31, 2021 and 2020 F-3
   
Consolidated Statements of Operations and Comprehensive Loss for the Years ended December 31, 2021 and 2020 F-4
   
Consolidated Statements of Changes in Stockholders’ Deficit for the Years ended December 31, 2021 and 2020 F-5
   
Consolidated Statements of Cash Flows for the Years ended December 31, 2021 and 2020 F-6
   
Notes to the Consolidated Financial Statements F-7

 

 

F-1

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Board of Directors and Stockholders of

CalEthos, Inc

 

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheets of CalEthos, Inc., (the Company) as of December 31, 2021 and 2020, and the related consolidated statements of operations and comprehensive loss, stockholders’ deficit and cash flows for each of the years in the two year period ended December 31, 2021, and the related notes (collectively referred to as the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the consolidated results of its operations and its cash flows for each of the years in the two year period ended December 31, 2021, in conformity with accounting principles generally accepted in the United States of America.

 

The Company’s Ability to Continue as a Going Concern

 

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has an accumulated deficit, recurring losses and expects future losses that raise substantial doubt about the Company’s ability to continue as a going concern. Management’s evaluation of the events and conditions and management’s plans regarding these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Basis for Opinion

 

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Critical Audit Matters

 

Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (i) relate to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.

 

RBSM LLP

 

We have served as the Company’s auditor since 2018

 

 /s/ RBSM LLP 

 

Larkspur, CA  
March 31, 2022  

 

F-2

 

 

CalEthos, Inc.

Consolidated Balance Sheets

As of December 31,

 

           
   2021   2020 
         
ASSETS          
Current assets          
Cash and cash equivalents  $3,047,000   $ 
Prepaid expenses   7,000    2,000 
Total current assets   3,054,000    2,000 
           
Other assets   38,000    - 
Total assets  $3,092,000   $2,000 
           
LIABILITIES AND STOCKHOLDERS’ DEFICIT          
Current liabilities          
Accounts payable and accrued expenses  $434,000   $611,000 
Notes payable, net   111,000    11,000 
Convertible promissory notes, net   3,087,000    703,000 
Total liabilities   3,632,000    1,325,000 
           
Commitments and contingencies (Note 6)        
           
Stockholders’ deficit          
Series A convertible preferred stock, par value $0.001, 3,600,000 shares authorized; no shares issued and outstanding        
Preferred stock, par value $0.001, 100,000,000 shares authorized; no shares issued and outstanding        
Common stock, par value $0.001, 100,000,000 shares authorized; 25,995,621 and 16,634,951 shares issued and outstanding   26,000    17,000 
Additional paid-in capital   16,269,000    8,744,000 
Other comprehensive loss   (2,000)   - 
Stock subscription receivable   (2,000)   (2,000)
Accumulated deficit   (16,831,000)   (10,082,000)
Total stockholders’ deficit   (540,000)   (1,323,000)
Total liabilities and stockholders’ deficit  $3,092,000   $2,000 

 

The accompanying notes are an integral part of these Consolidated Financial Statements.

 

F-3

 

 

CalEthos, Inc.

Consolidated Statements of Operations and Comprehensive Loss

For the Years Ended December 31,

 

          
   2021   2020 
         
Revenue  $   $ 
           
Operating expenses          
Professional fees   6,095,000    340,000 
General and administrative expenses   57,000    51,000 
Total operating expenses   6,152,000    391,000 
           
Loss from operations   (6,152,000)   (391,000)
           
Other expenses          
Financing costs   (597,000)   (227,000)
Loss on extinguishment of series A convertible preferred stock   -    (138,000)
Total other expenses   (597,000)   (365,000)
           
Loss before provision for income taxes   (6,749,000)   (756,000)
           
Provision for income taxes        
           
Net loss  $(6,749,000)  $(756,000)
           
Net loss per share, basic and diluted  $(0.35)  $(0.05)
           
Weighted average common shares outstanding – basic and diluted   19,482,261    16,634,951 
           
Comprehensive loss:          
Net loss  $(6,749,000)  $(756,000)
Change in foreign currency translation   (2,000)   - 
Comprehensive loss  $(6,751,000)  $(756,000)

 

The accompanying notes are an integral part of these Consolidated Financial Statements.

 

F-4

 

 

CalEthos, Inc.

Consolidated Statements of Changes in Stockholders’ Deficit

For the Years Ended December 31, 2021 and 2020

 

   Shares   Amount   Shares   Amount   Capital   Receivable   Loss   Deficit   Deficit 
  

Series A Convertible

Preferred Stock

   Common Stock   Additional Paid-In   Stock Subscription   Other Comprehensive   Accumulated  

Total

Stockholders’

 
   Shares   Amount   Shares   Amount   Capital   Receivable   Loss   Deficit   Deficit 
Balance, January 1, 2020   85,975   $    16,634,951   $17,000   $8,750,000   $(2,000)  $-   $(9,326,000)  $(561,000)
Conversion of series A preferred stock to convertible promissory notes   (85,975)               (119,000)       -        (119,000)
Fair value of warrants issued with the conversion of series A convertible preferred stock                   52,000        -        52,000 
Debt premium on issuance of convertible promissory notes for conversion of series A convertible preferred stock                   58,000        -        58,000 
Relative fair value of warrants issued with convertible promissory notes                   3,000        -        3,000 
Net loss                           -    (756,000)   (756,000)
Balance, December 31, 2020           16,634,951    17,000    8,744,000    (2,000)   -    (10,082,000)   (1,323,000)
Relative fair value of warrants issued with convertible promissory note                   1,690,000        -        1,690,000 
Stock options issued for services                   575,000        -        575,000 
Stock issued for debt forgiveness   -    -    75,000    -    166,000    -    -    -    166,000 
Stock issued for accrued compensation   -    -    -    -    38,000    -    -    -    38,000 
Stocks returned   -    -    (3,674,330)   (4,000)   4,000    -    -    -    - 
Stock issued on exercise of options   -    -    1,435,000    2,000    -    -    -    -    2,000 
Stock-based compensation   -    -    25,000    -    272,000    -    -    -    272,000 
Restricted common stock awards issued for compensation   -    -    11,500,000    11,000    4,780,000    -    -    -    4,791,000 
Foreign currency translation loss   -    -    -    -    -    -    (2,000)   -    (2,000)
Net loss   -    -    -    -    -    -    -    (6,749,000)   (6,749,000)
Balance, December 31, 2021      $    25,995,621   $26,000   $16,269,000   $(2,000)  $(2,000)  $(16,831,000)  $(540,000)

 

The accompanying notes are an integral part of these Consolidated Financial Statements.

 

F-5

 

 

CalEthos, Inc.

Consolidated Statements of Cash Flows

For the Years Ended December 31,

 

          
   2021   2020 
Cash flows from operating activities          
Net loss  $(6,749,000)  $(756,000)
Adjustments to reconcile net loss to net cash used in operating activities:          
Amortization of convertible promissory note discounts   524,000    188,000 
Loss on extinguishment of convertible preferred stock       86,000 
Fair value of warrants issued for extinguishment of convertible preferred stock       52,000 
Fair value of equity-based compensation   846,000     
Accretion of compensation cost for restricted stock awards   4,791,000     
Changes in operating asset and liabilities          
Prepaid expenses   (5,000)    
Accounts payable and accrued expenses   28,000    248,000 
Net cash used in operating activities   (565,000)   (182,000)
           
Cash flows from investing activity          
Payment for other assets   (38,000)    
Net cash used in investing activity   (38,000)    
           
Cash flows from financing activities          
Proceeds from the issuance of convertible promissory notes   3,550,000    49,000 
Proceeds from the issuance of notes payable   150,000    10,000 
Repayment of notes payable   (50,000)   - 
Proceeds from the exercise of options   2,000     
Net cash provided by financing activities   3,652,000    59,000 
           
Effect of exchange rate changes on cash and cash equivalents   (2,000)    
           
Net increase (decrease) in cash   3,047,000    (123,000)
Cash at beginning of reporting period       123,000 
Cash at end of reporting period  $3,047,000   $ 
           
Supplemental disclosure of cash flows information          
Interest paid  $   $ 
Income tax paid  $   $ 
           
Supplemental disclosure of non-cash financing activities:          
Conversion of series A preferred stock to convertible promissory notes  $   $119,000 
Fair value of warrants issued with the conversion of series A convertible preferred stock  $   $52,000 
Debt premium on issuance of convertible promissory notes for conversion of series A convertible preferred stock  $   $58,000 
Relative fair value of warrants issued with convertible promissory note  $1,690,000   $3,000 
Common stock issued for accrued compensation  $38,000   $ 
Common stock issued for debt forgiveness  $166,000   $ 
Original issue discount recorded on convertible promissory notes  $

355,000

   $ 

 

The accompanying notes are an integral part of these Consolidated Financial Statements.

 

F-6

 

 

CalEthos, Inc.

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2021 and 2020

 

Note 1 - Organization and Accounting Policies

 

CalEthos, Inc. (the “Company” or “we”) was incorporated on March 20, 2002 under the laws of the State of Nevada. Since the second quarter of 2016, the Company has been a “shell” company, as defined in Rule 12b-2 under the Exchange Act.

 

On December 20, 2018, we filed a Certificate of Amendment to our Articles of Incorporation with the Secretary of State of the State of Nevada to change the Company name from “RealSource Residential, Inc.” to “CalEthos, Inc.”. This amendment became effective immediately upon filing on December 20, 2018.

 

As of December 31, 2021, the primary activity of the Company’s management is to develop and implement a plan to manufacture high-performance computer systems that are scalable, upgradeable and cost effective for processing cryptocurrencies, tokens and blockchain-based transactions, and if other opportunities warrant, acquire assets and all or part of other companies operating in the cryptocurrency mining hardware industry and or invest or joint venture with other more established companies already in the industry. The Company will not restrict its search to any specific business segment of the cryptocurrency mining hardware industry or geographical location and the Company may participate in a business venture of virtually any kind or nature that is beneficial to the Company and its shareholders.

 

Amendments to Certificate of Incorporation

 

In October 2021, the Board of Directors authorized an amendment to the Articles of Incorporation of the Company to change the Company’s name of AIQ Blockchain, Inc. The name change has not yet been effected.

 

Incorporation of Korean entity

 

On November 5, 2021, AIQ System Inc. (“AIQ”) was incorporated in Seoul, Republic of Korea. AIQ is authorized to issue 3 million shares of common stock. At the date of incorporation, 10,000 shares were issued to the Company for 100,000,000 Korean Won or approximately $89,000 for 100% ownership of AIQ.

 

AIQ is in the business of (1) developing and manufacturing computer chips and system, (2) importing and exporting semiconductors and electronic products, (3) wholesale and retail business of semiconductors and electronic products, and (4) any and all business activities incidental to the foregoing activities.

 

Basis of Presentation

 

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary from the formation date. All material intercompany transactions and balances have been eliminated in consolidation.

 

F-7

 

 

Going Concern and Liquidity

 

The Company incurred a net loss of approximately $6,749,000 for the year ended December 31, 2021 and had an accumulated deficit of approximately $16,831,000 as of December 31, 2021. The Company has financed its activities principally through debt and equity financing and shareholder contributions. Management expects to incur additional losses and cash outflows in the foreseeable future in connection with its operating activities.

 

The Company’s consolidated financial statements have been presented on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.

 

The Company is subject to a number of risks similar to those of other similar stage companies, including dependence on key individuals; successful development, marketing and branding of products; uncertainty of product development and generation of revenues; dependence on outside sources of financing; risks associated with research and development; dependence on third-party suppliers and collaborators; protection of intellectual property; and competition with larger, better-capitalized companies. Ultimately, the attainment of profitable operations is dependent on future events, including obtaining adequate financing to fund its operations and generating a level of revenues adequate to support the Company’s cost structure.

 

The Company will need to raise debt or equity financing in the future in order to continue its operations and achieve its growth targets. However, there can be no assurance that such financing will be available in sufficient amounts and on acceptable terms, when and if needed, or at all. The precise amount and timing of the funding needs cannot be determined accurately at this time, and will depend on a number of factors, including market demand for the Company’s products and services, the success of product development efforts, the timing of receipts for customer deposits, the management of working capital, and the continuation of normal payment terms and conditions for purchase of goods and services. The Company believes its cash balances and cash flow from operations will not be sufficient to fund its operations and growth for the next twelve months from the issuance date of these financial statements. If the Company is unable to substantially increase revenues, reduce expenditures, or otherwise generate cash flows from operations, then the Company will likely need to raise additional funding from investors or through other avenues to continue as a going concern.

 

Use of Estimates

 

The preparation of consolidated financial statements in conformity with GAAP and requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods.

 

Foreign Currency Translation

 

The financial statements of foreign subsidiaries, for which the functional currency is the local currency, are translated into U.S. dollars using the exchange rate at the consolidated balance sheet date for assets and liabilities and a weighted-average exchange rate during the year for revenue, expenses, gains and losses. Translation adjustments are recorded as other comprehensive income (loss) within shareholders’ equity (deficit). Gains or losses from foreign currency transactions are recognized in the consolidated statements of operations.

 

Fair Value Measurement

 

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants as of the measurement date. Applicable accounting guidance provides an established hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors that market participants would use in valuing the asset or liability. There are three levels of inputs that may be used to measure fair value:

 

Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 2 - Other inputs that are directly or indirectly observable in the marketplace.

Level 3 - Unobservable inputs which are supported by little or no market activity.

 

F-8

 

 

The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

 

As of and for the year ended December 31, 2021, the Company had no assets or liabilities that require fair value measurement.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents. Cash and cash equivalents are recorded at cost, which approximates its fair value. The Company maintains its cash and cash equivalents in banks insured by the Federal Deposit Insurance Corporation (“FDIC”) in accounts that at times may be in excess of the federally insured limit of $250,000 per bank. The Company minimizes this risk by placing its cash deposits with major financial institutions. As of December 31, 2021 and 2020, the Company had $2,797,000 and $0 in excess of the federal insurance limit, respectively.

 

Prepaid Expense

 

Prepaid expenses are assets held by the Company, which are expected to be realized and consumed within twelve months after the reporting period.

 

Other Assets

 

Other assets consist of long-term advances paid for chip and processor design and development.

 

Related Parties

 

The Company follows Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) section 850-10 for the identification of related parties and disclosure of related party transactions.

 

Pursuant to ASC section 850-10-20 the related parties include (a.) affiliates of the Company (“Affiliate” means, with respect to any specified Person, any other Person that, directly or indirectly through one or more intermediaries, controls, is controlled by or is under common control with such Person, as such terms are used in and construed under Rule 405 under the Securities Act); (b.) entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option of ASC section 825–10–15, to be accounted for by the equity method by the investing entity; (c.) trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; (d.) principal owners of the Company; (e.) management of the Company; (f.) other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and (g.) other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.

 

F-9

 

 

The consolidated financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of consolidated or combined financial statements is not required in those statements. The disclosures shall include: (a.) the nature of the relationship(s) involved; (b.) a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; (c.) the dollar amounts of transactions for each of the periods for which income statements are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and (d.) amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement.

 

Commitments and Contingencies

 

The Company follows ASC section 450-20 to report accounting for contingencies. Certain conditions may exist as of the date the consolidated financial statements are issued, which may result in a loss to the Company, but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or un-asserted claims that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or un-asserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.

 

If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s consolidated financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed.

 

Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed.

 

Debt Discounts

 

The Company accounts for debt discounts originating in connection with conversion features that remain embedded in the related notes in accordance with ASC 470-20, Debt with Conversion and Other Options. These costs are classified on the balance sheet as a direct deduction from the debt liability. The Company amortizes these costs over the term of its debt agreements as financing cost in the consolidated statement of operations and comprehensive loss.

 

Warrant Liability

 

In connection with financing arrangements, the Company has issued warrants to purchase shares of its common stock. The outstanding warrants are standalone instruments that are not puttable or mandatorily redeemable by the holder and are classified as equity awards. The Company measures the fair value of the awards using the Black-Scholes Merton (“BSM”) option pricing model as of the measurement date.

 

F-10

 

 

Stock-Based Compensation

 

We account for our stock-based compensation under ASC 718, “Compensation – Stock Compensation” using the fair value based method. Under this method, compensation cost is measured at the grant date based on the value of the award and is recognized over the service period, which is usually the vesting period. This guidance establishes standards for the accounting for transactions in which an entity exchanges it equity instruments for goods or services. It also addresses transactions in which an entity incurs liabilities in exchange for goods or services that are based on the fair value of the entity’s equity instruments or that may be settled by the issuance of those equity instruments.

 

We use the fair value method for equity instruments granted to non-employees and use the BSM model for measuring the fair value of options. The stock based fair value compensation is determined as of the date of the grant (measurement date) and is recognized over the vesting periods.

 

Income Taxes

 

The Company accounts for income taxes in accordance with ASC 740, Income Taxes, deferred tax assets and liabilities are computed based on the difference between the financial reporting and income tax bases of assets and liabilities using the enacted marginal tax rate. ASC 740 requires that the net deferred tax asset be reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some portion or all of the net deferred tax asset will not be realized.

 

The Company accounts for income taxes using an asset and liability approach, which requires the recognition of taxes payable or refundable for the current year and deferred tax liabilities and assets for the future tax consequences of events that have been recognized in the Company’s financial statements or tax returns. The measurement of current and deferred tax assets and liabilities is based on provisions of enacted tax laws; the effects of future changes in tax laws or rates are not anticipated. If necessary, the measurement of deferred tax assets is reduced by the amount of any tax benefits that are not expected to be realized based on available evidence.

 

The Company has adopted guidance related to the accounting for uncertainty in income taxes which prescribes rules for recognition, measurement and classification in the financial statements of tax positions taken or expected to be taken in a tax return. The guidance prescribes a two-step approach which involves evaluating whether a tax position will be more likely than not (greater than 50 percent likelihood) sustained upon examination based on the technical merits of the position. The second step requires that any tax position that meets the more likely than not recognition threshold be measured and recognized in the financial statements at the largest amount of benefit that is a greater than 50 percent likelihood of being realized upon settlement.

 

The Company’s policy is to recognize interest and penalties, if any, related to unrecognized tax benefits in income tax expense. The Company is not currently under examination by any taxing authority nor has the Company been notified of a pending examination. The statute of limitations for which the Company is generally no longer subject to federal or state income tax examinations by tax authorities is for years before 2013.

 

Earnings Per Share

 

We use ASC 260, “Earnings Per Share” for calculating the basic and diluted earnings (loss) per share. We compute basic earnings (loss) per share by dividing net income (loss) by the weighted average number of common shares outstanding. Diluted earnings (loss) per share is computed based on the weighted average number of shares of common stock plus the effect of dilutive potential common shares outstanding during the period using the treasury stock method. Dilutive potential common shares include outstanding stock options and warrants and stock awards. For periods with a net loss, basic and diluted loss per share is the same, in that any potential common stock equivalents would have the effect of being anti-dilutive in the computation of net loss per share.

 

F-11

 

 

Securities that could potentially dilute income (loss) per share in the future were not included in the computation of diluted income (loss) per share on December 31 because their inclusion would be anti-dilutive as follows:

 

   2021   2020 
Restricted stock awards   11,500,000    - 
Convertible promissory notes and accrued interest   3,947,394    747,032 
Series A warrants issued with convertible promissory notes   1,921,304    353,804 
Series B warrants to be issued upon exercise of Series A warrants   1,921,304    353,804 
Warrants issued for services   100,000    - 
Stock options   -    385,000 
Total potential future shares   19,390,002    1,839,640 

 

Recent Accounting Pronouncements

 

The Company’s management reviewed all recently issued accounting standard updates (“ASU’s”) not yet adopted by the Company and does not believe the future adoptions of any such ASU’s may be expected to cause a material impact on the Company’s consolidated financial condition or the results of its operations.

 

Note 2 – Related Party Transactions

 

The Company incurred approximately $199,000 and $180,000 for years ended December 31, 2021 and 2020, and paid approximately $202,000 and $112,000, respectively, to M1 Advisors for the services of the Company’s CEO and miscellaneous operating expenses.

 

Note 3 – Accounts Payable and Accrued Expenses

 

Accounts payable and accrued expenses as of December 31, are as follows:

 

   2021   2020 
Accounts payable  $221,000   $316,000 
Accrued expenses   99,000    255,000 
Accrued interest   114,000    40,000 
Accounts payable and accrued expenses  $434,000   $611,000 

 

Accrued Interest

 

The following table presents the details of accrued interest of December 31:

 

    2021     2020  
Notes payable   $ 9,000     $ 1,000  
Convertible promissory notes     105,000       39,000  
Balance, end of the year   $ 114,000     $ 40,000  

 

Note 4 – Notes Payable

 

The table below summarizes the transactions for the years ended December 31:

 

   2021   2020 
Balance, beginning of the year  $11,000   $- 
Additions   150,000    11,000 
Payments   (50,000)   - 
Balance, end of the year  $111,000   $11,000 

 

F-12

 

 

On January 11, 2021, the Company issued a promissory note in the principal amount of $15,000. The interest on this note shall accrue beginning from the date of issuance, at an interest rate of 8% per annum. The principal and any accrued interest are payable on or before March 11, 2022. During any event of default under the note, the interest rate shall increase to 10% per annum. Events of default include failure to pay principal or interest, breach of covenants, breach of representations and warranties, borrower’s assignment of substantial part of its property or business, any money judgment, writ, or similar process shall be entered or filed against the borrower or any subsidiary of the borrower or any of its properties or other assets for more than $100,000, bankruptcy, liquidation of business, and cessation of operations. The principal and the accrued interest amounting to $15,000 and $1,000, respectively, was settled on October 27, 2021.

 

On February 19, 2021, the Company issued a promissory note in the principal amount of $25,000. The interest on the unpaid principal balance accrues at a rate of 10% per annum. The principal and any accrued interest shall be paid in a single installment on or before February 19, 2022. If the Company fails to pay the balance of this note in full on the due date or fails to make any payment due within 15 days of the due date, any unpaid principal shall accrue interest at the rate of 15% per annum during the default (default interest). Events of default include failure to make any payment including accrued interest when due, voluntary, or involuntary petition of bankruptcy, appointment of a receiver, custodian, trustee or similar party to take possession of the Company’s assets or property, or assignment made by the Company for the benefit of creditors. The principal amount outstanding under this note was $25,000 as of December 31, 2021. Interest accrued as of December 31, 2021 is $2,000.

 

On April 5, 2021, the Company issued a promissory note in the principal amount of $9,000. The interest on the unpaid principal balance accrues at a rate of 8% per annum. If the Company fails to pay the balance of this note in full on the date or fails to make any payments due within 15 days of the due date, any unpaid principal shall accrue interest at the rate of 8% per annum during the default. Events of default include failure to make any payment including accrued interest when due, voluntary, or involuntary petition of bankruptcy, appointment of a receiver, custodian, trustee or similar party to take possession of the Company’s assets or property, or assignment made by the Company for the benefit of creditors. The principal and accrued interest under this note was settled September 16, 2021.

 

On April 22, 2021, the Company issued a promissory note in the principal amount of $50,000. The interest on the unpaid principal balance accrues at a rate of 10% per annum. The principal and any accrued interest shall be paid in a single installment on or before April 22, 2022. If the Company fails to pay the balance of this note in full on the date or fails to make any payments due within 15 days of the due date, any unpaid principal shall accrue interest at the rate of 15% per annum during the default. Events of default include failure to make any payment including accrued interest when due, voluntary, or involuntary petition of bankruptcy, appointment of a receiver, custodian, trustee or similar party to take possession of the Company’s assets or property, or assignment made by the Company for the benefit of creditors. The principal amount outstanding under this note was $50,000 as of December 31, 2021. Interest accrued as of December 31, 2021 is $2,000.

 

On July 1, 2021, the Company issued a promissory note in the principal amount of $25,000. The interest on the unpaid principal balance accrues at a rate of 10% per annum. The principal and any accrued interest shall be paid in a single installment on or before July 1,2022. If the Company fails to pay the balance of this note in full on the date or fails to make any payments due within 15 days of the due date, any unpaid principal shall accrue interest at the rate of 15% per annum during the default (default interest). Events of default include failure to make any payment including accrued interest when due, voluntary, or involuntary petition of bankruptcy, appointment of a receiver, custodian, trustee or similar party to take possession of the Company’s assets or property, or assignment made by the Company for the benefit of creditors. The principal amount outstanding under this note was $25,000 as of December 31, 2021. Interest accrued as of December 31, 2021 is $1,000.

 

On July 12, 2021, the Company issued a promissory note in the principal amount of $5,000. The interest on the unpaid principal balance accrues at a rate of 8% per annum. The principal and any accrued interest shall be paid in a single installment on or before October 12, 2021. The principal amount of this note was settled on September 16, 2021.

 

F-13

 

 

On August 10, 2021, the Company issued a promissory note in the principal amount of $7,000. The interest on the unpaid principal balance accrues at a rate of 8% per annum. The principal and any accrued interest shall be paid in a single installment on or before November 10, 2021.The principal amount of this note was settled on September 16, 2021.

 

In August 2021, the Company issued four promissory notes to a single lender in the aggregate principal amount of $14,000. The interest on the unpaid principal balance of these notes accrues at a rate of 8% per annum. The principal for each note shall be paid in a single installment during November 2021. If the Company fails to pay the balance of these notes in full on the date or fails to make any payments due within 15 days of the due date, any unpaid principal shall accrue interest at the rate of 8% per annum during the default. Events of default include failure to make any payment including accrued interest when due, voluntary, or involuntary petition of bankruptcy, appointment of a receiver, custodian, trustee, or similar party to take possession of the Company’s assets or property, or assignment made by the Company for the benefit of creditors. The principal amount outstanding under these notes was $13,500 as of September 30, 2021. The principal and the accrued interest aggregating to $14,000 was settled in October 2021.

 

During the year ended December 31, 2020, the Company issued a promissory note for $11,000. The total proceeds were $10,000, due to approximately $1,000 for an original issue discount. This promissory note is non-interest bearing with the principal due and payable in August 2020. Any amount of unpaid principal on the date of maturity will accrue interest at rate of 10% per annum (default interest). The original issue discount was amortized over the term of the note, which was one month. The Company is in default on this promissory note as of December 31, 2021. The principal and accrued interest amounted to $11,000 and $2,000, as of December 31, 2021 and $11,000 and nil as of December 31, 2020, respectively.

 

Interest expense on notes payable amounted to $8,000 and $1,000 as of December 31, 2021 and 2020, respectively.

 

Note 5 – Convertible Promissory Notes

 

During the year ended December 31, 2021, the Company issued two convertible promissory notes amounting to $55,000 and $3,850,000 (the “Notes”), respectively. The total aggregate proceeds were $3,550,000 due to a $355,000 aggregate original issue discount. The Notes are non-interest bearing with the principal due and payable on March 1, 2022 and August 31, 2022, respectively. Any amount of unpaid principal on the date of maturity will accrue interest at rate of 10% per annum (default interest). The principal amount and all accrued interest are convertible into shares of the Company’s common stock, as of the date of issuance, at a rate of $1.00 and $1.25 per share (“Conversion Rate”), respectively. The Conversion Rate is adjustable if, at any time when any principal amount of the Notes remains unpaid or unconverted, the Company issues or sells any shares of the Company’s common stock for no consideration or for a consideration per share (before deduction of reasonable expenses or commissions or underwriting discounts or allowances in connection therewith), which is less than the Conversion Rate in effect on the date of such issuance (or deemed issuance) of such shares of common stock (a “Dilutive Issuance”). Immediately upon a Dilutive Issuance, the Conversion Rate will be reduced to the amount of the consideration per share received by the Company in such Dilutive Issuance. Events of default include failure to issue conversion shares, the occurrence of a breach or default under any other agreement, any money judgment, writ, or similar process entered or filed against the Company or any of its property or other assets for more than $100,000, bankruptcy filing, application for the appointment of a custodian, trustee or receiver, insolvency, the Company’s common stock delisted, or dissolution, winding up, or termination of the business of the Company.

 

In connection with the issuance of the Notes, the Company issued to the purchasers of the Notes stock purchase warrants (the “Warrants”) to purchase an aggregate of 1,567,500 shares of the Company’s common stock for a purchase price of $1.50 to $1.87 per share, subject to adjustments. The Warrants were valued using the Black Scholes option pricing model for a total fair value of $3,004,000 based on a 3-year term, volatility of 404.91% to 405.93%, a risk-free equivalent yield of 0.27% to 0.42%, and stock price ranging from $0.10 to $1.95.

 

F-14

 

 

In accordance with ASC 470 - Debt, the Company has allocated the cash proceeds amounts of the Notes among the Notes, the Warrants and the conversion feature. The relative fair value of the Warrants issued amounted to approximately $1,690,000 and the beneficial conversion amounted to $0, which amounts are being amortized and expensed over the term of the Notes.

 

During the year ended December 31, 2020, the Company issued convertible promissory notes in the amount of $213,000 (the “Notes”). The total cash proceeds were approximately $60,000, approximately $147,000 from the conversion of Series A Preferred Stock into convertible promissory note and approximately $6,000 original issue discount (“OID”). The Notes are non-interest bearing with the principal due and payable starting in February 2021. Any amount of unpaid principal on the date of maturity will accrue interest at rate of 10% per annum (default interest). The principal amount and all accrued interest are convertible into shares of the Company’s common stock, as of the date of issuance, at a rate of $1.00 per share (“Conversion Rate”). The conversion rate is adjustable if, at any time when any principal amount of the Notes remains unpaid or unconverted, the Company issues or sells any shares of the Company’s common stock for no consideration or for a consideration per share (before deduction of reasonable expenses or commissions or underwriting discounts or allowances in connection therewith), which is less than the Conversion Rate in effect on the date of such issuance (or deemed issuance) of such shares of common stock (a “Dilutive Issuance”). Immediately upon a Dilutive Issuance, the Conversion Rate will be reduced to the amount of the consideration per share received by the Company in such Dilutive Issuance. Events of default include failure to issue conversion shares, the occurrence of a breach or default under any other agreement, any money judgment, writ or similar process entered or filed against the Company or any its property or other assets for more than $100,000, bankruptcy filing, application for the appointment of a custodian, trustee or receiver, insolvency, the Company’s common stock delisted, or dissolution, winding up, or termination of the business of the Company.

 

In connection with the issuance of the Notes, the Company issued to the purchasers of the Notes stock purchase warrants to purchase an aggregate of 359,000 shares of the Company’s common stock for a purchase price of $1.50 per share, subject to adjustments.

 

In accordance with ASC 470 - Debt, the Company has accounted for the issuance of the Notes as an extinguishment of the series A preferred stock. Under extinguishment accounting, the difference between the fair value of the Notes and book basis of the series A preferred stock of $86,000 was accounted for as a loss on extinguishment. Also, the fair value of the Warrants of $52,000 was recorded as a loss on extinguishment. The difference between the fair value of the Notes and the face value of the notes of $58,000 was recorded as additional paid on capital. In addition, the Company has allocated the cash proceeds amounts of the Notes among the Notes, the warrants and the conversion feature. The relative fair value of the warrants issued totaled approximately $3,000 and of the beneficial conversion totaled approximately $0, which amounts are being amortized and expensed over the term of the Notes.

 

Financing cost recognized for the amortization of debt discount was approximately $524,000 and $187,000 for the years ended December 31, 2021 and 2020, respectively.

 

The Company determined that the conversion feature of the Notes would not be an embedded feature to be bifurcated and accounted for as a derivative in accordance with ASC 815-15 Derivatives and Hedging.

 

The convertible promissory notes consisted of the following as of December 31:

 

   2021   2020 
Principal          
Balance, beginning of year  $708,000   $506,000 
Additions   3,905,000    202,000 
Balance, end of year   4,613,000    708,000 
           
Discount          
Balance, beginning of year   5,000    183,000 
Additions   2,045,000    10,000 
Amortization   (524,000)   (188,000)
Balance, end of year   1,526,000    5,000 
Net carrying amount  $3,087,000   $703,000 

 

F-15

 

 

Effective interest rate used to amortize the debt discount for the years ended December 31, 2021 and 2020 ranges from 4.76% to 64.60%. The unamortized debt discounts will be amortized within one year as of December 31, 2021 and 2020, respectively.

 

Potential future shares to be issued on conversion of the notes as December 31, 2021 and 2020 are as follows:

 

   2021   2020 
Principal  $4,613,000   $708,000 
Interest   105,000    39,000 
Total   4,718,000    747,000 
Conversion price per share   1.001.25    1.00 
Potential future share   3,947,394    747,032 

 

Interest expense on default convertible promissory notes amounted to $65,000 and $39,000 for the year ended December 31, 2021 and 2020, respectively.

 

Note 6 – Commitments and Contingencies

 

Technology Development Agreement

 

On December 23, 2021, AIQ entered into a Technology Development Agreement (the “Agreement”) with PICOCEL, Co., Ltd. (the “Contractor” or “PICOCEL”) to develop a FPGA based Bitcoin mining simulation system. The Agreement is expected to be completed within 6 weeks for a total contract price of 198,000,000 Korean Won (“KRW”) or approximately $167,000. As of December 31, 2021, AIQ have made payments amounting to approximately $42,000. The remaining payments as of December 31, 2021 are scheduled, as follows:

 

   Amount 
   USD   KRW 
Within 14 days after signing the contract   42,000    49,500,000 
Within 14 days after delivery of the first set of PM103 FPGA prototype board   83,000    99,000,000 
Total   125,000    148,500,000 

 

Litigation

 

From time to time, the Company may become subject to legal proceedings, claims and litigation arising in the ordinary course of business. In addition, the Company may receive letters alleging infringement of patent or other intellectual property rights. The Company is not currently a party to any material legal proceedings, nor is the Company aware of any pending or threatened litigation that would have a material adverse effect on the Company’s business, operating results, cash flows or financial condition should such litigation be resolved unfavorably, except as follows.

 

On January 3, 2022, a complaint was filed against our company in the Superior Court of California, County of Los Angeles titled Michael Sekula v. CalEthos Inc, Michael Campbell and Does 1-25 (Case No. 22STCV00121) for, among other matters, failure to pay wages, fraud and other wage-related claims. In the complaint, the plaintiff claims he worked under a consulting agreement as Vice President of Brand Management of our company and was to be paid $4,000 per month and to receive an option to purchase 50,000 shares of our common stock that was to vest quarterly over the term of the agreement. In the complaint, the plaintiff alleges that, on or around March 27, 2020, we ceased paying the plaintiff despite the plaintiff’s continuing efforts on behalf of our company and that we agreed to continue to accrue his monthly retainer amount until such time that we received at least $100,000 in funding. Plaintiff further alleges that he continued to work for our company for 38 additional weeks in reliance on our promise of payment. The plaintiff claims that our refusal to make the promised payments amounts to violations of the California labor laws and seeks damages in excess of $450,000.

 

We intend to dispute these claims and to defend this litigation vigorously. However, due to the inherent uncertainties of litigation, the ultimate outcome of this litigations is uncertain. An unfavorable outcome in this litigation could materially and adversely affect our business, financial condition and results of operations.

 

Business Interruption

 

The continuing COVID-19 global pandemic has caused significant disruption to the economy and financial markets globally, and the full extent of the potential impacts of COVID-19 are not yet known. Circumstances caused by the COVID-19 pandemic are complex, uncertain and rapidly evolving. The impact of COVID-19 has not been significant to the Company’s results of operations, financial condition, and liquidity and capital resources. Although no material impairment or other effects have been identified to date, there is substantial uncertainty in the nature and degree of its continued effects over time. That uncertainty affects management’s accounting estimates and assumptions, which could result in greater variability in a variety of areas that depend on these estimates and assumptions as additional events and information become known. The Company will continue to consider the potential impact of the COVID-19 pandemic on its business operations.

 

F-16

 

 

Note 7 – Stockholders’ Deficit

 

Shares Authorized

 

The Company is authorized to issue 200,000,000 shares of which 100,000,000 shares shall be preferred stock, par value $0.001 per share, and 100,000,000 shares shall be common stock, par value $0.001 per share.

 

Preferred Stock

 

Series A Convertible Preferred Stock

 

The Series A Convertible Preferred Stock (“Series A”) is convertible into shares of the Company’s common stock at the rate of $1.38 per share, subject to adjustments based on the Company’s future sales of financial instruments at a value less than $1.38 per share. The holders of the Series A have the right to convert any time after the date of issuance. With the issuance of the convertible promissory notes, as explained in Note 5 above, the Series A’s conversion rate adjusted to $1.00 per share. In accordance with ASC 470, the Company has calculated the effect of the conversion rate adjustment, which was approximately $36,000. The conversion rate adjustment has been treated as a deemed dividend, which has been presented in the Statement of Changes in Stockholders’ Deficit.

 

The Series A is mandatorily convertible upon (i) the closing of the sale of shares of the Company’s common stock to the public in an underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, resulting in at least $10,000,000 of gross proceeds to the Company, (ii) the close of business on the sixtieth consecutive day on which the closing price of the Company’s common stock on the OTC Markets is at least $2.80 per share, subject to appropriate adjustment in the event of any stock dividend, stock split, stock combination or other similar recapitalization with respect to the common stock, or (iii) the affirmative vote of the holders of at least 66⅔% of the outstanding shares of Series A, given at a meeting of such stockholders duly called for that purpose or pursuant to a written consent of stockholders all outstanding shares of Series A shall automatically be converted into shares of the Company’s common stock, at the then effective conversion rate.

 

On any matter presented to the stockholders of the Company for their action or consideration at any meeting of stockholders of the Company (or by written consent of stockholders in lieu of meeting), each holder of outstanding shares of Series A shall be entitled to cast the number of votes equal to the number of whole shares of common stock into which the shares of Series A held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter. Except as provided by law or by the other provisions of the Articles of Incorporation, holders of Series A shall vote together with the holders of common stock as a single class.

 

From and after the date of the issuance of any shares of Series A, a cumulative dividend on each outstanding share of Series A Preferred Stock shall accrue at a rate per annum equal to ten percent of the Series A original issue price. Accrued dividends on the Series A shall be paid in shares of the Company’s common stock, such shares to be valued for such purpose at the applicable series A conversion price.

 

On February 11, 2020, the Company converted 85,975 shares of Series A into a Convertible Promissory Notes in the principal amount approximately $147,000.

 

Common Stock

 

In January 2021, the Company’s President and a member of the Board of Directors, resigned as an officer and director of the Company (“Termination Agreement”). Part of the Termination Agreement stipulates the return of 3,674,330 shares of the Company’s common stock (“Cancelled Shares”). The Cancelled Shares were returned and cancelled on April 20, 2021.

 

In March 2021, the Company’s Chief Executive Officer (“CEO’) agreed to forgive approximately $68,000 due to him, which was treated as contributed paid in capital.

 

In March 2021, the Company’s Chief Financial Officer agreed to reduce the amounts due to him from approximately $128,000 to $30,000. For the reduction of $98,000, the Company will issue 75,000 shares of common stock. The remaining liability of $30,000 will be paid in cash.

 

In September 2021, the Company entered into a release agreement with one of its consultants. As part of the separation payment, the Company issued 25,000 shares valued at $76,000 and paid $20,000 cash in October 2021.

 

F-17

 

 

Restricted Common Stock Awards

 

On August 17, 2021, the Company entered into Restricted Share Award Agreements (the “Award Agreements”) with two consultants pursuant to which the Company issued to the consultants shares of common stock of the Company in exchange for their future services. The Awards have an initial term of one year, which shall be automatically renewed on a year-to-year basis unless either party gives a written notice of termination. The two consultants who entered into these agreements include:

 

  1) A consultant who was granted 10,000,000 restricted share awards.
  2) An entity, which is owned by the Company’s CEO and majority shareholder, was granted 1,500,000 restricted share awards.

 

As indicated in the Awards Agreement, fifty percent (50%) of the shares shall vest upon the completion of the first two development phases of a 5 nanometer ASIC chip that includes the “FPGA Simulation” and “Tape Out”, and the remaining fifty (50%) of the shares shall vest upon the completion of the next phases of the chip development that include the completion of the Foundry Mask for production in the semiconductor foundry, initial production run of chips and the completion of a bitcoin mining system ready for sale to customers. Should the Company not raise sufficient capital to complete the Foundry Mask within 6 months of completing the first two development phases, then 100% of the shares shall be considered vested.

 

The Company’s management has accounted for the Award Grants as restricted stock compensation in accordance with ASC 718 – Stock Compensation (“ASC 718”). ASC 718 requires the Company to estimate the service period over which the compensation cost will be recognized. Management has estimated that the first two development phases will be completed within 15 months and the Foundry Mask will be completed within 6 months for a total of 21 months service period. Compensation cost will be recognized ratably over 21 months and in the same manner had the Company paid in cash. The estimated service period will be adjusted for changes in actual and expected completion dates. Any such change will be recognized prospectively, and the remaining deferred compensation will be recognized over the remaining service period.

 

As of December 31, 2021, a total of 11,500,000 shares were issued to the consultants. The value was $1.93 per share on the date of issuance (“Grant Date”) for an aggregate fair value of $22,195,000

 

The stock-based award compensation was recorded as an increase in deferred compensation expense, common stock, and additional paid-in capital in the Company’s books at the time of the grant.

 

The table below summarizes the transactions related to the Company restricted stock awards as of December 31, 2021:

 

   Shares   Deferred compensation 
Grant date fair value   11,500,000   $22,195,000 
Accretion   -    (4,791,000)
Balance as of December 31, 2021   11,500,000   $17,404,000 

 

Issuance of Stock Options and Warrants

 

In February 2021, the Company signed a new consulting agreement that granted one of its shareholders an option to purchase 750,000 shares of the Company’s common stock at $0.001 per share for the consultancy work provided from August 2020 to February 2021. The options were fully vested on the date of issuance. The fair value of the options was approximately $52,000, as of the grant date, of which approximately $38,000 was expensed and accrued during the year ended December 31, 2020 and $14,000 was expensed for the year ended December 31, 2021.

 

F-18

 

 

In May 2021, the Company signed a letter of understanding that granted one of its shareholders an option to purchase 300,000 shares of the Company’s common stock at $0.001 per share for the consultancy work provided during the Company’s restructuring phase from February 17, 2021 through April 30, 2021. The options were fully vested on the date of issuance. The fair value of the options was approximately $561,000, as of grant date, which was expensed during the year ended December 31, 2021.

 

In May 2021, an option holder exercised three options for 385,000, 750,000 and 300,000 shares of the Company’s common stock at an exercise price of $0.001 for each option, for total proceeds of approximately $2,000.

 

The table below summarizes the Company’s stock option activities for the years ended December 31, 2021 and 2020 (all share and per share data reflects the reverse stock split):

 

  

Number of

Stock Option

Shares

  

Exercise

Price

Range Per

Share

  

Weighted

Average

Exercise

Price

  

Relative

Fair

Value

  

Aggregate

Intrinsic

Value

 
Balance, January 1, 2020   569,800   $   $4.05   $   $423,000 
Granted                    
Forfeited                    
Exercised                    
Expired   (184,800)   12.50    12.50         
Balance, December 31, 2020   385,000        0.001        7,315 
Granted   1,050,000    0.001    0.001    1.94     
Forfeited                    
Exercised   (1,435,000)   0.001    0.001         
Expired                    
Balance, December 31, 2021      $   $   $   $ 
Vested and exercisable, December 31, 2021      $   $   $   $ 
Unvested, December 31, 2021      $   $   $   $ 

 

On September 15, 2021, the Company issued warrants to purchase 100,000 shares of the Company’s common stock. For the year ended December 31, 2021, the compensation expense, classified as professional fees in the consolidated statement of operations and comprehensive loss, was $195,000, which was calculated using the Black Scholes fair value option-pricing model with key input variables provided by management, as of the date of issuance: volatility of 359%, fair value of common stock $1.95, estimated life of 3 years, risk free rate of 0.43% and dividend rate of $0.

 

F-19

 

 

The table below summarizes the Company’s warrant activities for the years ended December 31, 2021 and 2020 (all share and per share data reflects the reverse stock split):

  

Number of

Shares

   Weighted Average Strike Price/Share   Weighted Average Remaining Contractual Term (Years)   Weighted Average Grant Date Fair Value/Share  

Aggregate

Intrinsic

Value

 
Balance, January 1, 2020   253,000   $1.50    2.81   $0.30   $ 
Granted   100,804    1.50    3.05    0.33     
Forfeited                    
Exercised                    
Expired                    
Balance, December 31, 2020   353,804    1.50    2.88    0.18     
Vested and exercisable, December 31, 2020   353,804    1.50    2.88    0.18     
Unvested, December 31, 2020                    
                          
Balance, December 31, 2020   353,804    1.50    2.88    0.18     
Granted   1,667,500    1.86    3.00    1.67    0.11 
Forfeited                    
Exercised                    
Expired                    
Balance, December 31, 2021   2,021,304    1.80    2.98    1.14    0.17 
Vested and exercisable, December 31, 2021   2,021,304    1.80    2.98    1.14    0.17 
Unvested, December 31, 2021      $       $   $ 

 

The following table sets forth the weighted-average assumptions used to estimate the fair value of warrants granted for the year ended December 31:

 

   2021   2020 
Expected life (in years)   3    2.33 - 3.25 
Risk-free interest rate   0.27% - 0.42%   0.18% - 2.49%
Expected volatility   405% - 406%   378% - 424%
Dividend yield   0.00%   0.00%
Stock price   $ 0.101.95    $ 0.11 1.60 

 

Note 8 – Deferred Tax Assets and Income Tax Provision

 

Deferred Tax Assets

 

At December 31, 2021, the Company had net operating loss (“NOL”) carry forwards for Federal income tax purposes of $3,354,000 that may be offset against future taxable income. No tax benefit has been reported with respect to these net operating loss carry-forwards in the accompanying financial statements because the Company believes that the realization of the Company’s net deferred tax assets of approximately $2,490,000 was not considered more likely than not and accordingly, the potential tax benefits of the net operating loss carry-forwards are fully offset by a full valuation allowance. Federal NOL’s have an indefinite carryover period and state NOL’s begin to expire at 12-31-2040 if not utilized by then.

 

Deferred tax assets consist primarily of the tax effect of NOL carry-forwards. The Company has provided a full valuation allowance on the deferred tax assets because of the uncertainty regarding its realization. The valuation allowance increased by approximately $2,191,000 and $93,000 for the reporting periods ended December 31, 2021 and 2020, respectively.

 

Components of deferred tax assets are as follows as of December 31:

   2021   2020 
Net deferred tax assets – Non-current:          
           
Stock-based compensation  $1,488,000   $- 
           
Expected income tax benefit from NOL carry-forwards  $1,002,000   $299,000 
           
Less valuation allowance   (2,490,000)   (299,000)
           
Deferred tax assets, net of valuation allowance  $-   $- 

 

Income Tax Provision in the Statements of Operations

 

A reconciliation of the federal statutory income tax rate and the effective income tax rate as a percentage of income before income taxes is as follows for the years ended December 31:

    2021     2020  
             
Federal statutory income tax rate     21.0 %     21.0 %
                 
Change in valuation allowance on net operating loss carry-forwards     (21.0 )     (21.0 )
                 
Effective income tax rate     0.0 %     0.0 %

 

Note 9 – Subsequent Events

 

The Company has evaluated all events that occurred after the balance sheet date through the date when the financial statements were issued to determine if they must be reported. The management of the Company determined the following reportable events:

 

Technology Development Agreement

 

In relation to the Technology Development Agreement entered on December 23, 2021, AIQ has made payments to PICOCEL amounting to approximately $42,000 as of the date of this report.

 

Notes Payable

 

Subsequent to December 31, 2021, the Company had made payments to its notes payable holders amounting to $25,000.

 

As of March 1, 2022, the Company did not pay the outstanding balance of $55,000 due and payable for a convertible promissory note. As per the promissory note, any unpaid balance as of maturity accrues interest at a rate of 10.0% per annum.

  

F-20

 

EX-10.12 2 ex10-12.htm

 

Exhibit 10.12

 

CONSULTING AGREEMENT

 

CONSULTING AGREEMENT, dated as of October 10, 2018 between DSS Consulting Corporation (the “Consultant”) and RealSource Residential, Inc. (the “Company”) (collectively the “Parties”).

 

WHEREAS, the Company desires to retain the consulting services of the Consultant and the Company wishes to acquire and be assured of Consultant’s consulting services on the terms and conditions hereinafter set forth; and

 

WHEREAS, the Consultant desires to consult with the Company on the terms and conditions hereinafter set forth.

 

NOW, THEREFORE, in consideration of the mutual terms, covenants, agreements and conditions hereinafter set forth, the Company and the Consultant hereby agree as follows:

 

1. Consulting Relationship.

 

(a) The Company hereby retains the Consultant to consult with the Company from time to time and to perform the consulting services provided in Section 3 hereof, and the Consultant hereby agrees to perform such consulting services, for the period set forth in Section 2 hereof. During the Consulting Term (as hereinafter defined), Consultant shall not be deemed to be an employee of the Company but shall be an independent contractor and all of the terms and conditions of this Agreement shall be interpreted in light of that relationship. This Agreement does not create any employer-employee, agency or partnership relationship. As an independent contractor, Consultant’s expenses shall be limited to those expressly stated in this Agreement.

 

(b) To the best of the Consultant’s knowledge: (i) the Consultant is under no obligation to any former employer or other party that is in any way inconsistent with, or that imposes any restriction upon, the Consultant’s acceptance of its engagement hereunder by the Company, the engagement of the Consultant by the Company, or the Consultant’s undertakings under this Agreement and (ii) its performance of all the terms of this Agreement and its engagement by the Company as a consultant does not and will not breach any agreement to keep in confidence proprietary information acquired by the Consultant, or any affiliate thereof, in confidence or in trust prior to its engagement by the Company.

 

2. Term.

 

(a) This Agreement commences as of the date set forth above and shall continue on an ongoing basis until either party hereto gives written notice of termination (the “Termination Notice”) to the other party hereto. Notwithstanding the foregoing, the Consulting Term shall terminate upon the death of the Consultant.

 

 

 

 

3. Duties.

 

(a) The Consultant and/or its affiliates shall consult with management of the Company as it relates to the Company’s overall financial accounting and reporting requirements. Also, the Consultant will be required to sign off on the Company’s SEC annual, quarterly and periodic filings as the “Principal Financial Officer”.

 

(b) During the Consulting Term, the Consultant and/or its affiliates shall not be required to provide any specified number of hours of service to the Company. The Consultant and his affiliates may, during the term of this Agreement, engage in such other employment and activities as they may see fit, it being agreed that the engagement of the Consultant is non-exclusive and that nothing herein contained shall be deemed to prohibit or bar the Consultant or any of its affiliates from engaging in such other activities as they may see fit so long as such activities do not interfere with the performance of the Consultant’s duties pursuant to the terms of this Agreement and do not violate the terms of sections 3.(a), 5 or 6 herein.

 

4. Fees and Expenses.

 

(a) Fee. During the Consulting Term, the Consultant will be paid a monthly retainer of $5,000 each month paid on the first day of each month. The first payment is due upon the execution of this agreement with the second payment due on November 1, 2018. As the operations of the Company increase, the Parties will evaluate and change the monthly retainer amount.

 

(b) Stock Compensation. The Company will assign to the Consultant (based on what structure is mutually agreed to as best for the Consultant) two hundred and fifty thousand (250,000) shares of the Company’s common stock, as soon as the Company establishes a stock compensation plan.

 

(c) Expenses. The Consultant shall be entitled to reimbursement for all reasonable and necessary out-of-pocket business expenses incurred by the Consultant and/or its affiliates in the performance of the Consultant’s duties hereunder in accordance with the Company’s policies applicable (on and after the date hereof) thereto. All amounts accrued and unpaid pursuant to section 4(b), shall be due and payable upon the termination of this Agreement pursuant to Section 2(a).

 

(d) Withholding, Etc. In conformity with the Consultant’s independent contractor status and without limiting any of the foregoing, the Company shall make no deduction or withholding for taxes or contributions of any kind. The Consultant agrees to accept exclusive liability for the payment of all self-employment taxes or contributions for unemployment insurance or pensions or annuities or social security payments which are measured by the remuneration paid to the Consultant or the Consultant’s agents, if any, as independent contractors and to reimburse and indemnify the Company for any such taxes or contributions or penalties which the Company may be compelled to pay as a result of the Consultant’s non-payment of the same as a self-employed individual. The Consultant also agrees to take all action and comply with all applicable administrative regulations necessary for the payment by the Consultant of such.

 

2

 

 

5. Inventions and Confidential Information. The Consultant hereby covenants, agrees and acknowledges as follows:

 

(a) The Company is engaged in a continuous program of research, design, development, production, marketing and servicing with respect to its businesses.

 

(b) The Consultant’s engagement hereunder creates a relationship of confidence and trust between the Consultant and the Company with respect to certain information pertaining to the business of the Company and its Affiliates (as hereinafter defined) or pertaining to the business of any client or customer of the Company or its Affiliates which may be made known to the Consultant by the Company or any of its Affiliates or by any client or customer of the Company or any of its Affiliates or learned by the Consultant during the period of Consultant’s engagement by the Company.

 

(c) The Company possesses and will continue to possess information that has been created, discovered or developed by, or otherwise become known to it (including, without limitation, information created, discovered or developed by, or made known to, the Consultant during the period of Consultant’s engagement or arising out of Consultant’s engagement) or in which property rights have been or may be assigned or otherwise conveyed to the Company, which information has commercial value in the business in which the Company is engaged and is treated by the Company as confidential.

 

(d) Any and all inventions, products, discoveries, improvements, processes, manufacturing, marketing and services methods or techniques, formulae, designs, styles, specifications, databases, computer programs (whether in source code or object code), know-how, strategies and data, whether or not patentable or registrable under copyright or similar statutes, made, developed or created by the Consultant (whether at the request or suggestion of the Company, any of its Affiliates, or otherwise, whether alone or in conjunction with others, and whether during regular hours of work or otherwise) during the period of Consultant’s engagement by the Company which may pertain to the business, products or processes of the Company or any of its Affiliates (collectively hereinafter referred to as “Inventions”), will be promptly and fully disclosed by the Consultant to an appropriate executive officer of the Company (other than Consultant) and will become property of the Company without any additional compensation therefor along with all papers, drawings, models, data, documents and other material pertaining to or in any way relating to any Inventions made, developed or created by Consultant as aforesaid. For the purposes of this Agreement, the term “Affiliate” or “Affiliates” shall mean any person, corporation or other entity directly or indirectly controlling or controlled by or under direct or indirect common control with the Company. For the purposes of this definition, “control” when used with respect to any person, corporation or other entity means the power to direct the management and policies of such person or entity, directly or indirectly, whether through the ownership of voting securities, by contract or otherwise; and the terms “controlling” and “controlled” have meanings correlative to the foregoing.

 

3

 

 

(e) The Consultant will keep confidential and will hold for the Company’s sole benefit any Invention which is to be the exclusive property of the Company under this Section 5 for which no patent, copyright, trademark or other right or protection is issued.

 

(f) The Consultant also agrees that the Consultant will not without the prior written consent of the Board of Directors of the Company (i) use for Consultant’s benefit or disclose at any time during Consultant’s engagement by the Company, or thereafter, except to the extent required by the performance by the Consultant of the Consultant’s duties as a consultant of the Company, any information obtained or developed by the Consultant while engaged by the Company with respect to any Inventions or with respect to any customers, clients, suppliers, products, employees, financial affairs, or methods of design, distribution, marketing, service, procurement or manufacture of the Company or any of its Affiliates, or any confidential matter, except information which at the time is generally known to the public other than as a result of disclosure by the Consultant not permitted hereunder, or (ii) take with the Consultant upon termination of its engagement by the Company any document or paper relating to any of the foregoing or any physical property of the Company or any of its Affiliates.

 

(g) The Consultant acknowledges and agrees that a remedy at law for any breach or threatened breach of the provisions of this Section 5 would be inadequate and, therefore, agrees that the Company and its Affiliates shall be entitled to injunctive relief in addition to any other available rights and remedies in case of any such breach or threatened breach; provided, however, that nothing contained herein shall be construed as prohibiting the Company or any of its Affiliates from pursuing any other rights and remedies available for any such breach or threatened breach.

 

(h) The Consultant agrees that upon termination of Consultant’s engagement by the Company for any reason, the Consultant shall immediately return to the Company all documents and other property in Consultant’s possession belonging to the Company or any of its Affiliates.

 

(i) Without limiting the generality of Section 8 hereof, the Consultant hereby expressly agrees that the foregoing provisions of this Section 6 shall be binding upon the Consultant’s partners, employees, successors and legal representatives.

 

6. Non-Competition.

 

(a) The term “Non-Compete Term” shall mean the period during which Consultant is engaged hereunder and the one-year period thereafter.

 

4

 

 

During the Non-Compete Term:

 

(i) the Consultant will not make any statement or perform any act intended to advance an interest of any direct competitor of the Company or any of its Affiliates in any way that will or may injure an interest of the Company or any of its Affiliates in its relationship and dealings with existing customers or clients, or knowingly solicit or encourage any employee of the Company or any of its Affiliates to do any act that is disloyal to the Company or any of its Affiliates or inconsistent with the interest of the Company or any of its Affiliate’s interests or in violation of any provision of this Agreement;

 

(ii) the Consultant will not discuss with any customers or clients of the Company or any of its Affiliates the present or future availability of services or products of a business, if the Consultant has or expects to acquire a proprietary interest in such business or is or expects to be a consultant, employee, officer or director of such business, where such services or products are directly competitive with services or products which the Company or any of its Affiliates provides;

 

(iii) the Consultant will not make any statement or do any act intended to cause any customers or clients of the Company or any of its Affiliates to make use of the services or purchase the products of any directly competitive business in which the Consultant has or expects to acquire a proprietary interest or in which the Consultant is or expects to be made an employee, officer or director, if such services or products directly compete with the services or products sold or provided or expected to be sold or provided by the Company or any of its Affiliates to any customer or client; and

 

(iv) the Consultant will not directly or indirectly (as a director, officer, employee, manager, consultant, independent contractor, advisor or otherwise) engage in direct competition with, or own any interest in, perform any services for, participate in or be connected with (A) any business or organization which engages in direct competition with the Company or any of its Affiliates in any geographical area where any business is presently carried on by the Company or any of its Affiliates, or (B) any business or organization which engages in direct competition with the Company or any of its Affiliates in any geographical area where any business shall be hereafter, during the period of the Consultant’s engagement by the Company, carried on by the Company or any of its Affiliates, if such business is then being carried on by the Company or any of its Affiliates in such geographical area; provided, however, that the provisions of this Section 6(a) shall not be deemed to prohibit the Consultant’s ownership of not more than one percent (1%) of the total shares of all classes of stock outstanding of any publicly held company.

 

(v) At the end of the Consultant’s engagement, the Company, in good faith, shall provide to the Consultant a list of the Company’s then-existing direct competitors, Affiliates, customers, businesses, organizations and others to which this Section 6 refers.

 

5

 

 

(b) During the Non-Compete Term, the Consultant will not directly or indirectly hire, engage, send any work to, place orders with, or in any manner be associated with any supplier, contractor, subcontractor or other person or firm which rendered manufacturing or other services, or sold any products, to the Company or any of its Affiliates if such action by Consultant would have a material adverse effect on the business, assets or financial condition of the Company or any of its Affiliates.

 

(c) In connection with the foregoing provisions of this Section 6, the Consultant represents that Consultant’s experience, capabilities and circumstances are such that such provisions will not prevent Consultant from earning a livelihood. The Consultant further agrees that the limitations set forth in this Section 6 (including, without limitation, any time or territorial limitations) are reasonable and properly required for the adequate protection of the businesses of the Company and its Affiliates. It is understood and agreed that the covenants made by the Consultant in this Section 6 (and in Section 5 hereof) shall survive the expiration or termination of this Agreement.

 

(d) For purposes of this Section 6, proprietary interest in a business is ownership, whether through direct or indirect stock holdings or otherwise, of one percent (1%) or more of such business.

 

(e) The Consultant acknowledges and agrees that a remedy at law for any breach or threatened breach of the provisions of this Section 6 would be inadequate and, therefore, agrees that the Company and any of its Affiliates shall be entitled to injunctive relief in addition to any other available rights and remedies in cases of any such breach or threatened breach; provided, however, that nothing contained herein shall be construed as prohibiting the Company or any of its Affiliates from pursuing any other rights and remedies available for any such breach or threatened breach.

 

7. Non-Assignability.

 

(a) Neither this Agreement nor any right or interest hereunder shall be assignable by the Consultant or its legal representatives without the Company’s prior written consent.

 

(b) Except as required by law, no right to receive payments under this Agreement shall be subject to anticipation, commutation, alienation, sale, assignment, encumbrance, charge, pledge, or hypothecation or to exclusion, attachment, levy or similar process or assignment by operation of law, and any attempt, voluntary or involuntary, to effect any such action shall be null, void and of no effect.

 

8. Binding Effect. Without limiting or diminishing the effect of Section 7 hereof, this Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective successors, legal representatives and assigns.

 

6

 

 

9. Notice. Any notice required or permitted to be given under this Agreement shall be sufficient if in writing and either delivered in person or sent by first class certified or registered mail, postage prepaid, if to the Company, at the Company’s principal place of business, attention: Chief Executive Officer and if to the Consultant, at Consultant’s office address set forth above, or to such other address or addresses as either party shall have designated in writing to the other party hereto.

 

10. Severability. The Consultant agrees that in the event that any court of competent jurisdiction shall finally hold that any provision of Section 5 or 6 hereof is void or constitutes an unreasonable restriction against the Consultant, such provision shall not be rendered void but shall apply with respect to such extent as such court may judicially determine constitutes a reasonable restriction under the circumstances. If any part of this Agreement other than Section 5 or 6 is held by a court of competent jurisdiction to be invalid, illegible or incapable of being enforced in whole or in part by reason of any rule of law or public policy, such part shall be deemed to be severed from the remainder of this Agreement for the purpose only of the particular legal proceedings in question and all other covenants and provisions of this Agreement shall in every other respect continue in full force and effect and no covenant or provision shall be deemed dependent upon any other covenant or provision.

 

11. Waiver. Failure to insist upon strict compliance with any of the terms, covenants or conditions hereof shall not be deemed a waiver of such term, covenant or condition, nor shall any waiver or relinquishment of any right or power hereunder at any one or more times be deemed a waiver or relinquishment of such right or power at any other time or times.

 

12. Entire Agreement; Modifications. This Agreement constitutes the entire and final expression of the agreement of the parties with respect to the subject matter hereof and supersedes all prior agreements, oral and written, between the parties hereto with respect to the subject matter hereof. This Agreement may be modified or amended only by an instrument in writing signed by both parties hereto.

 

13. Applicable Law and Venue. This Agreement shall be interpreted and construed in accordance with the laws of the State of California, without regard to its conflicts of law provisions.

 

14. Counterparts. This Agreement may be executed in two or more counterparts, each of which

shall be deemed an original, but all of which together shall constitute one and the same instrument.

 

15. Survival. The termination of Consultant’s engagement hereunder shall not affect the enforceability of Sections 5 or 6.

 

16. Further Assurances. The parties agree to execute and deliver all such further instruments and take such other and further action as may be reasonably necessary or appropriate to carry out the provisions of this Agreement.

 

17. Headings. The Section headings appearing in this Agreement are for purposes of easy reference and shall not be considered a part of this Agreement or in any way modify, amend or affect its provisions.

 

18. Facsimile or PDF Signatures. Facsimile or PDF signatures will be accepted as originals.

 

19. Legal Fees. If Consultant and/or its affiliates are required under a subpoena or other written requests to provide any information, testimony, or depositions, regarding the Company’s activities during the term of this agreement or after the termination of this agreement, for or by any persons, companies or agencies, the Company will pay for legal counsel to represent the Consultant and/or its affiliates.

 

7

 

 

IN WITNESS WHEREOF, the Company and the Consultant have duly executed and delivered this Agreement as of the day and year first above written.

 

  Consultant:
   
  /s/ Dean Skupen  
  DSS Consulting Corporation
  Dean S. Skupen, CPA(inactive)

 

  Company:
     
    /s/ Michael Campbell   
  By: Michael Campbell, CEO
    RealSource Residential, Inc.

 

8

 

EX-14 3 ex14.htm

 

Exhibit 14

 

CODE OF CONDUCT AND ETHICS

OF

CALETHOS, INC.

 

Adopted: March 28, 2022

 

The Board of Directors of CalEthos, Inc. (the “Company”) has adopted this Code of Ethics (this “Code”) to provide value for our stockholders; and

 

  To encourage honest and ethical conduct, including fair dealing and the ethical handling of conflicts of interest;
     
  To prompt full, fair, accurate, timely and understandable disclosure;
     
  To comply with applicable laws and governmental rules and regulations;
     
  To prompt internal reporting of violations of this Code;
     
  To protect the Company’s legitimate business interests, including corporate opportunities, assets and confidential information; and
     
  To deter wrongdoing.

 

All directors, officers, employees and independent contractors of the Company are expected to be familiar with this Code and to adhere to the principles and procedures set forth in this Code. For purposes of this Code, all directors, officers, employees and independent contractors are referred to collectively as “employees” or “you” throughout this Code.

 

I. Honest and Ethical Conduct

 

All directors, officers, employees and independent contractors owe duties to the Company to act with integrity. Integrity requires, among other things, being honest and ethical. This includes the ethical handling of actual or apparent conflicts of interest between personal and professional relationships. Deceit and subordination of principle are inconsistent with integrity.

 

All directors, officers, employees and independent contractors have the following duties:

 

  To conduct business with professional courtesy and integrity, and act honestly and fairly without prejudice in all commercial dealings;
     
  To work in a safe, healthy and efficient manner, using skills, time and experience to the maximum of abilities;
     
  To comply with applicable awards, Company policies and job requirements, and adhere to a high standard of business ethics;
     
  To observe both the form and spirit of laws, governmental rules, regulations and accounting standards;

 

 

 

 

  Not to knowingly make any misleading statements to any person or to be a party to any improper practice in relation to dealings with or by the Company;
     
  To ensure that Company resources and properties are used properly;
     
  To maintain the confidentiality of information where required or consistent with Company policies; and
     
  Not to disclose information or documents relating to the Company or its business, other than as required by law, not to make any unauthorized public comment on Company affairs and not to misuse any information about the Company or its associates, and not to accept improper or undisclosed material personal benefits from third parties as a result of any transaction or transactions of the Company.

 

II. Conflicts of Interest

 

A “conflict of interest” arises when an individual’s personal interest interferes or appears to interfere with the interests of the Company. A conflict of interest can arise when a director, officer or employee takes actions or has personal interests that may make it difficult to perform his or her Company work objectively and effectively.

 

There are a variety of situations in which a conflict of interest may arise. While it would be impractical to attempt to list all possible situations, some common types of conflicts may be:

 

  To serve as a director, employee or contractor for a company that has a business relationship with, or is a competitor of, the Company;
     
  To have a financial interest in a competitor, supplier or customer of the Company;
     
  To receive improper personal benefits from a competitor, supplier or customer, as a result of any transaction or transactions of the Company;
     
  To accept financial interest beyond entertainment or nominal gifts in the ordinary course of business, such as a meal or a coffee mug;
     
  To present at a conference where the conference sponsor has a real or potential business relationship with the Company (e.g. vendor, customer, or investor), and, the conference sponsor offers travel or accommodation arrangements or other benefits materially in excess of the Company’s standard; or
     
  To use for personal gain, rather than for the benefit of the Company, an opportunity that you discovered through your role with the Company.

 

Fidelity or service to the Company should never be subordinated to or dependent on personal gain or advantage. Conflicts of interest should be avoided.

 

In most cases, anything that would constitute a conflict for a director, officer or employee also would present a conflict if it is related to a member of his or her family.

 

2

 

 

Interests in other companies, including potential competitors and suppliers, that are purely for management of the other entity, or where an otherwise questionable relationship is disclosed to the Board and any necessary action is taken to ensure there will be no effect on the Company, are not considered conflicts unless otherwise determined by the Board.

 

Evaluating whether a conflict of interest exists can be difficult and may involve a number of considerations. Please refer to other policies, such as the employee handbook, for further information. We also encourage you to seek guidance from your manager, the Chief Executive Officer or the Chief Financial Officer, or their equivalents, when you have any questions or doubts.

 

III. Disclosure

 

Each director, officer or employee, to the extent involved in the Company’s disclosure process, including the Chief Executive Officer or Chief Financial Officer, or their equivalents (the “Senior Financial Officers”), is required to be familiar with the Company’s disclosure controls and procedures applicable to him or her so that the Company’s public reports and documents comply in all material respects with the applicable securities laws and rules. In addition, each such person having direct or supervisory authority regarding these securities filings or the Company’s other public communications concerning its general business, results, financial condition and prospects should, to the extent appropriate within his or her area of responsibility, consult with other Company officers and employees and take other appropriate steps regarding these disclosures with the goal of making full, fair, accurate, timely and understandable disclosure.

 

Each director, officer or employee, to the extent involved in the Company’s disclosure process, including the Senior Financial Officers, must:

 

  Familiarize himself or herself with the disclosure requirements applicable to the Company as well as the business and financial operations of the Company; and
     
  Not knowingly misrepresent, or cause others to misrepresent, facts about the Company to others, whether within or outside the Company, including to the Company’s independent auditors, governmental regulators and self-regulatory organizations.

 

IV. Compliance

 

It is the Company’s policy to comply with all applicable laws, rules and regulations. It is the personal responsibility of each employee, officer and director to adhere to the standards and restrictions imposed by those laws, rules and regulations in the performance of their duties for the Company, including those relating to accounting and auditing matters and insider trading.

 

The Board endeavors to ensure that the directors, officers and employees of the Company act with integrity and observe the highest standards of behavior and business ethics in relation to their corporate activities.

 

Specifically, directors, officers and employees must:

 

  Comply with the law;
     
  Act in the best interests of the Company;

 

3

 

 

  Be responsible and accountable for their actions; and
     
  Observe the ethical principles of fairness, honesty and truthfulness, including disclosure of potential conflicts.

 

Generally, it is against Company policies for any individual to profit from undisclosed information relating to the Company or any other company in violation of insider trading or other laws. Anyone who is aware of material nonpublic information relating to the Company, our customers, or other companies may not use the information to purchase or sell securities in violation of securities laws.

 

If you are uncertain about the legal rules involving your purchase or sale of any Company securities or any securities in companies with which you are familiar by virtue of your work for the Company, you should consult with the Chief Executive Officer or Chief Financial Officer, or their equivalents, before making any such purchase or sale. Other policies issued by the Company also provide guidance as to certain of the laws, rules and regulations that apply to the Company’s activities.

 

V. Reporting and Accountability

 

The Board of Directors has the authority to interpret this Code in any particular situation. Any director, officer or employee who becomes aware of any violation of this Code is required to notify the Chief Executive Officer or Chief Financial Officer, or their equivalents, promptly.

 

Any questions relating to how these policies should be interpreted or applied should be addressed to your manager, the Chief Executive Officer or the Chief Financial Officer, or their equivalents. Any material transaction or relationship that could reasonably be expected to give rise to a conflict of interest, as discussed in Section II of this Code, should be discussed with your manager, the Chief Executive Officer or the Chief Financial Officer, or their equivalents. A director, officer or employee who is unsure of whether a situation violates this Code should discuss the situation with the Chief Executive Officer or Chief Financial Officer, or their equivalents, to prevent possible misunderstandings and embarrassment at a later date.

 

Each director, officer or employee must:

 

  Notify the Chief Executive Officer or Chief Financial Officer, or their equivalents, promptly of any existing or potential violation of this Code.
     
  Not retaliate against any other director, officer or employee for reports of potential violations.

 

The Company will follow the following procedures in investigating and enforcing this Code and in reporting on the Code:

 

  The Chief Executive Officer or Chief Financial Officer, or their equivalents, as the case may be, will take all appropriate action to investigate any violations reported. In addition, the Chief Executive Officer or Chief Financial Officer, or their equivalents, as appropriate, shall report each violation and alleged violation involving a director or an executive officer to the Chairman of the Board of Directors. To the extent he or she deems appropriate, the Chairman of the Board of Directors shall participate in any investigation of a director or executive officer. After the conclusion of an investigation of a director or executive officer, the conclusions shall be reported to the Board of Directors.

 

4

 

 

  The Board of Directors will conduct such additional investigation as it deems necessary. The Board will determine that a director or executive officer has violated this Code. Upon being notified that a violation has occurred, the Chief Executive Officer or Chief Financial Officer, or their equivalents, as the case may be, will take such disciplinary or preventive action as deemed appropriate, up to and including dismissal or, in the event of criminal or other serious violations of law, notification of appropriate law enforcement authorities.

 

VI. Corporate Opportunities

 

Employees, officers and directors are prohibited from taking (or directing to a third party) a business opportunity that is discovered through the use of corporate property, information or position, unless the Company has already been offered the opportunity and turned it down. More generally, employees, officers and directors are prohibited from using corporate property, information or position for personal gain and from competing with the Company.

 

Sometimes, the line between personal and Company benefits is difficult to draw, and sometimes there are both personal and Company benefits in certain activities. Employees, officers and directors who intend to make use of Company property or services in a manner not solely for the benefit of the Company should consult beforehand with your manager, the Chief Executive Officer or the Chief Financial Officer, or their equivalents.

 

VII. Confidentiality

 

In carrying out the Company’s business, employees, officers and directors often learn confidential or proprietary information about the Company, its customers, suppliers, or joint venture parties. Employees, officers and directors must maintain the confidentiality of all information so entrusted to them, except when disclosure is authorized or legally mandated. Confidential or proprietary information of our Company, and of other companies, includes any non-public information that would be harmful to the relevant company or useful or helpful to competitors if disclosed.

 

VIII. Fair Dealing

 

Our core value of operating is based on responsiveness, openness, honesty and trust with our members, business partners, employees and stockholders. We do not seek competitive advantages through illegal or unethical business practices. Each employee, officer and director should endeavor to deal fairly with the Company’s customers, service providers, suppliers, competitors and employees. No employee, officer or director should take unfair advantage of anyone through manipulation, concealment, abuse of privileged information, misrepresentation of material facts, or any unfair dealing or practice.

 

IX. Protection and Proper Use of Company Assets

 

All employees, officers and directors should protect the Company’s assets and ensure their efficient use. All Company assets should be used only for legitimate business purposes. Theft, carelessness and waste have a direct impact on our profit.

 

XI. Waivers and Amendments

 

From time to time, the Company may waive provisions of this Code. Any employee or director who believes that a waiver may be called for should discuss the matter with your manager, the Chief Executive Officer or the Chief Financial Officer, or their equivalents.

 

Any waiver of the Code for executive officers (including Senior Financial Officers) or directors of the Company may be made only by the Board of Directors and must be promptly disclosed to stockholders along with the reasons for such waiver in a manner as required by applicable law or the rules of the applicable stock exchange. Any amendment or waiver of any provision of this Code must be approved in writing by the Board or, if appropriate, its delegate(s) and promptly disclosed pursuant to applicable laws and regulations.

 

Any waiver or modification of the Code for a Senior Financial Officer will be promptly disclosed to stockholders if and as required by applicable law or the rules of the applicable stock exchange.

 

The Company is committed to continuously reviewing and updating its policies, and therefore reserves the right to amend this Policy at any time, for any reason, subject to applicable law.

 

5

EX-31.1 4 ex31-1.htm

 

Exhibit 31.1

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

 

I, Michael Campbell, certify that:

 

1. I have reviewed this Annual Report on Form 10-K of CalEthos, Inc. (the “Registrant”);
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a) Designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c)  Evaluated the effectiveness of the registrant’s disclosure controls and procedures; and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and
     
  d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 31, 2022 /s/ Michael Campbell
  Michael Campbell
 

Chief Executive Officer

(Principal Executive Officer)

 

 

 

 

EX-31.2 5 ex31-2.htm

 

Exhibit 31.2

 

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

 

I, Dean S. Skupen, certify that:

 

1. I have reviewed this Annual Report on Form 10-K of CalEthos, Inc. (the “Registrant”);
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a) Designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures; and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and
     
  d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 31, 2022 /s/ Dean S. Skupen
  Dean S. Skupen
 

Chief Financial Officer

(Principal Financial Officer)

 

 

 

 

EX-32.1 6 ex32-1.htm

 

Exhibit 32.1

 

CERTIFICATION

OF PRINCIPAL EXECUTIVE OFFICER AND

PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U. S. C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report of CalEthos, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2021 (the “Report”), I, Michael Campbell, Chief Executive Officer of the Company, and I, Dean S. Skupen, Chief Financial Officer of the Company, hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that:

 

1. The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and
   
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: March 31, 2022 /s/ Michael Campbell
  Michael Campbell
 

Chief Executive Officer

(Principal Executive Officer)

 

Date: March 31, 2022 /s/ Dean S. Skupen
  Dean S. Skupen
 

Chief Financial Officer

(Principal Financial Officer)

 

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed from within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

 

 

EX-101.SCH 7 buuz-20211231.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations And Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statements of Changes in Stockholders' Deficit link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Organization and Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Accounts Payable and Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Convertible Promissory Notes link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Stockholders’ Deficit link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Deferred Tax Assets and Income Tax Provision link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Organization and Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Organization and Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Accounts Payable and Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Notes Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Convertible Promissory Notes (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Stockholders’ Deficit (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Deferred Tax Assets and Income Tax Provision (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Schedule of Income and Loss Per Share Anti-dilutive (Details) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Organization and Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Schedule of Accounts Payable and Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Schedule of Accrued Interest (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Schedule of Notes Payable (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Notes Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Schedule of Convertible Promissory Notes (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Schedule of Potential Future Shares Issuance of Conversion Notes (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Convertible Promissory Notes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Schedule of Remaining Payments (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Schedule of Company Restricted Stock Awards (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Schedule of Stock Option Activities (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Schedule of Warrants Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Schedule of Fair Value of Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Stockholders’ Deficit (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Schedule of Components of Deferred Tax Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Schedule of Reconciliation of Income Tax (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Deferred Tax Assets and Income Tax Provision (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 buuz-20211231_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 buuz-20211231_def.xml XBRL DEFINITION FILE EX-101.LAB 10 buuz-20211231_lab.xml XBRL LABEL FILE Class of Stock [Axis] Series A Convertible Preferred Stock [Member] Equity Components [Axis] Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Stock Subscription Receivable [Member] AOCI Attributable to Parent [Member] Retained Earnings [Member] Related Party Transaction [Axis] AIQ [Member] Geographical [Axis] KOREA, REPUBLIC OF Antidilutive Securities [Axis] Restricted Stock Award [Member] Convertible Promissory Notes and Accrued Interest [Member] Series A Warrants Issued with Convertible Promissory Notes [Member] Series B Warrants to Be Issued Upon Exercise of Series A Warrant [Member] Warrants Issued For Services [Member] Stock Options [Member] Title of Individual [Axis] M1 Advisors [Member] Debt Instrument [Axis] Promissory Note [Member] Borrower [Member] Promissory Note One [Member] Promissory Note Two [Member] Promissory Note Three [Member] Convertible Promissory Note One [Member] Convertible Promissory Note Two [Member] Warrant [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Convertible Promissory Note [Member] Series A Preferred Stock [Member] Convertible Notes Payable [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Technology Development Agreement [Member] Legal Entity [Axis] PICOCEL Co Ltd [Member] Termination Agreement [Member] Chief Executive Officer [Member] Chief Financial Officer [Member] Consultants [Member] New Consulting Agreement [Member] Shareholder [Member] Letter of Understanding [Member] Vesting [Axis] Share-based Payment Arrangement, Tranche One [Member] Share-based Payment Arrangement, Tranche Two [Member] Share-based Payment Arrangement, Tranche Three [Member] Award Type [Axis] Restricted Stock [Member] Measurement Input Type [Axis] Measurement Input, Expected Term [Member] Measurement Input, Risk Free Interest Rate [Member] Measurement Input, Price Volatility [Member] Measurement Input, Expected Dividend Rate [Member] Measurement Input, Share Price [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] ICFR Auditor Attestation Flag Auditor Firm ID Auditor Name Auditor Location Statement [Table] Statement [Line Items] ASSETS Current assets Cash and cash equivalents Prepaid expenses Total current assets Other assets Total assets LIABILITIES AND STOCKHOLDERS’ DEFICIT Current liabilities Accounts payable and accrued expenses Notes payable, net Convertible promissory notes, net Total liabilities Commitments and contingencies (Note 6) Stockholders’ deficit Preferred stock, par value $0.001, 100,000,000 shares authorized; no shares issued and outstanding Common stock, par value $0.001, 100,000,000 shares authorized; 25,995,621 and 16,634,951 shares issued and outstanding Additional paid-in capital Other comprehensive loss Stock subscription receivable Accumulated deficit Total stockholders’ deficit Total liabilities and stockholders’ deficit Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common Stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenue Operating expenses Professional fees General and administrative expenses Total operating expenses Loss from operations Other expenses Financing costs Loss on extinguishment of series A convertible preferred stock Total other expenses Loss before provision for income taxes Provision for income taxes Net loss Net loss per share, basic and diluted Weighted average common shares outstanding – basic and diluted Comprehensive loss: Change in foreign currency translation Comprehensive loss Balance Balance, shares Conversion of series A preferred stock to convertible promissory notes Conversion of series A preferred stock to convertible promissory notes, shares Fair value of warrants issued with the conversion of series A convertible preferred stock Debt premium on issuance of convertible promissory notes for conversion of series A convertible preferred stock Relative fair value of warrants issued with convertible promissory note Net loss Stock options issued for services Stock issued for debt forgiveness Stocks issued for debt forgiveness, shares Stock issued for accrued compensation Stocks returned Stocks returned, shares Stock issued on exercise of options Stock issued on exercise of options, shares Stock-based compensation Stock-based compensation, shares Restricted common stock awards issued for compensation Restricted common stock awards issued for compensation, shares Foreign currency translation loss Ending balance, value Balance, shares Statement of Cash Flows [Abstract] Cash flows from operating activities Adjustments to reconcile net loss to net cash used in operating activities: Amortization of convertible promissory note discounts Loss on extinguishment of convertible preferred stock Fair value of warrants issued for extinguishment of convertible preferred stock Fair value of equity-based compensation Accretion of compensation cost for restricted stock awards Changes in operating asset and liabilities Prepaid expenses Accounts payable and accrued expenses Net cash used in operating activities Cash flows from investing activity Payment for other assets Net cash used in investing activity Cash flows from financing activities Proceeds from the issuance of convertible promissory notes Proceeds from the issuance of notes payable Repayment of notes payable Proceeds from the exercise of options Net cash provided by financing activities Effect of exchange rate changes on cash and cash equivalents Net increase (decrease) in cash Cash at beginning of reporting period Cash at end of reporting period Supplemental disclosure of cash flows information Interest paid Income tax paid Supplemental disclosure of non-cash financing activities: Conversion of series A preferred stock to convertible promissory notes Fair value of warrants issued with the conversion of series A convertible preferred stock Debt premium on issuance of convertible promissory notes for conversion of series A convertible preferred stock Relative fair value of warrants issued with convertible promissory note Common stock issued for accrued compensation Common stock issued for debt forgiveness Original issue discount recorded on convertible promissory notes Accounting Policies [Abstract] Organization and Accounting Policies Related Party Transactions [Abstract] Related Party Transactions Payables and Accruals [Abstract] Accounts Payable and Accrued Expenses Notes Payable Notes Payable Debt Disclosure [Abstract] Convertible Promissory Notes Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Equity [Abstract] Stockholders’ Deficit Income Tax Disclosure [Abstract] Deferred Tax Assets and Income Tax Provision Subsequent Events [Abstract] Subsequent Events Amendments to Certificate of Incorporation Incorporation of Korean entity Basis of Presentation Principles of Consolidation Going Concern and Liquidity Use of Estimates Foreign Currency Translation Fair Value Measurement Cash and Cash Equivalents Prepaid Expense Other Assets Related Parties Commitments and Contingencies Debt Discounts Warrant Liability Stock-Based Compensation Income Taxes Earnings Per Share Recent Accounting Pronouncements Schedule of Income and Loss Per Share Anti-dilutive Schedule of Accounts Payable and Accrued Expenses Schedule of Accrued Interest Schedule of Notes Payable Schedule of Convertible Promissory Notes Schedule of Potential Future Shares Issuance of Conversion Notes Schedule of Remaining Payments Schedule of Company Restricted Stock Awards Schedule of Stock Option Activities Schedule of Warrants Activity Schedule of Fair Value of Warrants Schedule of Components of Deferred Tax Assets Schedule of Reconciliation of Income Tax Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Total potential future shares Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] Common stock shares authorized Issuance of common stock Issuance of common stock Ownership percentage Net Income (Loss) Attributable to Parent Retained Earnings (Accumulated Deficit) Cash, FDIC Insured Amount Prepaid Insurance Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table] Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items] Proceeds from related party Miscellaneous operating expenses Accounts payable Accrued expenses Accrued interest Accounts payable and accrued expenses Notes payable Convertible promissory notes Balance, end of the year Schedule Of Notes Payable Balance, beginning of the year Additions Payments Balance, end of the year Schedule of Short-term Debt [Table] Short-term Debt [Line Items] Debt instrument, face amount Debt instrument, interest rate Debt instrument, maturity date Increase in interest rate Debt instrument, periodic payment Debt instrument, maturity date Proceeds from notes payable Debt instrument, issue discount Interest Expense, Debt Balance, beginning of year Additions Balance, end of year Balance, beginning of year Additions Amortization Balance, end of year Net carrying amount Principal Interest Total Conversion price per share Potential future share Convertible promissory note Proceed from convertible debt Original issue discount Debt instruments, conversion price Events of default description Indebtedness for borrowed money maximum limit Issuance of warrants to purchase of common stock Issuance of warrant price per share Fair value of common stock Fair value of common stock estimated life Date of issuance volatility percentage Fair value of common stock risk free interest rate Share price Relative fair value of warrants issued with convertible promissory notes Debt instrument, convertible, beneficial conversion feature Debt Conversion, Converted Instrument, Amount Debt Instrument, Maturity Date, Description Fair value of warrants issued with conversion of convertible preferred stock Fair value and face value of notes Amortization of Debt Issuance Costs and Discounts Debt Instrument, Interest Rate, Effective Percentage Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Payments to be signing contract Payments upon delivery board Total Revenue, Remaining Performance Obligation, Amount [custom:PaymentsForCollaborators] Litigation description Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Grant date fair value, shares Deferred compensation grant date fair value Accretion, shares Deferred compensation accretion Shares, balance Deferred compensation Number of Stock Option Shares, Outstanding, Beginning of period Exercise Price Range Per Share, Outstanding, Beginning of period Weighted Average Exercise Price, Outstanding, Beginning of period Relative Fair Value, Outstanding, Beginning of period Aggregate Intrinsic Value, Beginning of period Number of Stock Option Shares, Granted Exercise Price Range Per Share, Granted Weighted Average Exercise Price, Granted Relative Fair Value, Granted Aggregate Intrinsic Value, Granted Number of Stock Option Shares, Forfeited Exercise Price Range Per Share, Forfeited Weighted Average Exercise Price, Forfeited Relative Fair Value, Forfeited Aggregate Intrinsic Value, Forfeited Number of Stock Option Shares, Exercised Exercise Price Range Per Share, Exercised Weighted Average Exercise Price, Exercised Relative Fair Value, Exercised Aggregate Intrinsic Value, Exercised Number of Stock Option Shares, Expired Exercise Price Range Per Share, Expired Weighted Average Exercise Price, Expired Relative Fair Value, Expired Aggregate Intrinsic Value, Expired Number of Stock Option Shares, Outstanding, Ending of period Exercise Price Range Per Share, Outstanding, Ending of period Weighted Average Exercise Price, Outstanding, Ending of period Relative Fair Value, Outstanding, Ending of period Aggregate Intrinsic Value, Ending of period Number of Stock Option, Vested and Exercisable, Ending Balance Exercise Price Range Per Share, Vested and Exercisable Weighted Average Exercise Price, Vested and Exercisable Relative Fair Value, Vested and Exercisable Aggregate Intrinsic Value, Vested and Exercisable Number of Stock Option, Unvested, Ending Balance Exercise Price Range Per Share, Unvested Weighted Average Exercise Price, Unvested Relative Fair Value, Unvested Aggregate Intrinsic Value, Unvested Number of warrants issued, Outstanding, Beginning of period Weighted Average Strike Price/Share, Outstanding, Beginning of period Weighted Average Remaining Contractual Term (Years) Weighted Average Grant Date Fair Value/Share, Beginning of period Aggregate intrinsic value, Beginning of period Number of warrants issued, Granted Weighted Average Strike Price/Share, Granted Weighted Average Remaining Contractual Term (Years), Granted Weighted Average Grant Date Fair Value/Share, Granted Aggregate intrinsic value, Granted Number of warrants issued, Forfeited Weighted Average Strike Price/Share, Forfeited Weighted Average Grant Date Fair Value/Share, forfeited Aggregate intrinsic value, forfeited Number of warrants issued, Exercised Weighted Average Strike Price/Share, Exercised Weighted Average Grant Date Fair Value/Share, Exercised Aggregate intrinsic value, Exercised Number of warrants issued, Expired Weighted Average Strike Price/Share, Expired Weighted Average Grant Date Fair Value/Share, Expired Aggregate intrinsic value, Expired Number of warrants issued, Outstanding, Ending of period Weighted Average Strike Price/Share, Outstanding, Ending of period Weighted Average Grant Date Fair Value/Share, Ending of period Aggregate intrinsic value, Ending of period Number of warrants issued, Vested and Exercisable, Ending of period Weighted Average Strike Price/Share, Vested and Exercisable, Ending of period Weighted Average Remaining Contractual Term (Years), Vested and Exercisable Weighted Average Grant Date Fair Value/Share, Vested and Exercisable, Ending of period Aggregate intrinsic value, Vested and Exercisable, Ending of period Number of warrants issued, Vested, Ending of period Weighted Average Strike Price/Share, Unvested, Ending of period Weighted Average Remaining Contractual Term (Years), Unvested Weighted Average Grant Date Fair Value/Share, Vested, Ending of period Aggregate intrinsic value, Vested, Ending of period Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Warrants and rights outstanding, term Dividend yield Schedule of Stock by Class [Table] Class of Stock [Line Items] Authorized to issue shares Common stock, par value Sale of stock shares price per share Debt Instrument, Convertible, Conversion Price Conversion rate adjustment, value Proceeds from Issuance of Common Stock Sale of Stock, Description of Transaction Conversion of shares Conversion of debt Return of shares Debt instrument decrease forgiveness Due to related parties Reduction amount Stock issued during period shares new issues Remaining cash liability Stock Issued During Period, Shares, Issued for Services Stock Issued During Period, Value, Issued for Services Restricted common stock shares granted Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Shares Issued, Price Per Share Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Option to purhase shares Fair value of options Option expense Share-based compensation arrangement by share-based payment award, options Number of share options exercised Class of warrant exercise price Proceeds from stock options exercised Number of securities called by warrants or rights Fair value assumptions, expected volatility rate Expected Term Risk Free Interest Rate Expected Dividend Payments Stock-based compensation Expected income tax benefit from NOL carry-forwards Less valuation allowance Deferred tax assets, net of valuation allowance Federal statutory income tax rate Change in valuation allowance on net operating loss carry-forwards Effective income tax rate Net operating loss deferred tax Deferred tax assets,net Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Subsequent Event [Table] Subsequent Event [Line Items] Payments to Related Parties Notes payable paid Convertible debt outstanding Converted instrument, rate Stock subscription receivable. Series A Convertible Preferred Stock [Member] Notes payable disclosure [Text Block] Loss on extinguishment of series A convertible preferred stock. Financing costs. Conversion of series A preferred stock to convertible promissory notes. Fair value of warrants issued with the conversion of series A convertible preferred stock. Debt premium on issuance convertible promissory notes for conversion of series A convertible preferred stock. Loss on extinguishment of convertible preferred stock. Fair value of warrants issued with convertible promissory notes. Payment for other assets. Relative fair value of warrants issued with convertible promissory note. Notes payable additions. Common stock issued for accrued compensation. Common stock issued for debt forgiveness. Promissory Note [Member] Stock Subscription Receivable [Member] Borrower [Member] Relative fair value of warrants issued with convertible promissory notes. Promissory Note One [Member] Promissory Note Two [Member] Accretion of compensation cost for restricted stock awards. Promissory Note Three [Member] Change in Control [Policy Text Block] Going Concern and Liquidity [Policy Text Block] Related Parties [Policy Text Block] Warrant Liability [Policy Text Block] Convertible Promissory Note One [Member] Convertible Promissory Note Two [Member] Prepaid expense [Policy Text Block] Non controlling Interests [Policy Text Block] M1 Advisors [Member] Convertible promissory notes. Indebtedness for borrowed money maximum limit. AIQ [Member] Share based compensation arrangement by share based payment award fair value of commonStock. Convertible Promissory Notes and Accrued Interest [Member] Series A Warrants Issued with Convertible Promissory Notes [Member] Series B Warrants to Be Issued Upon Exercise of Series A Warrant [Member] Relative fair value of warrants issued with convertible promissory notes. Warrants Issued For Services [Member] Stock Options [Member] Convertible Promissory Note [Member] Debt instrument additions. Debt instrument unamortized discount additions. Debt instrument unamortized discount amortization. Schedule of potential future shares issuance of conversion notes [Table Text Block] Debt instrument conversion note principal amount. Debt instrument conversion note interest expenses. Debt instrument conversion note. Debt instrument potential future share. Technology Development Agreement [Member] PICOCEL Co Ltd [Member] Payments for Collaborators. Payments to be made upon signing contract. Payments to be made upon completion of initial service delivery. Payments to be made upon contract and service delivery. Technology Development Agreement [Table Text Block] Number of authorized capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies. Conversion rate adjustment, value. Stock issued during period return of shares. Termination Agreement [Member] Reduction amount. Remaining liability paid for cash. Consultants [Member] Grant date fair value shares. Accretion Shares. Deferred compensation grant date fair value. Deferred compensation accretion. New Consulting Agreement [Member] Shareholder [Member] Letter of Understanding [Member] Number of Stock Option Shares, Canceled. Number of Stock Option Earned and Exercisable, Ending Balance. Share based compensation arrangement by share based payment award options vested and exercisable ending balance. Number of Stock Option Unvested, Ending Balance. Exercise Price Range Per Share, Outstanding, Beginning Exercise Price Range Per Share, Granted. Exercise Price Range Per Share, Canceled. Exercise Price Range Per Share, Exercised. Exercise Price Range Per Share, Expired. Exercise Price Range Per Share, Outstanding, Ending. Exercise Price Range Per Share, Earned and Exercisable. Share based compensation arrangements by share based payment award Optionsexercisable in period exercise price range per share vested and exercisable. Exercise Price Range Per Share, Unvested. Weighted Average Exercise Price, Earned and Exercisable. Weighted Average Exercise Price, Canceled. Share based compensation arrangement by share based payment award options outstanding weighted average exercise price vested and exercisable. Weighted Average Exercise Price, Unvested. Relative Fair Value, Outstanding, Beginning. Relative Fair Value, Granted. Relative Fair Value, Canceled Relative Fair Value, Exercised Relative Fair Value, Expired. Relative Fair Value, Earned and Exercisable. Share based compensation arrangements by share based payment award options exercisable in period relative fair value vested and exercisable. Relative Fair Value, Unvested. Share based compensation arrangement by share based payment award options grants in period canceled intrinsic value. Share based compensation arrangement by share based payment award options in period exercisedintrinsic value. Share based compensation arrangement by share based payment award options in period expired intrinsic value. Aggregate Intrinsic Value, Unvested Share based compensation arrangement by share based payment award options granted intrinsic value. Share based compensation arrangement by share based payment award options granted intrinsic value. Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expired Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Vested And Exercisable Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Vested And Exercisable Weighted average price at which grantees can acquire the shares reserved for issuance under the stock non-option equity plan. Weighted average per share amount at which grantees can acquire shares of common stock by exercise of non-option equity. Weighted average price at which grantees could have acquired the underlying shares with respect to stock non options that were terminated. Weighted Average Exercise Price, Warrants exercised. Share based compensation arrangements by share based payment award non options expired in period weighted average exercise price. Share based compensation arrangements by share based payment award non options expired in period weighted average price vested and exerciable. Share based compensation arrangement by share based paymentaward non option equity instruments weighted average price vested. Share based compensation arrangement by share based paymentaward non option equity instruments weighted average Remaining ContractualTerm. Share Based compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Remaining Contractual Term Share based compensation arrangement by share based payment award non option equity instruments weighted average grant fair value. Share based compensation arrangement by share based payment award non option equity instruments weighted average grant fair value. Share based compensation arrangement by share based payment award non option equity instruments weighted average grant fair value canceled. Share based compensation arrangement by share based payment award non option equity instruments weighted average grant fair value exercised. Share based compensation arrangement by share based payment award non option equity instruments weighted average grant fair value expired. Share based compensation arrangement by share based payment award non option equity instruments weighted average grant fair value vested and exercisable. Share based compensation arrangement by share based payment award non option equity instruments weighted average grant fair value vested. Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Aggregate Intrinsic Value. Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Grants In Period Aggregate Intrinsic Canceled. Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Grants In Period Aggregate Intrinsic Value Exercised Share based compensation arrangement by share based payment award non option equity instruments grants in period aggregate intrinsic value granted. Share based compensation arrangement by share based payment award non option equity instruments grants in period aggregate intrinsic value expired. Share based compensation arrangement by share based payment award non option equity instruments aggregate intrinsic value vested and exercisable. Share based compensation arrangement by share based payment award non option equity instruments aggregate intrinsic value vested. Restricted Stock Award [Member] Weighted average remaining contractual term unvested and exercisable. Weighted average remaining contracutal term unvested. Fair value of warrants issued for extinguishment of convertible preferred stock. Original issue discount recorded on convertible promissory notes. Sharebased compensation arrangements by ShareBased payment award options in period exercise price range per share forfeited. Sharebased compensation arrangements by ShareBased payment award options in period exercises in period relative fair value forfeited. ShareBased compensation arrangement By ShareBased payment award options grants in period forfeited intrinsic value. ShareBased compensation arrangement by shareBased payment award non option equity instruments grants in period weighted average grant fair value forfeited. ShareBased compensation arangement by shareBased payment award non option equity instruments grants in period aggregate intrinsic forfeited. Stock based compensation. Payments to Related Parties. Payments to Notes Holders. Other Assets [Policy Text Block] Separation payment made in cash. Assets, Current Assets Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Operating Income (Loss) LossOnExtinguishmentOfSeriesConvertiblePreferredStock Nonoperating Income (Expense) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Comprehensive Income (Loss), Net of Tax, Attributable to Parent Shares, Outstanding Increase (Decrease) in Prepaid Expense Increase (Decrease) in Accounts Payable and Accrued Liabilities Net Cash Provided by (Used in) Operating Activities Net Cash Provided by (Used in) Investing Activities Repayments of Notes Payable Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents ConversionOfSeriesPreferredStockToConvertiblePromissoryNotes RelativeFairValueOfWarrantsIssuedWithConvertiblePromissoryNote NotesPayableDisclosureTextBlock Commitments and Contingencies, Policy [Policy Text Block] Notes Payable, Current DebtInstrumentAdditions DebtInstrumentUnamortizedDiscountAdditions Convertible Notes Payable, Current PaymentsToBeMadeUponContractAndServiceDelivery Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceRangePerShareOutstandingBeginning Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRelativeFairValueOutstandingBeginning Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceRangePerShareOutstandingEnding ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableEndingBalance Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedEndingBalance ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAggregateIntrinsicValueUnvested Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageGrantFairValue ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAggregateIntrinsicValue StockBasedCompensation Deferred Tax Assets, Valuation Allowance Deferred Tax Assets, Net EX-101.PRE 11 buuz-20211231_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover - USD ($)
12 Months Ended
Dec. 31, 2021
Mar. 15, 2022
Jun. 30, 2021
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2021    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2021    
Current Fiscal Year End Date --12-31    
Entity File Number 000-50331    
Entity Registrant Name CalEthos, Inc.    
Entity Central Index Key 0001174891    
Entity Tax Identification Number 98-0371433    
Entity Incorporation, State or Country Code NV    
Entity Address, Address Line One 11753 Willard Avenue    
Entity Address, City or Town Tustin    
Entity Address, State or Province CA    
Entity Address, Postal Zip Code 92782    
City Area Code (714)    
Local Phone Number 352-5315    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 7,249,894
Entity Common Stock, Shares Outstanding   25,995,621  
ICFR Auditor Attestation Flag false    
Auditor Firm ID 587    
Auditor Name RBSM LLP    
Auditor Location Larkspur, CA    
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Current assets    
Cash and cash equivalents $ 3,047,000
Prepaid expenses 7,000 2,000
Total current assets 3,054,000 2,000
Other assets 38,000
Total assets 3,092,000 2,000
Current liabilities    
Accounts payable and accrued expenses 434,000 611,000
Notes payable, net 111,000 11,000
Convertible promissory notes, net 3,087,000 703,000
Total liabilities 3,632,000 1,325,000
Commitments and contingencies (Note 6)
Stockholders’ deficit    
Preferred stock, par value $0.001, 100,000,000 shares authorized; no shares issued and outstanding
Common stock, par value $0.001, 100,000,000 shares authorized; 25,995,621 and 16,634,951 shares issued and outstanding 26,000 17,000
Additional paid-in capital 16,269,000 8,744,000
Other comprehensive loss (2,000)
Stock subscription receivable (2,000) (2,000)
Accumulated deficit (16,831,000) (10,082,000)
Total stockholders’ deficit (540,000) (1,323,000)
Total liabilities and stockholders’ deficit 3,092,000 2,000
Series A Convertible Preferred Stock [Member]    
Stockholders’ deficit    
Preferred stock, par value $0.001, 100,000,000 shares authorized; no shares issued and outstanding
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Balance Sheets (Parenthetical) - $ / shares
Dec. 31, 2021
Dec. 31, 2020
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares authorized 100,000,000 100,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common Stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 100,000,000 100,000,000
Common stock, shares issued 25,995,621 16,634,951
Common stock, shares outstanding 25,995,621 16,634,951
Series A Convertible Preferred Stock [Member]    
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares authorized 3,600,000 3,600,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statements of Operations And Comprehensive Loss - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Income Statement [Abstract]    
Revenue
Operating expenses    
Professional fees 6,095,000 340,000
General and administrative expenses 57,000 51,000
Total operating expenses 6,152,000 391,000
Loss from operations (6,152,000) (391,000)
Other expenses    
Financing costs (597,000) (227,000)
Loss on extinguishment of series A convertible preferred stock (138,000)
Total other expenses (597,000) (365,000)
Loss before provision for income taxes (6,749,000) (756,000)
Provision for income taxes
Net loss $ (6,749,000) $ (756,000)
Net loss per share, basic and diluted $ (0.35) $ (0.05)
Weighted average common shares outstanding – basic and diluted 19,482,261 16,634,951
Comprehensive loss:    
Change in foreign currency translation $ (2,000)
Comprehensive loss $ (6,751,000) $ (756,000)
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statements of Changes in Stockholders' Deficit - USD ($)
Preferred Stock [Member]
Series A Convertible Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Stock Subscription Receivable [Member]
AOCI Attributable to Parent [Member]
Retained Earnings [Member]
Total
Balance at Dec. 31, 2019 $ 17,000 $ 8,750,000 $ (2,000) $ (9,326,000) $ (561,000)
Balance, shares at Dec. 31, 2019 85,975 16,634,951          
Conversion of series A preferred stock to convertible promissory notes (119,000) (119,000)
Conversion of series A preferred stock to convertible promissory notes, shares (85,975)            
Fair value of warrants issued with the conversion of series A convertible preferred stock 52,000 52,000
Debt premium on issuance of convertible promissory notes for conversion of series A convertible preferred stock 58,000 58,000
Relative fair value of warrants issued with convertible promissory note 3,000 3,000
Net loss (756,000) $ (756,000)
Stock issued on exercise of options, shares            
Foreign currency translation loss            
Ending balance, value at Dec. 31, 2020 $ 17,000 8,744,000 (2,000) (10,082,000) (1,323,000)
Balance, shares at Dec. 31, 2020 16,634,951          
Relative fair value of warrants issued with convertible promissory note 1,690,000 1,690,000
Net loss (6,749,000) (6,749,000)
Stock options issued for services 575,000 575,000
Stock issued for debt forgiveness 166,000 166,000
Stocks issued for debt forgiveness, shares   75,000          
Stock issued for accrued compensation 38,000 38,000
Stocks returned $ (4,000) 4,000
Stocks returned, shares   (3,674,330)          
Stock issued on exercise of options $ 2,000 $ 2,000
Stock issued on exercise of options, shares   1,435,000         1,435,000
Stock-based compensation 272,000 $ 272,000
Stock-based compensation, shares   25,000          
Restricted common stock awards issued for compensation $ 11,000 4,780,000 4,791,000
Restricted common stock awards issued for compensation, shares   11,500,000          
Foreign currency translation loss (2,000) (2,000)
Ending balance, value at Dec. 31, 2021 $ 26,000 $ 16,269,000 $ (2,000) $ (2,000) $ (16,831,000) $ (540,000)
Balance, shares at Dec. 31, 2021 25,995,621          
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statements of Cash Flows - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Cash flows from operating activities    
Net loss $ (6,749,000) $ (756,000)
Adjustments to reconcile net loss to net cash used in operating activities:    
Amortization of convertible promissory note discounts 524,000 188,000
Loss on extinguishment of convertible preferred stock 86,000
Fair value of warrants issued for extinguishment of convertible preferred stock 52,000
Fair value of equity-based compensation 846,000
Accretion of compensation cost for restricted stock awards 4,791,000
Changes in operating asset and liabilities    
Prepaid expenses (5,000)
Accounts payable and accrued expenses 28,000 248,000
Net cash used in operating activities (565,000) (182,000)
Cash flows from investing activity    
Payment for other assets (38,000)
Net cash used in investing activity (38,000)
Cash flows from financing activities    
Proceeds from the issuance of convertible promissory notes 3,550,000 49,000
Proceeds from the issuance of notes payable 150,000 10,000
Repayment of notes payable (50,000)
Proceeds from the exercise of options 2,000
Net cash provided by financing activities 3,652,000 59,000
Effect of exchange rate changes on cash and cash equivalents (2,000)
Net increase (decrease) in cash 3,047,000 (123,000)
Cash at beginning of reporting period 123,000
Cash at end of reporting period 3,047,000
Supplemental disclosure of cash flows information    
Interest paid
Income tax paid
Supplemental disclosure of non-cash financing activities:    
Conversion of series A preferred stock to convertible promissory notes 119,000
Fair value of warrants issued with the conversion of series A convertible preferred stock 52,000
Debt premium on issuance of convertible promissory notes for conversion of series A convertible preferred stock 58,000
Relative fair value of warrants issued with convertible promissory note 1,690,000 3,000
Common stock issued for accrued compensation 38,000
Common stock issued for debt forgiveness 166,000
Original issue discount recorded on convertible promissory notes $ 355,000
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.22.1
Organization and Accounting Policies
12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Organization and Accounting Policies

Note 1 - Organization and Accounting Policies

 

CalEthos, Inc. (the “Company” or “we”) was incorporated on March 20, 2002 under the laws of the State of Nevada. Since the second quarter of 2016, the Company has been a “shell” company, as defined in Rule 12b-2 under the Exchange Act.

 

On December 20, 2018, we filed a Certificate of Amendment to our Articles of Incorporation with the Secretary of State of the State of Nevada to change the Company name from “RealSource Residential, Inc.” to “CalEthos, Inc.”. This amendment became effective immediately upon filing on December 20, 2018.

 

As of December 31, 2021, the primary activity of the Company’s management is to develop and implement a plan to manufacture high-performance computer systems that are scalable, upgradeable and cost effective for processing cryptocurrencies, tokens and blockchain-based transactions, and if other opportunities warrant, acquire assets and all or part of other companies operating in the cryptocurrency mining hardware industry and or invest or joint venture with other more established companies already in the industry. The Company will not restrict its search to any specific business segment of the cryptocurrency mining hardware industry or geographical location and the Company may participate in a business venture of virtually any kind or nature that is beneficial to the Company and its shareholders.

 

Amendments to Certificate of Incorporation

 

In October 2021, the Board of Directors authorized an amendment to the Articles of Incorporation of the Company to change the Company’s name of AIQ Blockchain, Inc. The name change has not yet been effected.

 

Incorporation of Korean entity

 

On November 5, 2021, AIQ System Inc. (“AIQ”) was incorporated in Seoul, Republic of Korea. AIQ is authorized to issue 3 million shares of common stock. At the date of incorporation, 10,000 shares were issued to the Company for 100,000,000 Korean Won or approximately $89,000 for 100% ownership of AIQ.

 

AIQ is in the business of (1) developing and manufacturing computer chips and system, (2) importing and exporting semiconductors and electronic products, (3) wholesale and retail business of semiconductors and electronic products, and (4) any and all business activities incidental to the foregoing activities.

 

Basis of Presentation

 

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary from the formation date. All material intercompany transactions and balances have been eliminated in consolidation.

 

 

Going Concern and Liquidity

 

The Company incurred a net loss of approximately $6,749,000 for the year ended December 31, 2021 and had an accumulated deficit of approximately $16,831,000 as of December 31, 2021. The Company has financed its activities principally through debt and equity financing and shareholder contributions. Management expects to incur additional losses and cash outflows in the foreseeable future in connection with its operating activities.

 

The Company’s consolidated financial statements have been presented on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.

 

The Company is subject to a number of risks similar to those of other similar stage companies, including dependence on key individuals; successful development, marketing and branding of products; uncertainty of product development and generation of revenues; dependence on outside sources of financing; risks associated with research and development; dependence on third-party suppliers and collaborators; protection of intellectual property; and competition with larger, better-capitalized companies. Ultimately, the attainment of profitable operations is dependent on future events, including obtaining adequate financing to fund its operations and generating a level of revenues adequate to support the Company’s cost structure.

 

The Company will need to raise debt or equity financing in the future in order to continue its operations and achieve its growth targets. However, there can be no assurance that such financing will be available in sufficient amounts and on acceptable terms, when and if needed, or at all. The precise amount and timing of the funding needs cannot be determined accurately at this time, and will depend on a number of factors, including market demand for the Company’s products and services, the success of product development efforts, the timing of receipts for customer deposits, the management of working capital, and the continuation of normal payment terms and conditions for purchase of goods and services. The Company believes its cash balances and cash flow from operations will not be sufficient to fund its operations and growth for the next twelve months from the issuance date of these financial statements. If the Company is unable to substantially increase revenues, reduce expenditures, or otherwise generate cash flows from operations, then the Company will likely need to raise additional funding from investors or through other avenues to continue as a going concern.

 

Use of Estimates

 

The preparation of consolidated financial statements in conformity with GAAP and requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods.

 

Foreign Currency Translation

 

The financial statements of foreign subsidiaries, for which the functional currency is the local currency, are translated into U.S. dollars using the exchange rate at the consolidated balance sheet date for assets and liabilities and a weighted-average exchange rate during the year for revenue, expenses, gains and losses. Translation adjustments are recorded as other comprehensive income (loss) within shareholders’ equity (deficit). Gains or losses from foreign currency transactions are recognized in the consolidated statements of operations.

 

Fair Value Measurement

 

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants as of the measurement date. Applicable accounting guidance provides an established hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors that market participants would use in valuing the asset or liability. There are three levels of inputs that may be used to measure fair value:

 

Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 2 - Other inputs that are directly or indirectly observable in the marketplace.

Level 3 - Unobservable inputs which are supported by little or no market activity.

 

 

The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

 

As of and for the year ended December 31, 2021, the Company had no assets or liabilities that require fair value measurement.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents. Cash and cash equivalents are recorded at cost, which approximates its fair value. The Company maintains its cash and cash equivalents in banks insured by the Federal Deposit Insurance Corporation (“FDIC”) in accounts that at times may be in excess of the federally insured limit of $250,000 per bank. The Company minimizes this risk by placing its cash deposits with major financial institutions. As of December 31, 2021 and 2020, the Company had $2,797,000 and $0 in excess of the federal insurance limit, respectively.

 

Prepaid Expense

 

Prepaid expenses are assets held by the Company, which are expected to be realized and consumed within twelve months after the reporting period.

 

Other Assets

 

Other assets consist of long-term advances paid for chip and processor design and development.

 

Related Parties

 

The Company follows Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) section 850-10 for the identification of related parties and disclosure of related party transactions.

 

Pursuant to ASC section 850-10-20 the related parties include (a.) affiliates of the Company (“Affiliate” means, with respect to any specified Person, any other Person that, directly or indirectly through one or more intermediaries, controls, is controlled by or is under common control with such Person, as such terms are used in and construed under Rule 405 under the Securities Act); (b.) entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option of ASC section 825–10–15, to be accounted for by the equity method by the investing entity; (c.) trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; (d.) principal owners of the Company; (e.) management of the Company; (f.) other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and (g.) other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.

 

 

The consolidated financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of consolidated or combined financial statements is not required in those statements. The disclosures shall include: (a.) the nature of the relationship(s) involved; (b.) a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; (c.) the dollar amounts of transactions for each of the periods for which income statements are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and (d.) amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement.

 

Commitments and Contingencies

 

The Company follows ASC section 450-20 to report accounting for contingencies. Certain conditions may exist as of the date the consolidated financial statements are issued, which may result in a loss to the Company, but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or un-asserted claims that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or un-asserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.

 

If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s consolidated financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed.

 

Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed.

 

Debt Discounts

 

The Company accounts for debt discounts originating in connection with conversion features that remain embedded in the related notes in accordance with ASC 470-20, Debt with Conversion and Other Options. These costs are classified on the balance sheet as a direct deduction from the debt liability. The Company amortizes these costs over the term of its debt agreements as financing cost in the consolidated statement of operations and comprehensive loss.

 

Warrant Liability

 

In connection with financing arrangements, the Company has issued warrants to purchase shares of its common stock. The outstanding warrants are standalone instruments that are not puttable or mandatorily redeemable by the holder and are classified as equity awards. The Company measures the fair value of the awards using the Black-Scholes Merton (“BSM”) option pricing model as of the measurement date.

 

 

Stock-Based Compensation

 

We account for our stock-based compensation under ASC 718, “Compensation – Stock Compensation” using the fair value based method. Under this method, compensation cost is measured at the grant date based on the value of the award and is recognized over the service period, which is usually the vesting period. This guidance establishes standards for the accounting for transactions in which an entity exchanges it equity instruments for goods or services. It also addresses transactions in which an entity incurs liabilities in exchange for goods or services that are based on the fair value of the entity’s equity instruments or that may be settled by the issuance of those equity instruments.

 

We use the fair value method for equity instruments granted to non-employees and use the BSM model for measuring the fair value of options. The stock based fair value compensation is determined as of the date of the grant (measurement date) and is recognized over the vesting periods.

 

Income Taxes

 

The Company accounts for income taxes in accordance with ASC 740, Income Taxes, deferred tax assets and liabilities are computed based on the difference between the financial reporting and income tax bases of assets and liabilities using the enacted marginal tax rate. ASC 740 requires that the net deferred tax asset be reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some portion or all of the net deferred tax asset will not be realized.

 

The Company accounts for income taxes using an asset and liability approach, which requires the recognition of taxes payable or refundable for the current year and deferred tax liabilities and assets for the future tax consequences of events that have been recognized in the Company’s financial statements or tax returns. The measurement of current and deferred tax assets and liabilities is based on provisions of enacted tax laws; the effects of future changes in tax laws or rates are not anticipated. If necessary, the measurement of deferred tax assets is reduced by the amount of any tax benefits that are not expected to be realized based on available evidence.

 

The Company has adopted guidance related to the accounting for uncertainty in income taxes which prescribes rules for recognition, measurement and classification in the financial statements of tax positions taken or expected to be taken in a tax return. The guidance prescribes a two-step approach which involves evaluating whether a tax position will be more likely than not (greater than 50 percent likelihood) sustained upon examination based on the technical merits of the position. The second step requires that any tax position that meets the more likely than not recognition threshold be measured and recognized in the financial statements at the largest amount of benefit that is a greater than 50 percent likelihood of being realized upon settlement.

 

The Company’s policy is to recognize interest and penalties, if any, related to unrecognized tax benefits in income tax expense. The Company is not currently under examination by any taxing authority nor has the Company been notified of a pending examination. The statute of limitations for which the Company is generally no longer subject to federal or state income tax examinations by tax authorities is for years before 2013.

 

Earnings Per Share

 

We use ASC 260, “Earnings Per Share” for calculating the basic and diluted earnings (loss) per share. We compute basic earnings (loss) per share by dividing net income (loss) by the weighted average number of common shares outstanding. Diluted earnings (loss) per share is computed based on the weighted average number of shares of common stock plus the effect of dilutive potential common shares outstanding during the period using the treasury stock method. Dilutive potential common shares include outstanding stock options and warrants and stock awards. For periods with a net loss, basic and diluted loss per share is the same, in that any potential common stock equivalents would have the effect of being anti-dilutive in the computation of net loss per share.

 

 

Securities that could potentially dilute income (loss) per share in the future were not included in the computation of diluted income (loss) per share on December 31 because their inclusion would be anti-dilutive as follows:

 

   2021   2020 
Restricted stock awards   11,500,000    - 
Convertible promissory notes and accrued interest   3,947,394    747,032 
Series A warrants issued with convertible promissory notes   1,921,304    353,804 
Series B warrants to be issued upon exercise of Series A warrants   1,921,304    353,804 
Warrants issued for services   100,000    - 
Stock options   -    385,000 
Total potential future shares   19,390,002    1,839,640 

 

Recent Accounting Pronouncements

 

The Company’s management reviewed all recently issued accounting standard updates (“ASU’s”) not yet adopted by the Company and does not believe the future adoptions of any such ASU’s may be expected to cause a material impact on the Company’s consolidated financial condition or the results of its operations.

 

XML 19 R8.htm IDEA: XBRL DOCUMENT v3.22.1
Related Party Transactions
12 Months Ended
Dec. 31, 2021
Related Party Transactions [Abstract]  
Related Party Transactions

Note 2 – Related Party Transactions

 

The Company incurred approximately $199,000 and $180,000 for years ended December 31, 2021 and 2020, and paid approximately $202,000 and $112,000, respectively, to M1 Advisors for the services of the Company’s CEO and miscellaneous operating expenses.

 

XML 20 R9.htm IDEA: XBRL DOCUMENT v3.22.1
Accounts Payable and Accrued Expenses
12 Months Ended
Dec. 31, 2021
Payables and Accruals [Abstract]  
Accounts Payable and Accrued Expenses

Note 3 – Accounts Payable and Accrued Expenses

 

Accounts payable and accrued expenses as of December 31, are as follows:

 

   2021   2020 
Accounts payable  $221,000   $316,000 
Accrued expenses   99,000    255,000 
Accrued interest   114,000    40,000 
Accounts payable and accrued expenses  $434,000   $611,000 

 

Accrued Interest

 

The following table presents the details of accrued interest of December 31:

 

    2021     2020  
Notes payable   $ 9,000     $ 1,000  
Convertible promissory notes     105,000       39,000  
Balance, end of the year   $ 114,000     $ 40,000  

 

XML 21 R10.htm IDEA: XBRL DOCUMENT v3.22.1
Notes Payable
12 Months Ended
Dec. 31, 2021
Notes Payable  
Notes Payable

Note 4 – Notes Payable

 

The table below summarizes the transactions for the years ended December 31:

 

   2021   2020 
Balance, beginning of the year  $11,000   $- 
Additions   150,000    11,000 
Payments   (50,000)   - 
Balance, end of the year  $111,000   $11,000 

 

 

On January 11, 2021, the Company issued a promissory note in the principal amount of $15,000. The interest on this note shall accrue beginning from the date of issuance, at an interest rate of 8% per annum. The principal and any accrued interest are payable on or before March 11, 2022. During any event of default under the note, the interest rate shall increase to 10% per annum. Events of default include failure to pay principal or interest, breach of covenants, breach of representations and warranties, borrower’s assignment of substantial part of its property or business, any money judgment, writ, or similar process shall be entered or filed against the borrower or any subsidiary of the borrower or any of its properties or other assets for more than $100,000, bankruptcy, liquidation of business, and cessation of operations. The principal and the accrued interest amounting to $15,000 and $1,000, respectively, was settled on October 27, 2021.

 

On February 19, 2021, the Company issued a promissory note in the principal amount of $25,000. The interest on the unpaid principal balance accrues at a rate of 10% per annum. The principal and any accrued interest shall be paid in a single installment on or before February 19, 2022. If the Company fails to pay the balance of this note in full on the due date or fails to make any payment due within 15 days of the due date, any unpaid principal shall accrue interest at the rate of 15% per annum during the default (default interest). Events of default include failure to make any payment including accrued interest when due, voluntary, or involuntary petition of bankruptcy, appointment of a receiver, custodian, trustee or similar party to take possession of the Company’s assets or property, or assignment made by the Company for the benefit of creditors. The principal amount outstanding under this note was $25,000 as of December 31, 2021. Interest accrued as of December 31, 2021 is $2,000.

 

On April 5, 2021, the Company issued a promissory note in the principal amount of $9,000. The interest on the unpaid principal balance accrues at a rate of 8% per annum. If the Company fails to pay the balance of this note in full on the date or fails to make any payments due within 15 days of the due date, any unpaid principal shall accrue interest at the rate of 8% per annum during the default. Events of default include failure to make any payment including accrued interest when due, voluntary, or involuntary petition of bankruptcy, appointment of a receiver, custodian, trustee or similar party to take possession of the Company’s assets or property, or assignment made by the Company for the benefit of creditors. The principal and accrued interest under this note was settled September 16, 2021.

 

On April 22, 2021, the Company issued a promissory note in the principal amount of $50,000. The interest on the unpaid principal balance accrues at a rate of 10% per annum. The principal and any accrued interest shall be paid in a single installment on or before April 22, 2022. If the Company fails to pay the balance of this note in full on the date or fails to make any payments due within 15 days of the due date, any unpaid principal shall accrue interest at the rate of 15% per annum during the default. Events of default include failure to make any payment including accrued interest when due, voluntary, or involuntary petition of bankruptcy, appointment of a receiver, custodian, trustee or similar party to take possession of the Company’s assets or property, or assignment made by the Company for the benefit of creditors. The principal amount outstanding under this note was $50,000 as of December 31, 2021. Interest accrued as of December 31, 2021 is $2,000.

 

On July 1, 2021, the Company issued a promissory note in the principal amount of $25,000. The interest on the unpaid principal balance accrues at a rate of 10% per annum. The principal and any accrued interest shall be paid in a single installment on or before July 1,2022. If the Company fails to pay the balance of this note in full on the date or fails to make any payments due within 15 days of the due date, any unpaid principal shall accrue interest at the rate of 15% per annum during the default (default interest). Events of default include failure to make any payment including accrued interest when due, voluntary, or involuntary petition of bankruptcy, appointment of a receiver, custodian, trustee or similar party to take possession of the Company’s assets or property, or assignment made by the Company for the benefit of creditors. The principal amount outstanding under this note was $25,000 as of December 31, 2021. Interest accrued as of December 31, 2021 is $1,000.

 

On July 12, 2021, the Company issued a promissory note in the principal amount of $5,000. The interest on the unpaid principal balance accrues at a rate of 8% per annum. The principal and any accrued interest shall be paid in a single installment on or before October 12, 2021. The principal amount of this note was settled on September 16, 2021.

 

 

On August 10, 2021, the Company issued a promissory note in the principal amount of $7,000. The interest on the unpaid principal balance accrues at a rate of 8% per annum. The principal and any accrued interest shall be paid in a single installment on or before November 10, 2021.The principal amount of this note was settled on September 16, 2021.

 

In August 2021, the Company issued four promissory notes to a single lender in the aggregate principal amount of $14,000. The interest on the unpaid principal balance of these notes accrues at a rate of 8% per annum. The principal for each note shall be paid in a single installment during November 2021. If the Company fails to pay the balance of these notes in full on the date or fails to make any payments due within 15 days of the due date, any unpaid principal shall accrue interest at the rate of 8% per annum during the default. Events of default include failure to make any payment including accrued interest when due, voluntary, or involuntary petition of bankruptcy, appointment of a receiver, custodian, trustee, or similar party to take possession of the Company’s assets or property, or assignment made by the Company for the benefit of creditors. The principal amount outstanding under these notes was $13,500 as of September 30, 2021. The principal and the accrued interest aggregating to $14,000 was settled in October 2021.

 

During the year ended December 31, 2020, the Company issued a promissory note for $11,000. The total proceeds were $10,000, due to approximately $1,000 for an original issue discount. This promissory note is non-interest bearing with the principal due and payable in August 2020. Any amount of unpaid principal on the date of maturity will accrue interest at rate of 10% per annum (default interest). The original issue discount was amortized over the term of the note, which was one month. The Company is in default on this promissory note as of December 31, 2021. The principal and accrued interest amounted to $11,000 and $2,000, as of December 31, 2021 and $11,000 and nil as of December 31, 2020, respectively.

 

Interest expense on notes payable amounted to $8,000 and $1,000 as of December 31, 2021 and 2020, respectively.

 

XML 22 R11.htm IDEA: XBRL DOCUMENT v3.22.1
Convertible Promissory Notes
12 Months Ended
Dec. 31, 2021
Debt Disclosure [Abstract]  
Convertible Promissory Notes

Note 5 – Convertible Promissory Notes

 

During the year ended December 31, 2021, the Company issued two convertible promissory notes amounting to $55,000 and $3,850,000 (the “Notes”), respectively. The total aggregate proceeds were $3,550,000 due to a $355,000 aggregate original issue discount. The Notes are non-interest bearing with the principal due and payable on March 1, 2022 and August 31, 2022, respectively. Any amount of unpaid principal on the date of maturity will accrue interest at rate of 10% per annum (default interest). The principal amount and all accrued interest are convertible into shares of the Company’s common stock, as of the date of issuance, at a rate of $1.00 and $1.25 per share (“Conversion Rate”), respectively. The Conversion Rate is adjustable if, at any time when any principal amount of the Notes remains unpaid or unconverted, the Company issues or sells any shares of the Company’s common stock for no consideration or for a consideration per share (before deduction of reasonable expenses or commissions or underwriting discounts or allowances in connection therewith), which is less than the Conversion Rate in effect on the date of such issuance (or deemed issuance) of such shares of common stock (a “Dilutive Issuance”). Immediately upon a Dilutive Issuance, the Conversion Rate will be reduced to the amount of the consideration per share received by the Company in such Dilutive Issuance. Events of default include failure to issue conversion shares, the occurrence of a breach or default under any other agreement, any money judgment, writ, or similar process entered or filed against the Company or any of its property or other assets for more than $100,000, bankruptcy filing, application for the appointment of a custodian, trustee or receiver, insolvency, the Company’s common stock delisted, or dissolution, winding up, or termination of the business of the Company.

 

In connection with the issuance of the Notes, the Company issued to the purchasers of the Notes stock purchase warrants (the “Warrants”) to purchase an aggregate of 1,567,500 shares of the Company’s common stock for a purchase price of $1.50 to $1.87 per share, subject to adjustments. The Warrants were valued using the Black Scholes option pricing model for a total fair value of $3,004,000 based on a 3-year term, volatility of 404.91% to 405.93%, a risk-free equivalent yield of 0.27% to 0.42%, and stock price ranging from $0.10 to $1.95.

 

 

In accordance with ASC 470 - Debt, the Company has allocated the cash proceeds amounts of the Notes among the Notes, the Warrants and the conversion feature. The relative fair value of the Warrants issued amounted to approximately $1,690,000 and the beneficial conversion amounted to $0, which amounts are being amortized and expensed over the term of the Notes.

 

During the year ended December 31, 2020, the Company issued convertible promissory notes in the amount of $213,000 (the “Notes”). The total cash proceeds were approximately $60,000, approximately $147,000 from the conversion of Series A Preferred Stock into convertible promissory note and approximately $6,000 original issue discount (“OID”). The Notes are non-interest bearing with the principal due and payable starting in February 2021. Any amount of unpaid principal on the date of maturity will accrue interest at rate of 10% per annum (default interest). The principal amount and all accrued interest are convertible into shares of the Company’s common stock, as of the date of issuance, at a rate of $1.00 per share (“Conversion Rate”). The conversion rate is adjustable if, at any time when any principal amount of the Notes remains unpaid or unconverted, the Company issues or sells any shares of the Company’s common stock for no consideration or for a consideration per share (before deduction of reasonable expenses or commissions or underwriting discounts or allowances in connection therewith), which is less than the Conversion Rate in effect on the date of such issuance (or deemed issuance) of such shares of common stock (a “Dilutive Issuance”). Immediately upon a Dilutive Issuance, the Conversion Rate will be reduced to the amount of the consideration per share received by the Company in such Dilutive Issuance. Events of default include failure to issue conversion shares, the occurrence of a breach or default under any other agreement, any money judgment, writ or similar process entered or filed against the Company or any its property or other assets for more than $100,000, bankruptcy filing, application for the appointment of a custodian, trustee or receiver, insolvency, the Company’s common stock delisted, or dissolution, winding up, or termination of the business of the Company.

 

In connection with the issuance of the Notes, the Company issued to the purchasers of the Notes stock purchase warrants to purchase an aggregate of 359,000 shares of the Company’s common stock for a purchase price of $1.50 per share, subject to adjustments.

 

In accordance with ASC 470 - Debt, the Company has accounted for the issuance of the Notes as an extinguishment of the series A preferred stock. Under extinguishment accounting, the difference between the fair value of the Notes and book basis of the series A preferred stock of $86,000 was accounted for as a loss on extinguishment. Also, the fair value of the Warrants of $52,000 was recorded as a loss on extinguishment. The difference between the fair value of the Notes and the face value of the notes of $58,000 was recorded as additional paid on capital. In addition, the Company has allocated the cash proceeds amounts of the Notes among the Notes, the warrants and the conversion feature. The relative fair value of the warrants issued totaled approximately $3,000 and of the beneficial conversion totaled approximately $0, which amounts are being amortized and expensed over the term of the Notes.

 

Financing cost recognized for the amortization of debt discount was approximately $524,000 and $187,000 for the years ended December 31, 2021 and 2020, respectively.

 

The Company determined that the conversion feature of the Notes would not be an embedded feature to be bifurcated and accounted for as a derivative in accordance with ASC 815-15 Derivatives and Hedging.

 

The convertible promissory notes consisted of the following as of December 31:

 

   2021   2020 
Principal          
Balance, beginning of year  $708,000   $506,000 
Additions   3,905,000    202,000 
Balance, end of year   4,613,000    708,000 
           
Discount          
Balance, beginning of year   5,000    183,000 
Additions   2,045,000    10,000 
Amortization   (524,000)   (188,000)
Balance, end of year   1,526,000    5,000 
Net carrying amount  $3,087,000   $703,000 

 

 

Effective interest rate used to amortize the debt discount for the years ended December 31, 2021 and 2020 ranges from 4.76% to 64.60%. The unamortized debt discounts will be amortized within one year as of December 31, 2021 and 2020, respectively.

 

Potential future shares to be issued on conversion of the notes as December 31, 2021 and 2020 are as follows:

 

   2021   2020 
Principal  $4,613,000   $708,000 
Interest   105,000    39,000 
Total   4,718,000    747,000 
Conversion price per share   1.001.25    1.00 
Potential future share   3,947,394    747,032 

 

Interest expense on default convertible promissory notes amounted to $65,000 and $39,000 for the year ended December 31, 2021 and 2020, respectively.

 

XML 23 R12.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments and Contingencies
12 Months Ended
Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

Note 6 – Commitments and Contingencies

 

Technology Development Agreement

 

On December 23, 2021, AIQ entered into a Technology Development Agreement (the “Agreement”) with PICOCEL, Co., Ltd. (the “Contractor” or “PICOCEL”) to develop a FPGA based Bitcoin mining simulation system. The Agreement is expected to be completed within 6 weeks for a total contract price of 198,000,000 Korean Won (“KRW”) or approximately $167,000. As of December 31, 2021, AIQ have made payments amounting to approximately $42,000. The remaining payments as of December 31, 2021 are scheduled, as follows:

 

   Amount 
   USD   KRW 
Within 14 days after signing the contract   42,000    49,500,000 
Within 14 days after delivery of the first set of PM103 FPGA prototype board   83,000    99,000,000 
Total   125,000    148,500,000 

 

Litigation

 

From time to time, the Company may become subject to legal proceedings, claims and litigation arising in the ordinary course of business. In addition, the Company may receive letters alleging infringement of patent or other intellectual property rights. The Company is not currently a party to any material legal proceedings, nor is the Company aware of any pending or threatened litigation that would have a material adverse effect on the Company’s business, operating results, cash flows or financial condition should such litigation be resolved unfavorably, except as follows.

 

On January 3, 2022, a complaint was filed against our company in the Superior Court of California, County of Los Angeles titled Michael Sekula v. CalEthos Inc, Michael Campbell and Does 1-25 (Case No. 22STCV00121) for, among other matters, failure to pay wages, fraud and other wage-related claims. In the complaint, the plaintiff claims he worked under a consulting agreement as Vice President of Brand Management of our company and was to be paid $4,000 per month and to receive an option to purchase 50,000 shares of our common stock that was to vest quarterly over the term of the agreement. In the complaint, the plaintiff alleges that, on or around March 27, 2020, we ceased paying the plaintiff despite the plaintiff’s continuing efforts on behalf of our company and that we agreed to continue to accrue his monthly retainer amount until such time that we received at least $100,000 in funding. Plaintiff further alleges that he continued to work for our company for 38 additional weeks in reliance on our promise of payment. The plaintiff claims that our refusal to make the promised payments amounts to violations of the California labor laws and seeks damages in excess of $450,000.

 

We intend to dispute these claims and to defend this litigation vigorously. However, due to the inherent uncertainties of litigation, the ultimate outcome of this litigations is uncertain. An unfavorable outcome in this litigation could materially and adversely affect our business, financial condition and results of operations.

 

Business Interruption

 

The continuing COVID-19 global pandemic has caused significant disruption to the economy and financial markets globally, and the full extent of the potential impacts of COVID-19 are not yet known. Circumstances caused by the COVID-19 pandemic are complex, uncertain and rapidly evolving. The impact of COVID-19 has not been significant to the Company’s results of operations, financial condition, and liquidity and capital resources. Although no material impairment or other effects have been identified to date, there is substantial uncertainty in the nature and degree of its continued effects over time. That uncertainty affects management’s accounting estimates and assumptions, which could result in greater variability in a variety of areas that depend on these estimates and assumptions as additional events and information become known. The Company will continue to consider the potential impact of the COVID-19 pandemic on its business operations.

 

 

XML 24 R13.htm IDEA: XBRL DOCUMENT v3.22.1
Stockholders’ Deficit
12 Months Ended
Dec. 31, 2021
Equity [Abstract]  
Stockholders’ Deficit

Note 7 – Stockholders’ Deficit

 

Shares Authorized

 

The Company is authorized to issue 200,000,000 shares of which 100,000,000 shares shall be preferred stock, par value $0.001 per share, and 100,000,000 shares shall be common stock, par value $0.001 per share.

 

Preferred Stock

 

Series A Convertible Preferred Stock

 

The Series A Convertible Preferred Stock (“Series A”) is convertible into shares of the Company’s common stock at the rate of $1.38 per share, subject to adjustments based on the Company’s future sales of financial instruments at a value less than $1.38 per share. The holders of the Series A have the right to convert any time after the date of issuance. With the issuance of the convertible promissory notes, as explained in Note 5 above, the Series A’s conversion rate adjusted to $1.00 per share. In accordance with ASC 470, the Company has calculated the effect of the conversion rate adjustment, which was approximately $36,000. The conversion rate adjustment has been treated as a deemed dividend, which has been presented in the Statement of Changes in Stockholders’ Deficit.

 

The Series A is mandatorily convertible upon (i) the closing of the sale of shares of the Company’s common stock to the public in an underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, resulting in at least $10,000,000 of gross proceeds to the Company, (ii) the close of business on the sixtieth consecutive day on which the closing price of the Company’s common stock on the OTC Markets is at least $2.80 per share, subject to appropriate adjustment in the event of any stock dividend, stock split, stock combination or other similar recapitalization with respect to the common stock, or (iii) the affirmative vote of the holders of at least 66⅔% of the outstanding shares of Series A, given at a meeting of such stockholders duly called for that purpose or pursuant to a written consent of stockholders all outstanding shares of Series A shall automatically be converted into shares of the Company’s common stock, at the then effective conversion rate.

 

On any matter presented to the stockholders of the Company for their action or consideration at any meeting of stockholders of the Company (or by written consent of stockholders in lieu of meeting), each holder of outstanding shares of Series A shall be entitled to cast the number of votes equal to the number of whole shares of common stock into which the shares of Series A held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter. Except as provided by law or by the other provisions of the Articles of Incorporation, holders of Series A shall vote together with the holders of common stock as a single class.

 

From and after the date of the issuance of any shares of Series A, a cumulative dividend on each outstanding share of Series A Preferred Stock shall accrue at a rate per annum equal to ten percent of the Series A original issue price. Accrued dividends on the Series A shall be paid in shares of the Company’s common stock, such shares to be valued for such purpose at the applicable series A conversion price.

 

On February 11, 2020, the Company converted 85,975 shares of Series A into a Convertible Promissory Notes in the principal amount approximately $147,000.

 

Common Stock

 

In January 2021, the Company’s President and a member of the Board of Directors, resigned as an officer and director of the Company (“Termination Agreement”). Part of the Termination Agreement stipulates the return of 3,674,330 shares of the Company’s common stock (“Cancelled Shares”). The Cancelled Shares were returned and cancelled on April 20, 2021.

 

In March 2021, the Company’s Chief Executive Officer (“CEO’) agreed to forgive approximately $68,000 due to him, which was treated as contributed paid in capital.

 

In March 2021, the Company’s Chief Financial Officer agreed to reduce the amounts due to him from approximately $128,000 to $30,000. For the reduction of $98,000, the Company will issue 75,000 shares of common stock. The remaining liability of $30,000 will be paid in cash.

 

In September 2021, the Company entered into a release agreement with one of its consultants. As part of the separation payment, the Company issued 25,000 shares valued at $76,000 and paid $20,000 cash in October 2021.

 

 

Restricted Common Stock Awards

 

On August 17, 2021, the Company entered into Restricted Share Award Agreements (the “Award Agreements”) with two consultants pursuant to which the Company issued to the consultants shares of common stock of the Company in exchange for their future services. The Awards have an initial term of one year, which shall be automatically renewed on a year-to-year basis unless either party gives a written notice of termination. The two consultants who entered into these agreements include:

 

  1) A consultant who was granted 10,000,000 restricted share awards.
  2) An entity, which is owned by the Company’s CEO and majority shareholder, was granted 1,500,000 restricted share awards.

 

As indicated in the Awards Agreement, fifty percent (50%) of the shares shall vest upon the completion of the first two development phases of a 5 nanometer ASIC chip that includes the “FPGA Simulation” and “Tape Out”, and the remaining fifty (50%) of the shares shall vest upon the completion of the next phases of the chip development that include the completion of the Foundry Mask for production in the semiconductor foundry, initial production run of chips and the completion of a bitcoin mining system ready for sale to customers. Should the Company not raise sufficient capital to complete the Foundry Mask within 6 months of completing the first two development phases, then 100% of the shares shall be considered vested.

 

The Company’s management has accounted for the Award Grants as restricted stock compensation in accordance with ASC 718 – Stock Compensation (“ASC 718”). ASC 718 requires the Company to estimate the service period over which the compensation cost will be recognized. Management has estimated that the first two development phases will be completed within 15 months and the Foundry Mask will be completed within 6 months for a total of 21 months service period. Compensation cost will be recognized ratably over 21 months and in the same manner had the Company paid in cash. The estimated service period will be adjusted for changes in actual and expected completion dates. Any such change will be recognized prospectively, and the remaining deferred compensation will be recognized over the remaining service period.

 

As of December 31, 2021, a total of 11,500,000 shares were issued to the consultants. The value was $1.93 per share on the date of issuance (“Grant Date”) for an aggregate fair value of $22,195,000

 

The stock-based award compensation was recorded as an increase in deferred compensation expense, common stock, and additional paid-in capital in the Company’s books at the time of the grant.

 

The table below summarizes the transactions related to the Company restricted stock awards as of December 31, 2021:

 

   Shares   Deferred compensation 
Grant date fair value   11,500,000   $22,195,000 
Accretion   -    (4,791,000)
Balance as of December 31, 2021   11,500,000   $17,404,000 

 

Issuance of Stock Options and Warrants

 

In February 2021, the Company signed a new consulting agreement that granted one of its shareholders an option to purchase 750,000 shares of the Company’s common stock at $0.001 per share for the consultancy work provided from August 2020 to February 2021. The options were fully vested on the date of issuance. The fair value of the options was approximately $52,000, as of the grant date, of which approximately $38,000 was expensed and accrued during the year ended December 31, 2020 and $14,000 was expensed for the year ended December 31, 2021.

 

 

In May 2021, the Company signed a letter of understanding that granted one of its shareholders an option to purchase 300,000 shares of the Company’s common stock at $0.001 per share for the consultancy work provided during the Company’s restructuring phase from February 17, 2021 through April 30, 2021. The options were fully vested on the date of issuance. The fair value of the options was approximately $561,000, as of grant date, which was expensed during the year ended December 31, 2021.

 

In May 2021, an option holder exercised three options for 385,000, 750,000 and 300,000 shares of the Company’s common stock at an exercise price of $0.001 for each option, for total proceeds of approximately $2,000.

 

The table below summarizes the Company’s stock option activities for the years ended December 31, 2021 and 2020 (all share and per share data reflects the reverse stock split):

 

  

Number of

Stock Option

Shares

  

Exercise

Price

Range Per

Share

  

Weighted

Average

Exercise

Price

  

Relative

Fair

Value

  

Aggregate

Intrinsic

Value

 
Balance, January 1, 2020   569,800   $   $4.05   $   $423,000 
Granted                    
Forfeited                    
Exercised                    
Expired   (184,800)   12.50    12.50         
Balance, December 31, 2020   385,000        0.001        7,315 
Granted   1,050,000    0.001    0.001    1.94     
Forfeited                    
Exercised   (1,435,000)   0.001    0.001         
Expired                    
Balance, December 31, 2021      $   $   $   $ 
Vested and exercisable, December 31, 2021      $   $   $   $ 
Unvested, December 31, 2021      $   $   $   $ 

 

On September 15, 2021, the Company issued warrants to purchase 100,000 shares of the Company’s common stock. For the year ended December 31, 2021, the compensation expense, classified as professional fees in the consolidated statement of operations and comprehensive loss, was $195,000, which was calculated using the Black Scholes fair value option-pricing model with key input variables provided by management, as of the date of issuance: volatility of 359%, fair value of common stock $1.95, estimated life of 3 years, risk free rate of 0.43% and dividend rate of $0.

 

 

The table below summarizes the Company’s warrant activities for the years ended December 31, 2021 and 2020 (all share and per share data reflects the reverse stock split):

  

Number of

Shares

   Weighted Average Strike Price/Share   Weighted Average Remaining Contractual Term (Years)   Weighted Average Grant Date Fair Value/Share  

Aggregate

Intrinsic

Value

 
Balance, January 1, 2020   253,000   $1.50    2.81   $0.30   $ 
Granted   100,804    1.50    3.05    0.33     
Forfeited                    
Exercised                    
Expired                    
Balance, December 31, 2020   353,804    1.50    2.88    0.18     
Vested and exercisable, December 31, 2020   353,804    1.50    2.88    0.18     
Unvested, December 31, 2020                    
                          
Balance, December 31, 2020   353,804    1.50    2.88    0.18     
Granted   1,667,500    1.86    3.00    1.67    0.11 
Forfeited                    
Exercised                    
Expired                    
Balance, December 31, 2021   2,021,304    1.80    2.98    1.14    0.17 
Vested and exercisable, December 31, 2021   2,021,304    1.80    2.98    1.14    0.17 
Unvested, December 31, 2021      $       $   $ 

 

The following table sets forth the weighted-average assumptions used to estimate the fair value of warrants granted for the year ended December 31:

 

   2021   2020 
Expected life (in years)   3    2.33 - 3.25 
Risk-free interest rate   0.27% - 0.42%   0.18% - 2.49%
Expected volatility   405% - 406%   378% - 424%
Dividend yield   0.00%   0.00%
Stock price   $ 0.101.95    $ 0.11 1.60 

 

XML 25 R14.htm IDEA: XBRL DOCUMENT v3.22.1
Deferred Tax Assets and Income Tax Provision
12 Months Ended
Dec. 31, 2021
Income Tax Disclosure [Abstract]  
Deferred Tax Assets and Income Tax Provision

Note 8 – Deferred Tax Assets and Income Tax Provision

 

Deferred Tax Assets

 

At December 31, 2021, the Company had net operating loss (“NOL”) carry forwards for Federal income tax purposes of $3,354,000 that may be offset against future taxable income. No tax benefit has been reported with respect to these net operating loss carry-forwards in the accompanying financial statements because the Company believes that the realization of the Company’s net deferred tax assets of approximately $2,490,000 was not considered more likely than not and accordingly, the potential tax benefits of the net operating loss carry-forwards are fully offset by a full valuation allowance. Federal NOL’s have an indefinite carryover period and state NOL’s begin to expire at 12-31-2040 if not utilized by then.

 

Deferred tax assets consist primarily of the tax effect of NOL carry-forwards. The Company has provided a full valuation allowance on the deferred tax assets because of the uncertainty regarding its realization. The valuation allowance increased by approximately $2,191,000 and $93,000 for the reporting periods ended December 31, 2021 and 2020, respectively.

 

Components of deferred tax assets are as follows as of December 31:

   2021   2020 
Net deferred tax assets – Non-current:          
           
Stock-based compensation  $1,488,000   $- 
           
Expected income tax benefit from NOL carry-forwards  $1,002,000   $299,000 
           
Less valuation allowance   (2,490,000)   (299,000)
           
Deferred tax assets, net of valuation allowance  $-   $- 

 

Income Tax Provision in the Statements of Operations

 

A reconciliation of the federal statutory income tax rate and the effective income tax rate as a percentage of income before income taxes is as follows for the years ended December 31:

    2021     2020  
             
Federal statutory income tax rate     21.0 %     21.0 %
                 
Change in valuation allowance on net operating loss carry-forwards     (21.0 )     (21.0 )
                 
Effective income tax rate     0.0 %     0.0 %

 

XML 26 R15.htm IDEA: XBRL DOCUMENT v3.22.1
Subsequent Events
12 Months Ended
Dec. 31, 2021
Subsequent Events [Abstract]  
Subsequent Events

Note 9 – Subsequent Events

 

The Company has evaluated all events that occurred after the balance sheet date through the date when the financial statements were issued to determine if they must be reported. The management of the Company determined the following reportable events:

 

Technology Development Agreement

 

In relation to the Technology Development Agreement entered on December 23, 2021, AIQ has made payments to PICOCEL amounting to approximately $42,000 as of the date of this report.

 

Notes Payable

 

Subsequent to December 31, 2021, the Company had made payments to its notes payable holders amounting to $25,000.

 

As of March 1, 2022, the Company did not pay the outstanding balance of $55,000 due and payable for a convertible promissory note. As per the promissory note, any unpaid balance as of maturity accrues interest at a rate of 10.0% per annum.

XML 27 R16.htm IDEA: XBRL DOCUMENT v3.22.1
Organization and Accounting Policies (Policies)
12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Amendments to Certificate of Incorporation

Amendments to Certificate of Incorporation

 

In October 2021, the Board of Directors authorized an amendment to the Articles of Incorporation of the Company to change the Company’s name of AIQ Blockchain, Inc. The name change has not yet been effected.

 

Incorporation of Korean entity

Incorporation of Korean entity

 

On November 5, 2021, AIQ System Inc. (“AIQ”) was incorporated in Seoul, Republic of Korea. AIQ is authorized to issue 3 million shares of common stock. At the date of incorporation, 10,000 shares were issued to the Company for 100,000,000 Korean Won or approximately $89,000 for 100% ownership of AIQ.

 

AIQ is in the business of (1) developing and manufacturing computer chips and system, (2) importing and exporting semiconductors and electronic products, (3) wholesale and retail business of semiconductors and electronic products, and (4) any and all business activities incidental to the foregoing activities.

 

Basis of Presentation

Basis of Presentation

 

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

 

Principles of Consolidation

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary from the formation date. All material intercompany transactions and balances have been eliminated in consolidation.

 

 

Going Concern and Liquidity

Going Concern and Liquidity

 

The Company incurred a net loss of approximately $6,749,000 for the year ended December 31, 2021 and had an accumulated deficit of approximately $16,831,000 as of December 31, 2021. The Company has financed its activities principally through debt and equity financing and shareholder contributions. Management expects to incur additional losses and cash outflows in the foreseeable future in connection with its operating activities.

 

The Company’s consolidated financial statements have been presented on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.

 

The Company is subject to a number of risks similar to those of other similar stage companies, including dependence on key individuals; successful development, marketing and branding of products; uncertainty of product development and generation of revenues; dependence on outside sources of financing; risks associated with research and development; dependence on third-party suppliers and collaborators; protection of intellectual property; and competition with larger, better-capitalized companies. Ultimately, the attainment of profitable operations is dependent on future events, including obtaining adequate financing to fund its operations and generating a level of revenues adequate to support the Company’s cost structure.

 

The Company will need to raise debt or equity financing in the future in order to continue its operations and achieve its growth targets. However, there can be no assurance that such financing will be available in sufficient amounts and on acceptable terms, when and if needed, or at all. The precise amount and timing of the funding needs cannot be determined accurately at this time, and will depend on a number of factors, including market demand for the Company’s products and services, the success of product development efforts, the timing of receipts for customer deposits, the management of working capital, and the continuation of normal payment terms and conditions for purchase of goods and services. The Company believes its cash balances and cash flow from operations will not be sufficient to fund its operations and growth for the next twelve months from the issuance date of these financial statements. If the Company is unable to substantially increase revenues, reduce expenditures, or otherwise generate cash flows from operations, then the Company will likely need to raise additional funding from investors or through other avenues to continue as a going concern.

 

Use of Estimates

Use of Estimates

 

The preparation of consolidated financial statements in conformity with GAAP and requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods.

 

Foreign Currency Translation

Foreign Currency Translation

 

The financial statements of foreign subsidiaries, for which the functional currency is the local currency, are translated into U.S. dollars using the exchange rate at the consolidated balance sheet date for assets and liabilities and a weighted-average exchange rate during the year for revenue, expenses, gains and losses. Translation adjustments are recorded as other comprehensive income (loss) within shareholders’ equity (deficit). Gains or losses from foreign currency transactions are recognized in the consolidated statements of operations.

 

Fair Value Measurement

Fair Value Measurement

 

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants as of the measurement date. Applicable accounting guidance provides an established hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors that market participants would use in valuing the asset or liability. There are three levels of inputs that may be used to measure fair value:

 

Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 2 - Other inputs that are directly or indirectly observable in the marketplace.

Level 3 - Unobservable inputs which are supported by little or no market activity.

 

 

The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

 

As of and for the year ended December 31, 2021, the Company had no assets or liabilities that require fair value measurement.

 

Cash and Cash Equivalents

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents. Cash and cash equivalents are recorded at cost, which approximates its fair value. The Company maintains its cash and cash equivalents in banks insured by the Federal Deposit Insurance Corporation (“FDIC”) in accounts that at times may be in excess of the federally insured limit of $250,000 per bank. The Company minimizes this risk by placing its cash deposits with major financial institutions. As of December 31, 2021 and 2020, the Company had $2,797,000 and $0 in excess of the federal insurance limit, respectively.

 

Prepaid Expense

Prepaid Expense

 

Prepaid expenses are assets held by the Company, which are expected to be realized and consumed within twelve months after the reporting period.

 

Other Assets

Other Assets

 

Other assets consist of long-term advances paid for chip and processor design and development.

 

Related Parties

Related Parties

 

The Company follows Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) section 850-10 for the identification of related parties and disclosure of related party transactions.

 

Pursuant to ASC section 850-10-20 the related parties include (a.) affiliates of the Company (“Affiliate” means, with respect to any specified Person, any other Person that, directly or indirectly through one or more intermediaries, controls, is controlled by or is under common control with such Person, as such terms are used in and construed under Rule 405 under the Securities Act); (b.) entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option of ASC section 825–10–15, to be accounted for by the equity method by the investing entity; (c.) trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; (d.) principal owners of the Company; (e.) management of the Company; (f.) other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and (g.) other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.

 

 

The consolidated financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of consolidated or combined financial statements is not required in those statements. The disclosures shall include: (a.) the nature of the relationship(s) involved; (b.) a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; (c.) the dollar amounts of transactions for each of the periods for which income statements are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and (d.) amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement.

 

Commitments and Contingencies

Commitments and Contingencies

 

The Company follows ASC section 450-20 to report accounting for contingencies. Certain conditions may exist as of the date the consolidated financial statements are issued, which may result in a loss to the Company, but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or un-asserted claims that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or un-asserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.

 

If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s consolidated financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed.

 

Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed.

 

Debt Discounts

Debt Discounts

 

The Company accounts for debt discounts originating in connection with conversion features that remain embedded in the related notes in accordance with ASC 470-20, Debt with Conversion and Other Options. These costs are classified on the balance sheet as a direct deduction from the debt liability. The Company amortizes these costs over the term of its debt agreements as financing cost in the consolidated statement of operations and comprehensive loss.

 

Warrant Liability

Warrant Liability

 

In connection with financing arrangements, the Company has issued warrants to purchase shares of its common stock. The outstanding warrants are standalone instruments that are not puttable or mandatorily redeemable by the holder and are classified as equity awards. The Company measures the fair value of the awards using the Black-Scholes Merton (“BSM”) option pricing model as of the measurement date.

 

 

Stock-Based Compensation

Stock-Based Compensation

 

We account for our stock-based compensation under ASC 718, “Compensation – Stock Compensation” using the fair value based method. Under this method, compensation cost is measured at the grant date based on the value of the award and is recognized over the service period, which is usually the vesting period. This guidance establishes standards for the accounting for transactions in which an entity exchanges it equity instruments for goods or services. It also addresses transactions in which an entity incurs liabilities in exchange for goods or services that are based on the fair value of the entity’s equity instruments or that may be settled by the issuance of those equity instruments.

 

We use the fair value method for equity instruments granted to non-employees and use the BSM model for measuring the fair value of options. The stock based fair value compensation is determined as of the date of the grant (measurement date) and is recognized over the vesting periods.

 

Income Taxes

Income Taxes

 

The Company accounts for income taxes in accordance with ASC 740, Income Taxes, deferred tax assets and liabilities are computed based on the difference between the financial reporting and income tax bases of assets and liabilities using the enacted marginal tax rate. ASC 740 requires that the net deferred tax asset be reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some portion or all of the net deferred tax asset will not be realized.

 

The Company accounts for income taxes using an asset and liability approach, which requires the recognition of taxes payable or refundable for the current year and deferred tax liabilities and assets for the future tax consequences of events that have been recognized in the Company’s financial statements or tax returns. The measurement of current and deferred tax assets and liabilities is based on provisions of enacted tax laws; the effects of future changes in tax laws or rates are not anticipated. If necessary, the measurement of deferred tax assets is reduced by the amount of any tax benefits that are not expected to be realized based on available evidence.

 

The Company has adopted guidance related to the accounting for uncertainty in income taxes which prescribes rules for recognition, measurement and classification in the financial statements of tax positions taken or expected to be taken in a tax return. The guidance prescribes a two-step approach which involves evaluating whether a tax position will be more likely than not (greater than 50 percent likelihood) sustained upon examination based on the technical merits of the position. The second step requires that any tax position that meets the more likely than not recognition threshold be measured and recognized in the financial statements at the largest amount of benefit that is a greater than 50 percent likelihood of being realized upon settlement.

 

The Company’s policy is to recognize interest and penalties, if any, related to unrecognized tax benefits in income tax expense. The Company is not currently under examination by any taxing authority nor has the Company been notified of a pending examination. The statute of limitations for which the Company is generally no longer subject to federal or state income tax examinations by tax authorities is for years before 2013.

 

Earnings Per Share

Earnings Per Share

 

We use ASC 260, “Earnings Per Share” for calculating the basic and diluted earnings (loss) per share. We compute basic earnings (loss) per share by dividing net income (loss) by the weighted average number of common shares outstanding. Diluted earnings (loss) per share is computed based on the weighted average number of shares of common stock plus the effect of dilutive potential common shares outstanding during the period using the treasury stock method. Dilutive potential common shares include outstanding stock options and warrants and stock awards. For periods with a net loss, basic and diluted loss per share is the same, in that any potential common stock equivalents would have the effect of being anti-dilutive in the computation of net loss per share.

 

 

Securities that could potentially dilute income (loss) per share in the future were not included in the computation of diluted income (loss) per share on December 31 because their inclusion would be anti-dilutive as follows:

 

   2021   2020 
Restricted stock awards   11,500,000    - 
Convertible promissory notes and accrued interest   3,947,394    747,032 
Series A warrants issued with convertible promissory notes   1,921,304    353,804 
Series B warrants to be issued upon exercise of Series A warrants   1,921,304    353,804 
Warrants issued for services   100,000    - 
Stock options   -    385,000 
Total potential future shares   19,390,002    1,839,640 

 

Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

The Company’s management reviewed all recently issued accounting standard updates (“ASU’s”) not yet adopted by the Company and does not believe the future adoptions of any such ASU’s may be expected to cause a material impact on the Company’s consolidated financial condition or the results of its operations.

XML 28 R17.htm IDEA: XBRL DOCUMENT v3.22.1
Organization and Accounting Policies (Tables)
12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Schedule of Income and Loss Per Share Anti-dilutive

Securities that could potentially dilute income (loss) per share in the future were not included in the computation of diluted income (loss) per share on December 31 because their inclusion would be anti-dilutive as follows:

 

   2021   2020 
Restricted stock awards   11,500,000    - 
Convertible promissory notes and accrued interest   3,947,394    747,032 
Series A warrants issued with convertible promissory notes   1,921,304    353,804 
Series B warrants to be issued upon exercise of Series A warrants   1,921,304    353,804 
Warrants issued for services   100,000    - 
Stock options   -    385,000 
Total potential future shares   19,390,002    1,839,640 
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.22.1
Accounts Payable and Accrued Expenses (Tables)
12 Months Ended
Dec. 31, 2021
Payables and Accruals [Abstract]  
Schedule of Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses as of December 31, are as follows:

 

   2021   2020 
Accounts payable  $221,000   $316,000 
Accrued expenses   99,000    255,000 
Accrued interest   114,000    40,000 
Accounts payable and accrued expenses  $434,000   $611,000 
Schedule of Accrued Interest

The following table presents the details of accrued interest of December 31:

 

    2021     2020  
Notes payable   $ 9,000     $ 1,000  
Convertible promissory notes     105,000       39,000  
Balance, end of the year   $ 114,000     $ 40,000  
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.22.1
Notes Payable (Tables)
12 Months Ended
Dec. 31, 2021
Notes Payable  
Schedule of Notes Payable

The table below summarizes the transactions for the years ended December 31:

 

   2021   2020 
Balance, beginning of the year  $11,000   $- 
Additions   150,000    11,000 
Payments   (50,000)   - 
Balance, end of the year  $111,000   $11,000 
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.22.1
Convertible Promissory Notes (Tables)
12 Months Ended
Dec. 31, 2021
Debt Disclosure [Abstract]  
Schedule of Convertible Promissory Notes

The convertible promissory notes consisted of the following as of December 31:

 

   2021   2020 
Principal          
Balance, beginning of year  $708,000   $506,000 
Additions   3,905,000    202,000 
Balance, end of year   4,613,000    708,000 
           
Discount          
Balance, beginning of year   5,000    183,000 
Additions   2,045,000    10,000 
Amortization   (524,000)   (188,000)
Balance, end of year   1,526,000    5,000 
Net carrying amount  $3,087,000   $703,000 
Schedule of Potential Future Shares Issuance of Conversion Notes

Potential future shares to be issued on conversion of the notes as December 31, 2021 and 2020 are as follows:

 

   2021   2020 
Principal  $4,613,000   $708,000 
Interest   105,000    39,000 
Total   4,718,000    747,000 
Conversion price per share   1.001.25    1.00 
Potential future share   3,947,394    747,032 
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments and Contingencies (Tables)
12 Months Ended
Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Remaining Payments

 

   Amount 
   USD   KRW 
Within 14 days after signing the contract   42,000    49,500,000 
Within 14 days after delivery of the first set of PM103 FPGA prototype board   83,000    99,000,000 
Total   125,000    148,500,000 
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.22.1
Stockholders’ Deficit (Tables)
12 Months Ended
Dec. 31, 2021
Equity [Abstract]  
Schedule of Company Restricted Stock Awards

The table below summarizes the transactions related to the Company restricted stock awards as of December 31, 2021:

 

   Shares   Deferred compensation 
Grant date fair value   11,500,000   $22,195,000 
Accretion   -    (4,791,000)
Balance as of December 31, 2021   11,500,000   $17,404,000 
Schedule of Stock Option Activities

The table below summarizes the Company’s stock option activities for the years ended December 31, 2021 and 2020 (all share and per share data reflects the reverse stock split):

 

  

Number of

Stock Option

Shares

  

Exercise

Price

Range Per

Share

  

Weighted

Average

Exercise

Price

  

Relative

Fair

Value

  

Aggregate

Intrinsic

Value

 
Balance, January 1, 2020   569,800   $   $4.05   $   $423,000 
Granted                    
Forfeited                    
Exercised                    
Expired   (184,800)   12.50    12.50         
Balance, December 31, 2020   385,000        0.001        7,315 
Granted   1,050,000    0.001    0.001    1.94     
Forfeited                    
Exercised   (1,435,000)   0.001    0.001         
Expired                    
Balance, December 31, 2021      $   $   $   $ 
Vested and exercisable, December 31, 2021      $   $   $   $ 
Unvested, December 31, 2021      $   $   $   $ 
Schedule of Warrants Activity

The table below summarizes the Company’s warrant activities for the years ended December 31, 2021 and 2020 (all share and per share data reflects the reverse stock split):

  

Number of

Shares

   Weighted Average Strike Price/Share   Weighted Average Remaining Contractual Term (Years)   Weighted Average Grant Date Fair Value/Share  

Aggregate

Intrinsic

Value

 
Balance, January 1, 2020   253,000   $1.50    2.81   $0.30   $ 
Granted   100,804    1.50    3.05    0.33     
Forfeited                    
Exercised                    
Expired                    
Balance, December 31, 2020   353,804    1.50    2.88    0.18     
Vested and exercisable, December 31, 2020   353,804    1.50    2.88    0.18     
Unvested, December 31, 2020                    
                          
Balance, December 31, 2020   353,804    1.50    2.88    0.18     
Granted   1,667,500    1.86    3.00    1.67    0.11 
Forfeited                    
Exercised                    
Expired                    
Balance, December 31, 2021   2,021,304    1.80    2.98    1.14    0.17 
Vested and exercisable, December 31, 2021   2,021,304    1.80    2.98    1.14    0.17 
Unvested, December 31, 2021      $       $   $ 
Schedule of Fair Value of Warrants

The following table sets forth the weighted-average assumptions used to estimate the fair value of warrants granted for the year ended December 31:

 

   2021   2020 
Expected life (in years)   3    2.33 - 3.25 
Risk-free interest rate   0.27% - 0.42%   0.18% - 2.49%
Expected volatility   405% - 406%   378% - 424%
Dividend yield   0.00%   0.00%
Stock price   $ 0.101.95    $ 0.11 1.60 

XML 34 R23.htm IDEA: XBRL DOCUMENT v3.22.1
Deferred Tax Assets and Income Tax Provision (Tables)
12 Months Ended
Dec. 31, 2021
Income Tax Disclosure [Abstract]  
Schedule of Components of Deferred Tax Assets

Components of deferred tax assets are as follows as of December 31:

   2021   2020 
Net deferred tax assets – Non-current:          
           
Stock-based compensation  $1,488,000   $- 
           
Expected income tax benefit from NOL carry-forwards  $1,002,000   $299,000 
           
Less valuation allowance   (2,490,000)   (299,000)
           
Deferred tax assets, net of valuation allowance  $-   $- 
Schedule of Reconciliation of Income Tax

A reconciliation of the federal statutory income tax rate and the effective income tax rate as a percentage of income before income taxes is as follows for the years ended December 31:

    2021     2020  
             
Federal statutory income tax rate     21.0 %     21.0 %
                 
Change in valuation allowance on net operating loss carry-forwards     (21.0 )     (21.0 )
                 
Effective income tax rate     0.0 %     0.0 %
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Income and Loss Per Share Anti-dilutive (Details) - shares
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potential future shares 19,390,002 1,839,640
Restricted Stock Award [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potential future shares 11,500,000
Convertible Promissory Notes and Accrued Interest [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potential future shares 3,947,394 747,032
Series A Warrants Issued with Convertible Promissory Notes [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potential future shares 1,921,304 353,804
Series B Warrants to Be Issued Upon Exercise of Series A Warrant [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potential future shares 1,921,304 353,804
Warrants Issued For Services [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potential future shares 100,000
Stock Options [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potential future shares 385,000
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.22.1
Organization and Accounting Policies (Details Narrative) - USD ($)
12 Months Ended
Nov. 05, 2021
Dec. 31, 2021
Dec. 31, 2020
Related Party Transaction [Line Items]      
Common stock shares authorized   100,000,000 100,000,000
Issuance of common stock 10,000    
Issuance of common stock    
Net Income (Loss) Attributable to Parent   6,749,000 $ 756,000
Retained Earnings (Accumulated Deficit)   16,831,000 10,082,000
Cash, FDIC Insured Amount   250,000  
Prepaid Insurance   $ 2,797,000 $ 0
KOREA, REPUBLIC OF      
Related Party Transaction [Line Items]      
Issuance of common stock 100,000,000    
AIQ [Member]      
Related Party Transaction [Line Items]      
Common stock shares authorized 3,000,000    
AIQ [Member] | KOREA, REPUBLIC OF      
Related Party Transaction [Line Items]      
Issuance of common stock $ 89,000    
Ownership percentage 100.00%    
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.22.1
Related Party Transactions (Details Narrative) - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]    
Proceeds from related party $ 199,000 $ 180,000
M1 Advisors [Member]    
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]    
Miscellaneous operating expenses $ 202,000 $ 112,000
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Accounts Payable and Accrued Expenses (Details) - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Payables and Accruals [Abstract]    
Accounts payable $ 221,000 $ 316,000
Accrued expenses 99,000 255,000
Accrued interest 114,000 40,000
Accounts payable and accrued expenses $ 434,000 $ 611,000
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Accrued Interest (Details) - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Payables and Accruals [Abstract]    
Notes payable $ 9,000 $ 1,000
Convertible promissory notes 105,000 39,000
Balance, end of the year $ 114,000 $ 40,000
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Notes Payable (Details) - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Notes Payable    
Balance, beginning of the year $ 11,000
Additions 150,000 11,000
Payments (50,000)
Balance, end of the year $ 111,000 $ 11,000
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.22.1
Notes Payable (Details Narrative) - USD ($)
12 Months Ended
Aug. 31, 2021
Aug. 10, 2021
Jul. 12, 2021
Jul. 01, 2021
Apr. 22, 2021
Apr. 05, 2021
Feb. 19, 2021
Jan. 11, 2021
Dec. 31, 2021
Dec. 31, 2020
Oct. 31, 2021
Oct. 27, 2021
Sep. 30, 2021
Short-term Debt [Line Items]                          
Accrued interest                 $ 114,000 $ 40,000      
Proceeds from notes payable                 150,000 10,000      
Interest Expense, Debt                 65,000 $ 39,000      
Promissory Note [Member]                          
Short-term Debt [Line Items]                          
Debt instrument, face amount $ 14,000 $ 7,000 $ 5,000     $ 9,000 $ 25,000 $ 15,000 25,000   $ 14,000 $ 15,000 $ 13,500
Debt instrument, interest rate 8.00% 8.00% 8.00%     8.00% 10.00% 8.00%          
Debt instrument, maturity date   Nov. 10, 2021 Oct. 12, 2021       Feb. 19, 2022 Mar. 11, 2022          
Increase in interest rate 8.00%         8.00% 15.00% 10.00%          
Accrued interest                 2,000     $ 1,000  
Debt instrument, maturity date November 2021                 August 2020      
Interest Expense, Debt                 8,000 $ 1,000      
Promissory Note [Member] | Borrower [Member]                          
Short-term Debt [Line Items]                          
Debt instrument, periodic payment               $ 100,000          
Promissory Note One [Member]                          
Short-term Debt [Line Items]                          
Debt instrument, face amount         $ 50,000       50,000        
Debt instrument, interest rate         10.00%                
Debt instrument, maturity date         Apr. 22, 2022                
Increase in interest rate         15.00%                
Accrued interest                 2,000        
Promissory Note Two [Member]                          
Short-term Debt [Line Items]                          
Debt instrument, face amount       $ 25,000         25,000        
Debt instrument, interest rate       10.00%                  
Debt instrument, maturity date       Jul. 01, 2022                  
Increase in interest rate       15.00%                  
Accrued interest                 1,000        
Promissory Note Three [Member]                          
Short-term Debt [Line Items]                          
Debt instrument, face amount                 11,000 $ 11,000      
Increase in interest rate                   10.00%      
Accrued interest                 $ 2,000      
Proceeds from notes payable                   10,000      
Debt instrument, issue discount                   $ 1,000      
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Convertible Promissory Notes (Details) - Convertible Notes Payable [Member] - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Short-term Debt [Line Items]    
Balance, beginning of year $ 708,000 $ 506,000
Additions 3,905,000 202,000
Balance, end of year 4,613,000 708,000
Balance, beginning of year 5,000 183,000
Additions 2,045,000 10,000
Amortization (524,000) (188,000)
Balance, end of year 1,526,000 5,000
Net carrying amount $ 3,087,000 $ 703,000
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Potential Future Shares Issuance of Conversion Notes (Details) - Convertible Notes Payable [Member] - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Short-term Debt [Line Items]    
Principal $ 4,613,000 $ 708,000
Interest 105,000 39,000
Total $ 4,718,000 $ 747,000
Conversion price per share   $ 1.00
Potential future share 3,947,394 747,032
Minimum [Member]    
Short-term Debt [Line Items]    
Conversion price per share $ 1.00  
Maximum [Member]    
Short-term Debt [Line Items]    
Conversion price per share $ 1.25  
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.22.1
Convertible Promissory Notes (Details Narrative) - USD ($)
12 Months Ended
Sep. 15, 2021
Dec. 31, 2021
Dec. 31, 2020
May 31, 2021
Dec. 31, 2019
Short-term Debt [Line Items]          
Proceed from convertible debt   $ 3,550,000 $ 49,000    
Events of default description   Immediately upon a Dilutive Issuance, the Conversion Rate will be reduced to the amount of the consideration per share received by the Company in such Dilutive Issuance. Events of default include failure to issue conversion shares, the occurrence of a breach or default under any other agreement, any money judgment, writ, or similar process entered or filed against the Company or any of its property or other assets for more than $100,000, bankruptcy filing, application for the appointment of a custodian, trustee or receiver, insolvency, the Company’s common stock delisted, or dissolution, winding up, or termination of the business of the Company Immediately upon a Dilutive Issuance, the Conversion Rate will be reduced to the amount of the consideration per share received by the Company in such Dilutive Issuance. Events of default include failure to issue conversion shares, the occurrence of a breach or default under any other agreement, any money judgment, writ or similar process entered or filed against the Company or any its property or other assets for more than $    
Indebtedness for borrowed money maximum limit   $ 100,000 $ 100,000    
Issuance of warrants to purchase of common stock 100,000        
Issuance of warrant price per share       $ 0.001  
Fair value of common stock estimated life 3 years        
Date of issuance volatility percentage 359.00%        
Fair value of common stock risk free interest rate 43.00%        
Share price $ 1.95        
Relative fair value of warrants issued with convertible promissory notes   1,690,000 3,000    
Debt instrument, convertible, beneficial conversion feature   0 0    
Loss on extinguishment of convertible preferred stock   86,000    
Fair value of warrants issued with conversion of convertible preferred stock   52,000    
Fair value and face value of notes   58,000    
Amortization of Debt Issuance Costs and Discounts   524,000 187,000    
Interest Expense, Debt   $ 65,000 $ 39,000    
Warrant [Member]          
Short-term Debt [Line Items]          
Issuance of warrants to purchase of common stock   1,567,500 359,000    
Issuance of warrant price per share     $ 1.50    
Fair value of common stock   $ 3,004,000      
Fair value of common stock estimated life   3 years      
Warrant [Member] | Minimum [Member]          
Short-term Debt [Line Items]          
Issuance of warrant price per share   $ 1.50      
Date of issuance volatility percentage   404.91%      
Fair value of common stock risk free interest rate   0.27%      
Share price   $ 0.10      
Warrant [Member] | Maximum [Member]          
Short-term Debt [Line Items]          
Issuance of warrant price per share   $ 1.87      
Date of issuance volatility percentage   405.93%      
Fair value of common stock risk free interest rate   0.42%      
Share price   $ 1.95      
Convertible Promissory Note One [Member]          
Short-term Debt [Line Items]          
Convertible promissory note   $ 55,000      
Proceed from convertible debt   3,550,000      
Original issue discount   $ 355,000      
Debt instrument, maturity date   Mar. 01, 2022      
Increase in interest rate   10.00%      
Debt instruments, conversion price   $ 1.00      
Convertible Promissory Note Two [Member]          
Short-term Debt [Line Items]          
Convertible promissory note   $ 3,850,000      
Proceed from convertible debt   3,550,000      
Original issue discount   $ 355,000      
Debt instrument, maturity date   Aug. 31, 2022      
Increase in interest rate   10.00%      
Debt instruments, conversion price   $ 1.25      
Convertible Promissory Note [Member]          
Short-term Debt [Line Items]          
Convertible promissory note     $ 213,000    
Proceed from convertible debt     60,000    
Original issue discount     $ 6,000    
Increase in interest rate     10.00%    
Debt instruments, conversion price     $ 1.00    
Debt Instrument, Maturity Date, Description     February 2021    
Convertible Promissory Note [Member] | Series A Preferred Stock [Member]          
Short-term Debt [Line Items]          
Debt Conversion, Converted Instrument, Amount     $ 147,000    
Convertible Notes Payable [Member]          
Short-term Debt [Line Items]          
Original issue discount   $ 1,526,000 $ 5,000   $ 183,000
Debt instruments, conversion price     $ 1.00    
Convertible Notes Payable [Member] | Minimum [Member]          
Short-term Debt [Line Items]          
Debt instruments, conversion price   $ 1.00      
Debt Instrument, Interest Rate, Effective Percentage     4.76%    
Convertible Notes Payable [Member] | Maximum [Member]          
Short-term Debt [Line Items]          
Debt instruments, conversion price   $ 1.25      
Debt Instrument, Interest Rate, Effective Percentage     64.60%    
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Remaining Payments (Details) - 12 months ended Dec. 31, 2021
USD ($)
KRW (₩)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Total $ 125,000 ₩ 148,500,000
Technology Development Agreement [Member] | PICOCEL Co Ltd [Member]    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Payments to be signing contract 42,000 49,500,000
Payments upon delivery board $ 83,000 ₩ 99,000,000
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments and Contingencies (Details Narrative)
1 Months Ended 12 Months Ended
Dec. 31, 2021
USD ($)
Dec. 31, 2022
Dec. 23, 2021
USD ($)
Dec. 23, 2021
KRW (₩)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Litigation description   In the complaint, the plaintiff claims he worked under a consulting agreement as Vice President of Brand Management of our company and was to be paid $4,000 per month and to receive an option to purchase 50,000 shares of our common stock that was to vest quarterly over the term of the agreement. In the complaint, the plaintiff alleges that, on or around March 27, 2020, we ceased paying the plaintiff despite the plaintiff’s continuing efforts on behalf of our company and that we agreed to continue to accrue his monthly retainer amount until such time that we received at least $100,000 in funding. Plaintiff further alleges that he continued to work for our company for 38 additional weeks in reliance on our promise of payment. The plaintiff claims that our refusal to make the promised payments amounts to violations of the California labor laws and seeks damages in excess of $450,000.    
Technology Development Agreement [Member] | PICOCEL Co Ltd [Member]        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Revenue, Remaining Performance Obligation, Amount     $ 167,000 ₩ 198,000,000
[custom:PaymentsForCollaborators] $ 42,000      
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Company Restricted Stock Awards (Details) - Restricted Stock [Member]
Dec. 31, 2021
USD ($)
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Grant date fair value, shares | shares 11,500,000
Deferred compensation grant date fair value | $ $ 22,195,000
Accretion, shares | shares
Deferred compensation accretion | $ $ (4,791,000)
Shares, balance | shares 11,500,000
Deferred compensation | $ $ 17,404,000
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Stock Option Activities (Details) - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Equity [Abstract]    
Number of Stock Option Shares, Outstanding, Beginning of period 385,000 569,800
Exercise Price Range Per Share, Outstanding, Beginning of period
Weighted Average Exercise Price, Outstanding, Beginning of period 0.001 4.05
Relative Fair Value, Outstanding, Beginning of period
Aggregate Intrinsic Value, Beginning of period $ 7,315 $ 423,000
Number of Stock Option Shares, Granted 1,050,000
Exercise Price Range Per Share, Granted $ 0.001
Weighted Average Exercise Price, Granted 0.001
Relative Fair Value, Granted 1.94
Aggregate Intrinsic Value, Granted
Number of Stock Option Shares, Forfeited
Exercise Price Range Per Share, Forfeited
Weighted Average Exercise Price, Forfeited
Relative Fair Value, Forfeited
Aggregate Intrinsic Value, Forfeited
Number of Stock Option Shares, Exercised (1,435,000)
Exercise Price Range Per Share, Exercised $ 0.001
Weighted Average Exercise Price, Exercised 0.001
Relative Fair Value, Exercised
Aggregate Intrinsic Value, Exercised
Number of Stock Option Shares, Expired (184,800)
Exercise Price Range Per Share, Expired $ 12.50
Weighted Average Exercise Price, Expired 12.50
Relative Fair Value, Expired
Aggregate Intrinsic Value, Expired
Number of Stock Option Shares, Outstanding, Ending of period 385,000
Exercise Price Range Per Share, Outstanding, Ending of period  
Weighted Average Exercise Price, Outstanding, Ending of period $ 0.001
Relative Fair Value, Outstanding, Ending of period
Aggregate Intrinsic Value, Ending of period $ 7,315
Number of Stock Option, Vested and Exercisable, Ending Balance  
Exercise Price Range Per Share, Vested and Exercisable  
Weighted Average Exercise Price, Vested and Exercisable  
Relative Fair Value, Vested and Exercisable  
Aggregate Intrinsic Value, Vested and Exercisable  
Number of Stock Option, Unvested, Ending Balance  
Exercise Price Range Per Share, Unvested  
Weighted Average Exercise Price, Unvested  
Relative Fair Value, Unvested  
Aggregate Intrinsic Value, Unvested  
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Warrants Activity (Details) - $ / shares
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Equity [Abstract]      
Number of warrants issued, Outstanding, Beginning of period 353,804 253,000  
Weighted Average Strike Price/Share, Outstanding, Beginning of period $ 1.50 $ 1.50  
Weighted Average Remaining Contractual Term (Years) 2 years 11 months 23 days 2 years 10 months 17 days 2 years 9 months 21 days
Weighted Average Grant Date Fair Value/Share, Beginning of period $ 0.18 $ 0.30  
Aggregate intrinsic value, Beginning of period  
Number of warrants issued, Granted 1,667,500 100,804  
Weighted Average Strike Price/Share, Granted $ 1.86 $ 1.50  
Weighted Average Remaining Contractual Term (Years), Granted 3 years 3 years 18 days  
Weighted Average Grant Date Fair Value/Share, Granted $ 1.67 $ 0.33  
Aggregate intrinsic value, Granted $ 0.11  
Number of warrants issued, Forfeited  
Weighted Average Strike Price/Share, Forfeited  
Weighted Average Grant Date Fair Value/Share, forfeited  
Aggregate intrinsic value, forfeited  
Number of warrants issued, Exercised  
Weighted Average Strike Price/Share, Exercised  
Weighted Average Grant Date Fair Value/Share, Exercised  
Aggregate intrinsic value, Exercised  
Number of warrants issued, Expired  
Weighted Average Strike Price/Share, Expired  
Weighted Average Grant Date Fair Value/Share, Expired  
Aggregate intrinsic value, Expired  
Number of warrants issued, Outstanding, Ending of period 2,021,304 353,804 253,000
Weighted Average Strike Price/Share, Outstanding, Ending of period $ 1.80 $ 1.50 $ 1.50
Weighted Average Grant Date Fair Value/Share, Ending of period 1.14 0.18 0.30
Aggregate intrinsic value, Ending of period $ 0.17
Number of warrants issued, Vested and Exercisable, Ending of period 2,021,304 353,804  
Weighted Average Strike Price/Share, Vested and Exercisable, Ending of period 1.80 1.50  
Weighted Average Remaining Contractual Term (Years), Vested and Exercisable 2 years 11 months 23 days 2 years 10 months 17 days  
Weighted Average Grant Date Fair Value/Share, Vested and Exercisable, Ending of period 1.14 0.18  
Aggregate intrinsic value, Vested and Exercisable, Ending of period 0.17  
Number of warrants issued, Vested, Ending of period  
Weighted Average Strike Price/Share, Unvested, Ending of period  
Weighted Average Remaining Contractual Term (Years), Unvested 0 years 0 years  
Weighted Average Grant Date Fair Value/Share, Vested, Ending of period  
Aggregate intrinsic value, Vested, Ending of period    
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Fair Value of Warrants (Details)
Dec. 31, 2021
$ / shares
Sep. 15, 2021
$ / shares
Dec. 31, 2020
$ / shares
Fair Value Measurement Inputs and Valuation Techniques [Line Items]      
Share price   $ 1.95  
Measurement Input, Expected Term [Member]      
Fair Value Measurement Inputs and Valuation Techniques [Line Items]      
Warrants and rights outstanding, term 3 years    
Measurement Input, Expected Term [Member] | Minimum [Member]      
Fair Value Measurement Inputs and Valuation Techniques [Line Items]      
Warrants and rights outstanding, term     2 years 3 months 29 days
Measurement Input, Expected Term [Member] | Maximum [Member]      
Fair Value Measurement Inputs and Valuation Techniques [Line Items]      
Warrants and rights outstanding, term     3 years 3 months
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]      
Fair Value Measurement Inputs and Valuation Techniques [Line Items]      
Dividend yield 0.27   0.18
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]      
Fair Value Measurement Inputs and Valuation Techniques [Line Items]      
Dividend yield 0.42   2.49
Measurement Input, Price Volatility [Member] | Minimum [Member]      
Fair Value Measurement Inputs and Valuation Techniques [Line Items]      
Dividend yield 405   378
Measurement Input, Price Volatility [Member] | Maximum [Member]      
Fair Value Measurement Inputs and Valuation Techniques [Line Items]      
Dividend yield 406   424
Measurement Input, Expected Dividend Rate [Member]      
Fair Value Measurement Inputs and Valuation Techniques [Line Items]      
Dividend yield 0.00   0.00
Measurement Input, Share Price [Member] | Minimum [Member]      
Fair Value Measurement Inputs and Valuation Techniques [Line Items]      
Share price $ 0.10   $ 0.11
Measurement Input, Share Price [Member] | Maximum [Member]      
Fair Value Measurement Inputs and Valuation Techniques [Line Items]      
Share price $ 1.95   $ 1.60
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.22.1
Stockholders’ Deficit (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Nov. 05, 2021
Sep. 15, 2021
Aug. 17, 2021
Feb. 11, 2020
Oct. 31, 2021
May 31, 2021
Feb. 28, 2021
Jan. 31, 2021
Mar. 31, 2021
Dec. 31, 2021
Dec. 31, 2020
Mar. 30, 2021
Class of Stock [Line Items]                        
Authorized to issue shares                   200,000,000    
Preferred stock, shares authorized                   100,000,000 100,000,000  
Preferred stock, par value                   $ 0.001 $ 0.001  
Common stock, shares authorized                   100,000,000 100,000,000  
Common stock, par value                   $ 0.001 $ 0.001  
Proceeds from Issuance of Common Stock                   $ 10,000,000    
Sale of Stock, Description of Transaction                   the close of business on the sixtieth consecutive day on which the closing price of the Company’s common stock on the OTC Markets is at least $2.80 per share, subject to appropriate adjustment in the event of any stock dividend, stock split, stock combination or other similar recapitalization with respect to the common stock, or (iii) the affirmative vote of the holders of at least 66⅔% of the outstanding shares of Series A, given at a meeting of such stockholders duly called for that purpose or pursuant to a written consent of stockholders all outstanding shares of Series A shall automatically be converted into shares of the Company’s common stock, at the then effective conversion rate    
Stock issued during period shares new issues 10,000                      
Remaining cash liability                   $ 30,000    
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage                   100.00%    
Option to purhase shares                   1,050,000  
Share price   $ 1.95                    
Share-based compensation arrangement by share-based payment award, options                   $ 561,000    
Number of share options exercised                   1,435,000  
Class of warrant exercise price           $ 0.001            
Proceeds from stock options exercised           $ 2,000       $ 2,000  
Number of securities called by warrants or rights   100,000                    
Professional fees   $ 195,000               $ 6,095,000 340,000  
Fair value assumptions, expected volatility rate   359.00%                    
Expected Term   3 years                    
Risk Free Interest Rate   43.00%                    
Expected Dividend Payments   $ 0                    
Share-based Payment Arrangement, Tranche One [Member]                        
Class of Stock [Line Items]                        
Number of share options exercised           385,000            
Share-based Payment Arrangement, Tranche Two [Member]                        
Class of Stock [Line Items]                        
Number of share options exercised           750,000            
Share-based Payment Arrangement, Tranche Three [Member]                        
Class of Stock [Line Items]                        
Number of share options exercised           300,000            
Chief Executive Officer [Member]                        
Class of Stock [Line Items]                        
Debt instrument decrease forgiveness                 $ 68,000      
Restricted common stock shares granted     1,500,000                  
Chief Financial Officer [Member]                        
Class of Stock [Line Items]                        
Due to related parties                 30,000     $ 128,000
Reduction amount                 $ 98,000      
Stock issued during period shares new issues                 75,000      
Consultants [Member]                        
Class of Stock [Line Items]                        
Stock Issued During Period, Shares, Issued for Services         25,000              
Stock Issued During Period, Value, Issued for Services         $ 76,000              
Restricted common stock shares granted     10,000,000             11,500,000    
Shares Issued, Price Per Share                   $ 1.93    
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures                   $ 22,195,000    
Termination Agreement [Member]                        
Class of Stock [Line Items]                        
Return of shares               3,674,330        
New Consulting Agreement [Member] | Shareholder [Member]                        
Class of Stock [Line Items]                        
Option to purhase shares             750,000          
Share price             $ 0.001          
Fair value of options             $ 52,000          
Option expense                   $ 14,000 $ 38,000  
Letter of Understanding [Member]                        
Class of Stock [Line Items]                        
Common stock, shares authorized           300,000            
Common stock, par value           $ 0.001            
Series A Convertible Preferred Stock [Member]                        
Class of Stock [Line Items]                        
Preferred stock, shares authorized                   3,600,000 3,600,000  
Preferred stock, par value                   $ 0.001 $ 0.001  
Sale of stock shares price per share                   1.38    
Debt Instrument, Convertible, Conversion Price                   $ 1.00    
Conversion rate adjustment, value                   $ 36,000    
Conversion of shares       85,975                
Conversion of debt       $ 147,000                
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Components of Deferred Tax Assets (Details) - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Income Tax Disclosure [Abstract]    
Stock-based compensation $ 1,488,000
Expected income tax benefit from NOL carry-forwards 1 299,000
Less valuation allowance (2,490,000) (299,000)
Deferred tax assets, net of valuation allowance
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Reconciliation of Income Tax (Details)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Income Tax Disclosure [Abstract]    
Federal statutory income tax rate 21.00% 21.00%
Change in valuation allowance on net operating loss carry-forwards (21.00%) (21.00%)
Effective income tax rate 0.00% 0.00%
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.22.1
Deferred Tax Assets and Income Tax Provision (Details Narrative) - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Income Tax Disclosure [Abstract]    
Net operating loss deferred tax $ 3,354,000  
Deferred tax assets,net 2,490,000  
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount $ 2,191,000 $ 93,000
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.22.1
Subsequent Events (Details Narrative) - USD ($)
Mar. 03, 2022
Mar. 31, 2022
Mar. 01, 2022
Dec. 23, 2021
Subsequent Event [Member]        
Subsequent Event [Line Items]        
Notes payable paid   $ 25,000    
Convertible debt outstanding     $ 55,000  
Converted instrument, rate 10.00%      
AIQ [Member]        
Subsequent Event [Line Items]        
Payments to Related Parties       $ 42,000
XML 56 form10-k_htm.xml IDEA: XBRL DOCUMENT 0001174891 2021-01-01 2021-12-31 0001174891 2021-06-30 0001174891 2022-03-15 0001174891 2021-12-31 0001174891 2020-12-31 0001174891 BUUZ:SeriesAConvertiblePreferredStockMember 2021-12-31 0001174891 BUUZ:SeriesAConvertiblePreferredStockMember 2020-12-31 0001174891 2020-01-01 2020-12-31 0001174891 BUUZ:SeriesAConvertiblePreferredStockMember us-gaap:PreferredStockMember 2019-12-31 0001174891 us-gaap:CommonStockMember 2019-12-31 0001174891 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001174891 BUUZ:StockSubscriptionReceivableMember 2019-12-31 0001174891 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001174891 us-gaap:RetainedEarningsMember 2019-12-31 0001174891 2019-12-31 0001174891 BUUZ:SeriesAConvertiblePreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001174891 us-gaap:CommonStockMember 2020-12-31 0001174891 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001174891 BUUZ:StockSubscriptionReceivableMember 2020-12-31 0001174891 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001174891 us-gaap:RetainedEarningsMember 2020-12-31 0001174891 BUUZ:SeriesAConvertiblePreferredStockMember us-gaap:PreferredStockMember 2020-01-01 2020-12-31 0001174891 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001174891 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001174891 BUUZ:StockSubscriptionReceivableMember 2020-01-01 2020-12-31 0001174891 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0001174891 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001174891 BUUZ:SeriesAConvertiblePreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001174891 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001174891 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001174891 BUUZ:StockSubscriptionReceivableMember 2021-01-01 2021-12-31 0001174891 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0001174891 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001174891 BUUZ:SeriesAConvertiblePreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001174891 us-gaap:CommonStockMember 2021-12-31 0001174891 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001174891 BUUZ:StockSubscriptionReceivableMember 2021-12-31 0001174891 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001174891 us-gaap:RetainedEarningsMember 2021-12-31 0001174891 BUUZ:AIQMember 2021-11-05 0001174891 2021-11-04 2021-11-05 0001174891 country:KR 2021-11-04 2021-11-05 0001174891 country:KR BUUZ:AIQMember 2021-11-04 2021-11-05 0001174891 country:KR BUUZ:AIQMember 2021-11-05 0001174891 BUUZ:RestrictedStockAwardMember 2021-01-01 2021-12-31 0001174891 BUUZ:RestrictedStockAwardMember 2020-01-01 2020-12-31 0001174891 BUUZ:ConvertiblePromissoryNotesAndAccruedInterestMember 2021-01-01 2021-12-31 0001174891 BUUZ:ConvertiblePromissoryNotesAndAccruedInterestMember 2020-01-01 2020-12-31 0001174891 BUUZ:SeriesAWarrantsIssuedWithConvertiblePromissoryNotesMember 2021-01-01 2021-12-31 0001174891 BUUZ:SeriesAWarrantsIssuedWithConvertiblePromissoryNotesMember 2020-01-01 2020-12-31 0001174891 BUUZ:SeriesBWarrantsToBeIssuedUponExerciseOfSeriesAWarrantMember 2021-01-01 2021-12-31 0001174891 BUUZ:SeriesBWarrantsToBeIssuedUponExerciseOfSeriesAWarrantMember 2020-01-01 2020-12-31 0001174891 BUUZ:WarrantsIssuedForServicesMember 2021-01-01 2021-12-31 0001174891 BUUZ:WarrantsIssuedForServicesMember 2020-01-01 2020-12-31 0001174891 BUUZ:StockOptionsMember 2021-01-01 2021-12-31 0001174891 BUUZ:StockOptionsMember 2020-01-01 2020-12-31 0001174891 BUUZ:MOneAdvisorsMember 2021-01-01 2021-12-31 0001174891 BUUZ:MOneAdvisorsMember 2020-01-01 2020-12-31 0001174891 BUUZ:PromissoryNoteMember 2021-01-11 0001174891 BUUZ:PromissoryNoteMember 2021-01-10 2021-01-11 0001174891 BUUZ:BorrowerMember BUUZ:PromissoryNoteMember 2021-01-10 2021-01-11 0001174891 BUUZ:PromissoryNoteMember 2021-10-27 0001174891 BUUZ:PromissoryNoteMember 2021-02-19 0001174891 BUUZ:PromissoryNoteMember 2021-02-18 2021-02-19 0001174891 BUUZ:PromissoryNoteMember 2021-12-31 0001174891 BUUZ:PromissoryNoteMember 2021-04-05 0001174891 BUUZ:PromissoryNoteMember 2021-04-04 2021-04-05 0001174891 BUUZ:PromissoryNoteOneMember 2021-04-22 0001174891 BUUZ:PromissoryNoteOneMember 2021-04-20 2021-04-22 0001174891 BUUZ:PromissoryNoteOneMember 2021-12-31 0001174891 BUUZ:PromissoryNoteTwoMember 2021-07-01 0001174891 BUUZ:PromissoryNoteTwoMember 2021-06-29 2021-07-01 0001174891 BUUZ:PromissoryNoteTwoMember 2021-12-31 0001174891 BUUZ:PromissoryNoteMember 2021-07-12 0001174891 BUUZ:PromissoryNoteMember 2021-07-11 2021-07-12 0001174891 BUUZ:PromissoryNoteMember 2021-08-10 0001174891 BUUZ:PromissoryNoteMember 2021-08-09 2021-08-10 0001174891 BUUZ:PromissoryNoteMember 2021-08-31 0001174891 BUUZ:PromissoryNoteMember 2021-08-29 2021-08-31 0001174891 BUUZ:PromissoryNoteMember 2021-09-30 0001174891 BUUZ:PromissoryNoteMember 2021-10-31 0001174891 BUUZ:PromissoryNoteThreeMember 2020-12-31 0001174891 BUUZ:PromissoryNoteThreeMember 2020-01-01 2020-12-31 0001174891 BUUZ:PromissoryNoteMember 2020-01-01 2020-12-31 0001174891 BUUZ:PromissoryNoteThreeMember 2021-12-31 0001174891 BUUZ:PromissoryNoteMember 2021-01-01 2021-12-31 0001174891 BUUZ:ConvertiblePromissoryNoteOneMember 2021-12-31 0001174891 BUUZ:ConvertiblePromissoryNoteTwoMember 2021-12-31 0001174891 BUUZ:ConvertiblePromissoryNoteOneMember 2021-01-01 2021-12-31 0001174891 BUUZ:ConvertiblePromissoryNoteTwoMember 2021-01-01 2021-12-31 0001174891 us-gaap:WarrantMember 2021-12-31 0001174891 srt:MinimumMember us-gaap:WarrantMember 2021-12-31 0001174891 srt:MaximumMember us-gaap:WarrantMember 2021-12-31 0001174891 us-gaap:WarrantMember 2021-01-01 2021-12-31 0001174891 srt:MinimumMember us-gaap:WarrantMember 2021-01-01 2021-12-31 0001174891 srt:MaximumMember us-gaap:WarrantMember 2021-01-01 2021-12-31 0001174891 BUUZ:ConvertiblePromissoryNoteMember 2020-12-31 0001174891 BUUZ:ConvertiblePromissoryNoteMember 2020-01-01 2020-12-31 0001174891 BUUZ:ConvertiblePromissoryNoteMember us-gaap:SeriesAPreferredStockMember 2020-01-01 2020-12-31 0001174891 us-gaap:WarrantMember 2020-12-31 0001174891 srt:MinimumMember us-gaap:ConvertibleNotesPayableMember 2020-12-31 0001174891 srt:MaximumMember us-gaap:ConvertibleNotesPayableMember 2020-12-31 0001174891 us-gaap:ConvertibleNotesPayableMember 2020-12-31 0001174891 us-gaap:ConvertibleNotesPayableMember 2019-12-31 0001174891 us-gaap:ConvertibleNotesPayableMember 2021-01-01 2021-12-31 0001174891 us-gaap:ConvertibleNotesPayableMember 2020-01-01 2020-12-31 0001174891 us-gaap:ConvertibleNotesPayableMember 2021-12-31 0001174891 srt:MinimumMember us-gaap:ConvertibleNotesPayableMember 2021-12-31 0001174891 srt:MaximumMember us-gaap:ConvertibleNotesPayableMember 2021-12-31 0001174891 BUUZ:TechnologyDevelopmentAgreementMember BUUZ:PICOCELCoLtdMember 2021-12-23 0001174891 BUUZ:TechnologyDevelopmentAgreementMember BUUZ:PICOCELCoLtdMember 2021-12-01 2021-12-31 0001174891 2022-01-01 2022-12-31 0001174891 BUUZ:TechnologyDevelopmentAgreementMember BUUZ:PICOCELCoLtdMember 2021-01-01 2021-12-31 0001174891 BUUZ:SeriesAConvertiblePreferredStockMember 2021-01-01 2021-12-31 0001174891 BUUZ:SeriesAConvertiblePreferredStockMember 2020-02-10 2020-02-11 0001174891 BUUZ:TerminationAgreementMember 2021-01-01 2021-01-31 0001174891 srt:ChiefExecutiveOfficerMember 2021-01-01 2021-03-31 0001174891 srt:ChiefFinancialOfficerMember 2021-03-30 0001174891 srt:ChiefFinancialOfficerMember 2021-03-31 0001174891 srt:ChiefFinancialOfficerMember 2021-01-01 2021-03-31 0001174891 BUUZ:ConsultantsMember 2021-10-01 2021-10-31 0001174891 BUUZ:ConsultantsMember 2021-08-16 2021-08-17 0001174891 srt:ChiefExecutiveOfficerMember 2021-08-16 2021-08-17 0001174891 BUUZ:ConsultantsMember 2021-01-01 2021-12-31 0001174891 BUUZ:ConsultantsMember 2021-12-31 0001174891 BUUZ:ShareholderMember BUUZ:NewConsultingAgreementMember 2021-02-01 2021-02-28 0001174891 BUUZ:ShareholderMember BUUZ:NewConsultingAgreementMember 2021-02-28 0001174891 BUUZ:ShareholderMember BUUZ:NewConsultingAgreementMember 2020-01-01 2020-12-31 0001174891 BUUZ:ShareholderMember BUUZ:NewConsultingAgreementMember 2021-01-01 2021-12-31 0001174891 BUUZ:LetterofUnderstandingMember 2021-05-31 0001174891 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2021-05-01 2021-05-31 0001174891 us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2021-05-01 2021-05-31 0001174891 us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2021-05-01 2021-05-31 0001174891 2021-05-31 0001174891 2021-05-01 2021-05-31 0001174891 2021-09-15 0001174891 2021-09-14 2021-09-15 0001174891 us-gaap:RestrictedStockMember 2021-12-31 0001174891 2019-01-01 2019-12-31 0001174891 us-gaap:MeasurementInputExpectedTermMember 2021-12-31 0001174891 srt:MinimumMember us-gaap:MeasurementInputExpectedTermMember 2020-12-31 0001174891 srt:MaximumMember us-gaap:MeasurementInputExpectedTermMember 2020-12-31 0001174891 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-31 0001174891 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-31 0001174891 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-12-31 0001174891 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-12-31 0001174891 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember 2021-12-31 0001174891 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember 2021-12-31 0001174891 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember 2020-12-31 0001174891 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember 2020-12-31 0001174891 us-gaap:MeasurementInputExpectedDividendRateMember 2021-12-31 0001174891 us-gaap:MeasurementInputExpectedDividendRateMember 2020-12-31 0001174891 srt:MinimumMember us-gaap:MeasurementInputSharePriceMember 2021-12-31 0001174891 srt:MaximumMember us-gaap:MeasurementInputSharePriceMember 2021-12-31 0001174891 srt:MinimumMember us-gaap:MeasurementInputSharePriceMember 2020-12-31 0001174891 srt:MaximumMember us-gaap:MeasurementInputSharePriceMember 2020-12-31 0001174891 BUUZ:AIQMember 2021-12-23 0001174891 us-gaap:SubsequentEventMember 2022-03-31 0001174891 us-gaap:SubsequentEventMember 2022-03-01 0001174891 us-gaap:SubsequentEventMember 2022-03-02 2022-03-03 iso4217:USD shares iso4217:USD shares pure iso4217:KRW 0001174891 false FY 1000 P0Y P0Y 10-K true 2021-12-31 --12-31 2021 false 000-50331 CalEthos, Inc. NV 98-0371433 11753 Willard Avenue Tustin CA 92782 (714) 352-5315 No No Yes Yes Non-accelerated Filer true false false false 7249894 25995621 587 RBSM LLP Larkspur, CA 3047000 7000 2000 3054000 2000 38000 3092000 2000 434000 611000 111000 11000 3087000 703000 3632000 1325000 0.001 0.001 3600000 3600000 0 0 0 0 0.001 0.001 100000000 100000000 0 0 0 0 0.001 0.001 100000000 100000000 25995621 25995621 16634951 16634951 26000 17000 16269000 8744000 -2000 -2000 -2000 -16831000 -10082000 -540000 -1323000 3092000 2000 6095000 340000 57000 51000 6152000 391000 -6152000 -391000 -597000 -227000 138000 -597000 -365000 -6749000 -756000 -6749000 -756000 -0.35 -0.05 19482261 16634951 -6749000 -756000 -2000 -6751000 -756000 85975 16634951 17000 8750000 -2000 -9326000 -561000 -85975 -119000 -119000 52000 52000 58000 58000 3000 3000 -756000 -756000 16634951 17000 8744000 -2000 -10082000 -1323000 16634951 17000 8744000 -2000 -10082000 -1323000 1690000 1690000 575000 575000 75000 166000 166000 38000 38000 3674330 -4000 4000 1435000 2000 2000 25000 272000 272000 11500000 11000 4780000 4791000 -2000 -2000 -6749000 -6749000 25995621 26000 16269000 -2000 -2000 -16831000 -540000 -6749000 -756000 524000 188000 86000 52000 846000 4791000 5000 28000 248000 -565000 -182000 -38000 -38000 3550000 49000 150000 10000 50000 2000 3652000 59000 -2000 3047000 -123000 123000 3047000 119000 52000 58000 1690000 3000 38000 166000 355000 <p id="xdx_808_eus-gaap--OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_zXwJ3iAmLUE3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1 - <span id="xdx_82E_zGvJOqfTE3fg">Organization and Accounting Policies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CalEthos, Inc. (the “Company” or “we”) was incorporated on March 20, 2002 under the laws of the State of Nevada. Since the second quarter of 2016, the Company has been a “shell” company, as defined in Rule 12b-2 under the Exchange Act.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 20, 2018, we filed a Certificate of Amendment to our Articles of Incorporation with the Secretary of State of the State of Nevada to change the Company name from “RealSource Residential, Inc.” to “CalEthos, Inc.”. This amendment became effective immediately upon filing on December 20, 2018.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2021, the primary activity of the Company’s management is to develop and implement a plan to manufacture high-performance computer systems that are scalable, upgradeable and cost effective for processing cryptocurrencies, tokens and blockchain-based transactions, and if other opportunities warrant, acquire assets and all or part of other companies operating in the cryptocurrency mining hardware industry and or invest or joint venture with other more established companies already in the industry. The Company will not restrict its search to any specific business segment of the cryptocurrency mining hardware industry or geographical location and the Company may participate in a business venture of virtually any kind or nature that is beneficial to the Company and its shareholders.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_ecustom--ChangeInControlPolicyTextBlock_zhyfO1tQU" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zdRWGHdP6Tj5">Amendments to Certificate of Incorporation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2021, the Board of Directors authorized an amendment to the Articles of Incorporation of the Company to change the Company’s name of AIQ Blockchain, Inc. The name change has not yet been effected.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--BusinessCombinationsPolicy_zFnzepysbGid" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zSMbGaltBWqb">Incorporation of Korean entity</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 5, 2021, AIQ System Inc. (“AIQ”) was incorporated in Seoul, Republic of Korea. AIQ is authorized to issue <span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_pp6n6_c20211105__us-gaap--RelatedPartyTransactionAxis__custom--AIQMember_zbRN1NIX65xj" title="Common stock shares authorized">3</span> million shares of common stock. At the date of incorporation, <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20211104__20211105_zIaNSIxKx1gg" title="Issuance of common stock">10,000 </span>shares were issued to the Company for <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20211104__20211105__srt--StatementGeographicalAxis__country--KR_zt65GO21qt1i" title="Issuance of common stock">100,000,000</span> Korean Won or approximately $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20211104__20211105__srt--StatementGeographicalAxis__country--KR__us-gaap--RelatedPartyTransactionAxis__custom--AIQMember_zJMACk5VIcd6" title="Issuance of common stock">89,000</span> for <span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPercentage_c20211105__srt--StatementGeographicalAxis__country--KR__us-gaap--RelatedPartyTransactionAxis__custom--AIQMember_zSTqkFXNQQg9" title="Ownership percentage">100</span>% ownership of AIQ.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AIQ is in the business of (1) developing and manufacturing computer chips and system, (2) importing and exporting semiconductors and electronic products, (3) wholesale and retail business of semiconductors and electronic products, and (4) any and all business activities incidental to the foregoing activities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z3LOO5TqK5Zf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zNQZOWaQoJgd">Basis of Presentation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--ConsolidationPolicyTextBlock_zHzC1BONYA9a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zvInGH500Cjc">Principles of Consolidation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary from the formation date. All material intercompany transactions and balances have been eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_ecustom--GoingConcernAndLiquidityPolicyTextBlock_zv9b6y72Jb76" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_z4gQDGKzTXq">Going Concern and Liquidity</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company incurred a net loss of approximately $<span id="xdx_905_eus-gaap--NetIncomeLoss_iN_di_c20210101__20211231_zLeirh99dSGh">6,749,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the year ended December 31, 2021 and had an accumulated deficit of approximately $<span id="xdx_903_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20211231_znkejf8Gzbt">16,831,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as of December 31, 2021. The Company has financed its activities principally through debt and equity financing and shareholder contributions. Management expects to incur additional losses and cash outflows in the foreseeable future in connection with its operating activities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s consolidated financial statements have been presented on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is subject to a number of risks similar to those of other similar stage companies, including dependence on key individuals; successful development, marketing and branding of products; uncertainty of product development and generation of revenues; dependence on outside sources of financing; risks associated with research and development; dependence on third-party suppliers and collaborators; protection of intellectual property; and competition with larger, better-capitalized companies. Ultimately, the attainment of profitable operations is dependent on future events, including obtaining adequate financing to fund its operations and generating a level of revenues adequate to support the Company’s cost structure.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company will need to raise debt or equity financing in the future in order to continue its operations and achieve its growth targets. However, there can be no assurance that such financing will be available in sufficient amounts and on acceptable terms, when and if needed, or at all. The precise amount and timing of the funding needs cannot be determined accurately at this time, and will depend on a number of factors, including market demand for the Company’s products and services, the success of product development efforts, the timing of receipts for customer deposits, the management of working capital, and the continuation of normal payment terms and conditions for purchase of goods and services. The Company believes its cash balances and cash flow from operations will not be sufficient to fund its operations and growth for the next twelve months from the issuance date of these financial statements. If the Company is unable to substantially increase revenues, reduce expenditures, or otherwise generate cash flows from operations, then the Company will likely need to raise additional funding from investors or through other avenues to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--UseOfEstimates_zfbr5zMDpoAj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zteYsFArbc4f">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with GAAP and requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zc9l69fygkbe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zKTPRH1urtia">Foreign Currency Translation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The financial statements of foreign subsidiaries, for which the functional currency is the local currency, are translated into U.S. dollars using the exchange rate at the consolidated balance sheet date for assets and liabilities and a weighted-average exchange rate during the year for revenue, expenses, gains and losses. Translation adjustments are recorded as other comprehensive income (loss) within shareholders’ equity (deficit). Gains or losses from foreign currency transactions are recognized in the consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zxhkpvawY9W5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zsqrIC0rjTIg">Fair Value Measurement</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants as of the measurement date. Applicable accounting guidance provides an established hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors that market participants would use in valuing the asset or liability. There are three levels of inputs that may be used to measure fair value:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify; text-indent: -45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 - Other inputs that are directly or indirectly observable in the marketplace.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 - Unobservable inputs which are supported by little or no market activity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of and for the year ended December 31, 2021, the Company had no assets or liabilities that require fair value measurement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zNI6ZUXnrMsh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_z7VhS5yzEvxd">Cash and Cash Equivalents</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company considers all highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents. Cash and cash equivalents are recorded at cost, which approximates its fair value. The Company maintains its cash and cash equivalents in banks insured by the Federal Deposit Insurance Corporation (“FDIC”) in accounts that at times may be in excess of the federally insured limit of $<span id="xdx_905_eus-gaap--CashFDICInsuredAmount_iI_c20211231_zzXCQKxuHecl">250,000</span> per bank. The Company minimizes this risk by placing its cash deposits with major financial institutions. As of December 31, 2021 and 2020, the Company had $<span id="xdx_906_eus-gaap--PrepaidInsurance_iI_c20211231_zaQTnJ3WfN7l">2,797,000</span> and $<span id="xdx_903_eus-gaap--PrepaidInsurance_iI_c20201231_z8kXEVheTmk">0</span> in excess of the federal insurance limit, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_ecustom--PrepaidExpensePolicyTextBlock_zliSbjnpQHdf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zbkIIze0GG6k">Prepaid Expense</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses are assets held by the Company, which are expected to be realized and consumed within twelve months after the reporting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p id="xdx_84E_ecustom--OtherAssetsPolicyTextBlock_z2MyXxV1WLA3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86D_zBo1JbIlNmCb">Other Assets</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other assets consist of long-term advances paid for chip and processor design and development.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p id="xdx_84D_ecustom--RelatedPartiesPolicyTextBlock_zrf1PqbzGve6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zo1iCfYUGqB6">Related Parties</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company follows Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) section 850-10 for the identification of related parties and disclosure of related party transactions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to ASC section 850-10-20 the related parties include (a.) affiliates of the Company (“Affiliate” means, with respect to any specified Person, any other Person that, directly or indirectly through one or more intermediaries, controls, is controlled by or is under common control with such Person, as such terms are used in and construed under Rule 405 under the Securities Act); (b.) entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option of ASC section 825–10–15, to be accounted for by the equity method by the investing entity; (c.) trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; (d.) principal owners of the Company; (e.) management of the Company; (f.) other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and (g.) other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of consolidated or combined financial statements is not required in those statements. The disclosures shall include: (a.) the nature of the relationship(s) involved; (b.) a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; (c.) the dollar amounts of transactions for each of the periods for which income statements are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and (d.) amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--CommitmentsAndContingenciesPolicyTextBlock_zHzJcaG7fb1f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zUJxILxyIjC3">Commitments and Contingencies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company follows ASC section 450-20 to report accounting for contingencies. Certain conditions may exist as of the date the consolidated financial statements are issued, which may result in a loss to the Company, but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or un-asserted claims that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or un-asserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s consolidated financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--DebtPolicyTextBlock_zWzv32wE9Kb9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zWxAIog97ca4">Debt Discounts</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for debt discounts originating in connection with conversion features that remain embedded in the related notes in accordance with ASC 470-20, <i>Debt with Conversion and Other Options</i>. These costs are classified on the balance sheet as a direct deduction from the debt liability. The Company amortizes these costs over the term of its debt agreements as financing cost in the consolidated statement of operations and comprehensive loss.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_ecustom--WarrantLiabilityPolicyTextBlock_z7B9JwYnmYvb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zzFDOHnts4X9">Warrant Liability</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with financing arrangements, the Company has issued warrants to purchase shares of its common stock. The outstanding warrants are standalone instruments that are not puttable or mandatorily redeemable by the holder and are classified as equity awards. The Company measures the fair value of the awards using the Black-Scholes Merton (“BSM”) option pricing model as of the measurement date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zvmsP8WgKmx5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_z72PEwmblqMl">Stock-Based Compensation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We account for our stock-based compensation under ASC 718, “<i>Compensation – Stock Compensation</i>” using the fair value based method. Under this method, compensation cost is measured at the grant date based on the value of the award and is recognized over the service period, which is usually the vesting period. This guidance establishes standards for the accounting for transactions in which an entity exchanges it equity instruments for goods or services. It also addresses transactions in which an entity incurs liabilities in exchange for goods or services that are based on the fair value of the entity’s equity instruments or that may be settled by the issuance of those equity instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We use the fair value method for equity instruments granted to non-employees and use the BSM model for measuring the fair value of options. The stock based fair value compensation is determined as of the date of the grant (measurement date) and is recognized over the vesting periods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_zhRPqAimxhdc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zKqbWDtQzik6">Income Taxes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for income taxes in accordance with ASC 740, <i>Income Taxes</i>, deferred tax assets and liabilities are computed based on the difference between the financial reporting and income tax bases of assets and liabilities using the enacted marginal tax rate. ASC 740 requires that the net deferred tax asset be reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some portion or all of the net deferred tax asset will not be realized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for income taxes using an asset and liability approach, which requires the recognition of taxes payable or refundable for the current year and deferred tax liabilities and assets for the future tax consequences of events that have been recognized in the Company’s financial statements or tax returns. The measurement of current and deferred tax assets and liabilities is based on provisions of enacted tax laws; the effects of future changes in tax laws or rates are not anticipated. If necessary, the measurement of deferred tax assets is reduced by the amount of any tax benefits that are not expected to be realized based on available evidence.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has adopted guidance related to the accounting for uncertainty in income taxes which prescribes rules for recognition, measurement and classification in the financial statements of tax positions taken or expected to be taken in a tax return. The guidance prescribes a two-step approach which involves evaluating whether a tax position will be more likely than not (greater than 50 percent likelihood) sustained upon examination based on the technical merits of the position. The second step requires that any tax position that meets the more likely than not recognition threshold be measured and recognized in the financial statements at the largest amount of benefit that is a greater than 50 percent likelihood of being realized upon settlement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s policy is to recognize interest and penalties, if any, related to unrecognized tax benefits in income tax expense. The Company is not currently under examination by any taxing authority nor has the Company been notified of a pending examination. The statute of limitations for which the Company is generally no longer subject to federal or state income tax examinations by tax authorities is for years before 2013.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--EarningsPerSharePolicyTextBlock_zPNqspyqpgt8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zg3Jwtiip0Sh">Earnings Per Share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We use ASC 260, “<i>Earnings Per Share</i>” for calculating the basic and diluted earnings (loss) per share. We compute basic earnings (loss) per share by dividing net income (loss) by the weighted average number of common shares outstanding. Diluted earnings (loss) per share is computed based on the weighted average number of shares of common stock plus the effect of dilutive potential common shares outstanding during the period using the treasury stock method. Dilutive potential common shares include outstanding stock options and warrants and stock awards. For periods with a net loss, basic and diluted loss per share is the same, in that any potential common stock equivalents would have the effect of being anti-dilutive in the computation of net loss per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zgBJM1QIGgcc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities that could potentially dilute income (loss) per share in the future were not included in the computation of diluted income (loss) per share on December 31 because their inclusion would be anti-dilutive as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_z8iBjTOkhqVh" style="display: none">Schedule of Income and Loss Per Share Anti-dilutive</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_499_20210101__20211231_z69Q52aT6rKh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49F_20200101__20201231_zpbEeTkZsQwd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockAwardMember_zgXIEIB5Wm6b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Restricted stock awards</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,500,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0564"> </span></span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertiblePromissoryNotesAndAccruedInterestMember_zyVhL64ej3Lg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Convertible promissory notes and accrued interest</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,947,394</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">747,032</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAWarrantsIssuedWithConvertiblePromissoryNotesMember_z2kE5d3MEKHh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series A warrants issued with convertible promissory notes</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,921,304</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">353,804</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesBWarrantsToBeIssuedUponExerciseOfSeriesAWarrantMember_zALntQZfFjA5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series B warrants to be issued upon exercise of Series A warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,921,304</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">353,804</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsIssuedForServicesMember_zE6XsXUc8hp9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Warrants issued for services</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">100,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0576"> </span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zTVooVzTDee7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Stock options</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0578"> </span></span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">385,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zYX3gmJk7tyf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total potential future shares</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">19,390,002</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,839,640</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A8_zFqmB821eVig" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_znsh5XFSXtqj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zfGpmILVXOwj">Recent Accounting Pronouncements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s management reviewed all recently issued accounting standard updates (“ASU’s”) not yet adopted by the Company and does not believe the future adoptions of any such ASU’s may be expected to cause a material impact on the Company’s consolidated financial condition or the results of its operations.</span></p> <p id="xdx_85B_zZer23gIvyK7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_ecustom--ChangeInControlPolicyTextBlock_zhyfO1tQU" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zdRWGHdP6Tj5">Amendments to Certificate of Incorporation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2021, the Board of Directors authorized an amendment to the Articles of Incorporation of the Company to change the Company’s name of AIQ Blockchain, Inc. The name change has not yet been effected.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--BusinessCombinationsPolicy_zFnzepysbGid" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zSMbGaltBWqb">Incorporation of Korean entity</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 5, 2021, AIQ System Inc. (“AIQ”) was incorporated in Seoul, Republic of Korea. AIQ is authorized to issue <span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_pp6n6_c20211105__us-gaap--RelatedPartyTransactionAxis__custom--AIQMember_zbRN1NIX65xj" title="Common stock shares authorized">3</span> million shares of common stock. At the date of incorporation, <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20211104__20211105_zIaNSIxKx1gg" title="Issuance of common stock">10,000 </span>shares were issued to the Company for <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20211104__20211105__srt--StatementGeographicalAxis__country--KR_zt65GO21qt1i" title="Issuance of common stock">100,000,000</span> Korean Won or approximately $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20211104__20211105__srt--StatementGeographicalAxis__country--KR__us-gaap--RelatedPartyTransactionAxis__custom--AIQMember_zJMACk5VIcd6" title="Issuance of common stock">89,000</span> for <span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPercentage_c20211105__srt--StatementGeographicalAxis__country--KR__us-gaap--RelatedPartyTransactionAxis__custom--AIQMember_zSTqkFXNQQg9" title="Ownership percentage">100</span>% ownership of AIQ.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AIQ is in the business of (1) developing and manufacturing computer chips and system, (2) importing and exporting semiconductors and electronic products, (3) wholesale and retail business of semiconductors and electronic products, and (4) any and all business activities incidental to the foregoing activities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 3000000 10000 100000000 89000 1 <p id="xdx_848_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z3LOO5TqK5Zf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zNQZOWaQoJgd">Basis of Presentation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--ConsolidationPolicyTextBlock_zHzC1BONYA9a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zvInGH500Cjc">Principles of Consolidation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary from the formation date. All material intercompany transactions and balances have been eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_ecustom--GoingConcernAndLiquidityPolicyTextBlock_zv9b6y72Jb76" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_z4gQDGKzTXq">Going Concern and Liquidity</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company incurred a net loss of approximately $<span id="xdx_905_eus-gaap--NetIncomeLoss_iN_di_c20210101__20211231_zLeirh99dSGh">6,749,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the year ended December 31, 2021 and had an accumulated deficit of approximately $<span id="xdx_903_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20211231_znkejf8Gzbt">16,831,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as of December 31, 2021. The Company has financed its activities principally through debt and equity financing and shareholder contributions. Management expects to incur additional losses and cash outflows in the foreseeable future in connection with its operating activities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s consolidated financial statements have been presented on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is subject to a number of risks similar to those of other similar stage companies, including dependence on key individuals; successful development, marketing and branding of products; uncertainty of product development and generation of revenues; dependence on outside sources of financing; risks associated with research and development; dependence on third-party suppliers and collaborators; protection of intellectual property; and competition with larger, better-capitalized companies. Ultimately, the attainment of profitable operations is dependent on future events, including obtaining adequate financing to fund its operations and generating a level of revenues adequate to support the Company’s cost structure.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company will need to raise debt or equity financing in the future in order to continue its operations and achieve its growth targets. However, there can be no assurance that such financing will be available in sufficient amounts and on acceptable terms, when and if needed, or at all. The precise amount and timing of the funding needs cannot be determined accurately at this time, and will depend on a number of factors, including market demand for the Company’s products and services, the success of product development efforts, the timing of receipts for customer deposits, the management of working capital, and the continuation of normal payment terms and conditions for purchase of goods and services. The Company believes its cash balances and cash flow from operations will not be sufficient to fund its operations and growth for the next twelve months from the issuance date of these financial statements. If the Company is unable to substantially increase revenues, reduce expenditures, or otherwise generate cash flows from operations, then the Company will likely need to raise additional funding from investors or through other avenues to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> -6749000 -16831000 <p id="xdx_84B_eus-gaap--UseOfEstimates_zfbr5zMDpoAj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zteYsFArbc4f">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with GAAP and requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zc9l69fygkbe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zKTPRH1urtia">Foreign Currency Translation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The financial statements of foreign subsidiaries, for which the functional currency is the local currency, are translated into U.S. dollars using the exchange rate at the consolidated balance sheet date for assets and liabilities and a weighted-average exchange rate during the year for revenue, expenses, gains and losses. Translation adjustments are recorded as other comprehensive income (loss) within shareholders’ equity (deficit). Gains or losses from foreign currency transactions are recognized in the consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zxhkpvawY9W5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zsqrIC0rjTIg">Fair Value Measurement</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants as of the measurement date. Applicable accounting guidance provides an established hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors that market participants would use in valuing the asset or liability. There are three levels of inputs that may be used to measure fair value:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify; text-indent: -45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 - Other inputs that are directly or indirectly observable in the marketplace.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 - Unobservable inputs which are supported by little or no market activity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of and for the year ended December 31, 2021, the Company had no assets or liabilities that require fair value measurement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zNI6ZUXnrMsh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_z7VhS5yzEvxd">Cash and Cash Equivalents</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company considers all highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents. Cash and cash equivalents are recorded at cost, which approximates its fair value. The Company maintains its cash and cash equivalents in banks insured by the Federal Deposit Insurance Corporation (“FDIC”) in accounts that at times may be in excess of the federally insured limit of $<span id="xdx_905_eus-gaap--CashFDICInsuredAmount_iI_c20211231_zzXCQKxuHecl">250,000</span> per bank. The Company minimizes this risk by placing its cash deposits with major financial institutions. As of December 31, 2021 and 2020, the Company had $<span id="xdx_906_eus-gaap--PrepaidInsurance_iI_c20211231_zaQTnJ3WfN7l">2,797,000</span> and $<span id="xdx_903_eus-gaap--PrepaidInsurance_iI_c20201231_z8kXEVheTmk">0</span> in excess of the federal insurance limit, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 250000 2797000 0 <p id="xdx_847_ecustom--PrepaidExpensePolicyTextBlock_zliSbjnpQHdf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zbkIIze0GG6k">Prepaid Expense</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses are assets held by the Company, which are expected to be realized and consumed within twelve months after the reporting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p id="xdx_84E_ecustom--OtherAssetsPolicyTextBlock_z2MyXxV1WLA3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86D_zBo1JbIlNmCb">Other Assets</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other assets consist of long-term advances paid for chip and processor design and development.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p id="xdx_84D_ecustom--RelatedPartiesPolicyTextBlock_zrf1PqbzGve6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zo1iCfYUGqB6">Related Parties</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company follows Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) section 850-10 for the identification of related parties and disclosure of related party transactions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to ASC section 850-10-20 the related parties include (a.) affiliates of the Company (“Affiliate” means, with respect to any specified Person, any other Person that, directly or indirectly through one or more intermediaries, controls, is controlled by or is under common control with such Person, as such terms are used in and construed under Rule 405 under the Securities Act); (b.) entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option of ASC section 825–10–15, to be accounted for by the equity method by the investing entity; (c.) trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; (d.) principal owners of the Company; (e.) management of the Company; (f.) other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and (g.) other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of consolidated or combined financial statements is not required in those statements. The disclosures shall include: (a.) the nature of the relationship(s) involved; (b.) a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; (c.) the dollar amounts of transactions for each of the periods for which income statements are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and (d.) amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--CommitmentsAndContingenciesPolicyTextBlock_zHzJcaG7fb1f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zUJxILxyIjC3">Commitments and Contingencies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company follows ASC section 450-20 to report accounting for contingencies. Certain conditions may exist as of the date the consolidated financial statements are issued, which may result in a loss to the Company, but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or un-asserted claims that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or un-asserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s consolidated financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--DebtPolicyTextBlock_zWzv32wE9Kb9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zWxAIog97ca4">Debt Discounts</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for debt discounts originating in connection with conversion features that remain embedded in the related notes in accordance with ASC 470-20, <i>Debt with Conversion and Other Options</i>. These costs are classified on the balance sheet as a direct deduction from the debt liability. The Company amortizes these costs over the term of its debt agreements as financing cost in the consolidated statement of operations and comprehensive loss.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_ecustom--WarrantLiabilityPolicyTextBlock_z7B9JwYnmYvb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zzFDOHnts4X9">Warrant Liability</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with financing arrangements, the Company has issued warrants to purchase shares of its common stock. The outstanding warrants are standalone instruments that are not puttable or mandatorily redeemable by the holder and are classified as equity awards. The Company measures the fair value of the awards using the Black-Scholes Merton (“BSM”) option pricing model as of the measurement date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zvmsP8WgKmx5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_z72PEwmblqMl">Stock-Based Compensation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We account for our stock-based compensation under ASC 718, “<i>Compensation – Stock Compensation</i>” using the fair value based method. Under this method, compensation cost is measured at the grant date based on the value of the award and is recognized over the service period, which is usually the vesting period. This guidance establishes standards for the accounting for transactions in which an entity exchanges it equity instruments for goods or services. It also addresses transactions in which an entity incurs liabilities in exchange for goods or services that are based on the fair value of the entity’s equity instruments or that may be settled by the issuance of those equity instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We use the fair value method for equity instruments granted to non-employees and use the BSM model for measuring the fair value of options. The stock based fair value compensation is determined as of the date of the grant (measurement date) and is recognized over the vesting periods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_zhRPqAimxhdc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zKqbWDtQzik6">Income Taxes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for income taxes in accordance with ASC 740, <i>Income Taxes</i>, deferred tax assets and liabilities are computed based on the difference between the financial reporting and income tax bases of assets and liabilities using the enacted marginal tax rate. ASC 740 requires that the net deferred tax asset be reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some portion or all of the net deferred tax asset will not be realized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for income taxes using an asset and liability approach, which requires the recognition of taxes payable or refundable for the current year and deferred tax liabilities and assets for the future tax consequences of events that have been recognized in the Company’s financial statements or tax returns. The measurement of current and deferred tax assets and liabilities is based on provisions of enacted tax laws; the effects of future changes in tax laws or rates are not anticipated. If necessary, the measurement of deferred tax assets is reduced by the amount of any tax benefits that are not expected to be realized based on available evidence.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has adopted guidance related to the accounting for uncertainty in income taxes which prescribes rules for recognition, measurement and classification in the financial statements of tax positions taken or expected to be taken in a tax return. The guidance prescribes a two-step approach which involves evaluating whether a tax position will be more likely than not (greater than 50 percent likelihood) sustained upon examination based on the technical merits of the position. The second step requires that any tax position that meets the more likely than not recognition threshold be measured and recognized in the financial statements at the largest amount of benefit that is a greater than 50 percent likelihood of being realized upon settlement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s policy is to recognize interest and penalties, if any, related to unrecognized tax benefits in income tax expense. The Company is not currently under examination by any taxing authority nor has the Company been notified of a pending examination. The statute of limitations for which the Company is generally no longer subject to federal or state income tax examinations by tax authorities is for years before 2013.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--EarningsPerSharePolicyTextBlock_zPNqspyqpgt8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zg3Jwtiip0Sh">Earnings Per Share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We use ASC 260, “<i>Earnings Per Share</i>” for calculating the basic and diluted earnings (loss) per share. We compute basic earnings (loss) per share by dividing net income (loss) by the weighted average number of common shares outstanding. Diluted earnings (loss) per share is computed based on the weighted average number of shares of common stock plus the effect of dilutive potential common shares outstanding during the period using the treasury stock method. Dilutive potential common shares include outstanding stock options and warrants and stock awards. For periods with a net loss, basic and diluted loss per share is the same, in that any potential common stock equivalents would have the effect of being anti-dilutive in the computation of net loss per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zgBJM1QIGgcc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities that could potentially dilute income (loss) per share in the future were not included in the computation of diluted income (loss) per share on December 31 because their inclusion would be anti-dilutive as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_z8iBjTOkhqVh" style="display: none">Schedule of Income and Loss Per Share Anti-dilutive</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_499_20210101__20211231_z69Q52aT6rKh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49F_20200101__20201231_zpbEeTkZsQwd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockAwardMember_zgXIEIB5Wm6b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Restricted stock awards</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,500,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0564"> </span></span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertiblePromissoryNotesAndAccruedInterestMember_zyVhL64ej3Lg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Convertible promissory notes and accrued interest</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,947,394</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">747,032</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAWarrantsIssuedWithConvertiblePromissoryNotesMember_z2kE5d3MEKHh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series A warrants issued with convertible promissory notes</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,921,304</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">353,804</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesBWarrantsToBeIssuedUponExerciseOfSeriesAWarrantMember_zALntQZfFjA5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series B warrants to be issued upon exercise of Series A warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,921,304</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">353,804</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsIssuedForServicesMember_zE6XsXUc8hp9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Warrants issued for services</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">100,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0576"> </span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zTVooVzTDee7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Stock options</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0578"> </span></span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">385,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zYX3gmJk7tyf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total potential future shares</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">19,390,002</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,839,640</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A8_zFqmB821eVig" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zgBJM1QIGgcc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities that could potentially dilute income (loss) per share in the future were not included in the computation of diluted income (loss) per share on December 31 because their inclusion would be anti-dilutive as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_z8iBjTOkhqVh" style="display: none">Schedule of Income and Loss Per Share Anti-dilutive</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_499_20210101__20211231_z69Q52aT6rKh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49F_20200101__20201231_zpbEeTkZsQwd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockAwardMember_zgXIEIB5Wm6b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Restricted stock awards</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,500,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0564"> </span></span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertiblePromissoryNotesAndAccruedInterestMember_zyVhL64ej3Lg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Convertible promissory notes and accrued interest</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,947,394</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">747,032</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAWarrantsIssuedWithConvertiblePromissoryNotesMember_z2kE5d3MEKHh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series A warrants issued with convertible promissory notes</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,921,304</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">353,804</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesBWarrantsToBeIssuedUponExerciseOfSeriesAWarrantMember_zALntQZfFjA5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series B warrants to be issued upon exercise of Series A warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,921,304</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">353,804</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsIssuedForServicesMember_zE6XsXUc8hp9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Warrants issued for services</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">100,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0576"> </span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zTVooVzTDee7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Stock options</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0578"> </span></span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">385,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zYX3gmJk7tyf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total potential future shares</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">19,390,002</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,839,640</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 11500000 3947394 747032 1921304 353804 1921304 353804 100000 385000 19390002 1839640 <p id="xdx_84F_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_znsh5XFSXtqj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zfGpmILVXOwj">Recent Accounting Pronouncements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s management reviewed all recently issued accounting standard updates (“ASU’s”) not yet adopted by the Company and does not believe the future adoptions of any such ASU’s may be expected to cause a material impact on the Company’s consolidated financial condition or the results of its operations.</span></p> <p id="xdx_80C_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zSQuaeMbBHT3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2 – <span id="xdx_820_zQu7M9HTa6h8">Related Party Transactions</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company incurred approximately $<span id="xdx_900_eus-gaap--ProceedsFromRelatedPartyDebt_c20210101__20211231_zyT33pBe05zh" title="Proceeds from related party">199,000</span> and $<span id="xdx_905_eus-gaap--ProceedsFromRelatedPartyDebt_c20200101__20201231_zdYJAG6qyHO9" title="Proceeds from related party">180,000</span> for years ended December 31, 2021 and 2020, and paid approximately $<span id="xdx_902_eus-gaap--RepaymentsOfRelatedPartyDebt_c20210101__20211231__srt--TitleOfIndividualAxis__custom--MOneAdvisorsMember_zS6BB3L7Dqp3" title="Miscellaneous operating expenses">202,000</span> and $<span id="xdx_902_eus-gaap--RepaymentsOfRelatedPartyDebt_c20200101__20201231__srt--TitleOfIndividualAxis__custom--MOneAdvisorsMember_zZmrLD45F1P3" title="Miscellaneous operating expenses">112,000</span>, respectively, to M1 Advisors for the services of the Company’s CEO and miscellaneous operating expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 199000 180000 202000 112000 <p id="xdx_806_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_z6HHrS5joW4l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note <span style="font-variant: small-caps">3 – </span><span id="xdx_829_zu689r9Mk8r5">Accounts Payable and Accrued Expenses</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_z52j1Vd4y0j8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts payable and accrued expenses as of December 31, are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zZQw9CzHdB05" style="display: none">Schedule of Accounts Payable and Accrued Expenses</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_495_20211231_z37IN85SEeVb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_491_20201231_zzQSEiSCv2J2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_eus-gaap--AccountsPayableCurrent_iI_maAPAALzlqR_zGYdQy5uv9od" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts payable</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">221,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">316,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--AccruedLiabilitiesCurrent_iI_maAPAALzlqR_zUmQ74rf2mj9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">99,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">255,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--InterestPayableCurrent_iI_maAPAALzlqR_zCv09qSBGtg8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Accrued interest</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">114,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">40,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iTI_mtAPAALzlqR_zHgbw1rY2to8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Accounts payable and accrued expenses</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">434,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">611,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8AA_zvtmoAA8jw3c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Accrued Interest</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zLyPzxSivM0k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents the details of accrued interest of December 31:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B8_zcfJbyXHwXBd" style="display: none">Schedule of Accrued Interest</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" id="xdx_491_20210101__20211231_zSOrHm5Pk3Db" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" id="xdx_49D_20200101__20201231_zomgNfVhhHel" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr id="xdx_404_eus-gaap--NotesPayableCurrent_iS_z29QENLCgx17" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes payable</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,000</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">1,000</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_404_ecustom--ConvertiblePromissoryNotes_zfXZQbdIMPl5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible promissory notes</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">105,000</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39,000</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_401_eus-gaap--InterestPayableCurrent_iE_z5ZkCwB3Hd1a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, end of the year</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">114,000</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40,000</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A3_zEJ3iZU50b2h" style="display: none; margin-top: 0pt; margin-bottom: 0pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_z52j1Vd4y0j8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts payable and accrued expenses as of December 31, are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zZQw9CzHdB05" style="display: none">Schedule of Accounts Payable and Accrued Expenses</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_495_20211231_z37IN85SEeVb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_491_20201231_zzQSEiSCv2J2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_eus-gaap--AccountsPayableCurrent_iI_maAPAALzlqR_zGYdQy5uv9od" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts payable</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">221,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">316,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--AccruedLiabilitiesCurrent_iI_maAPAALzlqR_zUmQ74rf2mj9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">99,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">255,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--InterestPayableCurrent_iI_maAPAALzlqR_zCv09qSBGtg8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Accrued interest</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">114,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">40,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iTI_mtAPAALzlqR_zHgbw1rY2to8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Accounts payable and accrued expenses</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">434,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">611,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 221000 316000 99000 255000 114000 40000 434000 611000 <p id="xdx_890_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zLyPzxSivM0k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents the details of accrued interest of December 31:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B8_zcfJbyXHwXBd" style="display: none">Schedule of Accrued Interest</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" id="xdx_491_20210101__20211231_zSOrHm5Pk3Db" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" id="xdx_49D_20200101__20201231_zomgNfVhhHel" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr id="xdx_404_eus-gaap--NotesPayableCurrent_iS_z29QENLCgx17" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes payable</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,000</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">1,000</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_404_ecustom--ConvertiblePromissoryNotes_zfXZQbdIMPl5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible promissory notes</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">105,000</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39,000</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_401_eus-gaap--InterestPayableCurrent_iE_z5ZkCwB3Hd1a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, end of the year</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">114,000</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40,000</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 9000 1000 105000 39000 114000 40000 <p id="xdx_807_ecustom--NotesPayableDisclosureTextBlock_zMQwPrzQft86" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note <span style="font-variant: small-caps">4 – </span><span id="xdx_82D_zSYmnLGPLgkc">Notes Payable</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_896_eus-gaap--ScheduleOfDebtTableTextBlock_zFPzVPZEjx2c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below summarizes the transactions for the years ended December 31:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BA_zNAI6RFEjGm3" style="display: none">Schedule of Notes Payable</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_493_20210101__20211231_zogbGDDNdnm3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49E_20200101__20201231_zxbSMOQixfWl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_eus-gaap--NotesPayable_iS_zyZtZ2iGb66h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Balance, beginning of the year</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0628">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40B_ecustom--NotesPayableAdditions_zu5ZdIEQr9sj" style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif">Additions</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">150,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_eus-gaap--RepaymentsOfNotesPayable_iN_di_z3Qy42NMZV87" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Payments</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(50,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0634"> </span></span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_408_eus-gaap--NotesPayable_iE_zjC1d86BsKz7" style="font: 10pt Times New Roman, Times, Serif"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance, end of the year</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">111,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A4_z4guqir76cQe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 11, 2021, the Company issued a promissory note in the principal amount of $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20210111__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zEEJI55r8cQh" title="Principal amount">15,000</span>. The interest on this note shall accrue beginning from the date of issuance, at an interest rate of <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPercentage_c20210111__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zF4sKaPSqNv6" title="Debt instrument, interest rate">8</span>% per annum. The principal and any accrued interest are payable on or before <span id="xdx_90E_eus-gaap--DebtInstrumentMaturityDate_dd_c20210110__20210111__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_z20WsjXxnQw9" title="Debt instrument, maturity date">March 11, 2022</span>. During any event of default under the note, the interest rate shall increase to <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_pid_dp_uPercentage_c20210110__20210111__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zw1Mnd1ebUJf" title="Increase in interest rate">10</span>% per annum. Events of default include failure to pay principal or interest, breach of covenants, breach of representations and warranties, borrower’s assignment of substantial part of its property or business, any money judgment, writ, or similar process shall be entered or filed against the borrower or any subsidiary of the borrower or any of its properties or other assets for more than $<span id="xdx_901_eus-gaap--DebtInstrumentPeriodicPayment_c20210110__20210111__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--BorrowerMember_zqsXzDyOeC97" title="Debt instrument, periodic payment">100,000</span>, bankruptcy, liquidation of business, and cessation of operations. The principal and the accrued interest amounting to $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20211027__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zYcUECBaFKSg" title="Debt instrument, face amount">15,000</span> and $<span id="xdx_904_eus-gaap--InterestPayableCurrent_iI_c20211027__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zefMtbEdGObf" title="Accrued interest">1,000</span>, respectively, was settled on October 27, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 19, 2021, the Company issued a promissory note in the principal amount of $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20210219__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zaBcKUWsTKxi" title="Debt instrument, face amount">25,000</span>. The interest on the unpaid principal balance accrues at a rate of <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPercentage_c20210219__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zKYpgkZtJFe1" title="Debt instrument, interest rate">10</span>% per annum. The principal and any accrued interest shall be paid in a single installment on or before <span id="xdx_907_eus-gaap--DebtInstrumentMaturityDate_dd_c20210218__20210219__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_z0SgvPfRVIe2" title="Debt instrument, maturity date">February 19, 2022</span>. If the Company fails to pay the balance of this note in full on the due date or fails to make any payment due within 15 days of the due date, any unpaid principal shall accrue interest at the rate of <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_pid_dp_uPercentage_c20210218__20210219__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_z5hyI67Hdhse" title="Increase in interest rate">15</span>% per annum during the default (default interest). Events of default include failure to make any payment including accrued interest when due, voluntary, or involuntary petition of bankruptcy, appointment of a receiver, custodian, trustee or similar party to take possession of the Company’s assets or property, or assignment made by the Company for the benefit of creditors. The principal amount outstanding under this note was $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zMoscl4UhWc1" title="Debt instrument, face amount">25,000</span> as of December 31, 2021. Interest accrued as of December 31, 2021 is $<span id="xdx_906_eus-gaap--InterestPayableCurrent_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zPnvFsCzK4Sh" title="Accrued interest">2,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 5, 2021, the Company issued a promissory note in the principal amount of $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20210405__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zHRdQRnABJU1" title="Debt instrument, face amount">9,000</span>. The interest on the unpaid principal balance accrues at a rate of <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPercentage_c20210405__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zyasxQQfV6h1" title="Debt instrument, interest rate">8</span>% per annum. If the Company fails to pay the balance of this note in full on the date or fails to make any payments due within 15 days of the due date, any unpaid principal shall accrue interest at the rate of <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_pid_dp_uPercentage_c20210404__20210405__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zFMgNj604nn1" title="Increase in interest rate">8</span>% per annum during the default. Events of default include failure to make any payment including accrued interest when due, voluntary, or involuntary petition of bankruptcy, appointment of a receiver, custodian, trustee or similar party to take possession of the Company’s assets or property, or assignment made by the Company for the benefit of creditors. The principal and accrued interest under this note was settled September 16, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 22, 2021, the Company issued a promissory note in the principal amount of $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20210422__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember_zT0ZLXlpSGnk" title="Debt instrument, face amount">50,000</span>. The interest on the unpaid principal balance accrues at a rate of <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPercentage_c20210422__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember_zxxs9L5wawV8" title="Debt instrument, interest rate">10</span>% per annum. The principal and any accrued interest shall be paid in a single installment on or before <span id="xdx_908_eus-gaap--DebtInstrumentMaturityDate_dd_c20210420__20210422__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember_zhkUATo6zeW8" title="Debt instrument, maturity date">April 22, 2022</span>. If the Company fails to pay the balance of this note in full on the date or fails to make any payments due within 15 days of the due date, any unpaid principal shall accrue interest at the rate of <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_pid_dp_uPercentage_c20210420__20210422__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember_z7wlA4wOfYu5" title="Increase in interest rate">15</span>% per annum during the default. Events of default include failure to make any payment including accrued interest when due, voluntary, or involuntary petition of bankruptcy, appointment of a receiver, custodian, trustee or similar party to take possession of the Company’s assets or property, or assignment made by the Company for the benefit of creditors. The principal amount outstanding under this note was $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember_zZxpHnd1nVsd" title="Principal amount">50,000</span> as of December 31, 2021. Interest accrued as of December 31, 2021 is $<span id="xdx_90A_eus-gaap--InterestPayableCurrent_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember_z9usf5ITyfSi" title="Accrued interest">2,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 1, 2021, the Company issued a promissory note in the principal amount of $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_c20210701__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteTwoMember_zekx6ZMOlma" title="Debt instrument, face amount">25,000</span>. The interest on the unpaid principal balance accrues at a rate of <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPercentage_c20210701__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteTwoMember_zSenYEhBFDkk" title="Debt instrument, interest rate">10</span>% per annum. The principal and any accrued interest shall be paid in a single installment on or before <span id="xdx_906_eus-gaap--DebtInstrumentMaturityDate_c20210629__20210701__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteTwoMember_zAcFUEXt9Th4" title="Debt instrument, maturity date">July 1,2022</span>. If the Company fails to pay the balance of this note in full on the date or fails to make any payments due within 15 days of the due date, any unpaid principal shall accrue interest at the rate of <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_pid_dp_uPercentage_c20210629__20210701__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteTwoMember_zGBBaTVvmxOd" title="Increase in interest rate">15</span>% per annum during the default (default interest). Events of default include failure to make any payment including accrued interest when due, voluntary, or involuntary petition of bankruptcy, appointment of a receiver, custodian, trustee or similar party to take possession of the Company’s assets or property, or assignment made by the Company for the benefit of creditors. The principal amount outstanding under this note was $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteTwoMember_z43CXpoei4h9" title="Debt instrument, face amount">25,000</span> as of December 31, 2021. Interest accrued as of December 31, 2021 is $<span id="xdx_903_eus-gaap--InterestPayableCurrent_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteTwoMember_z3VH9m1Wr7zf" title="Accrued interest">1,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 12, 2021, the Company issued a promissory note in the principal amount of $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20210712__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zN5xBjsWAmy" title="Debt instrument, face amount">5,000</span>. The interest on the unpaid principal balance accrues at a rate of <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPercentage_c20210712__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zqIYymoq2eij" title="Debt instrument, interest rate">8</span>% per annum. The principal and any accrued interest shall be paid in a single installment on or before <span id="xdx_90A_eus-gaap--DebtInstrumentMaturityDate_c20210711__20210712__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zROQjqb1Hs96" title="Debt instrument, maturity date">October 12, 2021</span>. The principal amount of this note was settled on September 16, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 10, 2021, the Company issued a promissory note in the principal amount of $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20210810__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zfkLudctrVG" title="Debt instrument, face amount">7,000</span>. The interest on the unpaid principal balance accrues at a rate of <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPercentage_c20210810__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zlXIICmaxBz" title="Debt instrument, interest rate">8</span>% per annum. The principal and any accrued interest shall be paid in a single installment on or before <span id="xdx_903_eus-gaap--DebtInstrumentMaturityDate_c20210809__20210810__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zs8hrKq5dJw7" title="Debt instrument, maturity date">November 10, 2021</span>.The principal amount of this note was settled on September 16, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2021, the Company issued four promissory notes to a single lender in the aggregate principal amount of $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20210831__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zsebzvNRujn1" title="Debt instrument, face amount">14,000</span>. The interest on the unpaid principal balance of these notes accrues at a rate of <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPercentage_c20210831__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zFw6xrcuksHi" title="Debt instrument, interest rate">8</span>% per annum. The principal for each note shall be paid in a single installment during <span id="xdx_901_eus-gaap--DebtInstrumentMaturityDateDescription_c20210829__20210831__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zb0mrG5P4yI2" title="Debt instrument, maturity date">November 2021</span>. If the Company fails to pay the balance of these notes in full on the date or fails to make any payments due within 15 days of the due date, any unpaid principal shall accrue interest at the rate of <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_pid_dp_uPercentage_c20210829__20210831__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zChDqlwt0a6k" title="Increase in interest rate">8</span>% per annum during the default. Events of default include failure to make any payment including accrued interest when due, voluntary, or involuntary petition of bankruptcy, appointment of a receiver, custodian, trustee, or similar party to take possession of the Company’s assets or property, or assignment made by the Company for the benefit of creditors. The principal amount outstanding under these notes was $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_c20210930__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zhaGfbBKajb1" title="Debt instrument, face amount">13,500</span> as of September 30, 2021. The principal and the accrued interest aggregating to $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20211031__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_z5lpPD9szmm4" title="Debt instrument, face amount">14,000</span> was settled in October 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2020, the Company issued a promissory note for $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20201231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteThreeMember_zze9tfzdPba2" title="Debt instrument, face amount">11,000</span>. The total proceeds were $<span id="xdx_90A_eus-gaap--ProceedsFromNotesPayable_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteThreeMember_zTKu2ZFXxRDl" title="Proceeds from notes payable">10,000</span>, due to approximately $<span id="xdx_902_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20201231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteThreeMember_zYGfWeFzQVGg" title="Debt instrument, issue discount">1,000</span> for an original issue discount. This promissory note is non-interest bearing with the principal due and payable in <span id="xdx_901_eus-gaap--DebtInstrumentMaturityDateDescription_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zElW1ofQetal" title="Debt instrument, maturity date">August 2020</span>. Any amount of unpaid principal on the date of maturity will accrue interest at rate of <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_pid_dp_uPercentage_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteThreeMember_zdzSqDVDgiJ6" title="Increase in interest rate">10</span>% per annum (default interest). The original issue discount was amortized over the term of the note, which was one month. The Company is in default on this promissory note as of December 31, 2021. The principal and accrued interest amounted to $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteThreeMember_z9jCMa2uAlVb" title="Debt instrument, face amount">11,000</span> and $<span id="xdx_90E_eus-gaap--InterestPayableCurrent_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteThreeMember_zaRzn6QqqFUf" title="Accrued interest">2,000</span>, as of December 31, 2021 and $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_c20201231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteThreeMember_zOi2y91B7Pw7" title="Debt instrument, face amount">11,000</span> and <span id="xdx_90E_eus-gaap--InterestPayableCurrent_iI_dxL_c20201231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteThreeMember_z4sKQDueP1L6" title="Accrued interest::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0735">nil</span></span> as of December 31, 2020, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest expense on notes payable amounted to $<span id="xdx_903_eus-gaap--InterestExpenseDebt_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zOWoI4cuU4Rc">8,000</span> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90B_eus-gaap--InterestExpenseDebt_dxL_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zTywktxwGqZ7"><span style="-sec-ix-hidden: xdx2ixbrl0737">1,000</span></span> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as of December 31, 2021 and 2020, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--ScheduleOfDebtTableTextBlock_zFPzVPZEjx2c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below summarizes the transactions for the years ended December 31:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BA_zNAI6RFEjGm3" style="display: none">Schedule of Notes Payable</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_493_20210101__20211231_zogbGDDNdnm3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49E_20200101__20201231_zxbSMOQixfWl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_eus-gaap--NotesPayable_iS_zyZtZ2iGb66h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Balance, beginning of the year</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0628">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40B_ecustom--NotesPayableAdditions_zu5ZdIEQr9sj" style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif">Additions</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">150,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_eus-gaap--RepaymentsOfNotesPayable_iN_di_z3Qy42NMZV87" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Payments</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(50,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0634"> </span></span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_408_eus-gaap--NotesPayable_iE_zjC1d86BsKz7" style="font: 10pt Times New Roman, Times, Serif"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance, end of the year</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">111,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 11000 150000 11000 50000 111000 11000 15000 0.08 2022-03-11 0.10 100000 15000 1000 25000 0.10 2022-02-19 0.15 25000 2000 9000 0.08 0.08 50000 0.10 2022-04-22 0.15 50000 2000 25000 0.10 2022-07-01 0.15 25000 1000 5000 0.08 2021-10-12 7000 0.08 2021-11-10 14000 0.08 November 2021 0.08 13500 14000 11000 10000 1000 August 2020 0.10 11000 2000 11000 8000 <p id="xdx_804_eus-gaap--DebtDisclosureTextBlock_zxrNZ7xpwL3e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note <span style="font-variant: small-caps">5 – </span><span id="xdx_82B_z1GALKvnHa79">Convertible Promissory Notes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2021, the Company issued two convertible promissory notes amounting to $<span id="xdx_902_eus-gaap--ConvertibleDebt_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteOneMember_z8v1xBZuXyk9" title="Convertible promissory note">55,000</span> and $<span id="xdx_90D_eus-gaap--ConvertibleDebt_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteTwoMember_zTVLi1w6M1Yb" title="Convertible promissory note">3,850,000</span> (the “Notes”), respectively. The total aggregate proceeds were $<span id="xdx_900_eus-gaap--ProceedsFromConvertibleDebt_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteOneMember_zs3Fpp4UYcQg" title="Proceed from convertible debt"><span id="xdx_90C_eus-gaap--ProceedsFromConvertibleDebt_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteTwoMember_zBDxjnlHxGrj" title="Proceed from convertible debt">3,550,000</span></span> due to a $<span id="xdx_903_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteOneMember_zBgklVTQIdm1" title="Original issue discount"><span id="xdx_90F_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteTwoMember_zZWbIkItDtE9" title="Original issue discount">355,000</span></span> aggregate original issue discount. The Notes are non-interest bearing with the principal due and payable on <span id="xdx_908_eus-gaap--DebtInstrumentMaturityDate_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteOneMember_zr1iU4AWnMv5" title="Debt instrument, maturity date">March 1, 2022</span> and <span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteTwoMember_zzpEscCHvuu7" title="Debt instrument, maturity date">August 31, 2022</span>, respectively. Any amount of unpaid principal on the date of maturity will accrue interest at rate of <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_pid_dp_uPercentage_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteOneMember_zW15aXa8KsJ7" title="Increase in interest rate"><span id="xdx_902_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_pid_dp_uPercentage_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteTwoMember_zZ4mDKrGs6n3" title="Increase in interest rate">10</span></span>% per annum (default interest). The principal amount and all accrued interest are convertible into shares of the Company’s common stock, as of the date of issuance, at a rate of $<span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteOneMember_zV2yso2rvOx2" title="Debt instruments, conversion price">1.00</span> and $<span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteTwoMember_zhXpRvHmqg12" title="Debt instruments, conversion price">1.25</span> per share (“Conversion Rate”), respectively. The Conversion Rate is adjustable if, at any time when any principal amount of the Notes remains unpaid or unconverted, the Company issues or sells any shares of the Company’s common stock for no consideration or for a consideration per share (before deduction of reasonable expenses or commissions or underwriting discounts or allowances in connection therewith), which is less than the Conversion Rate in effect on the date of such issuance (or deemed issuance) of such shares of common stock (a “Dilutive Issuance”). <span id="xdx_900_eus-gaap--DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault_c20210101__20211231_zRQhJ3jCOy4l" title="Events of default description">Immediately upon a Dilutive Issuance, the Conversion Rate will be reduced to the amount of the consideration per share received by the Company in such Dilutive Issuance. Events of default include failure to issue conversion shares, the occurrence of a breach or default under any other agreement, any money judgment, writ, or similar process entered or filed against the Company or any of its property or other assets for more than $<span id="xdx_909_ecustom--IndebtednessForBorrowedMoneyMaximumLimit_iI_c20211231_zwVaP4edQxG3" title="Indebtedness for borrowed money maximum limit">100,000</span>, bankruptcy filing, application for the appointment of a custodian, trustee or receiver, insolvency, the Company’s common stock delisted, or dissolution, winding up, or termination of the business of the Company</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the issuance of the Notes, the Company issued to the purchasers of the Notes stock purchase warrants (the “Warrants”) to purchase an aggregate of <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDSyXgK4oGgl" title="Issuance of warrants to purchase of common stock">1,567,500</span> shares of the Company’s common stock for a purchase price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zS8WdQdLPwr9" title="Issuance of warrant price per share">1.50</span> to $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zi1KuakSSTUi" title="Issuance of warrant price per share">1.87</span> per share, subject to adjustments. The Warrants were valued using the Black Scholes option pricing model for a total fair value of $<span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonStock_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zEmUQvTCvi6b" title="Fair value of common stock">3,004,000</span> based on a <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPzERRS5yACd" title="Fair value of common stock estimated life">3</span>-year term, volatility of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPercentage_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zH7OfJ39eMaf" title="Date of issuance volatility percentage">404.91</span>% to <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPercentage_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zSPYBk2Ze0G4" title="Date of issuance volatility percentage">405.93</span>%, a risk-free equivalent yield of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPercentage_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zWXOX3c9TGE" title="Fair value of common stock risk free interest rate">0.27</span>% to <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPercentage_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zjil4cPFbtub" title="Fair value of common stock risk free interest rate">0.42</span>%, and stock price ranging from $<span id="xdx_908_eus-gaap--SharePrice_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zjSW1xvfH3ad" title="Share price">0.10</span> to $<span id="xdx_902_eus-gaap--SharePrice_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zj5FSbW6w7sd" title="Share price">1.95</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with ASC 470 - Debt, the Company has allocated the cash proceeds amounts of the Notes among the Notes, the Warrants and the conversion feature. The relative fair value of the Warrants issued amounted to approximately $<span id="xdx_90A_ecustom--RelativeFairValueOfWarrantsIssuedWithConvertiblePromissoryNotes_c20210101__20211231_zayP46NqWcB7" title="Relative fair value of warrants issued with convertible promissory notes">1,690,000</span> and the beneficial conversion amounted to $<span id="xdx_904_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_c20210101__20211231_zU8QjSjSNJF5" title="Debt Instrument, Convertible, Beneficial Conversion Feature">0</span>, which amounts are being amortized and expensed over the term of the Notes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2020, the Company issued convertible promissory notes in the amount of $<span id="xdx_90F_eus-gaap--ConvertibleDebt_iI_c20201231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_znbpze45PKVb">213,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(the “Notes”). The total cash proceeds were approximately $<span id="xdx_904_eus-gaap--ProceedsFromConvertibleDebt_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_z7GQE066MnRg">60,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approximately $<span id="xdx_908_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20200101__20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_z5DPUx2l4fc8">147,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">from the conversion of Series A Preferred Stock into convertible promissory note and approximately $<span id="xdx_908_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20201231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zQw8i5v8u4s8">6,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">original issue discount (“OID”). The Notes are non-interest bearing with the principal due and payable starting in <span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDateDescription_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zHDpeth2nISf">February 2021</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Any amount of unpaid principal on the date of maturity will accrue interest at rate of <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_pid_dp_uPercentage_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zHo6GDAIq9Yf">10</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% per annum (default interest). The principal amount and all accrued interest are convertible into shares of the Company’s common stock, as of the date of issuance, at a rate of $<span id="xdx_906_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20201231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zkcITy6PCFpc">1.00 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share (“Conversion Rate”). The conversion rate is adjustable if, at any time when any principal amount of the Notes remains unpaid or unconverted, the Company issues or sells any shares of the Company’s common stock for no consideration or for a consideration per share (before deduction of reasonable expenses or commissions or underwriting discounts or allowances in connection therewith), which is less than the Conversion Rate in effect on the date of such issuance (or deemed issuance) of such shares of common stock (a “Dilutive Issuance”). <span id="xdx_90E_eus-gaap--DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault_c20200101__20201231_z88vzoHSnhQe">Immediately upon a Dilutive Issuance, the Conversion Rate will be reduced to the amount of the consideration per share received by the Company in such Dilutive Issuance. Events of default include failure to issue conversion shares, the occurrence of a breach or default under any other agreement, any money judgment, writ or similar process entered or filed against the Company or any its property or other assets for more than $</span></span><span id="xdx_901_ecustom--IndebtednessForBorrowedMoneyMaximumLimit_iI_c20201231_zUjLHF7cwkc1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100,000</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, bankruptcy filing, application for the appointment of a custodian, trustee or receiver, insolvency, the Company’s common stock delisted, or dissolution, winding up, or termination of the business of the Company</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the issuance of the Notes, the Company issued to the purchasers of the Notes stock purchase warrants to purchase an aggregate of <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z26yLNjPjS21">359,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company’s common stock for a purchase price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRVXkAIYYhYg">1.50 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share, subject to adjustments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with ASC 470 - <i>Debt</i>, the Company has accounted for the issuance of the Notes as an extinguishment of the series A preferred stock. Under extinguishment accounting, the difference between the fair value of the Notes and book basis of the series A preferred stock of $<span id="xdx_903_ecustom--LossOnExtinguishmentOfConvertiblePreferredStock_c20200101__20201231_zYlflutjwNR5" title="Loss on extinguishment of convertible preferred stock">86,000</span> was accounted for as a loss on extinguishment. Also, the fair value of the Warrants of $<span id="xdx_908_ecustom--FairValueOfWarrantsIssuedWithConversionOfConvertiblePreferredStock_c20200101__20201231_zMOuJ8Y8Air1" title="Fair value of warrants issued with conversion of convertible preferred stock">52,000</span> was recorded as a loss on extinguishment. The difference between the fair value of the Notes and the face value of the notes of $<span id="xdx_906_ecustom--DebtPremiumOnIssuanceConvertiblePromissoryNotesForConversionOfConvertiblePreferredStock_c20200101__20201231_zOo4VaBkm0J1" title="Fair value and face value of notes">58,000</span> was recorded as additional paid on capital. In addition, the Company has allocated the cash proceeds amounts of the Notes among the Notes, the warrants and the conversion feature. The relative fair value of the warrants issued totaled approximately $<span id="xdx_905_ecustom--RelativeFairValueOfWarrantsIssuedWithConvertiblePromissoryNotes_c20200101__20201231_zKB6LUs38Y46" title="Relative fair value of warrants issued with convertible promissory notes">3,000</span> and of the beneficial conversion totaled approximately $<span id="xdx_909_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_c20200101__20201231_zOLvQzCSLUce" title="Debt instrument, convertible, beneficial conversion feature">0</span>, which amounts are being amortized and expensed over the term of the Notes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financing cost recognized for the amortization of debt discount was approximately $<span id="xdx_904_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_c20210101__20211231_zUuA6EbbuZ1f">524,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_909_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_c20200101__20201231_zAopkC4vhdd5">187,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the years ended December 31, 2021 and 2020, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company determined that the conversion feature of the Notes would not be an embedded feature to be bifurcated and accounted for as a derivative in accordance with ASC 815-15 <i>Derivatives and Hedging</i>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--ConvertibleDebtTableTextBlock_zkuCje5NUWUk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The convertible promissory notes consisted of the following as of December 31:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B9_ztml2bN4FQhd" style="display: none">Schedule of Convertible Promissory Notes</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_490_20210101__20211231_z2BWK8HmTOS7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49D_20200101__20201231_zSpxtdIaTJxc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Principal</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40A_eus-gaap--DebtInstrumentFaceAmount_iS_hus-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zbv9Wkzg7Qq2" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Balance, beginning of year</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">708,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">506,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_ecustom--DebtInstrumentAdditions_hus-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zx5h6Wyl2Cx1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Additions</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,905,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">202,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--DebtInstrumentFaceAmount_iE_hus-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zbNez5GVeT4g" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance, end of year</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,613,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">708,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Discount</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_eus-gaap--DebtInstrumentUnamortizedDiscount_iS_hus-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_z97tLQW4moCk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Balance, beginning of year</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">183,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_ecustom--DebtInstrumentUnamortizedDiscountAdditions_hus-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zXdX6cAgZTna" style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif">Additions</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,045,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_ecustom--DebtInstrumentUnamortizedDiscountAmortization_hus-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_z5ZTnLiF9Bsl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Amortization</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(524,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(188,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_40B_eus-gaap--DebtInstrumentUnamortizedDiscount_iE_hus-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_z7BTS62ptEG3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance, end of year</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,526,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40B_eus-gaap--ConvertibleNotesPayableCurrent_iE_hus-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zP1pVKVN2K8b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net carrying amount</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,087,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">703,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8AD_zmUrYWRpsyE9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective interest rate used to amortize the debt discount for the years ended December 31, 2021 and 2020 ranges from <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPercentage_c20201231__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember__srt--RangeAxis__srt--MinimumMember_za6Tp9qOjHOf">4.76</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPercentage_c20201231__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember__srt--RangeAxis__srt--MaximumMember_zgLaZ4JYpXfh">64.60</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%. </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The unamortized debt discounts will be amortized within one year as of December 31, 2021 and 2020, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_ecustom--ScheduleOfPotentialFutureSharesIssuanceOfConversionNotesTableTextBlock_zrmOB9dt4FY" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potential future shares to be issued on conversion of the notes as December 31, 2021 and 2020 are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zWGzQp0HpC86" style="display: none">Schedule of Potential Future Shares Issuance of Conversion Notes</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_495_20211231_zbnOXW3d0472" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_499_20201231_zVDC4bA10LL7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40A_ecustom--DebtInstrumentConversionNotePrincipalAmount_iI_hus-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zXhy3GHuiRS3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif">Principal</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,613,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">708,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_ecustom--DebtInstrumentConversionNoteInterestExpenses_iI_hus-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_ztdf2ZXP84Th" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Interest</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">105,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">39,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_ecustom--DebtInstrumentConversionNote_iI_hus-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_z4Edx4EE1As7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,718,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">747,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Conversion price per share</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20211231__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember__srt--RangeAxis__srt--MinimumMember_zaT1eM7tCOS3" title="Conversion price per share">1.00</span> – <span id="xdx_90C_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20211231__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember__srt--RangeAxis__srt--MaximumMember_zpm95iomtqn" title="Conversion price per share">1.25</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20201231__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zVDXz6iBSXrf" title="Conversion price per share">1.00</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_ecustom--DebtInstrumentPotentialFutureShare_iI_hus-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zJAytque9PYg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Potential future share</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,947,394</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">747,032</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A5_z2bNovXG5Xl1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest expense on default convertible promissory notes amounted to $<span id="xdx_90F_eus-gaap--InterestExpenseDebt_c20210101__20211231_zSCC8l6Pj5Rj">65,000</span> and $<span id="xdx_903_eus-gaap--InterestExpenseDebt_c20200101__20201231_zOfK62QtnGJc">39,000</span> for the year ended December 31, 2021 and 2020, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 55000 3850000 3550000 3550000 355000 355000 2022-03-01 2022-08-31 0.10 0.10 1.00 1.25 Immediately upon a Dilutive Issuance, the Conversion Rate will be reduced to the amount of the consideration per share received by the Company in such Dilutive Issuance. Events of default include failure to issue conversion shares, the occurrence of a breach or default under any other agreement, any money judgment, writ, or similar process entered or filed against the Company or any of its property or other assets for more than $100,000, bankruptcy filing, application for the appointment of a custodian, trustee or receiver, insolvency, the Company’s common stock delisted, or dissolution, winding up, or termination of the business of the Company 100000 1567500 1.50 1.87 3004000 P3Y 4.0491 4.0593 0.0027 0.0042 0.10 1.95 1690000 0 213000 60000 147000 6000 February 2021 0.10 1.00 Immediately upon a Dilutive Issuance, the Conversion Rate will be reduced to the amount of the consideration per share received by the Company in such Dilutive Issuance. Events of default include failure to issue conversion shares, the occurrence of a breach or default under any other agreement, any money judgment, writ or similar process entered or filed against the Company or any its property or other assets for more than $ 100000 359000 1.50 86000 52000 58000 3000 0 524000 187000 <p id="xdx_892_eus-gaap--ConvertibleDebtTableTextBlock_zkuCje5NUWUk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The convertible promissory notes consisted of the following as of December 31:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B9_ztml2bN4FQhd" style="display: none">Schedule of Convertible Promissory Notes</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_490_20210101__20211231_z2BWK8HmTOS7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49D_20200101__20201231_zSpxtdIaTJxc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Principal</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40A_eus-gaap--DebtInstrumentFaceAmount_iS_hus-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zbv9Wkzg7Qq2" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Balance, beginning of year</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">708,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">506,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_ecustom--DebtInstrumentAdditions_hus-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zx5h6Wyl2Cx1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Additions</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,905,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">202,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--DebtInstrumentFaceAmount_iE_hus-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zbNez5GVeT4g" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance, end of year</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,613,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">708,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Discount</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_eus-gaap--DebtInstrumentUnamortizedDiscount_iS_hus-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_z97tLQW4moCk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Balance, beginning of year</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">183,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_ecustom--DebtInstrumentUnamortizedDiscountAdditions_hus-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zXdX6cAgZTna" style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif">Additions</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,045,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_ecustom--DebtInstrumentUnamortizedDiscountAmortization_hus-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_z5ZTnLiF9Bsl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Amortization</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(524,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(188,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_40B_eus-gaap--DebtInstrumentUnamortizedDiscount_iE_hus-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_z7BTS62ptEG3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance, end of year</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,526,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40B_eus-gaap--ConvertibleNotesPayableCurrent_iE_hus-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zP1pVKVN2K8b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net carrying amount</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,087,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">703,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 708000 506000 3905000 202000 4613000 708000 5000 183000 2045000 10000 -524000 -188000 1526000 5000 3087000 703000 0.0476 0.6460 <p id="xdx_89F_ecustom--ScheduleOfPotentialFutureSharesIssuanceOfConversionNotesTableTextBlock_zrmOB9dt4FY" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potential future shares to be issued on conversion of the notes as December 31, 2021 and 2020 are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zWGzQp0HpC86" style="display: none">Schedule of Potential Future Shares Issuance of Conversion Notes</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_495_20211231_zbnOXW3d0472" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_499_20201231_zVDC4bA10LL7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40A_ecustom--DebtInstrumentConversionNotePrincipalAmount_iI_hus-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zXhy3GHuiRS3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif">Principal</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,613,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">708,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_ecustom--DebtInstrumentConversionNoteInterestExpenses_iI_hus-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_ztdf2ZXP84Th" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Interest</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">105,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">39,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_ecustom--DebtInstrumentConversionNote_iI_hus-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_z4Edx4EE1As7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,718,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">747,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Conversion price per share</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20211231__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember__srt--RangeAxis__srt--MinimumMember_zaT1eM7tCOS3" title="Conversion price per share">1.00</span> – <span id="xdx_90C_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20211231__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember__srt--RangeAxis__srt--MaximumMember_zpm95iomtqn" title="Conversion price per share">1.25</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20201231__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zVDXz6iBSXrf" title="Conversion price per share">1.00</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_ecustom--DebtInstrumentPotentialFutureShare_iI_hus-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zJAytque9PYg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Potential future share</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,947,394</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">747,032</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 4613000 708000 105000 39000 4718000 747000 1.00 1.25 1.00 3947394 747032 65000 39000 <p id="xdx_805_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z6Wt6MHAke4e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note <span style="font-variant: small-caps">6 –</span> <span id="xdx_829_zhmCzr43Xrv">Commitments and Contingencies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Technology Development Agreement</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 23, 2021, AIQ entered into a Technology Development Agreement (the “Agreement”) with PICOCEL, Co., Ltd. (the “Contractor” or “PICOCEL”) to develop a FPGA based Bitcoin mining simulation system. The Agreement is expected to be completed within 6 weeks for a total contract price of <span id="xdx_904_eus-gaap--RevenueRemainingPerformanceObligation_iI_uSouthKoreanWon_c20211223__us-gaap--TypeOfArrangementAxis__custom--TechnologyDevelopmentAgreementMember__dei--LegalEntityAxis__custom--PICOCELCoLtdMember_zMwAin9sldjk">198,000,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Korean Won (“KRW”) or approximately $<span id="xdx_905_eus-gaap--RevenueRemainingPerformanceObligation_iI_uUSD_c20211223__us-gaap--TypeOfArrangementAxis__custom--TechnologyDevelopmentAgreementMember__dei--LegalEntityAxis__custom--PICOCELCoLtdMember_zasYUMz8X4j9">167,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. As of December 31, 2021, AIQ have made payments amounting to approximately $<span id="xdx_909_ecustom--PaymentsForCollaborators_c20211201__20211231__us-gaap--TypeOfArrangementAxis__custom--TechnologyDevelopmentAgreementMember__dei--LegalEntityAxis__custom--PICOCELCoLtdMember_zo66msas0Uhf">42,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The remaining payments as of December 31, 2021 are scheduled, as follows:</span></p> <p id="xdx_892_ecustom--TechnologyDevelopmentAgreementTableTextBlock_zR9DmISvF7Uf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BC_zr8XzZc94yee" style="display: none">Schedule of Remaining Payments</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">KRW</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Within 14 days after signing the contract</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_ecustom--PaymentsToBeMadeUponSigningContract_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--TechnologyDevelopmentAgreementMember__dei--LegalEntityAxis__custom--PICOCELCoLtdMember_z4VorvVtbQQe" style="width: 16%; text-align: right" title="Payments to be signing contract"><span style="font-family: Times New Roman, Times, Serif">42,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_ecustom--PaymentsToBeMadeUponSigningContract_uSouthKoreanWon_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--TechnologyDevelopmentAgreementMember__dei--LegalEntityAxis__custom--PICOCELCoLtdMember_zyUifAGs2gWc" style="width: 16%; text-align: right" title="Payments to be signing contract"><span style="font-family: Times New Roman, Times, Serif">49,500,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Within 14 days after delivery of the first set of PM103 FPGA prototype board</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_ecustom--PaymentsToBeMadeUponCompletionOfInitialServiceDelivery_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--TechnologyDevelopmentAgreementMember__dei--LegalEntityAxis__custom--PICOCELCoLtdMember_zYpH4YpsFpah" style="border-bottom: Black 1.5pt solid; text-align: right" title="Payments upon delivery board"><span style="font-family: Times New Roman, Times, Serif">83,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_ecustom--PaymentsToBeMadeUponCompletionOfInitialServiceDelivery_uSouthKoreanWon_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--TechnologyDevelopmentAgreementMember__dei--LegalEntityAxis__custom--PICOCELCoLtdMember_z0taH15sBnBd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Payments upon delivery board"><span style="font-family: Times New Roman, Times, Serif">99,000,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_ecustom--PaymentsToBeMadeUponContractAndServiceDelivery_c20210101__20211231_zMOy9jzKx9Rj" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif">125,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_ecustom--PaymentsToBeMadeUponContractAndServiceDelivery_uSouthKoreanWon_c20210101__20211231_zI7hiJDts003" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif">148,500,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8AE_zQbUnz9LYoVh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Litigation</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, the Company may become subject to legal proceedings, claims and litigation arising in the ordinary course of business. In addition, the Company may receive letters alleging infringement of patent or other intellectual property rights. The Company is not currently a party to any material legal proceedings, nor is the Company aware of any pending or threatened litigation that would have a material adverse effect on the Company’s business, operating results, cash flows or financial condition should such litigation be resolved unfavorably, except as follows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">On January 3, 2022, a complaint was filed against our company in the Superior Court of California, County of Los Angeles titled <i>Michael Sekula v. CalEthos Inc, Michael Campbell and Does 1-25</i> (Case No. 22STCV00121) for, among other matters, failure to pay wages, fraud and other wage-related claims.<span id="xdx_907_eus-gaap--LossContingencyDomicileOfLitigation_c20220101__20221231_zJGaYaVADNHk" title="Litigation description"> In the complaint, the plaintiff claims he worked under a consulting agreement as Vice President of Brand Management of our company and was to be paid $4,000 per month and to receive an option to purchase 50,000 shares of our common stock that was to vest quarterly over the term of the agreement. In the complaint, the plaintiff alleges that, on or around March 27, 2020, we ceased paying the plaintiff despite the plaintiff’s continuing efforts on behalf of our company and that we agreed to continue to accrue his monthly retainer amount until such time that we received at least $100,000 in funding. Plaintiff further alleges that he continued to work for our company for 38 additional weeks in reliance on our promise of payment. The plaintiff claims that our refusal to make the promised payments amounts to violations of the California labor laws and seeks damages in excess of $450,000.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 45pt">We intend to dispute these claims and to defend this litigation vigorously. However, due to the inherent uncertainties of litigation, the ultimate outcome of this litigations is uncertain. An unfavorable outcome in this litigation could materially and adversely affect our business, financial condition and results of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Business Interruption</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The continuing COVID-19 global pandemic has caused significant disruption to the economy and financial markets globally, and the full extent of the potential impacts of COVID-19 are not yet known. Circumstances caused by the COVID-19 pandemic are complex, uncertain and rapidly evolving. The impact of COVID-19 has not been significant to the Company’s results of operations, financial condition, and liquidity and capital resources. Although no material impairment or other effects have been identified to date, there is substantial uncertainty in the nature and degree of its continued effects over time. That uncertainty affects management’s accounting estimates and assumptions, which could result in greater variability in a variety of areas that depend on these estimates and assumptions as additional events and information become known. The Company will continue to consider the potential impact of the COVID-19 pandemic on its business operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 198000000 167000 42000 <p id="xdx_892_ecustom--TechnologyDevelopmentAgreementTableTextBlock_zR9DmISvF7Uf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BC_zr8XzZc94yee" style="display: none">Schedule of Remaining Payments</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">KRW</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Within 14 days after signing the contract</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_ecustom--PaymentsToBeMadeUponSigningContract_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--TechnologyDevelopmentAgreementMember__dei--LegalEntityAxis__custom--PICOCELCoLtdMember_z4VorvVtbQQe" style="width: 16%; text-align: right" title="Payments to be signing contract"><span style="font-family: Times New Roman, Times, Serif">42,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_ecustom--PaymentsToBeMadeUponSigningContract_uSouthKoreanWon_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--TechnologyDevelopmentAgreementMember__dei--LegalEntityAxis__custom--PICOCELCoLtdMember_zyUifAGs2gWc" style="width: 16%; text-align: right" title="Payments to be signing contract"><span style="font-family: Times New Roman, Times, Serif">49,500,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Within 14 days after delivery of the first set of PM103 FPGA prototype board</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_ecustom--PaymentsToBeMadeUponCompletionOfInitialServiceDelivery_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--TechnologyDevelopmentAgreementMember__dei--LegalEntityAxis__custom--PICOCELCoLtdMember_zYpH4YpsFpah" style="border-bottom: Black 1.5pt solid; text-align: right" title="Payments upon delivery board"><span style="font-family: Times New Roman, Times, Serif">83,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_ecustom--PaymentsToBeMadeUponCompletionOfInitialServiceDelivery_uSouthKoreanWon_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--TechnologyDevelopmentAgreementMember__dei--LegalEntityAxis__custom--PICOCELCoLtdMember_z0taH15sBnBd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Payments upon delivery board"><span style="font-family: Times New Roman, Times, Serif">99,000,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_ecustom--PaymentsToBeMadeUponContractAndServiceDelivery_c20210101__20211231_zMOy9jzKx9Rj" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif">125,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_ecustom--PaymentsToBeMadeUponContractAndServiceDelivery_uSouthKoreanWon_c20210101__20211231_zI7hiJDts003" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif">148,500,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 42000 49500000 83000 99000000 125000 148500000 In the complaint, the plaintiff claims he worked under a consulting agreement as Vice President of Brand Management of our company and was to be paid $4,000 per month and to receive an option to purchase 50,000 shares of our common stock that was to vest quarterly over the term of the agreement. In the complaint, the plaintiff alleges that, on or around March 27, 2020, we ceased paying the plaintiff despite the plaintiff’s continuing efforts on behalf of our company and that we agreed to continue to accrue his monthly retainer amount until such time that we received at least $100,000 in funding. Plaintiff further alleges that he continued to work for our company for 38 additional weeks in reliance on our promise of payment. The plaintiff claims that our refusal to make the promised payments amounts to violations of the California labor laws and seeks damages in excess of $450,000. <p id="xdx_80F_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z4gY1vBaNa48" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 7 – <span id="xdx_820_zyOafCsHdfAd">Stockholders’ Deficit</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Shares Authorized</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is authorized to issue <span id="xdx_909_ecustom--AuthorizedToIssueShares_iI_c20211231_zaXu4us5c1W2" title="Authorized to issue shares">200,000,000</span> shares of which <span id="xdx_90C_eus-gaap--PreferredStockSharesAuthorized_iI_c20211231_ztnuAcsQ3jY2" title="Preferred stock, shares authorized">100,000,000</span> shares shall be preferred stock, par value $<span id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20211231_zgz733BdELCb" title="Preferred stock, par value">0.001</span> per share, and <span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_c20211231_zXZKugxt4qZ1" title="Common stock, shares authorized">100,000,000</span> shares shall be common stock, par value $<span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20211231_zRPQ1IBTthh2" title="Common stock, par value">0.001</span> per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Preferred Stock</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series A Convertible Preferred Stock</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Series A Convertible Preferred Stock (“Series A”) is convertible into shares of the Company’s common stock at the rate of $<span id="xdx_900_eus-gaap--SaleOfStockPricePerShare_iI_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zc1aQhtqKwf3" title="Sale of stock shares price per share">1.38</span> per share, subject to adjustments based on the Company’s future sales of financial instruments at a value less than $<span id="xdx_90A_eus-gaap--SaleOfStockPricePerShare_iI_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zTLwcBg9kZmi" title="Sale of stock shares price per share">1.38</span> per share. The holders of the Series A have the right to convert any time after the date of issuance. With the issuance of the convertible promissory notes, as explained in Note 5 above, the Series A’s conversion rate adjusted to $<span id="xdx_90B_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z0SGITi16d7c">1.00</span> per share. In accordance with ASC 470, the Company has calculated the effect of the conversion rate adjustment, which was approximately $<span id="xdx_909_ecustom--ConversionRateAdjustmentValue_pp0p0_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zoCQAwB8MWMd" title="Conversion rate adjustment, value">36,000</span>. The conversion rate adjustment has been treated as a deemed dividend, which has been presented in the Statement of Changes in Stockholders’ Deficit.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Series A is mandatorily convertible upon (i) the closing of the sale of shares of the Company’s common stock to the public in an underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, resulting in at least $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20210101__20211231_zGXzCrf2td2g">10,000,000</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of gross proceeds to the Company, (ii) <span id="xdx_904_eus-gaap--SaleOfStockDescriptionOfTransaction_c20210101__20211231_z69uEaiEtJd4">the close of business on the sixtieth consecutive day on which the closing price of the Company’s common stock on the OTC Markets is at least $2.80 per share, subject to appropriate adjustment in the event of any stock dividend, stock split, stock combination or other similar recapitalization with respect to the common stock, or (iii) the affirmative vote of the holders of at least 66⅔% of the outstanding shares of Series A, given at a meeting of such stockholders duly called for that purpose or pursuant to a written consent of stockholders all outstanding shares of Series A shall automatically be converted into shares of the Company’s common stock, at the then effective conversion rate</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On any matter presented to the stockholders of the Company for their action or consideration at any meeting of stockholders of the Company (or by written consent of stockholders in lieu of meeting), each holder of outstanding shares of Series A shall be entitled to cast the number of votes equal to the number of whole shares of common stock into which the shares of Series A held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter. Except as provided by law or by the other provisions of the Articles of Incorporation, holders of Series A shall vote together with the holders of common stock as a single class.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From and after the date of the issuance of any shares of Series A, a cumulative dividend on each outstanding share of Series A Preferred Stock shall accrue at a rate per annum equal to ten percent of the Series A original issue price. Accrued dividends on the Series A shall be paid in shares of the Company’s common stock, such shares to be valued for such purpose at the applicable series A conversion price.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 11, 2020, the Company converted <span id="xdx_90A_eus-gaap--ConversionOfStockSharesIssued1_c20200210__20200211__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zkroFCpyF9Oc" title="Conversion of shares">85,975</span> shares of Series A into a Convertible Promissory Notes in the principal amount approximately $<span id="xdx_90D_eus-gaap--DebtConversionOriginalDebtAmount1_pp0p0_c20200210__20200211__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zeesnkN8Vz3f" title="Conversion of debt">147,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Common Stock</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2021, the Company’s President and a member of the Board of Directors, resigned as an officer and director of the Company (“Termination Agreement”). Part of the Termination Agreement stipulates the return of <span id="xdx_90B_ecustom--StockIssuedDuringPeriodReturnOfShares_c20210101__20210131__us-gaap--TypeOfArrangementAxis__custom--TerminationAgreementMember_ztVSTsDB3SF7" title="Return of shares">3,674,330</span> shares of the Company’s common stock (“Cancelled Shares”). The Cancelled Shares were returned and cancelled on April 20, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2021, the Company’s Chief Executive Officer (“CEO’) agreed to forgive approximately $<span id="xdx_908_eus-gaap--DebtInstrumentDecreaseForgiveness_pp0p0_c20210101__20210331__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zDuxz00Dpbr2" title="Debt instrument decrease forgiveness">68,000</span> due to him, which was treated as contributed paid in capital.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2021, the Company’s Chief Financial Officer agreed to reduce the amounts due to him from approximately $<span id="xdx_90F_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pp0p0_c20210330__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zn6PETGWNcA7" title="Due to related parties">128,000</span> to $<span id="xdx_909_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pp0p0_c20210331__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zOXRbJOXLS5" title="Due to related parties">30,000</span>. For the reduction of $<span id="xdx_906_ecustom--ReductionAmount_pp0p0_c20210101__20210331__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_z9n3DwSzM1cl" title="Reduction amount">98,000</span>, the Company will issue <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20210331__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zfT8gohwaCHe" title="Stock issued during period shares new issues">75,000</span> shares of common stock. The remaining liability of $<span id="xdx_90F_ecustom--RemainingLiabilityPaidForCash_iI_pp0p0_c20211231_z22eKOAuNUVe" title="Remaining cash liability">30,000</span> will be paid in cash.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In September 2021, the Company entered into a release agreement with one of its consultants. As part of the separation payment, the Company issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20211001__20211031__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zEW75bOiBHzg">25,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares valued at $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20211001__20211031__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zITFfrGIeJni">76,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and paid $20,000 cash</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> in October 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted Common Stock Awards</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 17, 2021, the Company entered into Restricted Share Award Agreements (the “Award Agreements”) with two consultants pursuant to which the Company issued to the consultants shares of common stock of the Company in exchange for their future services. The Awards have an initial term of one year, which shall be automatically renewed on a year-to-year basis unless either party gives a written notice of termination. The two consultants who entered into these agreements include:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A consultant who was granted <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_pid_uShares_c20210816__20210817__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zgm5RdWeo0P9" title="Restricted common stock shares granted">10,000,000</span> restricted share awards.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An entity, which is owned by the Company’s CEO and majority shareholder, was granted <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_pid_uShares_c20210816__20210817__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zgLMbjhaTnii" title="Restricted common stock shares granted">1,500,000</span> restricted share awards. </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As indicated in the Awards Agreement, fifty percent (50%) of the shares shall vest upon the completion of the first two development phases of a 5 nanometer ASIC chip that includes the “FPGA Simulation” and “Tape Out”, and the remaining fifty (50%) of the shares shall vest upon the completion of the next phases of the chip development that include the completion of the Foundry Mask for production in the semiconductor foundry, initial production run of chips and the completion of a bitcoin mining system ready for sale to customers. Should the Company not raise sufficient capital to complete the Foundry Mask within 6 months of completing the first two development phases, then <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_c20210101__20211231_zjKlXs0bxe83">100</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% of the shares shall be considered vested.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s management has accounted for the Award Grants as restricted stock compensation in accordance with ASC 718 – Stock Compensation (“ASC 718”). ASC 718 requires the Company to estimate the service period over which the compensation cost will be recognized. Management has estimated that the first two development phases will be completed within 15 months and the Foundry Mask will be completed within 6 months for a total of 21 months service period. Compensation cost will be recognized ratably over 21 months and in the same manner had the Company paid in cash. The estimated service period will be adjusted for changes in actual and expected completion dates. Any such change will be recognized prospectively, and the remaining deferred compensation will be recognized over the remaining service period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2021, a total of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_pid_uShares_c20210101__20211231__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zTcJqQjdej5l">11,500,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares were issued to the consultants. The value was $<span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_c20211231__srt--TitleOfIndividualAxis__custom--ConsultantsMember_z2bLmDDuqSod">1.93 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share on the date of issuance (“Grant Date”) for an aggregate fair value of $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_uUSD_c20210101__20211231__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zmLmGzboXtFh">22,195,000</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The stock-based award compensation was recorded as an increase in deferred compensation expense, common stock, and additional paid-in capital in the Company’s books at the time of the grant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zJV2hQrwaSt5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below summarizes the transactions related to the Company restricted stock awards as of December 31, 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B2_zP6oC8g8S5vj" style="display: none">Schedule of Company Restricted Stock Awards</span> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Deferred compensation</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Grant date fair value</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_ecustom--GrantDateFairValueShares_iI_c20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zMfaMgiB3u56" style="width: 16%; text-align: right" title="Grant date fair value, shares"><span style="font-family: Times New Roman, Times, Serif">11,500,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_ecustom--DeferredCompensationGrantDateFairValue_iI_uUSD_c20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zdsPPTC7t2pa" style="width: 16%; text-align: right" title="Deferred compensation grant date fair value"><span style="font-family: Times New Roman, Times, Serif">22,195,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Accretion</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_ecustom--AccretionShares_iI_c20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zMDvsENUEKHb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accretion, shares"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0944">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_ecustom--DeferredCompensationAccretion_iI_c20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z8SI7gRM1GJj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Deferred compensation accretion"><span style="font-family: Times New Roman, Times, Serif">(4,791,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance as of December 31, 2021</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_c20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zVGd8I8d4oH4" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares, balance"><span style="font-family: Times New Roman, Times, Serif">11,500,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--DeferredCompensationShareBasedArrangementsLiabilityCurrent_iI_c20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zVOcFxCaHWc9" style="border-bottom: Black 2.5pt double; text-align: right" title="Deferred compensation"><span style="font-family: Times New Roman, Times, Serif">17,404,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8AE_zGCJ1I3kbFyg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Issuance of Stock Options and Warrants</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2021, the Company signed a new consulting agreement that granted one of its shareholders an option to purchase <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210201__20210228__us-gaap--TypeOfArrangementAxis__custom--NewConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--ShareholderMember_zJpV1TALKma4" title="Option to purhase shares">750,000</span> shares of the Company’s common stock at $<span id="xdx_905_eus-gaap--SharePrice_iI_c20210228__us-gaap--TypeOfArrangementAxis__custom--NewConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--ShareholderMember_zWhHGkvcVYO5" title="Share price">0.001</span> per share for the consultancy work provided from August 2020 to February 2021. The options were fully vested on the date of issuance. The fair value of the options was approximately $<span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20210201__20210228__us-gaap--TypeOfArrangementAxis__custom--NewConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--ShareholderMember_zoqwcyUazM71" title="Fair value of options">52,000</span>, as of the grant date, of which approximately $<span id="xdx_90F_eus-gaap--StockOptionPlanExpense_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--NewConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--ShareholderMember_zEXEJvYeZeqg" title="Option expense">38,000</span> was expensed and accrued during the year ended December 31, 2020 and $<span id="xdx_905_eus-gaap--StockOptionPlanExpense_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--NewConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--ShareholderMember_znM2W39hrP1" title="Option expense">14,000</span> was expensed for the year ended December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In May 2021, the Company signed a letter of understanding that granted one of its shareholders an option to purchase <span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_c20210531__us-gaap--TypeOfArrangementAxis__custom--LetterofUnderstandingMember_zsDxZdx2Re95" title="Common stock, shares authorized">300,000</span> shares of the Company’s common stock at $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20210531__us-gaap--TypeOfArrangementAxis__custom--LetterofUnderstandingMember_zE4f04qmA2O8" title="Common stock, par value">0.001</span> per share for the consultancy work provided during the Company’s restructuring phase from February 17, 2021 through April 30, 2021. The options were fully vested on the date of issuance. The fair value of the options was approximately $<span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20210101__20211231_zOaGDtWfJATi" title="Share-based compensation arrangement by share-based payment award, options">561,000</span>, as of grant date, which was expensed during the year ended December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In May 2021, an option holder exercised three options for <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210501__20210531__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zt2mSOgV9iD4" title="Number of share options exercised">385,000</span>, <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210501__20210531__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zAs90SOIjNe" title="Number of share options exercised">750,000</span> and <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210501__20210531__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember_zzbDiro0svMd" title="Number of share options exercised">300,000</span> shares of the Company’s common stock at an exercise price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210531_zXnjLHxvKc6g" title="Class of warrant exercise price">0.001</span> for each option, for total proceeds of approximately $<span id="xdx_907_eus-gaap--ProceedsFromStockOptionsExercised_c20210501__20210531_zRP9QOnmo6Je" title="Proceeds from stock options exercised">2,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zuc17PjRJc01" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below summarizes the Company’s stock option activities for the years ended December 31, 2021 and 2020 (all share and per share data reflects the reverse stock split):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zzfLGtQqXObl" style="display: none">Schedule of Stock Option Activities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock Option</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Range Per</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Relative</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intrinsic</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%"><span style="font-family: Times New Roman, Times, Serif">Balance, January 1, 2020</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20200101__20201231_zCQhLmW5AJrg" style="width: 9%; text-align: right" title="Number of Number of Stock Option Shares, Outstanding, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">569,800</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceRangePerShareOutstandingBeginning_iS_c20200101__20201231_zqtBJ0TIFxD5" style="width: 9%; text-align: right" title="Exercise Price Range Per Share, Outstanding, Beginning"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0982">–</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20200101__20201231_z5KsbljeLV6b" style="width: 9%; text-align: right" title="Weighted Average Exercise Price, Outstanding, Beginning"><span style="font-family: Times New Roman, Times, Serif">4.05</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRelativeFairValueOutstandingBeginning_iS_c20200101__20201231_zd8vHEi8xQSb" style="width: 9%; text-align: right" title="Relative Fair Value, Outstanding, Beginning"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0986">–</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pdp0_c20200101__20201231_zKvvczBnpEv7" style="width: 9%; text-align: right" title="Aggregate Intrinsic Value, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">423,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200101__20201231_zMiorzCDFIVg" style="text-align: right" title="Number of Stock Option Shares, Granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0990">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInExercisePriceRangePerShareGranted_c20200101__20201231_zsLUitielqp9" style="text-align: right" title="Exercise Price Range Per Share, Granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0992">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20201231_zLrb0M3BnD24" style="text-align: right" title="Weighted Average Exercise Price, Granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0994">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodRelativeFairValueGranted_c20200101__20201231_zDYgUeKqo3gd" style="text-align: right" title="Relative Fair Value, Granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0996">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue_c20200101__20201231_zSIuOva8w2H1" style="text-align: right" title="Aggregate Intrinsic Value, Granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0998">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20200101__20201231_zY1dKyRaO1i7" style="text-align: right" title="Number of Stock Option Shares, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1000">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsInPeriodExercisePriceRangePerShareForfeited_c20200101__20201231_zwHDHxUD0lfe" style="text-align: right" title="Exercise Price Range Per Share, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1002">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20200101__20201231_zDWURf3GP8ei" style="text-align: right" title="Weighted Average Exercise Price, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1004">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodRelativeFairValueForfeited_c20200101__20201231_zguvlLQMyLah" style="text-align: right" title="Relative Fair Value, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1006">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodForfeitedIntrinsicValue_c20200101__20201231_zT9yjFII3koi" style="text-align: right" title="Aggregate Intrinsic Value, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1008">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20200101__20201231_zvxiIqBe7tb1" style="text-align: right" title="Number of Stock Option Shares, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1010">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodExercisePriceRangePerShareExercised_c20200101__20201231_zgo8guvTZ1k9" style="text-align: right" title="Exercise Price Range Per Share, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1012">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20200101__20201231_zujV4WKSCSm6" style="text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1014">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodRelativeFairValueExercised_c20200101__20201231_zTeJBKnrFfnl" style="text-align: right" title="Relative Fair Value, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1016">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInPeriodExercisedIntrinsicValue_c20200101__20201231_zYBp4qnv8nbe" style="text-align: right" title="Aggregate Intrinsic Value, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1018">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Expired</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20200101__20201231_zBqCituYrUqg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Stock Option Shares, Expired"><span style="font-family: Times New Roman, Times, Serif">(184,800</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodExercisePriceRangePerShareExpired_c20200101__20201231_z0EjwNQwjr44" style="border-bottom: Black 1.5pt solid; text-align: right" title="Exercise Price Range Per Share, Expired"><span style="font-family: Times New Roman, Times, Serif">12.50</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20200101__20201231_zzPICW3DkaC9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Expired"><span style="font-family: Times New Roman, Times, Serif">12.50</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodRelativeFairValueExpired_c20200101__20201231_zfZrLKlmxRob" style="border-bottom: Black 1.5pt solid; text-align: right" title="Relative Fair Value, Expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1026">–</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInPeriodExpiredIntrinsicValue_c20200101__20201231_zLJcWIMXMR38" style="border-bottom: Black 1.5pt solid; text-align: right" title="Aggregate Intrinsic Value, Expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1028">–</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif">Balance, December 31, 2020</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231_zzXOIKCHR6mc" style="text-align: right" title="Number of Stock Option Shares, Outstanding, Beginning of period"><span style="font-family: Times New Roman, Times, Serif">385,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceRangePerShareOutstandingBeginning_iS_c20210101__20211231_zEp6CbAHGEO7" style="text-align: right" title="Exercise Price Range Per Share, Outstanding, Beginning of period"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1032">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231_zk3pzOg54Bsk" style="text-align: right" title="Weighted Average Exercise Price, Outstanding, Beginning of period"><span style="font-family: Times New Roman, Times, Serif">0.001</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRelativeFairValueOutstandingBeginning_iS_c20210101__20211231_zXOHcLnreccb" style="text-align: right" title="Relative Fair Value, Outstanding, Beginning of period"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1036">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20210101__20211231_z3yRdFQ9kvY4" style="text-align: right" title="Aggregate Intrinsic Value, Beginning of period"><span style="font-family: Times New Roman, Times, Serif">7,315</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231_zLcIqldPp9l1" style="text-align: right" title="Number of Stock Option Shares, Granted"><span style="font-family: Times New Roman, Times, Serif">1,050,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInExercisePriceRangePerShareGranted_c20210101__20211231_zVyuwVqtsgcb" style="text-align: right" title="Exercise Price Range Per Share, Granted"><span style="font-family: Times New Roman, Times, Serif">0.001</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231_zSW8ftrD9Pff" style="text-align: right" title="Weighted Average Exercise Price, Granted"><span style="font-family: Times New Roman, Times, Serif">0.001</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodRelativeFairValueGranted_c20210101__20211231_zk2bA1KY20jh" style="text-align: right" title="Relative Fair Value, Granted"><span style="font-family: Times New Roman, Times, Serif">1.94</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue_c20210101__20211231_z2pwzs3ZNwL1" style="text-align: right" title="Aggregate Intrinsic Value, Granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1048">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20210101__20211231_zYHoINX21Xv9" style="text-align: right" title="Number of Stock Option Shares, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1050">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsInPeriodExercisePriceRangePerShareForfeited_c20210101__20211231_zma7oCGRRhDg" style="text-align: right" title="Exercise Price Range Per Share, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1052">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231_zTN5sofm3pui" style="text-align: right" title="Weighted Average Exercise Price, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1054">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodRelativeFairValueForfeited_c20210101__20211231_zzVayrHNnRa7" style="text-align: right" title="Relative Fair Value, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1056">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodForfeitedIntrinsicValue_c20210101__20211231_zbrNsXtCOTXf" style="text-align: right" title="Aggregate Intrinsic Value, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1058">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20210101__20211231_zKg7LLgAC8Y3" style="text-align: right" title="Number of Stock Option Shares, Exercised"><span style="font-family: Times New Roman, Times, Serif">(1,435,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodExercisePriceRangePerShareExercised_c20210101__20211231_zSmqfPXwZ2c2" style="text-align: right" title="Exercise Price Range Per Share, Exercised"><span style="font-family: Times New Roman, Times, Serif">0.001</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20211231_zIayY4y6NtT7" style="text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="font-family: Times New Roman, Times, Serif">0.001</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodRelativeFairValueExercised_c20210101__20211231_z8KjMJkFxHok" style="text-align: right" title="Relative Fair Value, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1066">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInPeriodExercisedIntrinsicValue_c20210101__20211231_zgY1ScGax3vd" style="text-align: right" title="Aggregate Intrinsic Value, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1068">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Expired</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20210101__20211231_zgj3aUTcUvBk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Stock Option Shares, Expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1070">–</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodExercisePriceRangePerShareExpired_c20210101__20211231_z2EJaxBdX3x5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Exercise Price Range Per Share, Expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1072">–</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20210101__20211231_zAkGJ89ufUXg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1074">–</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodRelativeFairValueExpired_c20210101__20211231_zZL0p0VLuyig" style="border-bottom: Black 1.5pt solid; text-align: right" title="Relative Fair Value, Expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1076">–</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInPeriodExpiredIntrinsicValue_c20210101__20211231_zreba2qFkhel" style="border-bottom: Black 1.5pt solid; text-align: right" title="Aggregate Intrinsic Value, Expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1078">–</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance, December 31, 2021</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210101__20211231_zIsqQKw5MyA8" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Stock Option Shares, Outstanding, Ending of period"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1080">–</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceRangePerShareOutstandingEnding_iE_c20210101__20211231_zu7aXFoj5l5f" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercise Price Range Per Share, Outstanding, Ending of period"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1082">–</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231_zwD8FB2Cdii9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding, Ending of period"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1084">–</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRelativeFairValueOutstandingBeginning_iE_c20210101__20211231_z3N52yMZaJ63" style="border-bottom: Black 2.5pt double; text-align: right" title="Relative Fair Value, Outstanding, Ending of period"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1086">–</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20210101__20211231_zuSD5lpItZjk" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Ending of period"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1088">–</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Vested and exercisable, December 31, 2021</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableEndingBalance_iE_c20210101__20211231_z015rMtW2jij" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Stock Option, Vested and Exercisable, Ending Balance"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1090">–</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodExercisePriceRangePerShareVestedAndExercisable_c20210101__20211231_z4iJHIJ6pmGl" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercise Price Range Per Share, Vested and Exercisable"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1092">–</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceVestedAndExercisable_c20210101__20211231_zphoNtRtMsIi" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Vested and Exercisable"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1094">–</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodRelativeFairValueVestedAndExercisable_c20210101__20211231_zfd3C3Eh5iL4" style="border-bottom: Black 2.5pt double; text-align: right" title="Relative Fair Value, Vested and Exercisable"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1096">–</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pdp0_c20210101__20211231_zR7VEPU6Enrf" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Vested and Exercisable"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1098">–</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Unvested, December 31, 2021</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedEndingBalance_iE_c20210101__20211231_za1U1nkvEUxg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Stock Option, Unvested, Ending Balance"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1100">–</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsInPeriodExercisePriceRangePerShareUnvested_c20210101__20211231_zuLvoqSApMwd" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercise Price Range Per Share, Unvested"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1102">–</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iI_c20211231_zyJfdgmeVSpe" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Unvested"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1104">–</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsUnvestedInPeriodRelativeFairValueUnvested_c20210101__20211231_z4VIMkda70c" style="border-bottom: Black 2.5pt double; text-align: right" title="Relative Fair Value, Unvested"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1106">–</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAggregateIntrinsicValueUnvested_iE_pdp0_c20210101__20211231_z56cfpvof2jb" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Unvested"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1108">–</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A4_zvLhwbeqlGDe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 15, 2021, the Company issued warrants to purchase <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20210915_zlfsEyXOBRQi" title=" Number of securities called by warrants or rights">100,000 </span>shares of the Company’s common stock. For the year ended December 31, 2021, the compensation expense, classified as professional fees in the consolidated statement of operations and comprehensive loss, was $<span id="xdx_90A_eus-gaap--ProfessionalFees_c20210914__20210915_z88Pk8d0sCta" title="Professional fees">195,000</span>, which was calculated using the Black Scholes fair value option-pricing model with key input variables provided by management, as of the date of issuance: volatility of <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPercentage_c20210914__20210915_zmoULuZrsaMh" title=" Fair value assumptions, expected volatility rate">359</span>%, fair value of common stock $<span id="xdx_902_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20210915_zGcIMe9O3hBc" title="Share price">1.95</span>, estimated life of <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210914__20210915_zSW1TDyVSoU5" title=" Expected Term">3</span> years, risk free rate of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_uPercentage_c20210914__20210915_zDZMMrCM5vY5" title="Risk Free Interest Rate">0.43</span>% and dividend rate of $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_c20210914__20210915_z33El45DpcPi" title="Expected Dividend Payments">0</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zLX1yIvFuHxh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below summarizes the Company’s warrant activities for the years ended December 31, 2021 and 2020 (all share and per share data reflects the reverse stock split):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zilb6CGH6qKl" style="display: none"> Schedule of Warrants Activity</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted Average Strike Price/Share</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted Average Remaining Contractual Term (Years)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted Average Grant Date Fair Value/Share</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intrinsic</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%"><span style="font-family: Times New Roman, Times, Serif">Balance, January 1, 2020</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20200101__20201231_zEOl844j1Xk3" style="width: 9%; text-align: right" title="Number of warrants issued, Outstanding, Beginning of period"><span style="font-family: Times New Roman, Times, Serif">253,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20200101__20201231_zAmHtskb9im" style="width: 9%; text-align: right" title="Weighted Average Strike Price/Share, Outstanding, Beginning of period"><span style="font-family: Times New Roman, Times, Serif">1.50</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20190101__20191231_z6q4ejt4FWsk" title="Weighted Average Remaining Contractual Term (Years), ending of period">2.81</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageGrantFairValue_iS_c20200101__20201231_zlTWguqpU7lc" style="width: 9%; text-align: right" title="Weighted Average Grant Date Fair Value/Share, beginning balance"><span style="font-family: Times New Roman, Times, Serif">0.30</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAggregateIntrinsicValue_iS_c20200101__20201231_zNl1Oeca8dD6" style="width: 9%; text-align: right" title="Aggregate intrinsic value, beginning balance"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1134">–</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20200101__20201231_zCNQYb4ZnSYi" style="text-align: right" title="Number of warrants issued, Granted"><span style="font-family: Times New Roman, Times, Serif">100,804</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20201231_zbctHubFe7m2" style="text-align: right" title="Weighted Average Strike Price/Share, Granted"><span style="font-family: Times New Roman, Times, Serif">1.50</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageRemainingContractualTerm_dtY_c20200101__20201231_zyYcFLDZzK9c" title="Weighted Average Remaining Contractual Term (Years), Granted">3.05</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantFairValue_c20200101__20201231_zWSD1Vvzjuni" style="text-align: right" title="Weighted Average Grant Date Fair Value/Share, Granted"><span style="font-family: Times New Roman, Times, Serif">0.33</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodAggregateIntrinsicValueGranted_c20200101__20201231_zaAGSgrKKgGa" style="text-align: right" title="Aggregate intrinsic, Granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1144">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20200101__20201231_z164wmYJdfNb" style="text-align: right" title="Number of warrants issued, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1146">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20200101__20201231_zAPBQxg4L2R8" style="text-align: right" title="Weighted Average Strike Price/Share, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1148">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">–</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantFairValueForfeited_c20200101__20201231_zIGB0wciwzy9" style="text-align: right" title="Weighted Average Grant Date Fair Value/Share, forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1150">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodAggregateIntrinsicForfeited_c20200101__20201231_zKue2g55n4lk" style="text-align: right" title="Aggregate intrinsic value, forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1152">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20200101__20201231_zZ3vJczfw8Ub" style="text-align: right" title="Number of warrants issued, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1154">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExerciseInPeriodWeightedAverageExercisePrice_c20200101__20201231_zA5j2IYty3u7" style="text-align: right" title="Weighted Average Strike Price/Share, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1156">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">–</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantFairValueExercised_c20200101__20201231_zPgvBLFjK5Ui" style="text-align: right" title="Weighted Average Grant Date Fair Value/Share, exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1158">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodAggregateIntrinsicValueExercised_c20200101__20201231_zzBpCXXQKCAi" style="text-align: right" title="Aggregate intrinsic value exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1160">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Expired</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpired_c20200101__20201231_zQyhA040jrlc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of warrants issued, Expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1162">–</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice_c20200101__20201231_z165xDyI4EB5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Strike Price/Share, Expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1164">–</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">–</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantFairValueExpired_c20200101__20201231_zBnHPjN4nY06" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Grant Date Fair Value/Share, expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1166">–</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodAggregateIntrinsicValueExpired_c20200101__20201231_zswdLPtRQaj4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Aggregate intrinsic value expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1168">–</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance, December 31, 2020</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20200101__20201231_zYKSeiT6Reqi" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants issued, Outstanding, ending of period"><span style="font-family: Times New Roman, Times, Serif">353,804</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20200101__20201231_zf8h2uMdGOZ6" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Strike Price/Share, Outstanding, ending of period"><span style="font-family: Times New Roman, Times, Serif">1.50</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20200101__20201231_zlx2HrtFUakb" title="Weighted Average Remaining Contractual Term (Years)">2.88</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageGrantFairValue_iE_c20200101__20201231_zPSkBk7Oov6j" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Grant Date Fair Value/Share, ending balance"><span style="font-family: Times New Roman, Times, Serif">0.18</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAggregateIntrinsicValue_iE_c20200101__20201231_z0D0Ove4M6X7" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, ending balance"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1178">–</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Vested and exercisable, December 31, 2020</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExercisable_iI_c20201231_zzSm5cUY6gNl" style="border-bottom: Black 2.5pt double; text-align: right" title="Non option equity instruments vested and exercisable, ending of period"><span style="font-family: Times New Roman, Times, Serif">353,804</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceVestedAndExercisable_iI_c20201231_zLqIwRcCSdQb" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Strike Price/Share vested and exercisable, ending of period"><span style="font-family: Times New Roman, Times, Serif">1.50</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageRemainingContractualTermUnvestedAndExercisable_dtY_c20200101__20201231_zPuJdzPrkLE5" title="Weighted Average Remaining Contractual Term (Years), vested and exercisable">2.88</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantFairValueVestedAndExercisable_iI_c20201231_z9f7g4TDAn9j" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Grant Date Fair Value/Share vested and exercisable, ending of period"><span style="font-family: Times New Roman, Times, Serif">0.18</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueVestedAndExercisable_iI_c20201231_zyfeOJsqfPuf" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value vested and exercisable, ending of period"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1188">–</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Unvested, December 31, 2020</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVested_iI_c20201231_z3kxBdFSRYRd" style="border-bottom: Black 2.5pt double; text-align: right" title="Non option equity instruments vested, ending of period"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1190">–</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceVested_iI_c20201231_zs00XcgehIsf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Strike Price/Share unvested"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1192">–</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageRemainingContracutalTermUnvested_dxL_c20200101__20201231_zIY1iRiVdjP" title="Weighted Average Remaining Contractual Term (Years), unvested::XDX::P0Y"><span style="-sec-ix-hidden: xdx2ixbrl1194">–</span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantFairValueVested_iI_c20201231_zcnYVy2Dijgd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Grant Date Fair Value/Share vested, Ending of period"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1196">–</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueVested_iI_c20201231_zRFSD3k1Llz" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value vested, ending of period"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1198">–</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif">Balance, December 31, 2020</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20211231_zbzxN7T2qscb" style="text-align: right" title="Number of warrants issued, Outstanding, Beginning of period"><span style="font-family: Times New Roman, Times, Serif">353,804</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231_zHMKSvDWBYM6" style="text-align: right" title="Weighted Average Strike Price/Share, Outstanding, Beginning of period"><span style="font-family: Times New Roman, Times, Serif">1.50</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20200101__20201231_z8RM85sNiBr3" title="Weighted Average Remaining Contractual Term (Years)">2.88</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageGrantFairValue_iS_c20210101__20211231_zm3vKcvLeOg7" style="text-align: right" title="Weighted Average Grant Date Fair Value/Share, Beginning of period"><span style="font-family: Times New Roman, Times, Serif">0.18</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAggregateIntrinsicValue_iS_c20210101__20211231_zwK2DaQJstE8" style="text-align: right" title="Aggregate intrinsic value, Beginning of period"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1208">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231_z1CUnEWJcNB2" style="text-align: right" title="Number of warrants issued, Granted"><span style="font-family: Times New Roman, Times, Serif">1,667,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231_zj03HE8mnyX2" style="text-align: right" title="Weighted Average Strike Price/Share, Granted"><span style="font-family: Times New Roman, Times, Serif">1.86</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231_z1G9k57UiBTf" title="Weighted Average Remaining Contractual Term (Years), Granted">3.00</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantFairValue_c20210101__20211231_zFxiTKWJ7i2l" style="text-align: right" title="Weighted Average Grant Date Fair Value/Share, Granted"><span style="font-family: Times New Roman, Times, Serif">1.67</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodAggregateIntrinsicValueGranted_c20210101__20211231_zVACgnd5CLnj" style="text-align: right" title="Aggregate intrinsic value, Granted"><span style="font-family: Times New Roman, Times, Serif">0.11</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20210101__20211231_zA22mihvupS5" style="text-align: right" title="Number of warrants issued, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1220">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231_z1LW4dxvHGMl" style="text-align: right" title="Weighted Average Strike Price/Share, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1222">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">–</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantFairValueForfeited_c20210101__20211231_zYeZpUU3Bjz8" style="text-align: right" title="Weighted Average Grant Date Fair Value/Share, forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1224">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodAggregateIntrinsicForfeited_c20210101__20211231_z9C14Ff8Bbw5" style="text-align: right" title="Aggregate intrinsic value, forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1226">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20210101__20211231_zzcfHNIXyB5h" style="text-align: right" title="Number of warrants issued, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1228">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExerciseInPeriodWeightedAverageExercisePrice_c20210101__20211231_z4cO8F9cSAFf" style="text-align: right" title="Weighted Average Strike Price/Share, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1230">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">–</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantFairValueExercised_c20210101__20211231_z3UoIy1H8Rqk" style="text-align: right" title="Weighted Average Grant Date Fair Value/Share, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1232">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodAggregateIntrinsicValueExercised_c20210101__20211231_zPfnR7g7Nmh6" style="text-align: right" title="Aggregate intrinsic value, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1234">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Expired</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpired_c20210101__20211231_zgkizXyxvYck" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of warrants issued, Expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1236">–</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice_c20210101__20211231_zFIm0JcT5NLa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Strike Price/Share, Expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1238">–</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">–</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantFairValueExpired_c20210101__20211231_zzekrt7CGSTh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Grant Date Fair Value/Share, Expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1240">–</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodAggregateIntrinsicValueExpired_c20210101__20211231_zn3qSn3AzGQb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Aggregate intrinsic value, Expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1242">–</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance, December 31, 2021</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20211231_zjEjKsqVCSCj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants issued, Outstanding, Ending of period"><span style="font-family: Times New Roman, Times, Serif">2,021,304</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231_zkQJ5VbRDzIi" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Strike Price/Share, Outstanding, Ending of period"><span style="font-family: Times New Roman, Times, Serif">1.80</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231_zKQFejWDUhNj" title="Weighted Average Remaining Contractual Term (Years)">2.98</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageGrantFairValue_iE_c20210101__20211231_zt8tpNzyb6Ad" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Grant Date Fair Value/Share, Ending of period"><span style="font-family: Times New Roman, Times, Serif">1.14</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAggregateIntrinsicValue_iE_c20210101__20211231_zkkKTI7Ic68i" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, Ending of period"><span style="font-family: Times New Roman, Times, Serif">0.17</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Vested and exercisable, December 31, 2021</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExercisable_iI_c20211231_znv0KkUxhoEk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants issued, Vested and Exercisable, Ending of period"><span style="font-family: Times New Roman, Times, Serif">2,021,304</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceVestedAndExercisable_iI_c20211231_zi713nQeLRRf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Strike Price/Share, Vested and Exercisable, Ending of period"><span style="font-family: Times New Roman, Times, Serif">1.80</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageRemainingContractualTermUnvestedAndExercisable_dtY_c20210101__20211231_zTDx7TnQzbt6" title="Weighted Average Remaining Contractual Term (Years), Vested and Exercisable">2.98</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantFairValueVestedAndExercisable_iI_c20211231_zvONVkMmGpel" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Grant Date Fair Value/Share, Vested and Exercisable, Ending of period"><span style="font-family: Times New Roman, Times, Serif">1.14</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueVestedAndExercisable_iI_c20211231_zNXM3FVvPz96" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, Vested and Exercisable, Ending of period"><span style="font-family: Times New Roman, Times, Serif">0.17</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Unvested, December 31, 2021</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVested_iI_c20211231_zpNFhZ5Yt5O9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants issued, Vested, Ending of period"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1264">–</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceVested_iI_c20211231_zukIV2J5Oqe9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Strike Price/Share, Unvested, Ending of period"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1266">–</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageRemainingContracutalTermUnvested_dxL_c20210101__20211231_zXPnEBiob5Oh" title="Weighted Average Remaining Contractual Term (Years), Unvested::XDX::P0Y"><span style="-sec-ix-hidden: xdx2ixbrl1268">–</span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantFairValueVested_iI_c20211231_zgNlWec7N605" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Grant Date Fair Value/Share, Vested, Ending of period"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1270">–</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueVested_iI_c20201231_zCa49hq89Mu" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, Vested, Ending of period"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1272">–</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A9_zcnivZHuRprb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zrGc2c0CNRui" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth the weighted-average assumptions used to estimate the fair value of warrants granted for the year ended December 31:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B2_zQEd65NOf7j2" style="display: none">Schedule of Fair Value of Warrants</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected life (in years)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z2FKNgAAsde" title="Warrants and rights outstanding, term">3</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zBZoGGmDjQUh">2.33</span> -</span> <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zuRsMmvWkd7k" style="font-family: Times New Roman, Times, Serif">3.25</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk-free interest rate</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dtY_uPercentage_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zu6fBlA0sTth" title="Risk free interest rate">0.27</span>% - <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dtY_uPercentage_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zy1LdphiUBmk" title="Risk free interest rate">0.42</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dtY_uPercentage_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_ze5ya4S3cWuk" style="font-family: Times New Roman, Times, Serif">0.18</span><span style="font-family: Times New Roman, Times, Serif">% - <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dtY_uPercentage_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zE8yjgcDo7E5">2.49</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected volatility</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dtY_uPercentage_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zrkzm8Kxumwe" title="Expected volatility">405</span>% - <span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dtY_uPercentage_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_z7ftAzLt1Bub" title="Expected volatility">406</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dtY_uPercentage_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zlUmdDEKddRf" style="font-family: Times New Roman, Times, Serif">378</span><span style="font-family: Times New Roman, Times, Serif">% - <span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dtY_uPercentage_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zhkyy7q16BX8">424</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Dividend yield</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dtY_uPercentage_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zrzYXUKqN3Mb" title="Dividend yield">0.00</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dtY_uPercentage_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zvf9Rqld7uP6" title="Dividend yield">0.00</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Stock price</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">$ <span id="xdx_90D_eus-gaap--SharePrice_iI_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MinimumMember_zJ9MeNwkJgd9" title="Share price">0.10</span> – <span id="xdx_90E_eus-gaap--SharePrice_iI_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MaximumMember_zcm7qyQvWV89" title="Share price">1.95</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">$ <span id="xdx_905_eus-gaap--SharePrice_iI_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MinimumMember_zlhyRknYglAd">0.11 </span></span><span style="font-family: Times New Roman, Times, Serif">– <span id="xdx_907_eus-gaap--SharePrice_iI_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MaximumMember_zsY3pbAbZOo4">1.60</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p id="xdx_8A1_zbR0Lvqv81m1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 200000000 100000000 0.001 100000000 0.001 1.38 1.38 1.00 36000 10000000 the close of business on the sixtieth consecutive day on which the closing price of the Company’s common stock on the OTC Markets is at least $2.80 per share, subject to appropriate adjustment in the event of any stock dividend, stock split, stock combination or other similar recapitalization with respect to the common stock, or (iii) the affirmative vote of the holders of at least 66⅔% of the outstanding shares of Series A, given at a meeting of such stockholders duly called for that purpose or pursuant to a written consent of stockholders all outstanding shares of Series A shall automatically be converted into shares of the Company’s common stock, at the then effective conversion rate 85975 147000 3674330 68000 128000 30000 98000 75000 30000 25000 76000 10000000 1500000 1 11500000 1.93 22195000 <p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zJV2hQrwaSt5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below summarizes the transactions related to the Company restricted stock awards as of December 31, 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B2_zP6oC8g8S5vj" style="display: none">Schedule of Company Restricted Stock Awards</span> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Deferred compensation</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Grant date fair value</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_ecustom--GrantDateFairValueShares_iI_c20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zMfaMgiB3u56" style="width: 16%; text-align: right" title="Grant date fair value, shares"><span style="font-family: Times New Roman, Times, Serif">11,500,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_ecustom--DeferredCompensationGrantDateFairValue_iI_uUSD_c20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zdsPPTC7t2pa" style="width: 16%; text-align: right" title="Deferred compensation grant date fair value"><span style="font-family: Times New Roman, Times, Serif">22,195,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Accretion</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_ecustom--AccretionShares_iI_c20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zMDvsENUEKHb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accretion, shares"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0944">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_ecustom--DeferredCompensationAccretion_iI_c20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z8SI7gRM1GJj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Deferred compensation accretion"><span style="font-family: Times New Roman, Times, Serif">(4,791,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance as of December 31, 2021</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_c20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zVGd8I8d4oH4" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares, balance"><span style="font-family: Times New Roman, Times, Serif">11,500,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--DeferredCompensationShareBasedArrangementsLiabilityCurrent_iI_c20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zVOcFxCaHWc9" style="border-bottom: Black 2.5pt double; text-align: right" title="Deferred compensation"><span style="font-family: Times New Roman, Times, Serif">17,404,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 11500000 22195000 -4791000 11500000 17404000 750000 0.001 52000 38000 14000 300000 0.001 561000 385000 750000 300000 0.001 2000 <p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zuc17PjRJc01" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below summarizes the Company’s stock option activities for the years ended December 31, 2021 and 2020 (all share and per share data reflects the reverse stock split):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zzfLGtQqXObl" style="display: none">Schedule of Stock Option Activities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock Option</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Range Per</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Relative</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intrinsic</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%"><span style="font-family: Times New Roman, Times, Serif">Balance, January 1, 2020</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20200101__20201231_zCQhLmW5AJrg" style="width: 9%; text-align: right" title="Number of Number of Stock Option Shares, Outstanding, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">569,800</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceRangePerShareOutstandingBeginning_iS_c20200101__20201231_zqtBJ0TIFxD5" style="width: 9%; text-align: right" title="Exercise Price Range Per Share, Outstanding, Beginning"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0982">–</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20200101__20201231_z5KsbljeLV6b" style="width: 9%; text-align: right" title="Weighted Average Exercise Price, Outstanding, Beginning"><span style="font-family: Times New Roman, Times, Serif">4.05</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRelativeFairValueOutstandingBeginning_iS_c20200101__20201231_zd8vHEi8xQSb" style="width: 9%; text-align: right" title="Relative Fair Value, Outstanding, Beginning"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0986">–</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pdp0_c20200101__20201231_zKvvczBnpEv7" style="width: 9%; text-align: right" title="Aggregate Intrinsic Value, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">423,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200101__20201231_zMiorzCDFIVg" style="text-align: right" title="Number of Stock Option Shares, Granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0990">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInExercisePriceRangePerShareGranted_c20200101__20201231_zsLUitielqp9" style="text-align: right" title="Exercise Price Range Per Share, Granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0992">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20201231_zLrb0M3BnD24" style="text-align: right" title="Weighted Average Exercise Price, Granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0994">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodRelativeFairValueGranted_c20200101__20201231_zDYgUeKqo3gd" style="text-align: right" title="Relative Fair Value, Granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0996">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue_c20200101__20201231_zSIuOva8w2H1" style="text-align: right" title="Aggregate Intrinsic Value, Granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0998">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20200101__20201231_zY1dKyRaO1i7" style="text-align: right" title="Number of Stock Option Shares, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1000">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsInPeriodExercisePriceRangePerShareForfeited_c20200101__20201231_zwHDHxUD0lfe" style="text-align: right" title="Exercise Price Range Per Share, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1002">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20200101__20201231_zDWURf3GP8ei" style="text-align: right" title="Weighted Average Exercise Price, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1004">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodRelativeFairValueForfeited_c20200101__20201231_zguvlLQMyLah" style="text-align: right" title="Relative Fair Value, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1006">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodForfeitedIntrinsicValue_c20200101__20201231_zT9yjFII3koi" style="text-align: right" title="Aggregate Intrinsic Value, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1008">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20200101__20201231_zvxiIqBe7tb1" style="text-align: right" title="Number of Stock Option Shares, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1010">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodExercisePriceRangePerShareExercised_c20200101__20201231_zgo8guvTZ1k9" style="text-align: right" title="Exercise Price Range Per Share, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1012">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20200101__20201231_zujV4WKSCSm6" style="text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1014">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodRelativeFairValueExercised_c20200101__20201231_zTeJBKnrFfnl" style="text-align: right" title="Relative Fair Value, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1016">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInPeriodExercisedIntrinsicValue_c20200101__20201231_zYBp4qnv8nbe" style="text-align: right" title="Aggregate Intrinsic Value, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1018">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Expired</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20200101__20201231_zBqCituYrUqg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Stock Option Shares, Expired"><span style="font-family: Times New Roman, Times, Serif">(184,800</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodExercisePriceRangePerShareExpired_c20200101__20201231_z0EjwNQwjr44" style="border-bottom: Black 1.5pt solid; text-align: right" title="Exercise Price Range Per Share, Expired"><span style="font-family: Times New Roman, Times, Serif">12.50</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20200101__20201231_zzPICW3DkaC9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Expired"><span style="font-family: Times New Roman, Times, Serif">12.50</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodRelativeFairValueExpired_c20200101__20201231_zfZrLKlmxRob" style="border-bottom: Black 1.5pt solid; text-align: right" title="Relative Fair Value, Expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1026">–</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInPeriodExpiredIntrinsicValue_c20200101__20201231_zLJcWIMXMR38" style="border-bottom: Black 1.5pt solid; text-align: right" title="Aggregate Intrinsic Value, Expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1028">–</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif">Balance, December 31, 2020</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231_zzXOIKCHR6mc" style="text-align: right" title="Number of Stock Option Shares, Outstanding, Beginning of period"><span style="font-family: Times New Roman, Times, Serif">385,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceRangePerShareOutstandingBeginning_iS_c20210101__20211231_zEp6CbAHGEO7" style="text-align: right" title="Exercise Price Range Per Share, Outstanding, Beginning of period"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1032">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231_zk3pzOg54Bsk" style="text-align: right" title="Weighted Average Exercise Price, Outstanding, Beginning of period"><span style="font-family: Times New Roman, Times, Serif">0.001</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRelativeFairValueOutstandingBeginning_iS_c20210101__20211231_zXOHcLnreccb" style="text-align: right" title="Relative Fair Value, Outstanding, Beginning of period"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1036">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20210101__20211231_z3yRdFQ9kvY4" style="text-align: right" title="Aggregate Intrinsic Value, Beginning of period"><span style="font-family: Times New Roman, Times, Serif">7,315</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231_zLcIqldPp9l1" style="text-align: right" title="Number of Stock Option Shares, Granted"><span style="font-family: Times New Roman, Times, Serif">1,050,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInExercisePriceRangePerShareGranted_c20210101__20211231_zVyuwVqtsgcb" style="text-align: right" title="Exercise Price Range Per Share, Granted"><span style="font-family: Times New Roman, Times, Serif">0.001</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231_zSW8ftrD9Pff" style="text-align: right" title="Weighted Average Exercise Price, Granted"><span style="font-family: Times New Roman, Times, Serif">0.001</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodRelativeFairValueGranted_c20210101__20211231_zk2bA1KY20jh" style="text-align: right" title="Relative Fair Value, Granted"><span style="font-family: Times New Roman, Times, Serif">1.94</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue_c20210101__20211231_z2pwzs3ZNwL1" style="text-align: right" title="Aggregate Intrinsic Value, Granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1048">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20210101__20211231_zYHoINX21Xv9" style="text-align: right" title="Number of Stock Option Shares, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1050">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsInPeriodExercisePriceRangePerShareForfeited_c20210101__20211231_zma7oCGRRhDg" style="text-align: right" title="Exercise Price Range Per Share, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1052">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231_zTN5sofm3pui" style="text-align: right" title="Weighted Average Exercise Price, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1054">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodRelativeFairValueForfeited_c20210101__20211231_zzVayrHNnRa7" style="text-align: right" title="Relative Fair Value, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1056">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodForfeitedIntrinsicValue_c20210101__20211231_zbrNsXtCOTXf" style="text-align: right" title="Aggregate Intrinsic Value, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1058">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20210101__20211231_zKg7LLgAC8Y3" style="text-align: right" title="Number of Stock Option Shares, Exercised"><span style="font-family: Times New Roman, Times, Serif">(1,435,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodExercisePriceRangePerShareExercised_c20210101__20211231_zSmqfPXwZ2c2" style="text-align: right" title="Exercise Price Range Per Share, Exercised"><span style="font-family: Times New Roman, Times, Serif">0.001</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20211231_zIayY4y6NtT7" style="text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="font-family: Times New Roman, Times, Serif">0.001</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodRelativeFairValueExercised_c20210101__20211231_z8KjMJkFxHok" style="text-align: right" title="Relative Fair Value, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1066">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInPeriodExercisedIntrinsicValue_c20210101__20211231_zgY1ScGax3vd" style="text-align: right" title="Aggregate Intrinsic Value, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1068">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Expired</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20210101__20211231_zgj3aUTcUvBk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Stock Option Shares, Expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1070">–</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodExercisePriceRangePerShareExpired_c20210101__20211231_z2EJaxBdX3x5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Exercise Price Range Per Share, Expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1072">–</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20210101__20211231_zAkGJ89ufUXg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1074">–</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodRelativeFairValueExpired_c20210101__20211231_zZL0p0VLuyig" style="border-bottom: Black 1.5pt solid; text-align: right" title="Relative Fair Value, Expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1076">–</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInPeriodExpiredIntrinsicValue_c20210101__20211231_zreba2qFkhel" style="border-bottom: Black 1.5pt solid; text-align: right" title="Aggregate Intrinsic Value, Expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1078">–</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance, December 31, 2021</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210101__20211231_zIsqQKw5MyA8" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Stock Option Shares, Outstanding, Ending of period"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1080">–</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceRangePerShareOutstandingEnding_iE_c20210101__20211231_zu7aXFoj5l5f" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercise Price Range Per Share, Outstanding, Ending of period"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1082">–</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231_zwD8FB2Cdii9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding, Ending of period"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1084">–</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRelativeFairValueOutstandingBeginning_iE_c20210101__20211231_z3N52yMZaJ63" style="border-bottom: Black 2.5pt double; text-align: right" title="Relative Fair Value, Outstanding, Ending of period"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1086">–</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20210101__20211231_zuSD5lpItZjk" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Ending of period"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1088">–</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Vested and exercisable, December 31, 2021</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableEndingBalance_iE_c20210101__20211231_z015rMtW2jij" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Stock Option, Vested and Exercisable, Ending Balance"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1090">–</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodExercisePriceRangePerShareVestedAndExercisable_c20210101__20211231_z4iJHIJ6pmGl" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercise Price Range Per Share, Vested and Exercisable"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1092">–</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceVestedAndExercisable_c20210101__20211231_zphoNtRtMsIi" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Vested and Exercisable"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1094">–</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodRelativeFairValueVestedAndExercisable_c20210101__20211231_zfd3C3Eh5iL4" style="border-bottom: Black 2.5pt double; text-align: right" title="Relative Fair Value, Vested and Exercisable"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1096">–</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pdp0_c20210101__20211231_zR7VEPU6Enrf" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Vested and Exercisable"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1098">–</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Unvested, December 31, 2021</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedEndingBalance_iE_c20210101__20211231_za1U1nkvEUxg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Stock Option, Unvested, Ending Balance"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1100">–</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsInPeriodExercisePriceRangePerShareUnvested_c20210101__20211231_zuLvoqSApMwd" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercise Price Range Per Share, Unvested"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1102">–</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iI_c20211231_zyJfdgmeVSpe" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Unvested"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1104">–</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsUnvestedInPeriodRelativeFairValueUnvested_c20210101__20211231_z4VIMkda70c" style="border-bottom: Black 2.5pt double; text-align: right" title="Relative Fair Value, Unvested"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1106">–</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAggregateIntrinsicValueUnvested_iE_pdp0_c20210101__20211231_z56cfpvof2jb" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Unvested"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1108">–</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 569800 4.05 423000 184800 12.50 12.50 385000 0.001 7315 1050000 0.001 0.001 1.94 1435000 0.001 0.001 100000 195000 3.59 1.95 P3Y 0.43 0 <p id="xdx_89A_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zLX1yIvFuHxh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below summarizes the Company’s warrant activities for the years ended December 31, 2021 and 2020 (all share and per share data reflects the reverse stock split):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zilb6CGH6qKl" style="display: none"> Schedule of Warrants Activity</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted Average Strike Price/Share</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted Average Remaining Contractual Term (Years)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted Average Grant Date Fair Value/Share</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intrinsic</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%"><span style="font-family: Times New Roman, Times, Serif">Balance, January 1, 2020</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20200101__20201231_zEOl844j1Xk3" style="width: 9%; text-align: right" title="Number of warrants issued, Outstanding, Beginning of period"><span style="font-family: Times New Roman, Times, Serif">253,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20200101__20201231_zAmHtskb9im" style="width: 9%; text-align: right" title="Weighted Average Strike Price/Share, Outstanding, Beginning of period"><span style="font-family: Times New Roman, Times, Serif">1.50</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20190101__20191231_z6q4ejt4FWsk" title="Weighted Average Remaining Contractual Term (Years), ending of period">2.81</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageGrantFairValue_iS_c20200101__20201231_zlTWguqpU7lc" style="width: 9%; text-align: right" title="Weighted Average Grant Date Fair Value/Share, beginning balance"><span style="font-family: Times New Roman, Times, Serif">0.30</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAggregateIntrinsicValue_iS_c20200101__20201231_zNl1Oeca8dD6" style="width: 9%; text-align: right" title="Aggregate intrinsic value, beginning balance"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1134">–</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20200101__20201231_zCNQYb4ZnSYi" style="text-align: right" title="Number of warrants issued, Granted"><span style="font-family: Times New Roman, Times, Serif">100,804</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20201231_zbctHubFe7m2" style="text-align: right" title="Weighted Average Strike Price/Share, Granted"><span style="font-family: Times New Roman, Times, Serif">1.50</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageRemainingContractualTerm_dtY_c20200101__20201231_zyYcFLDZzK9c" title="Weighted Average Remaining Contractual Term (Years), Granted">3.05</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantFairValue_c20200101__20201231_zWSD1Vvzjuni" style="text-align: right" title="Weighted Average Grant Date Fair Value/Share, Granted"><span style="font-family: Times New Roman, Times, Serif">0.33</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodAggregateIntrinsicValueGranted_c20200101__20201231_zaAGSgrKKgGa" style="text-align: right" title="Aggregate intrinsic, Granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1144">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20200101__20201231_z164wmYJdfNb" style="text-align: right" title="Number of warrants issued, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1146">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20200101__20201231_zAPBQxg4L2R8" style="text-align: right" title="Weighted Average Strike Price/Share, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1148">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">–</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantFairValueForfeited_c20200101__20201231_zIGB0wciwzy9" style="text-align: right" title="Weighted Average Grant Date Fair Value/Share, forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1150">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodAggregateIntrinsicForfeited_c20200101__20201231_zKue2g55n4lk" style="text-align: right" title="Aggregate intrinsic value, forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1152">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20200101__20201231_zZ3vJczfw8Ub" style="text-align: right" title="Number of warrants issued, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1154">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExerciseInPeriodWeightedAverageExercisePrice_c20200101__20201231_zA5j2IYty3u7" style="text-align: right" title="Weighted Average Strike Price/Share, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1156">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">–</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantFairValueExercised_c20200101__20201231_zPgvBLFjK5Ui" style="text-align: right" title="Weighted Average Grant Date Fair Value/Share, exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1158">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodAggregateIntrinsicValueExercised_c20200101__20201231_zzBpCXXQKCAi" style="text-align: right" title="Aggregate intrinsic value exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1160">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Expired</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpired_c20200101__20201231_zQyhA040jrlc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of warrants issued, Expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1162">–</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice_c20200101__20201231_z165xDyI4EB5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Strike Price/Share, Expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1164">–</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">–</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantFairValueExpired_c20200101__20201231_zBnHPjN4nY06" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Grant Date Fair Value/Share, expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1166">–</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodAggregateIntrinsicValueExpired_c20200101__20201231_zswdLPtRQaj4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Aggregate intrinsic value expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1168">–</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance, December 31, 2020</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20200101__20201231_zYKSeiT6Reqi" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants issued, Outstanding, ending of period"><span style="font-family: Times New Roman, Times, Serif">353,804</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20200101__20201231_zf8h2uMdGOZ6" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Strike Price/Share, Outstanding, ending of period"><span style="font-family: Times New Roman, Times, Serif">1.50</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20200101__20201231_zlx2HrtFUakb" title="Weighted Average Remaining Contractual Term (Years)">2.88</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageGrantFairValue_iE_c20200101__20201231_zPSkBk7Oov6j" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Grant Date Fair Value/Share, ending balance"><span style="font-family: Times New Roman, Times, Serif">0.18</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAggregateIntrinsicValue_iE_c20200101__20201231_z0D0Ove4M6X7" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, ending balance"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1178">–</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Vested and exercisable, December 31, 2020</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExercisable_iI_c20201231_zzSm5cUY6gNl" style="border-bottom: Black 2.5pt double; text-align: right" title="Non option equity instruments vested and exercisable, ending of period"><span style="font-family: Times New Roman, Times, Serif">353,804</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceVestedAndExercisable_iI_c20201231_zLqIwRcCSdQb" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Strike Price/Share vested and exercisable, ending of period"><span style="font-family: Times New Roman, Times, Serif">1.50</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageRemainingContractualTermUnvestedAndExercisable_dtY_c20200101__20201231_zPuJdzPrkLE5" title="Weighted Average Remaining Contractual Term (Years), vested and exercisable">2.88</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantFairValueVestedAndExercisable_iI_c20201231_z9f7g4TDAn9j" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Grant Date Fair Value/Share vested and exercisable, ending of period"><span style="font-family: Times New Roman, Times, Serif">0.18</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueVestedAndExercisable_iI_c20201231_zyfeOJsqfPuf" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value vested and exercisable, ending of period"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1188">–</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Unvested, December 31, 2020</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVested_iI_c20201231_z3kxBdFSRYRd" style="border-bottom: Black 2.5pt double; text-align: right" title="Non option equity instruments vested, ending of period"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1190">–</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceVested_iI_c20201231_zs00XcgehIsf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Strike Price/Share unvested"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1192">–</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageRemainingContracutalTermUnvested_dxL_c20200101__20201231_zIY1iRiVdjP" title="Weighted Average Remaining Contractual Term (Years), unvested::XDX::P0Y"><span style="-sec-ix-hidden: xdx2ixbrl1194">–</span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantFairValueVested_iI_c20201231_zcnYVy2Dijgd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Grant Date Fair Value/Share vested, Ending of period"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1196">–</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueVested_iI_c20201231_zRFSD3k1Llz" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value vested, ending of period"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1198">–</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif">Balance, December 31, 2020</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20211231_zbzxN7T2qscb" style="text-align: right" title="Number of warrants issued, Outstanding, Beginning of period"><span style="font-family: Times New Roman, Times, Serif">353,804</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231_zHMKSvDWBYM6" style="text-align: right" title="Weighted Average Strike Price/Share, Outstanding, Beginning of period"><span style="font-family: Times New Roman, Times, Serif">1.50</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20200101__20201231_z8RM85sNiBr3" title="Weighted Average Remaining Contractual Term (Years)">2.88</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageGrantFairValue_iS_c20210101__20211231_zm3vKcvLeOg7" style="text-align: right" title="Weighted Average Grant Date Fair Value/Share, Beginning of period"><span style="font-family: Times New Roman, Times, Serif">0.18</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAggregateIntrinsicValue_iS_c20210101__20211231_zwK2DaQJstE8" style="text-align: right" title="Aggregate intrinsic value, Beginning of period"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1208">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231_z1CUnEWJcNB2" style="text-align: right" title="Number of warrants issued, Granted"><span style="font-family: Times New Roman, Times, Serif">1,667,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231_zj03HE8mnyX2" style="text-align: right" title="Weighted Average Strike Price/Share, Granted"><span style="font-family: Times New Roman, Times, Serif">1.86</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231_z1G9k57UiBTf" title="Weighted Average Remaining Contractual Term (Years), Granted">3.00</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantFairValue_c20210101__20211231_zFxiTKWJ7i2l" style="text-align: right" title="Weighted Average Grant Date Fair Value/Share, Granted"><span style="font-family: Times New Roman, Times, Serif">1.67</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodAggregateIntrinsicValueGranted_c20210101__20211231_zVACgnd5CLnj" style="text-align: right" title="Aggregate intrinsic value, Granted"><span style="font-family: Times New Roman, Times, Serif">0.11</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20210101__20211231_zA22mihvupS5" style="text-align: right" title="Number of warrants issued, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1220">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231_z1LW4dxvHGMl" style="text-align: right" title="Weighted Average Strike Price/Share, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1222">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">–</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantFairValueForfeited_c20210101__20211231_zYeZpUU3Bjz8" style="text-align: right" title="Weighted Average Grant Date Fair Value/Share, forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1224">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodAggregateIntrinsicForfeited_c20210101__20211231_z9C14Ff8Bbw5" style="text-align: right" title="Aggregate intrinsic value, forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1226">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20210101__20211231_zzcfHNIXyB5h" style="text-align: right" title="Number of warrants issued, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1228">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExerciseInPeriodWeightedAverageExercisePrice_c20210101__20211231_z4cO8F9cSAFf" style="text-align: right" title="Weighted Average Strike Price/Share, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1230">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">–</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantFairValueExercised_c20210101__20211231_z3UoIy1H8Rqk" style="text-align: right" title="Weighted Average Grant Date Fair Value/Share, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1232">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodAggregateIntrinsicValueExercised_c20210101__20211231_zPfnR7g7Nmh6" style="text-align: right" title="Aggregate intrinsic value, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1234">–</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Expired</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpired_c20210101__20211231_zgkizXyxvYck" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of warrants issued, Expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1236">–</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice_c20210101__20211231_zFIm0JcT5NLa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Strike Price/Share, Expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1238">–</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">–</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantFairValueExpired_c20210101__20211231_zzekrt7CGSTh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Grant Date Fair Value/Share, Expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1240">–</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodAggregateIntrinsicValueExpired_c20210101__20211231_zn3qSn3AzGQb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Aggregate intrinsic value, Expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1242">–</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance, December 31, 2021</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20211231_zjEjKsqVCSCj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants issued, Outstanding, Ending of period"><span style="font-family: Times New Roman, Times, Serif">2,021,304</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231_zkQJ5VbRDzIi" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Strike Price/Share, Outstanding, Ending of period"><span style="font-family: Times New Roman, Times, Serif">1.80</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231_zKQFejWDUhNj" title="Weighted Average Remaining Contractual Term (Years)">2.98</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageGrantFairValue_iE_c20210101__20211231_zt8tpNzyb6Ad" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Grant Date Fair Value/Share, Ending of period"><span style="font-family: Times New Roman, Times, Serif">1.14</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAggregateIntrinsicValue_iE_c20210101__20211231_zkkKTI7Ic68i" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, Ending of period"><span style="font-family: Times New Roman, Times, Serif">0.17</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Vested and exercisable, December 31, 2021</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExercisable_iI_c20211231_znv0KkUxhoEk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants issued, Vested and Exercisable, Ending of period"><span style="font-family: Times New Roman, Times, Serif">2,021,304</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceVestedAndExercisable_iI_c20211231_zi713nQeLRRf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Strike Price/Share, Vested and Exercisable, Ending of period"><span style="font-family: Times New Roman, Times, Serif">1.80</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageRemainingContractualTermUnvestedAndExercisable_dtY_c20210101__20211231_zTDx7TnQzbt6" title="Weighted Average Remaining Contractual Term (Years), Vested and Exercisable">2.98</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantFairValueVestedAndExercisable_iI_c20211231_zvONVkMmGpel" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Grant Date Fair Value/Share, Vested and Exercisable, Ending of period"><span style="font-family: Times New Roman, Times, Serif">1.14</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueVestedAndExercisable_iI_c20211231_zNXM3FVvPz96" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, Vested and Exercisable, Ending of period"><span style="font-family: Times New Roman, Times, Serif">0.17</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Unvested, December 31, 2021</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVested_iI_c20211231_zpNFhZ5Yt5O9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants issued, Vested, Ending of period"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1264">–</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceVested_iI_c20211231_zukIV2J5Oqe9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Strike Price/Share, Unvested, Ending of period"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1266">–</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageRemainingContracutalTermUnvested_dxL_c20210101__20211231_zXPnEBiob5Oh" title="Weighted Average Remaining Contractual Term (Years), Unvested::XDX::P0Y"><span style="-sec-ix-hidden: xdx2ixbrl1268">–</span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantFairValueVested_iI_c20211231_zgNlWec7N605" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Grant Date Fair Value/Share, Vested, Ending of period"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1270">–</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueVested_iI_c20201231_zCa49hq89Mu" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, Vested, Ending of period"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1272">–</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 253000 1.50 P2Y9M21D 0.30 100804 1.50 P3Y18D 0.33 353804 1.50 P2Y10M17D 0.18 353804 1.50 P2Y10M17D 0.18 353804 1.50 P2Y10M17D 0.18 1667500 1.86 P3Y 1.67 0.11 2021304 1.80 P2Y11M23D 1.14 0.17 2021304 1.80 P2Y11M23D 1.14 0.17 <p id="xdx_896_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zrGc2c0CNRui" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth the weighted-average assumptions used to estimate the fair value of warrants granted for the year ended December 31:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B2_zQEd65NOf7j2" style="display: none">Schedule of Fair Value of Warrants</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected life (in years)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z2FKNgAAsde" title="Warrants and rights outstanding, term">3</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zBZoGGmDjQUh">2.33</span> -</span> <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zuRsMmvWkd7k" style="font-family: Times New Roman, Times, Serif">3.25</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk-free interest rate</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dtY_uPercentage_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zu6fBlA0sTth" title="Risk free interest rate">0.27</span>% - <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dtY_uPercentage_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zy1LdphiUBmk" title="Risk free interest rate">0.42</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dtY_uPercentage_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_ze5ya4S3cWuk" style="font-family: Times New Roman, Times, Serif">0.18</span><span style="font-family: Times New Roman, Times, Serif">% - <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dtY_uPercentage_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zE8yjgcDo7E5">2.49</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected volatility</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dtY_uPercentage_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zrkzm8Kxumwe" title="Expected volatility">405</span>% - <span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dtY_uPercentage_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_z7ftAzLt1Bub" title="Expected volatility">406</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dtY_uPercentage_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zlUmdDEKddRf" style="font-family: Times New Roman, Times, Serif">378</span><span style="font-family: Times New Roman, Times, Serif">% - <span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dtY_uPercentage_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zhkyy7q16BX8">424</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Dividend yield</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dtY_uPercentage_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zrzYXUKqN3Mb" title="Dividend yield">0.00</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dtY_uPercentage_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zvf9Rqld7uP6" title="Dividend yield">0.00</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Stock price</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">$ <span id="xdx_90D_eus-gaap--SharePrice_iI_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MinimumMember_zJ9MeNwkJgd9" title="Share price">0.10</span> – <span id="xdx_90E_eus-gaap--SharePrice_iI_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MaximumMember_zcm7qyQvWV89" title="Share price">1.95</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">$ <span id="xdx_905_eus-gaap--SharePrice_iI_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MinimumMember_zlhyRknYglAd">0.11 </span></span><span style="font-family: Times New Roman, Times, Serif">– <span id="xdx_907_eus-gaap--SharePrice_iI_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MaximumMember_zsY3pbAbZOo4">1.60</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> P3Y P2Y3M29D P3Y3M 0.27 0.42 0.18 2.49 405 406 378 424 0.00 0.00 0.10 1.95 0.11 1.60 <p id="xdx_808_eus-gaap--IncomeTaxDisclosureTextBlock_zy60502yox5d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 8 – <span id="xdx_826_zU46hO21CQbg">Deferred Tax Assets and Income Tax Provision</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Deferred Tax Assets</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At December 31, 2021, the Company had net operating loss (“NOL”) carry forwards for Federal income tax purposes of $<span id="xdx_90D_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_c20211231_zPgRMA2nT1N1" title="Net operating loss deferred tax">3,354,000</span> that may be offset against future taxable income. No tax benefit has been reported with respect to these net operating loss carry-forwards in the accompanying financial statements because the Company believes that the realization of the Company’s net deferred tax assets of approximately $<span id="xdx_90A_eus-gaap--DeferredTaxAssetsNet_iI_c20211231_zvXbfmn68Nd2" title="Deferred tax assets,net">2,490,000</span> was not considered more likely than not and accordingly, the potential tax benefits of the net operating loss carry-forwards are fully offset by a full valuation allowance. Federal NOL’s have an indefinite carryover period and state NOL’s begin to expire at 12-31-2040 if not utilized by then.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax assets consist primarily of the tax effect of NOL carry-forwards. The Company has provided a full valuation allowance on the deferred tax assets because of the uncertainty regarding its realization. The valuation allowance increased by approximately $<span id="xdx_901_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20210101__20211231_z9yjCbwdTTG3">2,191,000</span> and $<span id="xdx_908_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20200101__20201231_zkb4L58jc1Yc">93,000</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the reporting periods ended December 31, 2021 and 2020, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zdJMk9qIDvcd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Components of deferred tax assets are as follows as of December 31:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zHKe7DDVcuJ9" style="display: none"> Schedule of Components of Deferred Tax Assets</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 90%; border-collapse: collapse; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_499_20211231_z0KOYlqWLngj" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_490_20201231_z5XeB2KzWwVh" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net deferred tax assets – Non-current:</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--StockBasedCompensation_iI_zD6UZbhDbUB8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Stock-based compensation</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,488,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1313">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxAssetsGross_iI_pp0p0_maDTALNzMTu_zwBygzETyE85" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 62%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected income tax benefit from NOL carry-forwards</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right">1,<span style="font-family: Times New Roman, Times, Serif">002,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">299,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTALNzMTu_zhIvSPEjIHRe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less valuation allowance</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,490,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(299,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pp0p0_mtDTALNzMTu_zm9FSBQphTA8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Deferred tax assets, net of valuation allowance</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1321">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1322">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8AA_zdmu4uPVnPk9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Income Tax Provision in the Statements of Operations</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zij27MLBBbf4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A reconciliation of the federal statutory income tax rate and the effective income tax rate as a percentage of income before income taxes is as follows for the years ended December 31:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zeQL8u9MUfMe" style="display: none"> Schedule of Reconciliation of Income Tax</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 90%; border-collapse: collapse; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 62%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal statutory income tax rate</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98F_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_uPercentage_c20210101__20211231_zZzmm7RIlsh" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Federal statutory income tax rate"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span title="Federal statutory income tax rate">21.0</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_984_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_uPercentage_c20200101__20201231_zVPzbjhK9Tp5" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Federal statutory income tax rate"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.0</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in valuation allowance on net operating loss carry-forwards</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_988_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_uPercentage_c20210101__20211231_zQhs5ekp7TTa" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in valuation allowance on net operating loss carry-forwards"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(21.0</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_uPercentage_c20200101__20201231_zjXTZnzkdqFc" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in valuation allowance on net operating loss carry-forwards"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(21.0</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective income tax rate</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_984_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_uPercentage_c20210101__20211231_zCMNJkxI2m2j" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Effective income tax rate"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_980_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_uPercentage_c20200101__20201231_zvbrxmahrfrl" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Effective income tax rate"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> </table> <p id="xdx_8A9_znGJVPSfcke6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 3354000 2490000 2191000 93000 <p id="xdx_893_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zdJMk9qIDvcd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Components of deferred tax assets are as follows as of December 31:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zHKe7DDVcuJ9" style="display: none"> Schedule of Components of Deferred Tax Assets</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 90%; border-collapse: collapse; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_499_20211231_z0KOYlqWLngj" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_490_20201231_z5XeB2KzWwVh" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net deferred tax assets – Non-current:</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--StockBasedCompensation_iI_zD6UZbhDbUB8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Stock-based compensation</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,488,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1313">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxAssetsGross_iI_pp0p0_maDTALNzMTu_zwBygzETyE85" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 62%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected income tax benefit from NOL carry-forwards</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right">1,<span style="font-family: Times New Roman, Times, Serif">002,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">299,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTALNzMTu_zhIvSPEjIHRe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less valuation allowance</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,490,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(299,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pp0p0_mtDTALNzMTu_zm9FSBQphTA8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Deferred tax assets, net of valuation allowance</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1321">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1322">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 1488000 1 299000 2490000 299000 <p id="xdx_89A_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zij27MLBBbf4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A reconciliation of the federal statutory income tax rate and the effective income tax rate as a percentage of income before income taxes is as follows for the years ended December 31:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zeQL8u9MUfMe" style="display: none"> Schedule of Reconciliation of Income Tax</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 90%; border-collapse: collapse; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 62%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal statutory income tax rate</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98F_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_uPercentage_c20210101__20211231_zZzmm7RIlsh" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Federal statutory income tax rate"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span title="Federal statutory income tax rate">21.0</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_984_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_uPercentage_c20200101__20201231_zVPzbjhK9Tp5" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Federal statutory income tax rate"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.0</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in valuation allowance on net operating loss carry-forwards</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_988_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_uPercentage_c20210101__20211231_zQhs5ekp7TTa" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in valuation allowance on net operating loss carry-forwards"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(21.0</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_uPercentage_c20200101__20201231_zjXTZnzkdqFc" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in valuation allowance on net operating loss carry-forwards"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(21.0</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective income tax rate</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_984_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_uPercentage_c20210101__20211231_zCMNJkxI2m2j" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Effective income tax rate"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_980_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_uPercentage_c20200101__20201231_zvbrxmahrfrl" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Effective income tax rate"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> </table> 0.210 0.210 -0.210 -0.210 0.000 0.000 <p id="xdx_805_eus-gaap--SubsequentEventsTextBlock_zs7WTKL9blDg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 9 – <span id="xdx_829_zr7YuYjEor2b">Subsequent Events</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has evaluated all events that occurred after the balance sheet date through the date when the financial statements were issued to determine if they must be reported. The management of the Company determined the following reportable events:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Technology Development Agreement</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In relation to the Technology Development Agreement entered on December 23, 2021, AIQ has made payments to PICOCEL amounting to approximately $<span id="xdx_90F_ecustom--PaymentsToRelatedParties_iI_c20211223__us-gaap--RelatedPartyTransactionAxis__custom--AIQMember_zbvvRSauuzXf" title="Payments to Related Parties">42,000</span> as of the date of this report.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Notes Payable</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subsequent to December 31, 2021, the Company had made payments to its notes payable holders amounting to $<span id="xdx_908_ecustom--PaymentsToNotesHolders_iI_c20220331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zNimnj35POfg" title="Notes payable paid">25,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 1, 2022, the Company did not pay the outstanding balance of $<span id="xdx_90A_eus-gaap--ConvertibleDebt_iI_c20220301__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zjgDdMpTDP18" title="Convertible debt outstanding">55,000</span> due and payable for a convertible promissory note. As per the promissory note, any unpaid balance as of maturity accrues interest at a rate of <span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentRate_dp_uPercentage_c20220302__20220303__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_za5OM8Fqv2E8" title="Converted instrument, rate">10.0</span>% per annum.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> 42000 25000 55000 0.100 EXCEL 57 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end

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end XML 58 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 59 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 60 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 160 320 1 false 48 0 false 5 false false R1.htm 00000001 - Document - Cover Sheet http://calethos.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets Sheet http://calethos.com/role/BalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://calethos.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations And Comprehensive Loss Sheet http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss Consolidated Statements of Operations And Comprehensive Loss Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statements of Changes in Stockholders' Deficit Sheet http://calethos.com/role/StatementsOfChangesInStockholdersDeficit Consolidated Statements of Changes in Stockholders' Deficit Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statements of Cash Flows Sheet http://calethos.com/role/StatementsOfCashFlows Consolidated Statements of Cash Flows Statements 6 false false R7.htm 00000007 - Disclosure - Organization and Accounting Policies Sheet http://calethos.com/role/OrganizationAndAccountingPolicies Organization and Accounting Policies Notes 7 false false R8.htm 00000008 - Disclosure - Related Party Transactions Sheet http://calethos.com/role/RelatedPartyTransactions Related Party Transactions Notes 8 false false R9.htm 00000009 - Disclosure - Accounts Payable and Accrued Expenses Sheet http://calethos.com/role/AccountsPayableAndAccruedExpenses Accounts Payable and Accrued Expenses Notes 9 false false R10.htm 00000010 - Disclosure - Notes Payable Notes http://calethos.com/role/NotesPayable Notes Payable Notes 10 false false R11.htm 00000011 - Disclosure - Convertible Promissory Notes Notes http://calethos.com/role/ConvertiblePromissoryNotes Convertible Promissory Notes Notes 11 false false R12.htm 00000012 - Disclosure - Commitments and Contingencies Sheet http://calethos.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 12 false false R13.htm 00000013 - Disclosure - Stockholders??? Deficit Sheet http://calethos.com/role/StockholdersDeficit Stockholders??? Deficit Notes 13 false false R14.htm 00000014 - Disclosure - Deferred Tax Assets and Income Tax Provision Sheet http://calethos.com/role/DeferredTaxAssetsAndIncomeTaxProvision Deferred Tax Assets and Income Tax Provision Notes 14 false false R15.htm 00000015 - Disclosure - Subsequent Events Sheet http://calethos.com/role/SubsequentEvents Subsequent Events Notes 15 false false R16.htm 00000016 - Disclosure - Organization and Accounting Policies (Policies) Sheet http://calethos.com/role/OrganizationAndAccountingPoliciesPolicies Organization and Accounting Policies (Policies) Policies http://calethos.com/role/OrganizationAndAccountingPolicies 16 false false R17.htm 00000017 - Disclosure - Organization and Accounting Policies (Tables) Sheet http://calethos.com/role/OrganizationAndAccountingPoliciesTables Organization and Accounting Policies (Tables) Tables http://calethos.com/role/OrganizationAndAccountingPolicies 17 false false R18.htm 00000018 - Disclosure - Accounts Payable and Accrued Expenses (Tables) Sheet http://calethos.com/role/AccountsPayableAndAccruedExpensesTables Accounts Payable and Accrued Expenses (Tables) Tables http://calethos.com/role/AccountsPayableAndAccruedExpenses 18 false false R19.htm 00000019 - Disclosure - Notes Payable (Tables) Notes http://calethos.com/role/NotesPayableTables Notes Payable (Tables) Tables http://calethos.com/role/NotesPayable 19 false false R20.htm 00000020 - Disclosure - Convertible Promissory Notes (Tables) Notes http://calethos.com/role/ConvertiblePromissoryNotesTables Convertible Promissory Notes (Tables) Tables http://calethos.com/role/ConvertiblePromissoryNotes 20 false false R21.htm 00000021 - Disclosure - Commitments and Contingencies (Tables) Sheet http://calethos.com/role/CommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://calethos.com/role/CommitmentsAndContingencies 21 false false R22.htm 00000022 - Disclosure - Stockholders??? Deficit (Tables) Sheet http://calethos.com/role/StockholdersDeficitTables Stockholders??? Deficit (Tables) Tables http://calethos.com/role/StockholdersDeficit 22 false false R23.htm 00000023 - Disclosure - Deferred Tax Assets and Income Tax Provision (Tables) Sheet http://calethos.com/role/DeferredTaxAssetsAndIncomeTaxProvisionTables Deferred Tax Assets and Income Tax Provision (Tables) Tables http://calethos.com/role/DeferredTaxAssetsAndIncomeTaxProvision 23 false false R24.htm 00000024 - Disclosure - Schedule of Income and Loss Per Share Anti-dilutive (Details) Sheet http://calethos.com/role/ScheduleOfIncomeAndLossPerShareAnti-dilutiveDetails Schedule of Income and Loss Per Share Anti-dilutive (Details) Details 24 false false R25.htm 00000025 - Disclosure - Organization and Accounting Policies (Details Narrative) Sheet http://calethos.com/role/OrganizationAndAccountingPoliciesDetailsNarrative Organization and Accounting Policies (Details Narrative) Details http://calethos.com/role/OrganizationAndAccountingPoliciesTables 25 false false R26.htm 00000026 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://calethos.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://calethos.com/role/RelatedPartyTransactions 26 false false R27.htm 00000027 - Disclosure - Schedule of Accounts Payable and Accrued Expenses (Details) Sheet http://calethos.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails Schedule of Accounts Payable and Accrued Expenses (Details) Details 27 false false R28.htm 00000028 - Disclosure - Schedule of Accrued Interest (Details) Sheet http://calethos.com/role/ScheduleOfAccruedInterestDetails Schedule of Accrued Interest (Details) Details 28 false false R29.htm 00000029 - Disclosure - Schedule of Notes Payable (Details) Notes http://calethos.com/role/ScheduleOfNotesPayableDetails Schedule of Notes Payable (Details) Details 29 false false R30.htm 00000030 - Disclosure - Notes Payable (Details Narrative) Notes http://calethos.com/role/NotesPayableDetailsNarrative Notes Payable (Details Narrative) Details http://calethos.com/role/NotesPayableTables 30 false false R31.htm 00000031 - Disclosure - Schedule of Convertible Promissory Notes (Details) Notes http://calethos.com/role/ScheduleOfConvertiblePromissoryNotesDetails Schedule of Convertible Promissory Notes (Details) Details 31 false false R32.htm 00000032 - Disclosure - Schedule of Potential Future Shares Issuance of Conversion Notes (Details) Notes http://calethos.com/role/ScheduleOfPotentialFutureSharesIssuanceOfConversionNotesDetails Schedule of Potential Future Shares Issuance of Conversion Notes (Details) Details 32 false false R33.htm 00000033 - Disclosure - Convertible Promissory Notes (Details Narrative) Notes http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative Convertible Promissory Notes (Details Narrative) Details http://calethos.com/role/ConvertiblePromissoryNotesTables 33 false false R34.htm 00000034 - Disclosure - Schedule of Remaining Payments (Details) Sheet http://calethos.com/role/ScheduleOfRemainingPaymentsDetails Schedule of Remaining Payments (Details) Details 34 false false R35.htm 00000035 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://calethos.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://calethos.com/role/CommitmentsAndContingenciesTables 35 false false R36.htm 00000036 - Disclosure - Schedule of Company Restricted Stock Awards (Details) Sheet http://calethos.com/role/ScheduleOfCompanyRestrictedStockAwardsDetails Schedule of Company Restricted Stock Awards (Details) Details 36 false false R37.htm 00000037 - Disclosure - Schedule of Stock Option Activities (Details) Sheet http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails Schedule of Stock Option Activities (Details) Details 37 false false R38.htm 00000038 - Disclosure - Schedule of Warrants Activity (Details) Sheet http://calethos.com/role/ScheduleOfWarrantsActivityDetails Schedule of Warrants Activity (Details) Details 38 false false R39.htm 00000039 - Disclosure - Schedule of Fair Value of Warrants (Details) Sheet http://calethos.com/role/ScheduleOfFairValueOfWarrantsDetails Schedule of Fair Value of Warrants (Details) Details 39 false false R40.htm 00000040 - Disclosure - Stockholders??? Deficit (Details Narrative) Sheet http://calethos.com/role/StockholdersDeficitDetailsNarrative Stockholders??? Deficit (Details Narrative) Details http://calethos.com/role/StockholdersDeficitTables 40 false false R41.htm 00000041 - Disclosure - Schedule of Components of Deferred Tax Assets (Details) Sheet http://calethos.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails Schedule of Components of Deferred Tax Assets (Details) Details 41 false false R42.htm 00000042 - Disclosure - Schedule of Reconciliation of Income Tax (Details) Sheet http://calethos.com/role/ScheduleOfReconciliationOfIncomeTaxDetails Schedule of Reconciliation of Income Tax (Details) Details 42 false false R43.htm 00000043 - Disclosure - Deferred Tax Assets and Income Tax Provision (Details Narrative) Sheet http://calethos.com/role/DeferredTaxAssetsAndIncomeTaxProvisionDetailsNarrative Deferred Tax Assets and Income Tax Provision (Details Narrative) Details http://calethos.com/role/DeferredTaxAssetsAndIncomeTaxProvisionTables 43 false false R44.htm 00000044 - Disclosure - Subsequent Events (Details Narrative) Sheet http://calethos.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://calethos.com/role/SubsequentEvents 44 false false All Reports Book All Reports form10-k.htm buuz-20211231.xsd buuz-20211231_cal.xml buuz-20211231_def.xml buuz-20211231_lab.xml buuz-20211231_pre.xml ex10-12.htm ex14.htm ex31-1.htm ex31-2.htm ex32-1.htm http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 63 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form10-k.htm": { "axisCustom": 0, "axisStandard": 14, "contextCount": 160, "dts": { "calculationLink": { "local": [ "buuz-20211231_cal.xml" ] }, "definitionLink": { "local": [ "buuz-20211231_def.xml" ] }, "inline": { "local": [ "form10-k.htm" ] }, "labelLink": { "local": [ "buuz-20211231_lab.xml" ] }, "presentationLink": { "local": [ "buuz-20211231_pre.xml" ] }, "schema": { "local": [ "buuz-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 474, "entityCount": 1, "hidden": { "http://calethos.com/20211231": 93, "http://fasb.org/us-gaap/2021-01-31": 127, "http://xbrl.sec.gov/dei/2021q4": 3, "total": 223 }, "keyCustom": 104, "keyStandard": 216, "memberCustom": 25, "memberStandard": 23, "nsprefix": "BUUZ", "nsuri": "http://calethos.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://calethos.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "BUUZ:NotesPayableDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - Notes Payable", "role": "http://calethos.com/role/NotesPayable", "shortName": "Notes Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "BUUZ:NotesPayableDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - Convertible Promissory Notes", "role": "http://calethos.com/role/ConvertiblePromissoryNotes", "shortName": "Convertible Promissory Notes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - Commitments and Contingencies", "role": "http://calethos.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - Stockholders\u2019 Deficit", "role": "http://calethos.com/role/StockholdersDeficit", "shortName": "Stockholders\u2019 Deficit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - Deferred Tax Assets and Income Tax Provision", "role": "http://calethos.com/role/DeferredTaxAssetsAndIncomeTaxProvision", "shortName": "Deferred Tax Assets and Income Tax Provision", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - Subsequent Events", "role": "http://calethos.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "BUUZ:ChangeInControlPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - Organization and Accounting Policies (Policies)", "role": "http://calethos.com/role/OrganizationAndAccountingPoliciesPolicies", "shortName": "Organization and Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "BUUZ:ChangeInControlPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - Organization and Accounting Policies (Tables)", "role": "http://calethos.com/role/OrganizationAndAccountingPoliciesTables", "shortName": "Organization and Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - Accounts Payable and Accrued Expenses (Tables)", "role": "http://calethos.com/role/AccountsPayableAndAccruedExpensesTables", "shortName": "Accounts Payable and Accrued Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "BUUZ:NotesPayableDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - Notes Payable (Tables)", "role": "http://calethos.com/role/NotesPayableTables", "shortName": "Notes Payable (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "BUUZ:NotesPayableDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Consolidated Balance Sheets", "role": "http://calethos.com/role/BalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - Convertible Promissory Notes (Tables)", "role": "http://calethos.com/role/ConvertiblePromissoryNotesTables", "shortName": "Convertible Promissory Notes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "BUUZ:TechnologyDevelopmentAgreementTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - Commitments and Contingencies (Tables)", "role": "http://calethos.com/role/CommitmentsAndContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "BUUZ:TechnologyDevelopmentAgreementTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - Stockholders\u2019 Deficit (Tables)", "role": "http://calethos.com/role/StockholdersDeficitTables", "shortName": "Stockholders\u2019 Deficit (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - Deferred Tax Assets and Income Tax Provision (Tables)", "role": "http://calethos.com/role/DeferredTaxAssetsAndIncomeTaxProvisionTables", "shortName": "Deferred Tax Assets and Income Tax Provision (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - Schedule of Income and Loss Per Share Anti-dilutive (Details)", "role": "http://calethos.com/role/ScheduleOfIncomeAndLossPerShareAnti-dilutiveDetails", "shortName": "Schedule of Income and Loss Per Share Anti-dilutive (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - Organization and Accounting Policies (Details Narrative)", "role": "http://calethos.com/role/OrganizationAndAccountingPoliciesDetailsNarrative", "shortName": "Organization and Accounting Policies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "lang": null, "name": "us-gaap:CashFDICInsuredAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromRelatedPartyDebt", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - Related Party Transactions (Details Narrative)", "role": "http://calethos.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "Related Party Transactions (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromRelatedPartyDebt", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - Schedule of Accounts Payable and Accrued Expenses (Details)", "role": "http://calethos.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails", "shortName": "Schedule of Accounts Payable and Accrued Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - Schedule of Accrued Interest (Details)", "role": "http://calethos.com/role/ScheduleOfAccruedInterestDetails", "shortName": "Schedule of Accrued Interest (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesPayable", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - Schedule of Notes Payable (Details)", "role": "http://calethos.com/role/ScheduleOfNotesPayableDetails", "shortName": "Schedule of Notes Payable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "BUUZ:NotesPayableDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "lang": null, "name": "BUUZ:NotesPayableAdditions", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)", "role": "http://calethos.com/role/BalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "lang": null, "name": "us-gaap:PreferredStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InterestPayableCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - Notes Payable (Details Narrative)", "role": "http://calethos.com/role/NotesPayableDetailsNarrative", "shortName": "Notes Payable (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "BUUZ:NotesPayableDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-08-31_custom_PromissoryNoteMember", "decimals": "0", "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ConvertibleDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31_us-gaap_ConvertibleNotesPayableMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - Schedule of Convertible Promissory Notes (Details)", "role": "http://calethos.com/role/ScheduleOfConvertiblePromissoryNotesDetails", "shortName": "Schedule of Convertible Promissory Notes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ConvertibleDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2019-12-31_us-gaap_ConvertibleNotesPayableMember", "decimals": "0", "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "BUUZ:ScheduleOfPotentialFutureSharesIssuanceOfConversionNotesTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31_us-gaap_ConvertibleNotesPayableMember", "decimals": "0", "first": true, "lang": null, "name": "BUUZ:DebtInstrumentConversionNotePrincipalAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - Schedule of Potential Future Shares Issuance of Conversion Notes (Details)", "role": "http://calethos.com/role/ScheduleOfPotentialFutureSharesIssuanceOfConversionNotesDetails", "shortName": "Schedule of Potential Future Shares Issuance of Conversion Notes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "BUUZ:ScheduleOfPotentialFutureSharesIssuanceOfConversionNotesTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31_us-gaap_ConvertibleNotesPayableMember", "decimals": "0", "first": true, "lang": null, "name": "BUUZ:DebtInstrumentConversionNotePrincipalAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromConvertibleDebt", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - Convertible Promissory Notes (Details Narrative)", "role": "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative", "shortName": "Convertible Promissory Notes (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "lang": "en-US", "name": "us-gaap:DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "BUUZ:TechnologyDevelopmentAgreementTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "BUUZ:PaymentsToBeMadeUponContractAndServiceDelivery", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - Schedule of Remaining Payments (Details)", "role": "http://calethos.com/role/ScheduleOfRemainingPaymentsDetails", "shortName": "Schedule of Remaining Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "BUUZ:TechnologyDevelopmentAgreementTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "BUUZ:PaymentsToBeMadeUponContractAndServiceDelivery", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-012022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LossContingencyDomicileOfLitigation", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - Commitments and Contingencies (Details Narrative)", "role": "http://calethos.com/role/CommitmentsAndContingenciesDetailsNarrative", "shortName": "Commitments and Contingencies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-012022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LossContingencyDomicileOfLitigation", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31_us-gaap_RestrictedStockMember", "decimals": "INF", "first": true, "lang": null, "name": "BUUZ:GrantDateFairValueShares", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - Schedule of Company Restricted Stock Awards (Details)", "role": "http://calethos.com/role/ScheduleOfCompanyRestrictedStockAwardsDetails", "shortName": "Schedule of Company Restricted Stock Awards (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31_us-gaap_RestrictedStockMember", "decimals": "INF", "first": true, "lang": null, "name": "BUUZ:GrantDateFairValueShares", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - Schedule of Stock Option Activities (Details)", "role": "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails", "shortName": "Schedule of Stock Option Activities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2019-12-31", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - Schedule of Warrants Activity (Details)", "role": "http://calethos.com/role/ScheduleOfWarrantsActivityDetails", "shortName": "Schedule of Warrants Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "lang": "en-US", "name": "BUUZ:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-09-15", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000039 - Disclosure - Schedule of Fair Value of Warrants (Details)", "role": "http://calethos.com/role/ScheduleOfFairValueOfWarrantsDetails", "shortName": "Schedule of Fair Value of Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31_us-gaap_MeasurementInputExpectedTermMember", "decimals": null, "lang": "en-US", "name": "us-gaap:WarrantsAndRightsOutstandingTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfessionalFees", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Consolidated Statements of Operations And Comprehensive Loss", "role": "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss", "shortName": "Consolidated Statements of Operations And Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "BUUZ:AuthorizedToIssueShares", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000040 - Disclosure - Stockholders\u2019 Deficit (Details Narrative)", "role": "http://calethos.com/role/StockholdersDeficitDetailsNarrative", "shortName": "Stockholders\u2019 Deficit (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "BUUZ:AuthorizedToIssueShares", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "BUUZ:StockBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000041 - Disclosure - Schedule of Components of Deferred Tax Assets (Details)", "role": "http://calethos.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails", "shortName": "Schedule of Components of Deferred Tax Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "BUUZ:StockBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Percentage", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000042 - Disclosure - Schedule of Reconciliation of Income Tax (Details)", "role": "http://calethos.com/role/ScheduleOfReconciliationOfIncomeTaxDetails", "shortName": "Schedule of Reconciliation of Income Tax (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Percentage", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000043 - Disclosure - Deferred Tax Assets and Income Tax Provision (Details Narrative)", "role": "http://calethos.com/role/DeferredTaxAssetsAndIncomeTaxProvisionDetailsNarrative", "shortName": "Deferred Tax Assets and Income Tax Provision (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-03-31_us-gaap_SubsequentEventMember", "decimals": "0", "first": true, "lang": null, "name": "BUUZ:PaymentsToNotesHolders", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000044 - Disclosure - Subsequent Events (Details Narrative)", "role": "http://calethos.com/role/SubsequentEventsDetailsNarrative", "shortName": "Subsequent Events (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-03-31_us-gaap_SubsequentEventMember", "decimals": "0", "first": true, "lang": null, "name": "BUUZ:PaymentsToNotesHolders", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2019-12-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Consolidated Statements of Changes in Stockholders' Deficit", "role": "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit", "shortName": "Consolidated Statements of Changes in Stockholders' Deficit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2019-12-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Consolidated Statements of Cash Flows", "role": "http://calethos.com/role/StatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "lang": null, "name": "us-gaap:AmortizationOfDebtDiscountPremium", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - Organization and Accounting Policies", "role": "http://calethos.com/role/OrganizationAndAccountingPolicies", "shortName": "Organization and Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - Related Party Transactions", "role": "http://calethos.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - Accounts Payable and Accrued Expenses", "role": "http://calethos.com/role/AccountsPayableAndAccruedExpenses", "shortName": "Accounts Payable and Accrued Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 48, "tag": { "BUUZ_AIQMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AIQ [Member]", "label": "AIQ [Member]" } } }, "localname": "AIQMember", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesDetailsNarrative", "http://calethos.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "BUUZ_AccretionOfCompensationCostForRestrictedStockAwards": { "auth_ref": [], "calculation": { "http://calethos.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Accretion of compensation cost for restricted stock awards.", "label": "Accretion of compensation cost for restricted stock awards" } } }, "localname": "AccretionOfCompensationCostForRestrictedStockAwards", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "BUUZ_AccretionShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accretion Shares.", "label": "Accretion, shares" } } }, "localname": "AccretionShares", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfCompanyRestrictedStockAwardsDetails" ], "xbrltype": "sharesItemType" }, "BUUZ_AdjustmentsToAdditionalPaidInCapitalRelativeFairValueOfWarrantsIssuedWithConvertiblePromissoryNotes": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Relative fair value of warrants issued with convertible promissory notes.", "label": "Relative fair value of warrants issued with convertible promissory note" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalRelativeFairValueOfWarrantsIssuedWithConvertiblePromissoryNotes", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "BUUZ_AuthorizedToIssueShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of authorized capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies.", "label": "Authorized to issue shares" } } }, "localname": "AuthorizedToIssueShares", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "BUUZ_BorrowerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Borrower [Member]", "label": "Borrower [Member]" } } }, "localname": "BorrowerMember", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "BUUZ_ChangeInControlPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Change in Control [Policy Text Block]", "label": "Amendments to Certificate of Incorporation" } } }, "localname": "ChangeInControlPolicyTextBlock", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "BUUZ_CommonStockIssuedForAccruedCompensation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Common stock issued for accrued compensation.", "label": "Common stock issued for accrued compensation" } } }, "localname": "CommonStockIssuedForAccruedCompensation", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "BUUZ_CommonStockIssuedForDebtForgiveness": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Common stock issued for debt forgiveness.", "label": "Common stock issued for debt forgiveness" } } }, "localname": "CommonStockIssuedForDebtForgiveness", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "BUUZ_ConsultantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consultants [Member]", "label": "Consultants [Member]" } } }, "localname": "ConsultantsMember", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "BUUZ_ConversionOfSeriesPreferredStockToConvertiblePromissoryNotes": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Conversion of series A preferred stock to convertible promissory notes.", "label": "ConversionOfSeriesPreferredStockToConvertiblePromissoryNotes", "verboseLabel": "Conversion of series A preferred stock to convertible promissory notes" } } }, "localname": "ConversionOfSeriesPreferredStockToConvertiblePromissoryNotes", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "BUUZ_ConversionRateAdjustmentValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Conversion rate adjustment, value.", "label": "Conversion rate adjustment, value" } } }, "localname": "ConversionRateAdjustmentValue", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "BUUZ_ConvertiblePromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Promissory Note [Member]", "label": "Convertible Promissory Note [Member]" } } }, "localname": "ConvertiblePromissoryNoteMember", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "BUUZ_ConvertiblePromissoryNoteOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Promissory Note One [Member]", "label": "Convertible Promissory Note One [Member]" } } }, "localname": "ConvertiblePromissoryNoteOneMember", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "BUUZ_ConvertiblePromissoryNoteTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Promissory Note Two [Member]", "label": "Convertible Promissory Note Two [Member]" } } }, "localname": "ConvertiblePromissoryNoteTwoMember", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "BUUZ_ConvertiblePromissoryNotes": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Convertible promissory notes.", "label": "Convertible promissory notes" } } }, "localname": "ConvertiblePromissoryNotes", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfAccruedInterestDetails" ], "xbrltype": "monetaryItemType" }, "BUUZ_ConvertiblePromissoryNotesAndAccruedInterestMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Promissory Notes and Accrued Interest [Member]", "label": "Convertible Promissory Notes and Accrued Interest [Member]" } } }, "localname": "ConvertiblePromissoryNotesAndAccruedInterestMember", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfIncomeAndLossPerShareAnti-dilutiveDetails" ], "xbrltype": "domainItemType" }, "BUUZ_DebtInstrumentAdditions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt instrument additions.", "label": "DebtInstrumentAdditions", "verboseLabel": "Additions" } } }, "localname": "DebtInstrumentAdditions", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfConvertiblePromissoryNotesDetails" ], "xbrltype": "monetaryItemType" }, "BUUZ_DebtInstrumentConversionNote": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt instrument conversion note.", "label": "Total" } } }, "localname": "DebtInstrumentConversionNote", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfPotentialFutureSharesIssuanceOfConversionNotesDetails" ], "xbrltype": "monetaryItemType" }, "BUUZ_DebtInstrumentConversionNoteInterestExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt instrument conversion note interest expenses.", "label": "Interest" } } }, "localname": "DebtInstrumentConversionNoteInterestExpenses", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfPotentialFutureSharesIssuanceOfConversionNotesDetails" ], "xbrltype": "monetaryItemType" }, "BUUZ_DebtInstrumentConversionNotePrincipalAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt instrument conversion note principal amount.", "label": "Principal" } } }, "localname": "DebtInstrumentConversionNotePrincipalAmount", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfPotentialFutureSharesIssuanceOfConversionNotesDetails" ], "xbrltype": "monetaryItemType" }, "BUUZ_DebtInstrumentPotentialFutureShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument potential future share.", "label": "Potential future share" } } }, "localname": "DebtInstrumentPotentialFutureShare", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfPotentialFutureSharesIssuanceOfConversionNotesDetails" ], "xbrltype": "sharesItemType" }, "BUUZ_DebtInstrumentUnamortizedDiscountAdditions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt instrument unamortized discount additions.", "label": "DebtInstrumentUnamortizedDiscountAdditions", "verboseLabel": "Additions" } } }, "localname": "DebtInstrumentUnamortizedDiscountAdditions", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfConvertiblePromissoryNotesDetails" ], "xbrltype": "monetaryItemType" }, "BUUZ_DebtInstrumentUnamortizedDiscountAmortization": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt instrument unamortized discount amortization.", "label": "Amortization" } } }, "localname": "DebtInstrumentUnamortizedDiscountAmortization", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfConvertiblePromissoryNotesDetails" ], "xbrltype": "monetaryItemType" }, "BUUZ_DebtPremiumOnIssuanceConvertiblePromissoryNotesForConversionOfConvertiblePreferredStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt premium on issuance convertible promissory notes for conversion of series A convertible preferred stock.", "label": "Fair value and face value of notes", "verboseLabel": "Debt premium on issuance of convertible promissory notes for conversion of series A convertible preferred stock" } } }, "localname": "DebtPremiumOnIssuanceConvertiblePromissoryNotesForConversionOfConvertiblePreferredStock", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "BUUZ_DeferredCompensationAccretion": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred compensation accretion.", "label": "Deferred compensation accretion" } } }, "localname": "DeferredCompensationAccretion", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfCompanyRestrictedStockAwardsDetails" ], "xbrltype": "monetaryItemType" }, "BUUZ_DeferredCompensationGrantDateFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred compensation grant date fair value.", "label": "Deferred compensation grant date fair value" } } }, "localname": "DeferredCompensationGrantDateFairValue", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfCompanyRestrictedStockAwardsDetails" ], "xbrltype": "monetaryItemType" }, "BUUZ_DisclosureNotesPayableAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes Payable", "verboseLabel": "Schedule Of Notes Payable" } } }, "localname": "DisclosureNotesPayableAbstract", "nsuri": "http://calethos.com/20211231", "xbrltype": "stringItemType" }, "BUUZ_FairValueOfWarrantsIssuedForExtinguishmentOfConvertiblePreferredStock": { "auth_ref": [], "calculation": { "http://calethos.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of warrants issued for extinguishment of convertible preferred stock.", "label": "Fair value of warrants issued for extinguishment of convertible preferred stock" } } }, "localname": "FairValueOfWarrantsIssuedForExtinguishmentOfConvertiblePreferredStock", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "BUUZ_FairValueOfWarrantsIssuedWithConversionOfConvertiblePreferredStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of warrants issued with the conversion of series A convertible preferred stock.", "label": "Fair value of warrants issued with conversion of convertible preferred stock", "verboseLabel": "Fair value of warrants issued with the conversion of series A convertible preferred stock" } } }, "localname": "FairValueOfWarrantsIssuedWithConversionOfConvertiblePreferredStock", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "BUUZ_FinancingCosts": { "auth_ref": [], "calculation": { "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Financing costs.", "label": "Financing costs" } } }, "localname": "FinancingCosts", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "BUUZ_GoingConcernAndLiquidityPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Going Concern and Liquidity [Policy Text Block]", "label": "Going Concern and Liquidity" } } }, "localname": "GoingConcernAndLiquidityPolicyTextBlock", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "BUUZ_GrantDateFairValueShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Grant date fair value shares.", "label": "Grant date fair value, shares" } } }, "localname": "GrantDateFairValueShares", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfCompanyRestrictedStockAwardsDetails" ], "xbrltype": "sharesItemType" }, "BUUZ_IndebtednessForBorrowedMoneyMaximumLimit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Indebtedness for borrowed money maximum limit.", "label": "Indebtedness for borrowed money maximum limit" } } }, "localname": "IndebtednessForBorrowedMoneyMaximumLimit", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "BUUZ_LetterofUnderstandingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Letter of Understanding [Member]", "label": "Letter of Understanding [Member]" } } }, "localname": "LetterofUnderstandingMember", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "BUUZ_LossOnExtinguishmentOfConvertiblePreferredStock": { "auth_ref": [], "calculation": { "http://calethos.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Loss on extinguishment of convertible preferred stock.", "label": "Loss on extinguishment of convertible preferred stock" } } }, "localname": "LossOnExtinguishmentOfConvertiblePreferredStock", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "BUUZ_LossOnExtinguishmentOfSeriesConvertiblePreferredStock": { "auth_ref": [], "calculation": { "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Loss on extinguishment of series A convertible preferred stock.", "label": "LossOnExtinguishmentOfSeriesConvertiblePreferredStock", "negatedLabel": "Loss on extinguishment of series A convertible preferred stock" } } }, "localname": "LossOnExtinguishmentOfSeriesConvertiblePreferredStock", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "BUUZ_MOneAdvisorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "M1 Advisors [Member]", "label": "M1 Advisors [Member]" } } }, "localname": "MOneAdvisorsMember", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "BUUZ_NewConsultingAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "New Consulting Agreement [Member]", "label": "New Consulting Agreement [Member]" } } }, "localname": "NewConsultingAgreementMember", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "BUUZ_NotesPayableAdditions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Notes payable additions.", "label": "Additions" } } }, "localname": "NotesPayableAdditions", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "BUUZ_NotesPayableDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Notes payable disclosure [Text Block]", "label": "NotesPayableDisclosureTextBlock", "verboseLabel": "Notes Payable" } } }, "localname": "NotesPayableDisclosureTextBlock", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/NotesPayable" ], "xbrltype": "textBlockItemType" }, "BUUZ_OriginalIssueDiscountRecordedOnConvertiblePromissoryNotes": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Original issue discount recorded on convertible promissory notes.", "label": "Original issue discount recorded on convertible promissory notes" } } }, "localname": "OriginalIssueDiscountRecordedOnConvertiblePromissoryNotes", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "BUUZ_OtherAssetsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Assets [Policy Text Block]", "label": "Other Assets" } } }, "localname": "OtherAssetsPolicyTextBlock", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "BUUZ_PICOCELCoLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "PICOCEL Co Ltd [Member]", "label": "PICOCEL Co Ltd [Member]" } } }, "localname": "PICOCELCoLtdMember", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://calethos.com/role/ScheduleOfRemainingPaymentsDetails" ], "xbrltype": "domainItemType" }, "BUUZ_PaymentForOtherAssets": { "auth_ref": [], "calculation": { "http://calethos.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Payment for other assets.", "label": "Payment for other assets" } } }, "localname": "PaymentForOtherAssets", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "BUUZ_PaymentsForCollaborators": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments for Collaborators.", "label": "[custom:PaymentsForCollaborators]" } } }, "localname": "PaymentsForCollaborators", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "BUUZ_PaymentsToBeMadeUponCompletionOfInitialServiceDelivery": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments to be made upon completion of initial service delivery.", "label": "Payments upon delivery board" } } }, "localname": "PaymentsToBeMadeUponCompletionOfInitialServiceDelivery", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfRemainingPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "BUUZ_PaymentsToBeMadeUponContractAndServiceDelivery": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments to be made upon contract and service delivery.", "label": "PaymentsToBeMadeUponContractAndServiceDelivery", "verboseLabel": "Total" } } }, "localname": "PaymentsToBeMadeUponContractAndServiceDelivery", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfRemainingPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "BUUZ_PaymentsToBeMadeUponSigningContract": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments to be made upon signing contract.", "label": "Payments to be signing contract" } } }, "localname": "PaymentsToBeMadeUponSigningContract", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfRemainingPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "BUUZ_PaymentsToNotesHolders": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments to Notes Holders.", "label": "Notes payable paid" } } }, "localname": "PaymentsToNotesHolders", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "BUUZ_PaymentsToRelatedParties": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Payments to Related Parties.", "label": "Payments to Related Parties" } } }, "localname": "PaymentsToRelatedParties", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "BUUZ_PrepaidExpensePolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prepaid expense [Policy Text Block]", "label": "Prepaid Expense" } } }, "localname": "PrepaidExpensePolicyTextBlock", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "BUUZ_PromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Promissory Note [Member]", "label": "Promissory Note [Member]" } } }, "localname": "PromissoryNoteMember", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "BUUZ_PromissoryNoteOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Promissory Note One [Member]", "label": "Promissory Note One [Member]" } } }, "localname": "PromissoryNoteOneMember", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "BUUZ_PromissoryNoteThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Promissory Note Three [Member]", "label": "Promissory Note Three [Member]" } } }, "localname": "PromissoryNoteThreeMember", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "BUUZ_PromissoryNoteTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Promissory Note Two [Member]", "label": "Promissory Note Two [Member]" } } }, "localname": "PromissoryNoteTwoMember", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "BUUZ_ReductionAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Reduction amount.", "label": "Reduction amount" } } }, "localname": "ReductionAmount", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "BUUZ_RelatedPartiesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Parties [Policy Text Block]", "label": "Related Parties" } } }, "localname": "RelatedPartiesPolicyTextBlock", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "BUUZ_RelativeFairValueOfWarrantsIssuedWithConvertiblePromissoryNote": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Relative fair value of warrants issued with convertible promissory note.", "label": "RelativeFairValueOfWarrantsIssuedWithConvertiblePromissoryNote", "verboseLabel": "Relative fair value of warrants issued with convertible promissory note" } } }, "localname": "RelativeFairValueOfWarrantsIssuedWithConvertiblePromissoryNote", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "BUUZ_RelativeFairValueOfWarrantsIssuedWithConvertiblePromissoryNotes": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Relative fair value of warrants issued with convertible promissory notes.", "label": "Relative fair value of warrants issued with convertible promissory notes" } } }, "localname": "RelativeFairValueOfWarrantsIssuedWithConvertiblePromissoryNotes", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "BUUZ_RemainingLiabilityPaidForCash": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Remaining liability paid for cash.", "label": "Remaining cash liability" } } }, "localname": "RemainingLiabilityPaidForCash", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "BUUZ_RestrictedStockAwardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted Stock Award [Member]", "label": "Restricted Stock Award [Member]" } } }, "localname": "RestrictedStockAwardMember", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfIncomeAndLossPerShareAnti-dilutiveDetails" ], "xbrltype": "domainItemType" }, "BUUZ_ScheduleOfPotentialFutureSharesIssuanceOfConversionNotesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of potential future shares issuance of conversion notes [Table Text Block]", "label": "Schedule of Potential Future Shares Issuance of Conversion Notes" } } }, "localname": "ScheduleOfPotentialFutureSharesIssuanceOfConversionNotesTableTextBlock", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesTables" ], "xbrltype": "textBlockItemType" }, "BUUZ_SeriesAConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A Convertible Preferred Stock [Member]", "label": "Series A Convertible Preferred Stock [Member]" } } }, "localname": "SeriesAConvertiblePreferredStockMember", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/BalanceSheets", "http://calethos.com/role/BalanceSheetsParenthetical", "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit", "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "BUUZ_SeriesAWarrantsIssuedWithConvertiblePromissoryNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A Warrants Issued with Convertible Promissory Notes [Member]", "label": "Series A Warrants Issued with Convertible Promissory Notes [Member]" } } }, "localname": "SeriesAWarrantsIssuedWithConvertiblePromissoryNotesMember", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfIncomeAndLossPerShareAnti-dilutiveDetails" ], "xbrltype": "domainItemType" }, "BUUZ_SeriesBWarrantsToBeIssuedUponExerciseOfSeriesAWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series B Warrants to Be Issued Upon Exercise of Series A Warrant [Member]", "label": "Series B Warrants to Be Issued Upon Exercise of Series A Warrant [Member]" } } }, "localname": "SeriesBWarrantsToBeIssuedUponExerciseOfSeriesAWarrantMember", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfIncomeAndLossPerShareAnti-dilutiveDetails" ], "xbrltype": "domainItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award fair value of commonStock.", "label": "Fair value of common stock" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonStock", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueVested": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award non option equity instruments aggregate intrinsic value vested.", "label": "Aggregate intrinsic value, Vested, Ending of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueVested", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueVestedAndExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award non option equity instruments aggregate intrinsic value vested and exercisable.", "label": "Aggregate intrinsic value, Vested and Exercisable, Ending of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueVestedAndExercisable", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expired", "label": "Number of warrants issued, Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpired", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodAggregateIntrinsicForfeited": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ShareBased compensation arangement by shareBased payment award non option equity instruments grants in period aggregate intrinsic forfeited.", "label": "Aggregate intrinsic value, forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodAggregateIntrinsicForfeited", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodAggregateIntrinsicValueExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Grants In Period Aggregate Intrinsic Value Exercised", "label": "Aggregate intrinsic value, Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodAggregateIntrinsicValueExercised", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodAggregateIntrinsicValueExpired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award non option equity instruments grants in period aggregate intrinsic value expired.", "label": "Aggregate intrinsic value, Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodAggregateIntrinsicValueExpired", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodAggregateIntrinsicValueGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award non option equity instruments grants in period aggregate intrinsic value granted.", "label": "Aggregate intrinsic value, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodAggregateIntrinsicValueGranted", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of non-option equity.", "label": "Weighted Average Strike Price/Share, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award non option equity instruments weighted average grant fair value.", "label": "Weighted Average Grant Date Fair Value/Share, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantFairValue", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantFairValueExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award non option equity instruments weighted average grant fair value exercised.", "label": "Weighted Average Grant Date Fair Value/Share, Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantFairValueExercised", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantFairValueExpired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award non option equity instruments weighted average grant fair value expired.", "label": "Weighted Average Grant Date Fair Value/Share, Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantFairValueExpired", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantFairValueForfeited": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ShareBased compensation arrangement by shareBased payment award non option equity instruments grants in period weighted average grant fair value forfeited.", "label": "Weighted Average Grant Date Fair Value/Share, forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantFairValueForfeited", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Remaining Contractual Term", "label": "Weighted Average Remaining Contractual Term (Years), Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageRemainingContractualTerm", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "durationItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAggregateIntrinsicValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Aggregate Intrinsic Value.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAggregateIntrinsicValue", "periodEndLabel": "Aggregate intrinsic value, Ending of period", "periodStartLabel": "Aggregate intrinsic value, Beginning of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAggregateIntrinsicValue", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock non-option equity plan.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice", "periodEndLabel": "Weighted Average Strike Price/Share, Outstanding, Ending of period", "periodStartLabel": "Weighted Average Strike Price/Share, Outstanding, Beginning of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageGrantFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award non option equity instruments weighted average grant fair value.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageGrantFairValue", "periodEndLabel": "Weighted Average Grant Date Fair Value/Share, Ending of period", "periodStartLabel": "Weighted Average Grant Date Fair Value/Share, Beginning of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageGrantFairValue", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based paymentaward non option equity instruments weighted average Remaining ContractualTerm.", "label": "Weighted Average Remaining Contractual Term (Years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "durationItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVested": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Vested And Exercisable", "label": "Number of warrants issued, Vested, Ending of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVested", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Vested And Exercisable", "label": "Number of warrants issued, Vested and Exercisable, Ending of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExercisable", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantFairValueVested": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award non option equity instruments weighted average grant fair value vested.", "label": "Weighted Average Grant Date Fair Value/Share, Vested, Ending of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantFairValueVested", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantFairValueVestedAndExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award non option equity instruments weighted average grant fair value vested and exercisable.", "label": "Weighted Average Grant Date Fair Value/Share, Vested and Exercisable, Ending of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantFairValueVestedAndExercisable", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceVested": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based paymentaward non option equity instruments weighted average price vested.", "label": "Weighted Average Strike Price/Share, Unvested, Ending of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceVested", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceVestedAndExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangements by share based payment award non options expired in period weighted average price vested and exerciable.", "label": "Weighted Average Strike Price/Share, Vested and Exercisable, Ending of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceVestedAndExercisable", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageRemainingContractualTermUnvestedAndExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term unvested and exercisable.", "label": "Weighted Average Remaining Contractual Term (Years), Vested and Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageRemainingContractualTermUnvestedAndExercisable", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "durationItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageRemainingContracutalTermUnvested": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contracutal term unvested.", "label": "Weighted Average Remaining Contractual Term (Years), Unvested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageRemainingContracutalTermUnvested", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "durationItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceRangePerShareOutstandingBeginning": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range Per Share, Outstanding, Beginning", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceRangePerShareOutstandingBeginning", "periodStartLabel": "Exercise Price Range Per Share, Outstanding, Beginning of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceRangePerShareOutstandingBeginning", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceRangePerShareOutstandingEnding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range Per Share, Outstanding, Ending.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceRangePerShareOutstandingEnding", "periodEndLabel": "Exercise Price Range Per Share, Outstanding, Ending of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceRangePerShareOutstandingEnding", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options granted intrinsic value.", "label": "Aggregate Intrinsic Value, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodForfeitedIntrinsicValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ShareBased compensation arrangement By ShareBased payment award options grants in period forfeited intrinsic value.", "label": "Aggregate Intrinsic Value, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodForfeitedIntrinsicValue", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInPeriodExercisedIntrinsicValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options in period exercisedintrinsic value.", "label": "Aggregate Intrinsic Value, Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInPeriodExercisedIntrinsicValue", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInPeriodExpiredIntrinsicValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options in period expired intrinsic value.", "label": "Aggregate Intrinsic Value, Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInPeriodExpiredIntrinsicValue", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAggregateIntrinsicValueUnvested": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Aggregate Intrinsic Value, Unvested", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAggregateIntrinsicValueUnvested", "periodEndLabel": "Aggregate Intrinsic Value, Unvested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAggregateIntrinsicValueUnvested", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRelativeFairValueOutstandingBeginning": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Relative Fair Value, Outstanding, Beginning.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRelativeFairValueOutstandingBeginning", "periodEndLabel": "Relative Fair Value, Outstanding, Ending of period", "periodStartLabel": "Relative Fair Value, Outstanding, Beginning of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRelativeFairValueOutstandingBeginning", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Exercise Price, Unvested.", "label": "Weighted Average Exercise Price, Unvested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceVestedAndExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options outstanding weighted average exercise price vested and exercisable.", "label": "Weighted Average Exercise Price, Vested and Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceVestedAndExercisable", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedEndingBalance": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Stock Option Unvested, Ending Balance.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedEndingBalance", "periodEndLabel": "Number of Stock Option, Unvested, Ending Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedEndingBalance", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "sharesItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableEndingBalance": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options vested and exercisable ending balance.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableEndingBalance", "periodEndLabel": "Number of Stock Option, Vested and Exercisable, Ending Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableEndingBalance", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "sharesItemType" }, "BUUZ_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExerciseInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Exercise Price, Warrants exercised.", "label": "Weighted Average Strike Price/Share, Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExerciseInPeriodWeightedAverageExercisePrice", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangements by share based payment award non options expired in period weighted average exercise price.", "label": "Weighted Average Strike Price/Share, Expired" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock non options that were terminated.", "label": "Weighted Average Strike Price/Share, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodExercisePriceRangePerShareVestedAndExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangements by share based payment award Optionsexercisable in period exercise price range per share vested and exercisable.", "label": "Exercise Price Range Per Share, Vested and Exercisable" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodExercisePriceRangePerShareVestedAndExercisable", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodRelativeFairValueVestedAndExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangements by share based payment award options exercisable in period relative fair value vested and exercisable.", "label": "Relative Fair Value, Vested and Exercisable" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodRelativeFairValueVestedAndExercisable", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodExercisePriceRangePerShareExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range Per Share, Exercised.", "label": "Exercise Price Range Per Share, Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodExercisePriceRangePerShareExercised", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodRelativeFairValueExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Relative Fair Value, Exercised", "label": "Relative Fair Value, Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodRelativeFairValueExercised", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodRelativeFairValueForfeited": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sharebased compensation arrangements by ShareBased payment award options in period exercises in period relative fair value forfeited.", "label": "Relative Fair Value, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodRelativeFairValueForfeited", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodExercisePriceRangePerShareExpired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range Per Share, Expired.", "label": "Exercise Price Range Per Share, Expired" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodExercisePriceRangePerShareExpired", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodRelativeFairValueExpired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Relative Fair Value, Expired.", "label": "Relative Fair Value, Expired" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodRelativeFairValueExpired", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInExercisePriceRangePerShareGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range Per Share, Granted.", "label": "Exercise Price Range Per Share, Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInExercisePriceRangePerShareGranted", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodRelativeFairValueGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Relative Fair Value, Granted.", "label": "Relative Fair Value, Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodRelativeFairValueGranted", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsInPeriodExercisePriceRangePerShareForfeited": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sharebased compensation arrangements by ShareBased payment award options in period exercise price range per share forfeited.", "label": "Exercise Price Range Per Share, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsInPeriodExercisePriceRangePerShareForfeited", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsInPeriodExercisePriceRangePerShareUnvested": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range Per Share, Unvested.", "label": "Exercise Price Range Per Share, Unvested" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsInPeriodExercisePriceRangePerShareUnvested", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsUnvestedInPeriodRelativeFairValueUnvested": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Relative Fair Value, Unvested.", "label": "Relative Fair Value, Unvested" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsUnvestedInPeriodRelativeFairValueUnvested", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareholderMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shareholder [Member]", "label": "Shareholder [Member]" } } }, "localname": "ShareholderMember", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "BUUZ_StockBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Stock based compensation.", "label": "StockBasedCompensation", "verboseLabel": "Stock-based compensation" } } }, "localname": "StockBasedCompensation", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "BUUZ_StockIssuedDuringPeriodReturnOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period return of shares.", "label": "Return of shares" } } }, "localname": "StockIssuedDuringPeriodReturnOfShares", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "BUUZ_StockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Options [Member]", "label": "Stock Options [Member]" } } }, "localname": "StockOptionsMember", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfIncomeAndLossPerShareAnti-dilutiveDetails" ], "xbrltype": "domainItemType" }, "BUUZ_StockSubscriptionReceivable": { "auth_ref": [], "calculation": { "http://calethos.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock subscription receivable.", "label": "Stock subscription receivable" } } }, "localname": "StockSubscriptionReceivable", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "BUUZ_StockSubscriptionReceivableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Subscription Receivable [Member]", "label": "Stock Subscription Receivable [Member]" } } }, "localname": "StockSubscriptionReceivableMember", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "BUUZ_TechnologyDevelopmentAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Technology Development Agreement [Member]", "label": "Technology Development Agreement [Member]" } } }, "localname": "TechnologyDevelopmentAgreementMember", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://calethos.com/role/ScheduleOfRemainingPaymentsDetails" ], "xbrltype": "domainItemType" }, "BUUZ_TechnologyDevelopmentAgreementTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Technology Development Agreement [Table Text Block]", "label": "Schedule of Remaining Payments" } } }, "localname": "TechnologyDevelopmentAgreementTableTextBlock", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/CommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "BUUZ_TerminationAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Termination Agreement [Member]", "label": "Termination Agreement [Member]" } } }, "localname": "TerminationAgreementMember", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "BUUZ_WarrantLiabilityPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant Liability [Policy Text Block]", "label": "Warrant Liability" } } }, "localname": "WarrantLiabilityPolicyTextBlock", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "BUUZ_WarrantsIssuedForServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants Issued For Services [Member]", "label": "Warrants Issued For Services [Member]" } } }, "localname": "WarrantsIssuedForServicesMember", "nsuri": "http://calethos.com/20211231", "presentation": [ "http://calethos.com/role/ScheduleOfIncomeAndLossPerShareAnti-dilutiveDetails" ], "xbrltype": "domainItemType" }, "country_KR": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "KOREA, REPUBLIC OF" } } }, "localname": "KR", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r422" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r422" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r419", "r421", "r422" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r419", "r421", "r422" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r419", "r421", "r422" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r421" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r419", "r421", "r422" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r420" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r408" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r421" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r421" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r423" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r411" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r414" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://calethos.com/role/ScheduleOfRemainingPaymentsDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r425" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r422" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r426" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r419", "r421", "r422" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://calethos.com/role/ScheduleOfRemainingPaymentsDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r421" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r415" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r416" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r409" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r413" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r412" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r417" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r418" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r138" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ChiefFinancialOfficerMember": { "auth_ref": [ "r138" ], "lang": { "en-us": { "role": { "label": "Chief Financial Officer [Member]" } } }, "localname": "ChiefFinancialOfficerMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r173", "r210", "r242", "r243", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r382", "r384", "r406", "r407" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://calethos.com/role/ScheduleOfFairValueOfWarrantsDetails", "http://calethos.com/role/ScheduleOfPotentialFutureSharesIssuanceOfConversionNotesDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r173", "r210", "r242", "r243", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r382", "r384", "r406", "r407" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://calethos.com/role/ScheduleOfFairValueOfWarrantsDetails", "http://calethos.com/role/ScheduleOfPotentialFutureSharesIssuanceOfConversionNotesDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r173", "r210", "r240", "r242", "r243", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r382", "r384", "r406", "r407" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://calethos.com/role/ScheduleOfFairValueOfWarrantsDetails", "http://calethos.com/role/ScheduleOfPotentialFutureSharesIssuanceOfConversionNotesDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r173", "r210", "r240", "r242", "r243", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r382", "r384", "r406", "r407" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://calethos.com/role/ScheduleOfFairValueOfWarrantsDetails", "http://calethos.com/role/ScheduleOfPotentialFutureSharesIssuanceOfConversionNotesDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r135", "r136", "r236", "r237", "r383", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405" ], "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r135", "r136", "r236", "r237", "r383", "r394", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r138", "r338" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://calethos.com/role/NotesPayableDetailsNarrative", "http://calethos.com/role/RelatedPartyTransactionsDetailsNarrative", "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://calethos.com/role/NotesPayableDetailsNarrative", "http://calethos.com/role/RelatedPartyTransactionsDetailsNarrative", "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r28" ], "calculation": { "http://calethos.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://calethos.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts payable and accrued expenses", "totalLabel": "Accounts payable and accrued expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/BalanceSheets", "http://calethos.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/AccountsPayableAndAccruedExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r25", "r344" ], "calculation": { "http://calethos.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r30" ], "calculation": { "http://calethos.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r20", "r41", "r42", "r43", "r373", "r389", "r390" ], "calculation": { "http://calethos.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r40", "r43", "r50", "r51", "r52", "r86", "r87", "r88", "r308", "r385", "r386", "r429" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r18", "r273", "r344" ], "calculation": { "http://calethos.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r86", "r87", "r88", "r270", "r271", "r272", "r314" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentToAdditionalPaidInCapitalConvertibleDebtInstrumentIssuedAtSubstantialPremium": { "auth_ref": [ "r183" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in additional paid-in capital (APIC) from recognition of substantial premium at which convertible debt instrument is issued.", "label": "Debt premium on issuance of convertible promissory notes for conversion of series A convertible preferred stock" } } }, "localname": "AdjustmentToAdditionalPaidInCapitalConvertibleDebtInstrumentIssuedAtSubstantialPremium", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r244", "r246", "r275", "r276" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Stock issued for accrued compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "auth_ref": [ "r224", "r231" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.", "label": "Stock options issued for services" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r169", "r224", "r231" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Fair value of warrants issued with the conversion of series A convertible preferred stock" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r58", "r65", "r193", "r328" ], "calculation": { "http://calethos.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of convertible promissory note discounts" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r65", "r193", "r202", "r203", "r330" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r106" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Total potential future shares" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ScheduleOfIncomeAndLossPerShareAnti-dilutiveDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r106" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ScheduleOfIncomeAndLossPerShareAnti-dilutiveDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ScheduleOfIncomeAndLossPerShareAnti-dilutiveDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r106" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ScheduleOfIncomeAndLossPerShareAnti-dilutiveDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://calethos.com/role/ScheduleOfRemainingPaymentsDetails", "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r79", "r123", "r126", "r132", "r141", "r156", "r157", "r158", "r160", "r161", "r162", "r163", "r164", "r165", "r167", "r168", "r305", "r311", "r318", "r342", "r344", "r358", "r371" ], "calculation": { "http://calethos.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r7", "r38", "r79", "r141", "r156", "r157", "r158", "r160", "r161", "r162", "r163", "r164", "r165", "r167", "r168", "r305", "r311", "r318", "r342", "r344" ], "calculation": { "http://calethos.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r248", "r268" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ScheduleOfCompanyRestrictedStockAwardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationsPolicy": { "auth_ref": [ "r302" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.", "label": "Incorporation of Korean entity" } } }, "localname": "BusinessCombinationsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r24", "r67" ], "calculation": { "http://calethos.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r10", "r68" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r62", "r67", "r73" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash at end of reporting period", "periodStartLabel": "Cash at beginning of reporting period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r62", "r319" ], "calculation": { "http://calethos.com/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFDICInsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.", "label": "Cash, FDIC Insured Amount" } } }, "localname": "CashFDICInsuredAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of non-cash financing activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r76", "r79", "r99", "r100", "r101", "r103", "r105", "r109", "r110", "r111", "r141", "r156", "r161", "r162", "r163", "r167", "r168", "r208", "r209", "r213", "r217", "r318", "r424" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/BalanceSheets", "http://calethos.com/role/BalanceSheetsParenthetical", "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit", "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r225" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Issuance of warrant price per share", "verboseLabel": "Class of warrant exercise price" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r225" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Issuance of warrants to purchase of common stock", "verboseLabel": "Number of securities called by warrants or rights" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://calethos.com/role/ScheduleOfRemainingPaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r34", "r149", "r363", "r376" ], "calculation": { "http://calethos.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and contingencies (Note 6)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r146", "r147", "r148", "r152", "r395" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "auth_ref": [ "r153", "r396" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.", "label": "Commitments and Contingencies, Policy [Policy Text Block]", "verboseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r86", "r87", "r314" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, par value", "verboseLabel": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/BalanceSheetsParenthetical", "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized", "verboseLabel": "Common stock shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/BalanceSheetsParenthetical", "http://calethos.com/role/OrganizationAndAccountingPoliciesDetailsNarrative", "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r17", "r224" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r17", "r344" ], "calculation": { "http://calethos.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, par value $0.001, 100,000,000 shares authorized; 25,995,621 and 16,634,951 shares issued and outstanding" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r45", "r47", "r48", "r55", "r366", "r379" ], "calculation": { "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Comprehensive loss:" } } }, "localname": "ComprehensiveIncomeNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r74", "r307" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConversionOfStockSharesIssued1": { "auth_ref": [ "r70", "r71", "r72" ], "lang": { "en-us": { "role": { "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of shares" } } }, "localname": "ConversionOfStockSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ConvertibleDebt": { "auth_ref": [ "r14", "r360", "r372" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.", "label": "Convertible promissory note", "verboseLabel": "Convertible debt outstanding" } } }, "localname": "ConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://calethos.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtCurrent": { "auth_ref": [ "r12" ], "calculation": { "http://calethos.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Convertible promissory notes, net" } } }, "localname": "ConvertibleDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.", "label": "Schedule of Convertible Promissory Notes" } } }, "localname": "ConvertibleDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConvertibleNotesPayableCurrent": { "auth_ref": [ "r30" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Convertible Notes Payable, Current", "periodEndLabel": "Net carrying amount" } } }, "localname": "ConvertibleNotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ScheduleOfConvertiblePromissoryNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayableMember": { "auth_ref": [ "r12", "r359", "r369", "r391" ], "lang": { "en-us": { "role": { "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible Notes Payable [Member]" } } }, "localname": "ConvertibleNotesPayableMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://calethos.com/role/ScheduleOfConvertiblePromissoryNotesDetails", "http://calethos.com/role/ScheduleOfPotentialFutureSharesIssuanceOfConversionNotesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "auth_ref": [ "r70", "r72" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Converted Instrument, Amount" } } }, "localname": "DebtConversionConvertedInstrumentAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentRate": { "auth_ref": [ "r70", "r72" ], "lang": { "en-us": { "role": { "documentation": "Dividend or interest rate associated with the financial instrument issued in exchange for the original debt being converted in a noncash or part noncash transaction. Noncash are transactions that affect recognized assets or liabilities but that do not result in cash receipts or cash payments. Part noncash refers to that portion of the transaction not resulting in cash receipts or cash payments.", "label": "Converted instrument, rate" } } }, "localname": "DebtConversionConvertedInstrumentRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtConversionOriginalDebtAmount1": { "auth_ref": [ "r70", "r72" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of debt" } } }, "localname": "DebtConversionOriginalDebtAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r75", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r187", "r194", "r195", "r196", "r204" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Convertible Promissory Notes" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r12", "r13", "r14", "r78", "r84", "r170", "r171", "r172", "r173", "r174", "r175", "r177", "r183", "r184", "r185", "r186", "r188", "r189", "r190", "r191", "r192", "r193", "r200", "r201", "r202", "r203", "r331", "r359", "r360", "r369" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://calethos.com/role/NotesPayableDetailsNarrative", "http://calethos.com/role/ScheduleOfConvertiblePromissoryNotesDetails", "http://calethos.com/role/ScheduleOfPotentialFutureSharesIssuanceOfConversionNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature": { "auth_ref": [ "r230" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.", "label": "Debt instrument, convertible, beneficial conversion feature" } } }, "localname": "DebtInstrumentConvertibleBeneficialConversionFeature", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r172", "r197" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Conversion price per share", "terseLabel": "Debt Instrument, Convertible, Conversion Price", "verboseLabel": "Debt instruments, conversion price" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://calethos.com/role/ScheduleOfPotentialFutureSharesIssuanceOfConversionNotesDetails", "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentDecreaseForgiveness": { "auth_ref": [ "r78" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.", "label": "Debt instrument decrease forgiveness" } } }, "localname": "DebtInstrumentDecreaseForgiveness", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r170", "r200", "r201", "r329", "r331", "r332" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt instrument, face amount", "periodEndLabel": "Balance, end of year", "periodStartLabel": "Balance, beginning of year" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/NotesPayableDetailsNarrative", "http://calethos.com/role/ScheduleOfConvertiblePromissoryNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r31", "r198", "r329", "r331" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateIncreaseDecrease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Incremental percentage increase (decrease) in the stated rate on a debt instrument.", "label": "Increase in interest rate" } } }, "localname": "DebtInstrumentInterestRateIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://calethos.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r31", "r171" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt instrument, interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r32", "r173", "r317" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Debt instrument, maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://calethos.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentMaturityDateDescription": { "auth_ref": [ "r32" ], "lang": { "en-us": { "role": { "documentation": "Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.", "label": "Debt Instrument, Maturity Date, Description", "verboseLabel": "Debt instrument, maturity date" } } }, "localname": "DebtInstrumentMaturityDateDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://calethos.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r33", "r78", "r84", "r170", "r171", "r172", "r173", "r174", "r175", "r177", "r183", "r184", "r185", "r186", "r188", "r189", "r190", "r191", "r192", "r193", "r200", "r201", "r202", "r203", "r331" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://calethos.com/role/NotesPayableDetailsNarrative", "http://calethos.com/role/ScheduleOfConvertiblePromissoryNotesDetails", "http://calethos.com/role/ScheduleOfPotentialFutureSharesIssuanceOfConversionNotesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPeriodicPayment": { "auth_ref": [ "r33", "r368" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments including both interest and principal payments.", "label": "Debt instrument, periodic payment" } } }, "localname": "DebtInstrumentPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r183", "r328", "r332" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt instrument, issue discount", "periodEndLabel": "Balance, end of year", "periodStartLabel": "Balance, beginning of year", "verboseLabel": "Original issue discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://calethos.com/role/NotesPayableDetailsNarrative", "http://calethos.com/role/ScheduleOfConvertiblePromissoryNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtPolicyTextBlock": { "auth_ref": [ "r154" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.", "label": "Debt Discounts" } } }, "localname": "DebtPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault": { "auth_ref": [ "r83", "r155" ], "lang": { "en-us": { "role": { "documentation": "Discussion of the facts and amounts pertaining to each failure to comply with an affirmative or negative covenant of a long-term debt instrument, including violating payment terms or an inability to meet certain minimum financial requirements or achieve or maintain certain financial ratios. The discussion would generally be expected to also include whether or not the failure can and will be overcome and a description of the terms of any waivers, including the amount of the waiver and the period of time covered by the waiver, and if reclassification of long-term debt to current has been made in the current balance sheet.", "label": "Events of default description" } } }, "localname": "DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]" } } }, "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent": { "auth_ref": [ "r30" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable within one year (or the operating cycle, if longer).", "label": "Deferred compensation" } } }, "localname": "DeferredCompensationShareBasedArrangementsLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ScheduleOfCompanyRestrictedStockAwardsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r284" ], "calculation": { "http://calethos.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Expected income tax benefit from NOL carry-forwards" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r286" ], "calculation": { "http://calethos.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "totalLabel": "Deferred tax assets, net of valuation allowance" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r286" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred tax assets,net" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/DeferredTaxAssetsAndIncomeTaxProvisionDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": { "auth_ref": [ "r289", "r290" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.", "label": "Net operating loss deferred tax" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/DeferredTaxAssetsAndIncomeTaxProvisionDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r285" ], "calculation": { "http://calethos.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Less valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": { "auth_ref": [ "r82", "r159", "r161", "r162", "r166", "r167", "r168", "r336", "r362", "r377" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.", "label": "Due to related parties" } } }, "localname": "DueToRelatedPartiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r104" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Net loss per share, basic and diluted" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r106", "r107" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r319" ], "calculation": { "http://calethos.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of exchange rate changes on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r280" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective income tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ScheduleOfReconciliationOfIncomeTaxDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r80", "r280", "r296" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Federal statutory income tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ScheduleOfReconciliationOfIncomeTaxDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r280", "r296" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Change in valuation allowance on net operating loss carry-forwards" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ScheduleOfReconciliationOfIncomeTaxDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r50", "r51", "r52", "r86", "r87", "r88", "r90", "r95", "r97", "r108", "r142", "r224", "r231", "r270", "r271", "r272", "r292", "r293", "r314", "r320", "r321", "r322", "r323", "r324", "r325", "r385", "r386", "r387", "r429" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r140" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Ownership percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ScheduleOfFairValueOfWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ScheduleOfFairValueOfWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Schedule of Fair Value of Warrants" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StockholdersDeficitTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r327" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Translation" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r56" ], "calculation": { "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r53", "r123", "r125", "r128", "r131", "r133", "r356", "r364", "r367", "r380" ], "calculation": { "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before provision for income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r80", "r281", "r282", "r288", "r294", "r297", "r299", "r300", "r301" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Deferred Tax Assets and Income Tax Provision" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/DeferredTaxAssetsAndIncomeTaxProvision" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r81", "r96", "r97", "r122", "r279", "r295", "r298", "r381" ], "calculation": { "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r49", "r277", "r278", "r282", "r283", "r287", "r291" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r69" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income tax paid" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r64" ], "calculation": { "http://calethos.com/role/StatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "verboseLabel": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating asset and liabilities" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r64" ], "calculation": { "http://calethos.com/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r58", "r191", "r199", "r202", "r203" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://calethos.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaid": { "auth_ref": [ "r69" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.", "label": "Interest paid" } } }, "localname": "InterestPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r8", "r9", "r30" ], "calculation": { "http://calethos.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued interest", "periodEndLabel": "Balance, end of the year" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/NotesPayableDetailsNarrative", "http://calethos.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails", "http://calethos.com/role/ScheduleOfAccruedInterestDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r29", "r79", "r127", "r141", "r156", "r157", "r158", "r161", "r162", "r163", "r164", "r165", "r167", "r168", "r306", "r311", "r312", "r318", "r342", "r343" ], "calculation": { "http://calethos.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r23", "r79", "r141", "r318", "r344", "r361", "r375" ], "calculation": { "http://calethos.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 deficit" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyDomicileOfLitigation": { "auth_ref": [ "r149", "r150", "r151" ], "lang": { "en-us": { "role": { "documentation": "Identifies the domicile or jurisdiction of the court of law, arbitration or mediation proceeding.", "label": "Litigation description" } } }, "localname": "LossContingencyDomicileOfLitigation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.", "label": "Measurement Input, Expected Dividend Rate [Member]" } } }, "localname": "MeasurementInputExpectedDividendRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ScheduleOfFairValueOfWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input, Expected Term [Member]" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ScheduleOfFairValueOfWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ScheduleOfFairValueOfWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ScheduleOfFairValueOfWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputSharePriceMember": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using share price of saleable stock.", "label": "Measurement Input, Share Price [Member]" } } }, "localname": "MeasurementInputSharePriceMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ScheduleOfFairValueOfWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ScheduleOfFairValueOfWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability." } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ScheduleOfFairValueOfWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r62" ], "calculation": { "http://calethos.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r62" ], "calculation": { "http://calethos.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activity" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from investing activity" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r62", "r63", "r66" ], "calculation": { "http://calethos.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r44", "r46", "r52", "r54", "r66", "r79", "r89", "r91", "r92", "r93", "r94", "r96", "r97", "r102", "r123", "r125", "r128", "r131", "r133", "r141", "r156", "r157", "r158", "r161", "r162", "r163", "r164", "r165", "r167", "r168", "r315", "r318", "r365", "r378" ], "calculation": { "http://calethos.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "negatedLabel": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesDetailsNarrative", "http://calethos.com/role/StatementsOfCashFlows", "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit", "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r57" ], "calculation": { "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other expenses" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other expenses" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r14", "r360", "r372" ], "calculation": { "http://calethos.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Notes payable, net", "periodEndLabel": "Balance, end of the year", "periodStartLabel": "Balance, beginning of the year" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/BalanceSheets", "http://calethos.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r28" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Notes Payable, Current", "periodStartLabel": "Notes payable" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ScheduleOfAccruedInterestDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r123", "r125", "r128", "r131", "r133" ], "calculation": { "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r85", "r98", "r119", "r313" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.", "label": "Organization and Accounting Policies" } } }, "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssets": { "auth_ref": [ "r11", "r357", "r370" ], "calculation": { "http://calethos.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets classified as other.", "label": "Other assets" } } }, "localname": "OtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r39" ], "calculation": { "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Change in foreign currency translation", "verboseLabel": "Foreign currency translation loss" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit", "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r16", "r208" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/BalanceSheetsParenthetical", "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/BalanceSheetsParenthetical", "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r16", "r208" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r16", "r344" ], "calculation": { "http://calethos.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock, par value $0.001, 100,000,000 shares authorized; no shares issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r3", "r6", "r144", "r145" ], "calculation": { "http://calethos.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidInsurance": { "auth_ref": [ "r4", "r6", "r143", "r145" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Insurance" } } }, "localname": "PrepaidInsurance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r60" ], "calculation": { "http://calethos.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from the issuance of convertible promissory notes", "verboseLabel": "Proceed from convertible debt" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r59" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromNotesPayable": { "auth_ref": [ "r60" ], "calculation": { "http://calethos.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.", "label": "Proceeds from the issuance of notes payable", "verboseLabel": "Proceeds from notes payable" } } }, "localname": "ProceedsFromNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/NotesPayableDetailsNarrative", "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRelatedPartyDebt": { "auth_ref": [ "r60" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.", "label": "Proceeds from related party" } } }, "localname": "ProceedsFromRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r59", "r269" ], "calculation": { "http://calethos.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from the exercise of options", "verboseLabel": "Proceeds from stock options exercised" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StatementsOfCashFlows", "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfessionalFees": { "auth_ref": [ "r392", "r393" ], "calculation": { "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.", "label": "Professional fees" } } }, "localname": "ProfessionalFees", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss", "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r241", "r335", "r336", "r339" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesDetailsNarrative", "http://calethos.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r241" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party." } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesDetailsNarrative", "http://calethos.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r333", "r334", "r336", "r340", "r341" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfNotesPayable": { "auth_ref": [ "r61" ], "calculation": { "http://calethos.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.", "label": "Repayments of Notes Payable", "negatedLabel": "Repayment of notes payable", "negatedTerseLabel": "Payments" } } }, "localname": "RepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ScheduleOfNotesPayableDetails", "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "auth_ref": [ "r61" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.", "label": "Miscellaneous operating expenses" } } }, "localname": "RepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r106" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ScheduleOfCompanyRestrictedStockAwardsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r19", "r231", "r273", "r344", "r374", "r388", "r390" ], "calculation": { "http://calethos.com/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit", "negatedLabel": "Retained Earnings (Accumulated Deficit)" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/BalanceSheets", "http://calethos.com/role/OrganizationAndAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r86", "r87", "r88", "r90", "r95", "r97", "r142", "r270", "r271", "r272", "r292", "r293", "r314", "r385", "r387" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r120", "r121", "r124", "r129", "r130", "r134", "r135", "r137", "r235", "r236", "r355" ], "calculation": { "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r234" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Revenue, Remaining Performance Obligation, Amount" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockDescriptionOfTransaction": { "auth_ref": [ "r304", "r309", "r310" ], "lang": { "en-us": { "role": { "documentation": "Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination.", "label": "Sale of Stock, Description of Transaction" } } }, "localname": "SaleOfStockDescriptionOfTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of stock shares price per share" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule of Accounts Payable and Accrued Expenses" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/AccountsPayableAndAccruedExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Interest" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/AccountsPayableAndAccruedExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r106" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ScheduleOfIncomeAndLossPerShareAnti-dilutiveDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r106" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Income and Loss Per Share Anti-dilutive" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r303" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://calethos.com/role/ScheduleOfRemainingPaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Notes Payable" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/NotesPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": { "auth_ref": [ "r238", "r239" ], "lang": { "en-us": { "role": { "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability.", "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]" } } }, "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Components of Deferred Tax Assets" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/DeferredTaxAssetsAndIncomeTaxProvisionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r280" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Reconciliation of Income Tax" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/DeferredTaxAssetsAndIncomeTaxProvisionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r337", "r339" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r248", "r268" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ScheduleOfCompanyRestrictedStockAwardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r253" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Schedule of Company Restricted Stock Awards" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StockholdersDeficitTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r253", "r261", "r263" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule of Stock Option Activities" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StockholdersDeficitTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShortTermDebtTable": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-term Debt [Table]" } } }, "localname": "ScheduleOfShortTermDebtTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://calethos.com/role/NotesPayableDetailsNarrative", "http://calethos.com/role/ScheduleOfConvertiblePromissoryNotesDetails", "http://calethos.com/role/ScheduleOfPotentialFutureSharesIssuanceOfConversionNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r35", "r76", "r109", "r110", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r213", "r217", "r222", "r225", "r226", "r227", "r228", "r229", "r230", "r231" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r232", "r245" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Schedule of Warrants Activity" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StockholdersDeficitTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series A Preferred Stock [Member]" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r64" ], "calculation": { "http://calethos.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Fair value of equity-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments": { "auth_ref": [ "r266" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends.", "label": "Expected Dividend Payments" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r265" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Date of issuance volatility percentage", "verboseLabel": "Fair value assumptions, expected volatility rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Fair value of common stock risk free interest rate", "verboseLabel": "Risk Free Interest Rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ScheduleOfCompanyRestrictedStockAwardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "auth_ref": [ "r258" ], "lang": { "en-us": { "role": { "documentation": "Number of non-option equity instruments exercised by participants.", "label": "Number of warrants issued, Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": { "auth_ref": [ "r259" ], "lang": { "en-us": { "role": { "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.", "label": "Number of warrants issued, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "Net number of non-option equity instruments granted to participants.", "label": "Number of warrants issued, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "auth_ref": [ "r254", "r256" ], "lang": { "en-us": { "role": { "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "periodEndLabel": "Number of warrants issued, Outstanding, Ending of period", "periodStartLabel": "Number of warrants issued, Outstanding, Beginning of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period", "negatedLabel": "Number of Stock Option Shares, Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r259" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Number of Stock Option Shares, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Number of Stock Option Shares, Granted", "verboseLabel": "Option to purhase shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails", "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r268" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "periodEndLabel": "Aggregate Intrinsic Value, Ending of period", "periodStartLabel": "Aggregate Intrinsic Value, Beginning of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r255", "r268" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Number of Stock Option Shares, Outstanding, Ending of period", "periodStartLabel": "Number of Stock Option Shares, Outstanding, Beginning of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r254" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price, Outstanding, Ending of period", "periodStartLabel": "Weighted Average Exercise Price, Outstanding, Beginning of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r245", "r250" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ScheduleOfCompanyRestrictedStockAwardsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Weighted Average Exercise Price, Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Weighted Average Exercise Price, Expired" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Weighted Average Exercise Price, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Weighted Average Exercise Price, Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-based Payment Arrangement, Tranche One [Member]" } } }, "localname": "ShareBasedCompensationAwardTrancheOneMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-based Payment Arrangement, Tranche Three [Member]" } } }, "localname": "ShareBasedCompensationAwardTrancheThreeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-based Payment Arrangement, Tranche Two [Member]" } } }, "localname": "ShareBasedCompensationAwardTrancheTwoMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r248", "r251" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://calethos.com/role/ScheduleOfFairValueOfWarrantsDetails", "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r249" ], "lang": { "en-us": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r264", "r274" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Fair value of common stock estimated life", "verboseLabel": "Expected Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r268" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "periodEndLabel": "Aggregate Intrinsic Value, Vested and Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of non-vested options outstanding.", "label": "Shares, balance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ScheduleOfCompanyRestrictedStockAwardsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "auth_ref": [ "r252" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "Share-based compensation arrangement by share-based payment award, options" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of options vested.", "label": "Fair value of options" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-term Debt [Line Items]" } } }, "localname": "ShortTermDebtLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://calethos.com/role/NotesPayableDetailsNarrative", "http://calethos.com/role/ScheduleOfConvertiblePromissoryNotesDetails", "http://calethos.com/role/ScheduleOfPotentialFutureSharesIssuanceOfConversionNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r15", "r16", "r17", "r76", "r79", "r99", "r100", "r101", "r103", "r105", "r109", "r110", "r111", "r141", "r156", "r161", "r162", "r163", "r167", "r168", "r208", "r209", "r213", "r217", "r224", "r318", "r424" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/BalanceSheets", "http://calethos.com/role/BalanceSheetsParenthetical", "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit", "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r37", "r50", "r51", "r52", "r86", "r87", "r88", "r90", "r95", "r97", "r108", "r142", "r224", "r231", "r270", "r271", "r272", "r292", "r293", "r314", "r320", "r321", "r322", "r323", "r324", "r325", "r385", "r386", "r387", "r429" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/BalanceSheets", "http://calethos.com/role/BalanceSheetsParenthetical", "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r86", "r87", "r88", "r108", "r355" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/BalanceSheets", "http://calethos.com/role/BalanceSheetsParenthetical", "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r36", "r188", "r224", "r225", "r231" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Conversion of series A preferred stock to convertible promissory notes, shares" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Stock Issued During Period, Shares, Issued for Services" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r16", "r17", "r224", "r231" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Issuance of common stock", "negatedLabel": "Stocks returned, shares", "verboseLabel": "Stock issued during period shares new issues" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesDetailsNarrative", "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit", "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Stocks issued for debt forgiveness, shares" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r224", "r231" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Restricted common stock awards issued for compensation, shares" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r16", "r17", "r224", "r231" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Restricted common stock shares granted" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r16", "r17", "r224", "r231" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Stock-based compensation, shares" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r16", "r17", "r224", "r231", "r258" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Stock issued on exercise of options, shares", "negatedLabel": "Number of Stock Option Shares, Exercised", "verboseLabel": "Number of share options exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails", "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit", "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r37", "r224", "r231" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Conversion of series A preferred stock to convertible promissory notes" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Stock Issued During Period, Value, Issued for Services" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r16", "r17", "r224", "r231" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stocks returned", "verboseLabel": "Issuance of common stock" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesDetailsNarrative", "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued attributable to transactions classified as other.", "label": "Stock issued for debt forgiveness" } } }, "localname": "StockIssuedDuringPeriodValueOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "auth_ref": [ "r16", "r17", "r224", "r231" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.", "label": "Restricted common stock awards issued for compensation" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r224", "r231" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r16", "r17", "r231", "r247", "r262" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Stock-based compensation" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r37", "r224", "r231" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock issued on exercise of options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionPlanExpense": { "auth_ref": [ "r65" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for option under share-based payment arrangement.", "label": "Option expense" } } }, "localname": "StockOptionPlanExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r17", "r21", "r22", "r79", "r139", "r141", "r318", "r344" ], "calculation": { "http://calethos.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Balance", "totalLabel": "Total stockholders\u2019 deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/BalanceSheets", "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 deficit" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r77", "r209", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r223", "r231", "r233" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders\u2019 Deficit" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StockholdersDeficit" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r326", "r346" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r326", "r346" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r326", "r346" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r326", "r346" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r345", "r347" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of cash flows information" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r303" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://calethos.com/role/ScheduleOfRemainingPaymentsDetails", "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r112", "r113", "r114", "r115", "r116", "r117", "r118" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r286" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/DeferredTaxAssetsAndIncomeTaxProvisionDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r268" ], "lang": { "en-us": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Axis]" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r268" ], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.", "label": "Dividend yield" } } }, "localname": "WarrantsAndRightsOutstandingMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ScheduleOfFairValueOfWarrantsDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants and rights outstanding, term" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/ScheduleOfFairValueOfWarrantsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted average common shares outstanding \u2013 basic and diluted" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r119": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r148": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r152": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12565-110249" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r204": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r233": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19524-108361" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r301": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569655-111683" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r313": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r327": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "http://asc.fasb.org/topic&trid=2175825" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r341": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r347": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(3),(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.17)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(k)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "450", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r408": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r409": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r410": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r411": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r412": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r413": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r414": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r415": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r416": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r417": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r418": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r419": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r420": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r421": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r422": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r423": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r424": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r425": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r426": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r427": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r428": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r85": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r98": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" } }, "version": "2.1" } ZIP 64 0001493152-22-008391-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-22-008391-xbrl.zip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�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�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